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ABSTRACT 
Gout is an inflammatory arthritis that is prevalent in New Zealand (NZ) populations, with 
a higher frequency in Māori (6.06%) and Pacific Islanders (7.60%) in comparison to NZ 
Europeans (3.24%). This inflammatory arthritis arises from an innate immune response to 
monosodium urate (MSU) crystals that accumulate in joints and surrounded tissues. MSU 
crystals are formed in the presence of hyperuricaemia (elevated serum urate levels). 
Hyperuricaemia (HU) is a prerequisite for gout, but not sufficient. Therefore, it suggests the 
contribution of other factors that are causal to gout. Genome-wide association studies, an 
indispensable approach in population genetics, have reported dozens of loci associated with 
serum urate levels and confirm the importance of urate excretion in controlling urate levels and 
gout. However, genetic contribution to the progression from hyperuricaemia to gout is poorly 
understood. Some candidate gene studies have identified genes encoding proteins that are 
involved in the NLRP3 (NOD-LRR and pyrin domain-containing 3) inflammasome activation 
that is a key regulator in gout pathogenesis. Thereby, the current research project aims to 
investigate causal association between non-urate, inflammatory loci and gout. 
The current study provides evidence of association between non-urate transporters 
CNIH2, CUX2, FAM35A and NIPAL1 and inflammatory loci PPARGC1B, IL37 and IL23R with 
gout in NZ Polynesian and European populations. Recent studies reported association of some 
of these loci with gout in the Japanese population such as CUX2 (rs4766566), CNIH2 
(rs4073582), NIPAL1 (rs11733284), FAM35A (rs7903456), PPARGC1B (rs45520937) and 
IL23R (rs7517847). The causal role that these variants have in gout pathogenesis in NZ 
populations has not been reported before and is important for understanding disease 
mechanisms and developing effective therapeutic stratigies to cure gout. 
Population-specific genetic effects on gout are also evident but are not being explored as 
much as in other complex phenotypes. With the help of an in-silico resequencing approach 
applied to whole genome sequencing (WGS) gout data, several novel population-specific 
association signals were found and among these CACNA1S (rs13374149), TAP2 (rs2071) and 
IL37 (rs17521135) were successfully validated for their association with gout in the New 
Zealand Polynesian cohort. They were identified with a high prevalence and increasing risk of 
gout only in a Polynesian sample set. Notably the IL37 (rs17521135) G-allele increased the risk 
of gout using hyperuricaemic controls compared to gout cases (OR= 1.81, P = 0.031), indicating 
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Lastly, the current study attempted to evaluate the cause-effect relationship between 
mitochondria and gout susceptibility through influencing mitochondrial copy number. The 
hypothesis was generated based on a recent report of identification of low mitochondrial DNA 
(mtDNA) copy number in Polynesian (Māori and Pacific) gout individuals (Gosling et al. 
2018). My study replicated the Gosling et al. (2018) association but did not find association of 
mtDNA copy number with gout in European.  My study evidenced the association of nuclear 
genome encoded variant rs149132393 (in a FCRL6 gene) with increased mtDNA copy number 
(in the Eastern Polynesian group) and protected from risk of gout in the Polynesian (Western 
Polynesian group) population using HU controls versus gout cases. In addition, a previously 
identified mitochondrial variant 16189C in Polynesian gout patients (Gosling et al. 2018) was 
associated with gout risk (OR = 0.45, P = 0.045) through mitochondrial-wide association 
analysis among this NZ Polynesian cohort. Collectively my study indicates a potential 
contribution of mitochondrial genome variation in gout pathophysiology by affecting 
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PICTORIAL ABSTRACT 
Figure: Summary Diagram of Inflammatory Genes Included in the Current Study and Connected Possible 
Underlying Pathways In Gout Pathogenesis. 
 
Gout is an inflammatory arthritis that is caused by the formation of monosodium urate (MSU) crystals as a result 
of elevated serum urate levels. These crystals are phagocytosed by macrophages; require a secondary signal 
through Toll-like receptors for the activation of NLRP3 inflammasome (a key component in the inflammation) 
and release pro-inflammatory cytokines such as IL1β, which leads to acute gout flares. The activation of the 
NLRP3 inflammasome is associated with various regulatory pathways (integrated with each other) that has been 
summarized in the above diagram, which also involves the other essential components of the cell such as the 
mitochondrion. Damaged mitochondria can influence NLRP3 inflammasome activation via releasing mtDNA and 
ROS as danger signals. Furthermore, various genes contribute significantly to regulate these signalling pathways 
in the inflammatory response to MSU crystals. In the above diagram, mentioned inflammatory genes were selected 
for the current research (e.g. IL23R, IL37) to identify their role in gout pathogenesis. IL23R encodes a receptor, 
when binds to its ligand IL23 where upon it influences the release of IL1β. Similarly, the IL37 cytokine binds IL-
18R through IL18Rα (extra-cellular), it affects the release of pro- IL1β. The release of cytokines from affected 
macrophages also causes the infiltration of other immune cells such as neutrophils at the affected site. Other 
inflammatory markers also contribute to enhancing the inflammatory response such as release of alpha-1 
antitrypsin (encoded by SERPINA1 gene) from the liver may also affect the neutrophil infiltration to aggravate the 
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Progression from Hyperuricaemia to Gout 
1.1. Introduction 
Gout is a common form of inflammatory arthritis and develops from the deposition of 
monosodium urate (MSU) crystals in joints and other tissues. MSU crystals arise due to chronic 
elevation of serum urate levels in the blood. Gout is characterized by a sudden and severe pain 
in the joint along with swelling and redness and most frequently affects the first 
metatarsophalangeal joint of the toe (Shiozawa et al. 2017). 
The prevalence of gout is rising worldwide and affects more than 1% of the population 
in developed countries. In New Zealand (NZ), the prevalence of gout is particularly high (~4%) 
with Māori and Pacific Islanders being most affected (6 and 8%, respectively) (Dalbeth et al. 
2018a, Kuo et al. 2015b, Winnard et al. 2012). In gout, elevated serum urate levels lead to the 
supersaturation of urate that provokes the formation of MSU crystals. Upon ingestion by 
resident immune cells, these crystals cause the activation of the NOD-like receptor family, pyrin 
containing domain 3 (NLRP3) inflammasome, which in turn releases interleukin 1β (IL1β) and 
amplifies the inflammatory process leading to gout. This process is accompanied by the 
stimulation of cytokine cascades and release of other pro-inflammatory mediators with the 
subsequent infiltration of neutrophils at the site of inflammation (Akahoshi et al. 2003, Liu-
Bryan et al. 2005, Fabio Martinon et al. 2006, Shi et al. 2010). Gout is also associated with 
various metabolic conditions such as diabetes, obesity, dyslipidaemia, and hypertension, in 
addition to being associated with kidney and heart disease (Hyon K Choi et al. 2007). 
Hyperuricaemia (elevated serum urate levels) is also necessary but not sufficient to cause gout 
(Dalbeth et al. 2018b, Joosten et al. 2010, Rock et al. 2013). This indicates that gout is a 
complex disease and various factors are involved in the progression from hyperuricaemia to 
gout. 
 
1.2. Background to the problem 
1.2.1. Gout is an ancient disorder 
A historical chronology of gout provides important milestones in understanding the 
complexity of the disease. Archaeological evidence of bone erosions, suggestive of gout, has 
been identified in metatarsophalangeal joints of Tyrannosaurus rex specimens. It was accurately 
documented for the first time by Hippocrates, an ancient Greek physician, in the fifth century 
BC, who referred to it as “the un-walkable disease” (Nuki and Simkin 2006, Rothschild et al. 
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1997). Further, he was the first to link this disease to an intemperate life style referring to 
“podagra (pous meaning food and agra a seizure)” as an ‘arthritis of the rich’. He noted the 
disease only affected affluent people who could afford excess food and alcohol (Adams 1886). 
There were also some eras when gout was presumed socially desirable because of its prevalence 
among political and socially powerful entities (as shown in the Figure 1.1) and remained the 
marker of status and wealth for several decades (Copeman 1964). 
 
Figure 1.1: Artistic work by George Cruikshank (1792-1878); depicting an era when gout was considered as a 
disease of the ‘upper class’ and associated with excess. 
 
The image is sourced from https://wellcomeimages.org/indexplus/image/V0010850.html 
 
The Greek surgeon, physician and philosopher Galen, first characterised tophi (swollen 
growths on joints formed by the aggregation of sodium urate monohydrate crystals under the 
skin) as crystallized MSU deposits and also associated gout with a hereditary trait— debauchery 
and intemperance (Kühn 2011). A Dominican monk, Randolphus of Bocking, was the person 
who used the word gout for the first time, derived from the Latin word gutta which means drop, 
to describe podagra: “gutta quampodagram vel artiticamvocant – gout that is called podagra or 
arthritis”. This origin of the word gout came from a medieval belief that an excess of one of the 
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The discovery of the contribution of urate in the pathophysiology of gout has its own 
parallel history which begins with Antoni van Leeuwenhoek, who described the appearance of 
MSU crystals in a tophus, although their chemical nature was unidentified at that time (Storey 
2001). The chemical identity of urate (formerly called uric acid) was first established in 1776 
from a bladder stone by a Swedish chemist Karl Wilheim Scheele, who named it “lithic acid” 
(Scheele 1776). Later lithic acid was converted to the term ‘urate’ by George Pearson (Pearson 
1798) and Antoine Fourcory (Fourcroy 1800). Alfred Baring Garrod then linked the condition 
of hyperuricaemia with gout and developed a semi-quantitative method “thread test” for 
measuring urate in serum and urine, also recognized as the first clinical chemical test 
undertaken at that time (Nuki and Simkin 2006). 
The phenomena of genetic heredity of gout arthritis remained unknown until the mid 19th 
century when Sir Archibald indicated that gout could be a consequence of ‘inborn errors of 
metabolism’ or malfunctioning of the purine metabolism enzyme; hypoxanthine-guanine 
phosphoribosyl transferase (Seegmiller et al. 1967). 
 
1.2.2. Global Prevalence of Hyperuricaemia and Gout 
Cumulated data indicate an uneven distribution of gout prevalence and incidence across 
the globe (Kuo et al. 2015b). Hyperuricaemia is a primary cause of gout and the cut-off value 
is serum urate concentration ≥ 0.41 mmolL-1 for both men and women (Riuz et al., 2019). Like 
gout, average recorded levels of serum urate vary in different populations, which reflect the 
uneven distribution of the hyperuricaemic condition across diverse geographical regions. For 
example, the average serum urate level in Brazilian men was recorded as 0.24 mmolL-1 but was 
found as high as 0.46 mmolL-1 in Taiwanese Aborigine men. Similarly, the average varied from 
0.22 mmolL-1 in Brazilian women to 0.37mmolL-1 in Tibetan women (Acheson and Florey Cdu 
1969, W Chen et al. 2011, Chou and Lai 1998, Gosling et al. 2014). These high levels of serum 
urate indicate a high prevalence of hyperuricaemia in some populations. 
Hyperuricaemia and gout also have uneven prevalence rates between men and women 
and across age groups. Gout is more prevalent in males than females and also more commonly 
occurs in old age. This is supported by a study that indicated men possess a four-fold higher 
rate than women in the group of those below 65 years of age (KL Wallace et al. 2004). 
Moreover, a National Health and Nutrition Examination Health Survey (NHANES: a publicly 
available data of health and nutritional status of adults and children in the U.S.A.) and other 
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relevant databases also demonstrate the increasing burden of gout with increasing age groups 
(J Fang and Alderman 2000, KL Wallace et al. 2004). 
Regarding gout, the highest rates have been recorded in Oceanic and developed countries, 
such as Taiwan, New Zealand, U.S.A., Canada and Western Europe. For example, in a review 
by Kuo et al., (2015) more than 1% of gout prevalence has been recorded in developed 
countries, particularly in Europe and North America (Kuo et al. 2015b). According to a 
National Health and Nutrition Examination Survey (NHANES), the prevalence of gout in the 
U.S.A rose from 2.9% between 1988-1994 to 3.9% over the period 2007-2008 (Kuo et al. 
2015a, Zhu et al. 2011). In Canada, approximately 3% of adults have been found to be affected 
with gout (Badley and DesMeules 2003). Greece has been reported with the highest prevalence 
of gout in the adult population in Europe at 4.75% (Anagnostopoulos et al. 2010). The Clinical 
Practice Research Data-link (CPRD) in the UK (2012) reported the latest estimate of gout 
prevalence to be 3.22% in adults (age ≥ 20 years) and overall 2.49% in the entire population 
(Kuo et al. 2015a). A similar pattern of prevalence was observed in Spain (3.3%) and the 
Netherlands (3.7%) (Picavet and Hazes 2003, Sicras-Mainar et al. 2013). However, a lower 
prevalence of gout at 0.9% has been found in France and Italy in the years 2013 and 2009, 
respectively (Bardin et al. 2014, Trifirò et al. 2013). By comparison, epidemiological data 
report lower gout prevalence in developing and under-developed countries (Figure 1.2). For 
example, the lowest gout rate (0.3%) has been estimated in Portugal and Czech Republic adult 
population (Hanova et al. 2006, Reis and Viana Queiroz 2014). In Asia, gout has been reported 
most prevalent in a specific ethnic group of Taiwanese aboriginals at 10.42% through a National 
Health Insurance Research Database (NHIRD) conducted in 2006 (F-Y Tu et al. 2015). High 
rates of gout have also been noted in Hong Kong (2001), where 5.1% of individuals (aged 45-
59 years) have been recorded to suffer with gout, whereas, Japan and South Korea are 
considered as low gout countries (T Kawasaki and Shichikawa 2006, CH Lee and Sung 2011).  
Since observing a high prevalence of gout in some populations, it has been suggested 
that gout is also unequally distributed across multiple ethnic groups where some groups are 
more susceptible to gout (e.g. Taiwanese aboriginals and NZ Māori) than others. The variation 
in prevalance, in different studies, is the result of the differences in age bands, geographic 
locations, ethnicities of study individuals, genetic predisposition, sex distribution, the 
difference in methodologies, the definition of the condition used and year of the investigation 
(Kuo et al. 2015b, Wijnands et al. 2015). Moreover, the variation in prevalence, in different 
regions, owes to the differences in genetic background, environmental factors (e.g. diet (sea 
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food, alcohol and sweetened beverages consumption) and temperature) and gene-environment 
interactions. For example, the prevalence of gout is less than 1% in underdeveloped and 
developing countries such as India, Pakistan, Bangladesh, Thailand, Philippines and Iran. 
Considering the effect of non-genetic factors on gout susceptibility, it is thought that high 
temperatures in these regions prevent the formation of serum urate crystals (Elliot et al., 2009). 
Moreover, people consume less purine rich food (e.g. meat, seafood and alcohol) that is 
commonly consumed in developed countries like U.S.A. It is possible that the population 
attributable fraction to gout determined by genetics is less in Asian countries. 
 
Figure 1.2: Estimated prevalence of gout across the globe. a) Representing prevalence by age in seven selected 
countries b) Prevalence by age. 
 
Gout seems to be dominant in Taiwan, USA, UK, New Zealand, and the Netherlands while it is less prevalent in 
Korea and Czech Republic (Kuo et al., 2015; permission of using image was allowed under licence no. 
4655711151129). . 
 
Although hyperuricaemia is a key factor for developing gout, many people with the 
hyperuricaemia do not develop the disease. This is supported by a recent study (Dalbeth et al. 
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2018b), in which individual participant data from four publicly-available cohorts 
(Atherosclerosis Risk in Communities Study, both the Original and Offspring cohorts of the 
Framingham Heart Study and Coronary Artery Risk Development in Young Adults Study) were 
used to test the relation of baseline urate categories with gout incidence. The database was 
comprised of longitudinal observations and 15 years of follow up data related to gout and serum 
urate measurements. This study indicated a low risk of incident gout in people with modestly 
increased serum urate levels and even some of those with high concentrations of serum urate 
did not develop gout even over a prolonged follow up. Moreover, a small proportion of people 
were found with low serum urate concentrations (below 6mg/dL) subsequently developing gout 
(Dalbeth et al. 2018b). These observations clearly suggest the role of additional factors in gout 
pathogenesis. Hence, inhibitors or promoters of MSU crystallization in the presence of elevated 
urate levels, genetic and environmental factors influencing the innate immune response to 
deposited crystals have all been suggested as contributing factors. 
Regarding gout prevalence in Australasian populations (Australia and New Zealand), 
national health data suggests a region-wide trend in gout frequency (Robinson et al. 2015). 
Minaur et al. (2004) suggested that 3.8% of adults were affected with gout in the Australian 
Aboriginal community in North Queensland and among these 22% were found with 
subcutaneous tophi (Minaur et al. 2004). However, gout is considered one of the biggest health 
problems in New Zealand and each ethnicity within the country has a different gout prevalence 
(Winnard et al. 2012). According to a recent economic report (Arthritis New Zealand, 2018 
(https://www.arthritis.org.nz)), published by Arthritis New Zealand, high rates of gout 
prevalence have been found in Māori (~13%) and Pacific (20%) people with consistently higher 
rates in men compared to NZ European (7%), which is approximately double the rates (apart 
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Figure 1.3: Prevalence of gout in New Zealand men and women. Top) Ethnicity-specific prevalence rates, gout 
arthritis, in New Zealand, 2018. Bottom) Age-specific prevalence rates, gout arthritis, in New Zealand, 2018. 
 
 
The bar graphs have been sourced from https://www.arthritis.org.nz under the economic cost of arthritis in NZ. 
 
1.3. Serum Urate and Hyperuricaemia 
Urate is a weak diprotic acid with an acidic dissociation constant (pKa) of 5.5 and 
predominantly circulating in the body in urate-ionized (a monovalent, anion salt) form under 
normal physiological conditions (pH=7.5 and T= 37°C). As sodium exists abundantly in 
extracellular fluid, most of this urate is found as monosodium urate. But when urate 
concentration exceeds its solubility limit, urate precipitates and forms crystals (predominantly 
MSU crystals). This condition of elevated serum urate level is characterised as hyperuricaemia 
and is an extremely strong risk factor to the development of gout (Jin et al. 2012, Maiuolo et 
al. 2016, Wortmann 2002). In all species, serum urate level is determined by the balance 
between its production in the liver from metabolic processes or degradation of endogenously 
produced purine nucleotides and its excretion from the gastrointestinal tract or kidneys. 
Disruption in any mechanism ultimately leads to abnormal levels of urate in the body 
(hypouricemia and hyperuricaemia) (X Xu et al. 2016). The increased levels of serum urate 
 
 
9 | Page 
results from the overproduction of urate (accounts for 10%) and under-excretion (account for 
90%) (reviewed in (Hediger et al. 2005)). 
 
1.4. Pathogenesis of Hyperuricaemia 
1.4.1. The Absence of Uricase in Human, Through Evolutionary 
Perspective 
In many other organisms including, fish, amphibians, and non-primate mammals, urate 
undergoes oxidative degradation by the uricase enzyme and produces the soluble compound, 
allantoin. However, humans and higher primates lack this uricase enzyme due to the mutational 
silencing of uricase through an evolutionary process (Oda et al. 2002, XW Wu et al. 1989). 
Evolutionary evidence suggests that during hominid evolution, 10-20 million years ago the 
uricase gene incurred several distinct mutations in the promoter and coding regions, and 
consequently a gradual loss of uricase function in the primate lineage. The sequence analysis 
of urate oxidase in modern humans, chimpanzee, orangutan and gibbon indicates two parallel 
nonsense mutations at codon 33 and 187 and a splice mutation in exon 3 associated with the 
inactivation of uricase (Oda et al. 2002, XW Wu et al. 1992). As a consequence, urate remained 
the end product of purine metabolism and is excreted by the kidneys and gut (Oda et al. 2002). 
 
1.4.2. Production of Urate 
Urate is an end product of purine metabolism, both endogenous and exogenous. It is 
mainly produced in the liver but also to a lesser extent in the small intestine. The production of 
the urate depends on protein ingestion, de-novo synthesis in the cells, recycling (salvage 
pathway), and majorly, from degradation of nucleic acid and proteins in the purine metabolism 
pathway. In the latter pathway, proteins and nucleotides are degraded into hypoxanthine and 
xanthine through a series of enzymatic steps and produce urate via xanthine oxidoreductase 
(also known as xanthine oxidase) (Jalal 2016). The breakdown of purine nucleic acids 
(adenosine and guanine) is dependent on two catabolic pathways; the adenosine 
monophosphate (AMP) pathway and guanine monophosphate (GMP) pathway. The AMP 
pathway begins with the deamination of amino acid from AMP to inosine (IMP), followed by 
the phosphorylation of inosine to generate hypoxanthine, which in turn is oxidized to xanthine 
(Maiuolo et al. 2016). While in the GMP pathway, the process starts with dephosphorylation 
of GMP into guanosine, followed by the deamination of guanosine, which produces guanine 
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and then xanthine (Figure 1.4). Finally, the common end product (xanthine) of these two 
pathways is further subjected to oxidation to produce urate (Jin et al. 2012, Maiuolo et al. 2016) 
(Figure 1.4). Certain conditions such as increased cellular turnover like haemolysis, tumour 
necrosis, malignancies, and inflammatory diseases (including arthritis) accelerate the increased 
production of adenosine, inosine and guanosine thus increasing the biosynthesis of urate 
(Dessein et al. 2000, Emmerson 1998, Mahmoud et al. 1998). 
Purines derived from tissue nucleic acid can also be reutilized through the salvage 
pathway, involving hypoxanthine-guanine phosphoribosyl transferase (HPRT) that salvages 
hypoxanthine to inosine monophosphate (IMP) and guanine to GMP. However, the genetic 
deficiency of HPRT (inborn error in metabolism) leads to the overproduction of urate and is 
associated with hyperuricaemia and gout in Lesch-Nyhan syndrome— an X-linked disorder (M 
Ahmed et al. 1999, Torres and Puig 2007). Moreover, the de-novo synthesis of purines, which 
starts with 5’phosphoribosyl 1-pyrophosphate (PRPP) that is produced by addition of the 
phosphate group from ATP to ribose-5-phosphate; modified ribose sugar. PRPP synthetase is 
the enzyme which catalyses this process; the genetic super activity of this enzyme is also 
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Figure 1.4: Urate Homeostasis and the Process of MSU crystals Formation in the Joints. 
 
Purine nucleotides are degraded into urate through a series of enzymatic steps in the liver that is also influenced 
by dietary intake (purine rich food). Urate is excreted from the body through the gut and kidney. Over production 
of urate and urate under-excretion leads to aberrant levels of urate (elevated urate levels) in the blood that leads to 
the formation of MSU crystals in joints. 
 
1.4.3. Diet and Alcohol Consumption as Risk Factors 
Since increased urate levels are linked with impaired purine metabolism, the high intake 
of purine can also influence the urate levels. And as hyperuricaemia is a prerequisite of gout 
then higher intake of purine can also affect the risk of developing gout. In this instance, purine-
rich food including meat, seafood, animal proteins and some vegetables have been theorized to 
increase the risk of gout arthritis (Hyon K Choi et al. 2004b, Y Zhang et al. 2012). High intake 
of fructose/sugar-sweetened beverages has also been identified to confer a dose-dependent 
effect pre to gout. There is evidence that an increase in urate levels with high fructose intake 
that undergoes a phosphorylation process and induces urate formation by regenerating ATP 
(Hyon K Choi and Curhan 2008). A study also reported an increased risk of gout in New 
Zealand Europeans and Polynesians associated with increased utilization of sweetened 
beverages (Batt et al. 2014). 
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For centuries, alcohol intake has also been correlated with an increased risk of 
hyperuricaemia and gout. Formal evidence of a significant association between alcohol 
consumption and high risk of gout has been documented in recent years. A study from Choi 
and co-workers (2004), reported a dose-response relationship of alcohol intake to gout risk 
(Hyon K Choi et al. 2004a). Beer has a high content of purine guanosine and confers an 
increased gout risk, however, wine, spirits and other liquors showed a moderate to nil risk 
towards gout arthritis (Hyon K Choi et al. 2004a). For example, consumption of 2 or more beers 
a day increased the risk of gout 2.5-fold compared to no beer intake, whereas the same amount 
of spirits intake per day increased the risk of gout 1.6-fold as compared to no intake of spirits. 
A subsequent study by Choi and Curhan evaluated the relationship between beer, liquor, and 
wine intake and serum urate levels using participants from the third NHANES survey (Hyon K 
Choi et al. 2007). Beer consumption was positively associated with increased urate levels after 
adjusting by confounders (β = 0.46 mg/dl, P value <0.01): in contrast, wine intake was 
associated with reduced serum urate levels, although the significant effect disappeared after 
adjustment with confounders (β = 0.04 mg/dl P = 0.6) (Hyon K Choi and Curhan 2004). Alcohol 
induces urate production by degradation of ATP into ADP and because its transformation to 
lactic acid inhibits the secretion of urate through renal proximal tubules (Hyon K Choi et al. 
2004a, Y Zhang et al. 2006).  
 
1.4.4. Excretion of Urate 
Urate is excreted through two mechanisms 1) through the gastrointestinal tract and 2) 
through the kidneys. The gastrointestinal tract excretes approximately one-third of the urate 
produced daily via the uricolysis process where gut microbes degrade it into waste products, 
which are then excreted in the faeces (Buzard et al. 1955, Sorensen 1965). The remaining (two-
thirds) proportion of urate is processed through the kidneys and this processing involves 
secretion as well as the reabsorption of serum urate carried through specialized transporters 
located at the basolateral and apical membranes of proximal tubules (Mandal and Mount 2015, 
TaF Merriman, Tanya 2013). 
 
1.4.4.1. The Role of Kidneys in Urate Handling via Urate Transporters— 
Impairment in Function Leads to Gout 
Once urate reaches the kidneys, it is freely filtered at the glomerulus, where 90% of the 
filtered urate is reabsorbed and only 10% secreted in urine. Urate homeostasis is primarily 
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maintained by a complex interplay of reabsorption and secretory transport pathways: 
dysfunctionality in either pathway leads to abnormal urate levels (Jalal 2016). 
The process of urate excretion by the kidneys has long been proposed as a four-
component model, consisting of four stages; glomerular filtration, tubular reabsorption from 
the glomerulus ultra-filtrate, subsequent secretion into urine and post-secretory reabsorption. 
However, new evidence from the literature no longer supports this old model, instead it brings 
a revised model with a reinterpretation of the model into the urate excretion picture. The revised 
model suggests the concurrent absorption and secretion of urate in the renal proximal tubules, 
instead of this occurring in two discrete steps (Bobulescu and Moe 2012, Mount 2005, Sica and 
Schoolwerth 2002). 
Given that renal filtration including reabsorption operates in the kidney, multiple 
transporters have been identified as playing a role in this process (Figure 1.5). Urate transporter 
1 (URAT1 encoded by SLC22A12) is a well characterised transporter involved in urate 
reabsorption, located in proximal tubules. URAT1 is a urate anion exchanger that is expressed 
on the renal apical membrane and transfers urate from the glomerular filtrate into the lumen of 
tubular epithelial cells (Enomoto et al. 2002, Lipkowitz 2012). Compelling genetic evidence 
indicates that loss-of-function variation in SLC22A12  leads to hypouricaemia (Ichida et al. 
2004). The other reabsorptive transporter GLUT9 encoded by SLC2A9 is identified as voltage 
dependent and its isoforms (SLC2A9v1 and SLC2A9v2) are expressed on the basolateral and 
apical membranes of the kidney, respectively (Köttgen et al. 2013, Lipkowitz 2012). Various 
studies have proven that genetic variants in these reabsorptive transporters are causal to 
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Figure 1.5: Current Knowledge of Urate Transporters Within the Renal Proximal tubule. 
 
The apical membrane faces the lumen side of the cell and the basolateral membrane faces the blood side of the 
cell. Arrows indicate the direction of urate movement. Sodium dependent monocarboxylate transporters— 
SLC5A8 and SLC5A12; voltage-driven organic ion transporter—NPT1; urate transporter (with unknown 
direction)—OAT1 and OAT3; ABCG2 expresses on the apical membrane and SLC2A9 isoforms: SLC2A9v2 
expresses on apical memberane while SLC2A9v1 expresses on a basolateral memberane (diagram has been 
adopted from Merriman, 2015 copyright © Merriman; licensee BioMed Central. 2015). 
 
Variations in secretory transporters have also been shown to be associated with increased 
risk of hyperuricaemia and gout. For example, ABCG2 is located on the apical membrane of 
the proximal tubule and small intestine epithelium and regulates serum urate levels (Woodward 
et al. 2009). Moreover, genome wide association studies supported ABCG2’s role as a strong 
genetic regulator of serum urate and gout (Dehghan et al. 2008, Köttgen et al. 2013, Woodward 
et al. 2009). Loss-of-function variations in ABCG2 were found to be associated with diminished 
urate secretion in both kidneys and intestine (Hosomi et al. 2012, Woodward et al. 2009). The 
ABCG2 missense genetic variation (141K), was also identified in people predisposed to high 
serum urate and gout (Phipps-Green et al. 2016, B Wang et al. 2010). The ABCG2 141K variant 
is also important because it has been reported to decrease gut excretion of urate and cause a 
compensatory increase in urate output in the kidneys (Ichida et al. 2012). OAT1, OAT2, OAT3 
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and OAT4 are secretory organic anion exchangers and functionally related to URAT1 
(Ekaratanawong et al. 2004, Ichida et al. 2012). Various other loci controlling serum urate 
levels were also found to be functionally involved in urate transport e.g. NPT1/SLC17A1, 
NPT4/SLC1A3 and PDZK1 (Anzai et al. 2004, Ichida et al. 2012, Ishibashi et al. 2003, Kolz 
et al. 2009).The above literature clearly indicates the potential contribution of urate transporters 
in maintaining serum urate levels and impairment in their function can contribute to the 
development of gout. 
 
1.5. Gout Pathogenesis: Progression from Hyperuricaemia 
to Gout 
Gout is an inflammatory arthritis that affects 10-20% of people with elevated serum urate 
levels (Dalbeth et al. 2018b). There are three pathophysiological stages, which are required for 
the development of gout 1) hyperuricaemia, 2) formation/deposition of MSU crystals and 3) 
innate immune response to these crystals (that is represented as a flare). Progression through 
each stage is regulated by genetic variations and environmental exposures that are not well 
understood. The hyperuricaemia stage has been described in detail previously while the 
following paragraphs will give extensive descriptions for the rest of the stages. 
 
1.5.1. High Serum Urate Levels Leads to the Formation of MSU 
Crystals 
Deposition of urate in the form of MSU crystals in the joint cavity is a necessary cause 
of gout and these crystals are formed as a consequence of a longstanding hyperuricaemic state. 
A definitive diagnosis of gout is considered with the identification of MSU crystals through 
microscopic examination. These MSU crystals have a triclinicin structure with a needle-shaped 
appearance and form under certain physical and chemical conditions (Chhana et al. 2015, 
Dalbeth et al. 2016b, Mandel and Mandel 1976). 
In general, crystal formation from a liquid mixture undergoes a sequential chemical 
process, comprised of three major steps; reduced solubility (leading to super-saturation), 
nucleation (cluster formation of solute particles and reaching to a critical size) and growth of 
crystals (growth of a stable cluster) (Mersmann 2001). The MSU crystallization in gout follows 
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1.5.2. Reduced Urate Solubility 
Solubility is a property of a given substance (solute) to dissolve in a liquid (solvent) to 
form a homogenous solution. Saturation of a solute is obtained when the maximum amount of 
this substance gets dissolved in a solvent at a given temperature, however, a further addition of 
solute (excess amount) leads to a super-saturated state (Ruoff and Edwards 2016). Similarly, in 
the context of MSU crystallization, when the concentration of serum urate increases, the body 
fluids and blood become super saturated which elicits the formation of MSU crystals in the 
joints and tissues. 
Various observational and experimental studies suggest the pronounced influence of 
many physical/physiological variables including temperature, pH, ion concentrations, proteins 
and connective tissue factors on the solubility of MSU crystals (Loeb 1972, Martillo et al. 
2014). Low temperature, high pH (7-8) and increased ion concentrations (Na+, Ca2+, Cu2+) 
reduces the solubility of urate that leads to the formation of MSU crystals (Kippen et al. 1974, 
Martillo et al. 2014, Mcnabb and Mcnabb 1980). 
 
1.5.3. MSU Nucleation 
A nucleation step, followed by reduced urate solubility, is involved in the creation of 
MSU crystals. The super-saturation state is necessary but not sufficient to induce 
crystallization, however, it requires pre-existing solid particles ‘nuclei’ to act as the 
crystallization centre (Figure 1.6). In the context of MSU crystal formation, it has been 
hypothesized that nucleation occurs after MSU molecules become clustered and reach a certain 
size, whereby they are stabilized and not dispersed in the solution (Chhana et al. 2015). 
Evidence suggests that the factors, ion concentration, protein and antibodies in connective 
tissues have a greater influence on MSU nucleation (Kanevets et al. 2009, Khalaf and Wilcox 
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Figure 1.6: Schematic Presentation of Formation of MSU Crystals and Factors Influencing the Crystallizing 
Mechanism 
 
This illustration has been adopted from Chhana et al., 2015. 
 
1.5.4. MSU Crystal Growth 
It has been suggested that the physical environments in which MSU crystallization occurs 
may affect its growth patterns. The MSU crystals’ growth rate over time is dependent on urate 
concentration. Allen et al. measured the growth of urate crystals and found a linear relationship 
between urate concentration and crystal growth (Allen et al. 1965a, Allen et al. 1965b). The 
influence of other factors such as connective tissue factors and proteins have been less studied 
as compared to their effect on urate solubility and MSU nucleation (McGill et al. 1992). 
 
1.5.5. Clinical Representation of Gout 
Clinically, gout has been characterized into three phases: acute gout, intercritical gout and 
chronic gout (Richette and Bardin 2010, HS Smith et al. 2011). Typically, gout presents for the 
first time as self-limiting episodes of inflammation, which usually affect the foot and ankle, 
coming under the category of the acute gout phase (Hench 1941). The first flare occurs after an 
asymptomatic hyperuricaemic period and is characterized by abrupt and intense pain and 
swelling (Teng et al. 2006). The condition lasts spontaneously between 1-2 weeks with the 
resolution of symptoms in inflammatory joints, leading to the intercritical phase of gout. 
However, most patients experience a second flare attack within 6 months to 2 years and this 
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subsequent attack normally persists longer and may adversely affect joints (Grassi and De 
Angelis 2012). 
If hyperuricaemia persists longer without treating acute gout flares, the recurrent attacks 
increasingly affect other joints including elbow, wrist, fingers, and shoulders with the 
appearance of tophi (advance gout structures). Advanced or chronic gout is characterized by 
chronic pain, frequent flares, structural joint damage and body activity limitations. Tophi 
usually affect peripheral joints but can also occur in the nose, eye, ear helix, bursae, tendons, 
and spine (atypical locations) (Dalbeth et al. 2007, Grassi and De Angelis 2012, Wernick et al. 
1992). Chronic gout also influences quality of life significantly. Poorly managed gout leads to 
a poor health condition, work absences and low social interaction (PP Khanna et al. 2012). 
 
1.6. Innate Immune System Responses in Gout 
1.6.1. An Overview of the Immune System 
In all living environments, humans continuously encounter millions of micro-organisms 
and require an effective mechanism of host defence (the immune system) to eradicate infectious 
threats. The immune system constitutes a distinct group of cells and tissues that protect the body 
from microorganism invasion and toxins and is categorised into two distinct types; the innate 
immune system and the adaptive immune system. Innate immunity acts as the first line of 
defence against invading pathogens while tolerating normal host flora (Elliott et al. 2014). It is 
non-specific but highly complex and comprises antimicrobial antibodies, proteins, cellular 
components (i.e. neutrophils, monocytes/macrophages, innate lymphoid cells and dendritic 
cells), complement and opsonins. These factors are triggered by a rapid mechanism and able to 
recognise a wide range of infectious elements (Alberts et al. 2002). Conversely, the acquired 
immune responses are continually refined over the lifetime and are highly specific. These 
responses develop slowly upon first exposure to a pathogen, resulting in formation and 
activation of T and B cells clones to that specific antigen (pathogen). These cells of adaptive 
immunity remember previous encounters with specific antigens so that they eradicate such 
antigens’ recurrence of infections. 
1.6.2. The Innate Immune System 
The innate immune system comprises a broad range of cell types, majorly phagocytic 
cells (e.g. macrophages, neutrophils), killing cells (e.g. natural killer cells) and antigen-
presenting cells (dendritic cells) (Figure 1.7). 
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Macrophages, derived from a Greek word, meaning “large eaters”, are phagocytic 
components of the immune system (Janeway Jr et al. 2001). These cells play a fundamental 
role in the host defence mechanism and respond promptly to environmental cues (bacteria, 
virus, MSU crystals, oxygen and pH concentrations). Therefore, it is unsurprising that altered 
macrophage behaviour has been implicated in several human diseases including gout (Byrne et 
al. 2015, Montell et al. 2014, Murray and Wynn 2011, Okabe and Medzhitov 2016). The other 
important, and most abundant, type of phagocyte is the neutrophil which are usually the first 
cells to arrive at the site of tissue insult or infection. A massive number of neutrophils were also 
observed in the synovial fluid aspirated from the joints of gout patients (Agudelo and 
Schumacher 1973). Like macrophages, they attack pathogens or irritant particles by the 
activation of a respiratory burst (Stvrtinová et al. 1995). The important characteristic of 
neutrophils is that they extrude their own nuclear and mitochondrial DNA as neutrophil 
extracellular traps (NETs): the phenomenon is known as ‘beneficial suicide” (Brinkmann and 
Zychlinsky 2007). In inflammatory disorders like gout NETs are involved in resolution of 
inflammatory episodes (Schauer et al. 2014). Mast cells are a type of immune system cell that 
inhabits mucous membranes and connective tissue. Upon exposure to danger signals, in 
particular MSU crystals, these cells release histamine and heparin along with cytokines and 
chemokines into the environment that causes infiltration of neutrophil (Stvrtinová et al. 1995). 
In addition, mast cells are also able to induce IL1β secretion on NLRP3 inflammasome 
activation (Getting et al. 1997). Regarding natural killer (NK) cells, they do not directly attack 
foreign invaders, rather they kill host-compromised cells like tumour, virus-infected or 
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Figure 1.7: Key Components of the Innate Immune System. 
 
Innate immune cells and their extracellular vesicles that participate in modulating the immune response. These 
cell types include mast cells, neutrophils, macrophages, eosinophils and natural killer (NK) cells (this diagram is 
sourced from (Moyano and Aguirre 2019)). 
 
1.6.3. Pattern Recognition by the Innate Immune System 
Pattern recognition receptors (PRRs) cells of the innate immune system can recognize 
smaller foreign molecules or pathogens, present in extracellular and intracellular spaces, using 
germline-encoded receptors (Brubaker et al. 2015). Unlike the adaptive immune response 
(which possesses a vast repertoire of the individualised receptor), the innate immune system 
respond through a limited number of PRRs, which are highly specific for infectious substances 
or molecules coined by the term pathogen-associated molecular patterns (PAMPs) and non-
infectious substances termed damage-associated molecular patterns (DAMPs) (Akira 2009). 
PAMPs are recognized by PRRs that induce the release of cell surface proteins, interleukins 
and chemokines via the activation of complex signalling pathways. On the other hand DAMPs 
such as reactive oxygen species (ROS), misfolded proteins and ATP are cell endogenous 
signals, recognized by PRRs that more or less follow the same pattern of immune response 
elicited by PAMPs. These PRR types play a primordial part in sensing DAMP signals and 
eliciting immune response and inflammatory reactions in gout arthritis (Akira 2009, Iwasaki 
and Medzhitov 2010, H Kumar et al. 2009, O Takeuchi and Akira 2010). 
To date, PRRs have been classified into C-type lectin receptors (CLRs), RIG-like 
receptors (RLRs), toll-like receptors (TLRs), AIM2-like receptors (ALRs) and nucleotide-
binding leucine-rich repeat-containing receptors (LRR) and node like receptors (NLRs) on the 
basis of their structure and location. TLRs and CLRs serve either as extracellular membrane 
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bound proteins or reside in endoplasmic compartments (vesicles) while RLRs, NLRs and ALRs 
survey the cytoplasm and are involved in maturation of the cytokines IL1β and IL-18 (Brubaker 
et al. 2015, O Takeuchi and Akira 2007, Thompson et al. 2011). 
 
1.6.4. NLRP3 Inflammasome –The Paradigm and its Role in Gout 
The term inflammasome, is an assembly of two words inflammation and some (the Greek 
suffix) that define a molecular complex, and resides in the cytosol of cells (F. Martinon et al. 
2009). The inflammasome was first described in 2002 as a complex of NLRs receptors and 
adaptor proteins that mediate the activation of inflammatory caspases. Caspases are proteases, 
which require proteolytic processing to become activated (F. Martinon et al. 2009, F. Martinon 
and Tschopp 2004). 
Among various inflammasomes, the NLRP3 inflammasome is the most characterized 
member of the NLR family that has been found to be a critical central mediator in various 
complex inflammatory conditions (Ozaki et al. 2015). It is formed by oligomerization of 
NLRP3 receptor (cryoprin), an adaptor protein apoptosis-associated speck-like protein 
containing a caspase recruitment domain (ASC) and procaspase-1. NLRP3 and ASC proteins 
interact by pyrin domain (PYD) whereas ASC recruits caspase-1 through the interaction of 
caspase activation and recruitment domain (CARD). Once activated, the NLRP3 
inflammasome mediates the cleavage of inactive IL1β accompanied with the release of mature 
IL1β and other cytokines (Motta et al. 2015). 
The activation of the NLRP3 inflammasome depends on two signals; a priming signal 
also known as signal 1 that primes the NLRP3 inflammasome as a result of engagement of 
transmembrane receptors. This process involves the assembly and activation of the 
inflammasome components whose expression is controlled by this signal 1. Generally, as a 
result of the inflammatory milieu, the inflammasome-competent stage (assembly of NLRP3 
inflammasome components) is originated by engagement of innate immune receptors on the 
cell surface. The best known of these receptors are TLR2 and TLR4, which have been 
particularly implicated in gout inflammation. For example, a study by Ru et al., (2005) reported 
an impaired neutrophil response to MSU crystals in TLR2 and TLR4 deficient mice (Ru et al. 
2005). Moreover, another study demonstrated that TLRs regulate gout inflammation upon 
binding of their ligands (S100A8 and S100A9) in response to MSU crystals (Holzinger et al. 
2014). Furthermore, another TLR ligand that might have a role in macrophage priming is long-
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chain free fatty acids. In a murine model of gout, arthritis was observed by injecting MSU 
crystals and free fatty acids together (Joosten et al. 2010). This ligand binding of 
transmembrane receptors resulted in stimulation of a protein complex named as nuclear factor 
kappa-light-chain-enhancer (NFKB), which causes assembly of the NLRP3 inflammasome and 
upregulation of pro-inflammatory cytokines precursors (IL1β and IL18). The first signal does 
not trigger the inflammatory reaction alone, however, it is assisted by a second signal. 
The second activation signal involves the activation of the NLRP3 inflammasome 
complex and is known to be mediated by various PAMP and DAMP stimulation (more specific 
signal than signal 1) (Hornung and Latz 2010, Motta et al. 2015). Thus, the priming and 
activating signals mediate co-localization of the NLRP3 inflammasome with ASC molecules—
it may also be driven by mitochondrial processes/mitochondria, and instigate the activation of 
pro-caspase-1 (as a result of inflammasome activation) that causes the proteolytic cleavage of 
immature IL1β and IL-18 into a mature form (Misawa et al. 2013, Subramanian et al. 2013). 
Binding of IL1β with the IL1-receptor (IL1R) further downstream of the signalling cascade 
induces the release of pro-inflammatory cytokines and chemokines.  
The role of IL1β is predominant in any sterile inflammation. It acts on multiple cell types 
and triggers inflammatory responses with promotion of vasodilation, inducing release of acute 
phase proteins from the liver and rapid recruitment of neutrophils to the tissue insult site: these 
responses are important to combat infection and restore tissue homeostasis. However, sustained 
IL1β secretion results in the influx of matrix-degrading enzymes that cause damage to cartilage 
and bone (C. A. Dinarello 2005, 2009; Schlesinger & Thiele 2010; C. A. Dinarello 2011). IL1β 
is synthesized as a 31KDa inactive precursor peptide (pro-I IL-1β) by the activation of a number 
of signalling pathways including MyD88-dependent IL-1R and MyD88-dependent TLR4 
pathways. The immature pro-IL1β in the cytoplasm is cleaved by active caspase-1 through 
activation of the NLRP3 inflammasome (as mentioned in the above paragraph) to produce 
mature IL1β (Guma et al. 2009, F. Martinon and Tschopp 2007). The increased production of 
mature IL1β in response to danger signals thus leads to the extracellular release of IL1β where 
it binds to its natural receptor IL-1R, exposed on endothelium of other immune cells and causes 
overall tissue insult (Figure 1.8). This process of inflammation is common in multiple 
inflammatory disorders including gout that highlights an integral role of IL1β in inducing and 
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Figure 1.8: Processing and Release of IL1β in Response to MSU crystals in a Monocyte. 
 
MSU crystals activate monocytes via the TLR pathway and inflammasome activation. The NLRP3 inflammasome 
complex activation causes the cleavage of immature IL1β into biologically active IL1β. Upon release from the 
cell, it binds to its receptor (IL1R) on other immune cells. The activation of endothelium by IL1β increases 
trafficking of neutrophils to the inflammatory site. This diagram has been sourced from So, 2008 review article 
and was allowed to be used under the licence no. 4659270158727). 
 
Upon exposure, the  ingestion of MSU crystals by resident macrophages leads to the 
lysosomal rupture that causes a release of lysosomal contents (cathepsin B, ROS, TXNIP), 
which are sensed as danger signals by the inflammasome (Hoffstein and Weissmann 1975, 
Hornung et al. 2008). How these signals induce NLRP3 inflammasome complex activation is 
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Figure 1.9: NLRP3 Inflammasome Activation by Monosodium Urate Crystals. 
 
Activation of the NLRP3 inflammasome requires two signals; the priming signal (signal 1) that mediates NF-KB 
activation when it is activated by transmembrane receptors such as toll like receptors (TLR2/TLR4). This priming 
step is assisted by the secondary signal (signal 2), provided by MSU crystals that trigger the assembly of the 
inflammasome. The interaction of MSU crystals with the plasma membrane also promotes cellular responses that 
are poorly understood, including the NLRP3 inflammasome activation hallmarks, such as potassium efflux through 
ion channels and mitochondrial perturbations that result in the release of ROS and mtDNA into the cytosol. The 
oligomerization of the NLRP3 inflammasome complex causes recruitment of Caspase-1 that promotes proteolytic 
cleavage of pro-IL1β into mature IL1β. Caspase-1 also promotes the formation of pyroptotic pores, which 
contribute to the release of IL1β outside the cell. This has been sourced from a review article (AK So and Martinon 
2017) and was allowed to be used under the licence no. 4667300467295). 
 
Various studies have demonstrated that the aberrant activation of the inflammasome and 
associated components lead to the development of many infectious and inflammatory disorders 
including gout (contribution of inflammatory genes in gout pathogenesis has been explained in 
the Section 1.10.3Genetics). 
 
1.6.5. Other Contributing Cytokines in Gout Pathogenesis 
A variety of other cytokines from the same IL-1 family as well as from other families 
have also been identified as potential regulators of inflammation that may contribute to the 
development of gout. For example, interleukin 23 (IL-23), a member of the IL-12 family, plays 
a critical role in the immune system by integrating innate and adaptive immunity. The IL-23 
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production originates in the innate immune system when antigen-presenting cells 
(macrophages, dendritic cells, monocytes etc.) sense PAMPs or any DAMPs signals. After 
binding to the IL-23 receptor (IL-23R), it stimulates the release of a variety of other 
inflammatory elements such as IL-6, IL-8, IL-1 and TNFα. This further induces the release of 
IL-17 and IL-22 from T helper cells and macrophages and enhances the inflammatory process 
(Brombacher et al. 2003, S Liu et al. 2015, S Liu et al. 2013). Genetic variations in IL23R have 
previously been associated with various inflammatory and auto-inflammatory conditions 
(Cargill et al. 2007, M Chang et al. 2008, Chen-Xu et al. 2012, Karaderi et al. 2009, Wellcome 
Trust Case Control Consortium 2007) therefore these could also cause gout. 
Another fundamental cytokine of the IL-1 family is interleukin 37 (IL37) that has recently 
emerged as an important inhibitor of innate immunity. In this way, it functions distinctly from 
other pro-inflammatory cytokines by shifting cytokine equilibrium away from excessive 
inflammation (Charles A Dinarello 2010, Nold et al. 2010). IL37 activation is also caspase-1 
dependent that not only participates in producing mature IL37 intracellularly but also 
translocates it to the nucleus. In addition, IL37 is recognized as a dual-function cytokine that 
exhibits both intracellular and extracellular properties. It binds to mammalian homologs of the 
Drosophila Mad gene 3 (Smad3) intracellularly and undergoes caspase-1 dependent cleavage 
with a subsequent translocation to the nucleus that in turns regulates gene transcription and 
inhibits Toll-like-receptor-induced expression of proinflammatory cytokines such as IL-1β, IL-
16, and IFN- γ. However, extracellular IL37 binds to the IL-1R8–IL-18Rα complex (a cell 
surface receptor for IL37) through which it activates a number of intracellular switches to block 
the inflammatory process (Bulau et al. 2014, Nold-Petry et al. 2015). As IL37 is recognized as 
a natural suppressor of innate immunity, however, genetic variations in IL37 can promote 
excessive inflammatory reactions in response to external stimuli such as MSU crystals. In this 
instance, earlier evidence supports this hypothesis, such as a study in human and murine models 
of gout which revealed that recombinant IL37 (rhIL37) limited the inflammation initiated by 
MSU crystals by enhancing expression of Smad3 and IL-1R8 (L Liu et al. 2016). Another study 
found IL37 highly active in reducing the expression of IL1β, IL-6 and TNFα in THP-1 cells 
when treated with MSU crystals (M Zeng et al. 2016). Such studies thus suggest IL37 as a 
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1.7. Contribution of Other Possible Mechanisms to Gout 
Inflammation 
1.7.1. Impaired Autophagy 
Autophagy (the process of self-eating) maintains inflammatory balance and thus 
contributes to cell homeostasis. It is one of the adaptive responses by which the cell not only 
removes unwanted and damaged organelles but also effectively responds during nutrient 
starvation, cell death and to other extracellular and intracellular stimulants. As a consequence, 
inflammatory mediators arbitrate autophagy and in contrast autophagy shapes the inflammatory 
response (Lapaquette et al. 2015). Autophagy acts as a negative regulator of inflammasomes 
but in stress conditions, the induced or inhibited autophagy promotes inflammation (Saitoh et 
al. 2008). Prominent inflammatory mediators which induce autophagy include PAMPs and 
DAMPs such as ATP, reactive oxygen species (ROS), misfolded proteins and various cytokines 
categorized as (a) inducers: including IL-2, TNF-α, IFN-gamma and IFN-beta (b) repressors: 
such as IL-4, IL-5, IL-6, IL-10 and IL-13 and ROS (Gewirtz et al. 2001, Harris 2011, T. 
Kawasaki and Kawai 2014, Motta et al. 2015). 
Various genetic studies support the participation of autophagy in enhancing inflammatory 
responses. In relation to that, an earlier study indicated the association of polymorphisms in the 
immunity-related GTPase family M (IRGM) and autophagy related 16 like 1 (ATG16L1) with 
the auto-inflammatory condition, Crohn’s disease (Barrett et al. 2008). Other studies also 
reported the association of IRGM variations with increased risk of systemic lupus 
erythematosus (SLE) and ulcerative colitis (UC) (Ramos et al. 2011) (Evidence of association 
of  the IRGM variant with such auto-inflammatory conditions is detailed in Chapter 2 of this 
thesis). These targeted studies suggest the potential role of autophagy genes in the inflammatory 
environment, which can also contribute to the development of inflammatory gout. 
 
1.7.2. Mitochondrial Dysfunction and Inflammation 
DAMPs derived from mitochondria (ROS, mtDNA, cardiolipin, ATP, cytochrome c) 
causing inflammation are of particular interest (Krysko et al. 2011). The degenerated 
mitochondria secret N-formyl peptides (NFPs) at the site of tissue damage, may attract 
inflammatory cells including neutrophils (Carp 1982) and degranulation of these neutrophils 
promotes the inflammatory response. ROS is a major hallmark of dysfunctional mitochondria 
and essential for netosis. This is supported by a study in which impairment in ROS production 
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was accompanied with dysfunctional netosis and caused inflammation in mice with 
granulomatous disease when challenged with MSU crystals (Nishinaka et al. 2011, Schauer et 
al. 2014). Other studies also reported superoxides induced ROS generation in MSU-mediated 
inflammation and its direct linkage to tissue injury and gout (Levonen et al. 2014). Indeed, 
evidence suggests that mitochondrial generated ROS and released mtDNA are important 
activators of NLRP3 inflammasome activation that is central to gout inflammation (Nakahira 
et al. 2011, R Zhou et al. 2011). In addition, mitochondrial transcription factors, for instance 
mitochondrial transcription factor A (TFAM), have been found to be associated with the 
induction of increased IL-8 release from monocytes in an inflammatory response (Crouser et 
al. 2009). There is an also genetic evidence of the direct role of TFAM in regulating 
mitochondrial DNA (mtDNA) copy number and alteration in mtDNA copy number has been 
associated with various metabolic and inflammatory conditions including gout (Gosling et al. 
2018, Lan et al. 2017, HC Lee et al. 2005, Y. Wang et al. 2006, J Wong et al. 2009). 
As inflammation is a complex process and accounts for interaction among multiple 
mechanisms a study by Zhong et al., (2016) reports a signalling pathway that determines the 
connection between mitochondrial dysfunction and autophagy in acute inflammation (ZY 
Zhong et al. 2016). A proposed mechanism in this study can be summarized as when 
macrophages are stimulated with DAMPs (MSU crystals, carcinogenic particles) or PAMPs it 
results in mitochondrial damage that is characterized by the release of mtDNA and mtROS. 
These signals induce secretion of IL1β and IL18 from the activated NLRP3 inflammasome that 
results in ubiquitination of mitochondrial outer membrane proteins associated with the 
increased expression of p62 (encoded by SQSTM1 gene). This p62 binds to LC3 (autophagy 
component) that is encoded by MAP1LC3B gene and targets autophagosomal clearance of 
ubiquitinated mitochondria and limits NLRP3 inflammasome activation (Figure 1.10). 
However, genetic ablation of p62 (associated with impaired p62 function) may promote the 
NLRP3 inflammasome activation and excessive release of IL1β and IL18 from macrophages 
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Figure 1.10: Integrated Mechanisms (Mitophagy/Autophagy) Dials Down Inflammation. 
 
Stimulation of macrophages with DAMPs (i.e. MSU crystals) and PAMPs results in mitochondrial damage with 
a subsequent release of mtDNA and mtROS. These signals activate NLRP3 inflammasome and induce IL1β and 
IL-8 secretion. Damaged mitochondria are ubiquitinated and recognized by p62 whose expression is induced upon 
NF-KB activation. P62 also binds to LC3and targets ubiquitinated mitochondria to autophagosomal clearance. 
This diagram is sourced from (Zhong et al., 2016 and allowed to be used under with the permission under licence 
no. 4659580622157). 
 
All of the above information highlights integration among autophagy, dysfunctional 
mitochondria, and inflammatory response. Since gout is an auto-inflammatory condition 
genetic variation linking to these integrated mechanisms could be causal to gout. 
 
1.8. Gout and Comorbid Diseases 
A wide range of studies indicates the presence of comorbid and chronic disorders as a 
common risk factor for gout. The most common comorbidities that coexist in gout patients 
include hypertension, cardiovascular diseases (CVD), renal insufficiencies, diabetes, and 
obesity (Hyon K Choi et al. 2007). These comorbidities are commonly associated with 
asymptomatic hyperuricaemia, which raises therapeutic issues. Various studies have indicated 
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a strong link between hyperuricaemia and adverse cardiovascular and renal outcomes. A cross-
sectional study, for example, reported a higher risk of developing heart disease in 
hyperuricaemic people with asymptomatic MSU crystal deposition than normouricaemic or 
hyperuricaemic individuals with no sign of MSU crystal deposits (Andres et al. 2016). Other 
prospective studies showed a significant relationship of hyperuricaemia with increased blood 
pressure and became more refractory when associated with other metabolic components; type 
2 diabetes, kidney disease and altered lipid profile (Grayson et al. 2011, Q Lv et al. 2013, Saito 
et al. 2015). However, strong evidence of correlation does not prove causality and may be 
explained by confounders or intervention of common unidentified causal factors. 
As mentioned previously metabolic syndrome components are common comorbidities of 
gout. An American-based study, using data from 57057 participants in The National Health 
Nutrition Examination Survey (NHANES) survey reported that people with gout also had 
hypertension (74%), obesity (26%), diabetes (24%), nephrolithiasis (14%), heart failure (11%) 
and stroke (10%) (Zhu et al. 2012). Association between hypertension and gout has been known 
since the 1940s and 1950s, when gout was prevalent in hypertensive individuals at 20-40% 
(Edwards 2008). Recent epidemiological studies indicate high rates of concurrent hypertension 
in gout patients. An analysis of 9482 US gout patients reported 57.9% comorbidity with 
hypertension (Riedel et al. 2004). 
Gout patients have a greater risk of developing type 2 diabetes mellitus (T2D). The third 
NHANES investigated a high prevalence of T2D in gout versus non-gout individuals, at 33.1% 
and 10.8%, respectively. In another study, gout increased the risk of T2D (Rho et al. 2016), 
however, a reverse relationship was observed for T2D causing decreased gout risk. This 
observation was later explained by the fact that glycosuria increases the excretion of urate 
(Lytvyn et al. 2014, Pan et al. 2016).  
Evidence for association of hypertriglyceridemia with gout is also definitive. The 
prevalence of hypertriglyceridemia was found higher in gout patients (53.7%) than non-gout 
participants (27.9%). Similarly, the third NHANES survey reported elevated low-density 
lipoprotein in people with gout (47.4%) as compared to non-gout individuals (36.6%) (Hyon K 
Choi et al. 2007). 
The prevalence of kidney disorders is unsurprising in gout patients as the kidneys 
contribute majorly to urate handling. The literature provides a strong link between 
hyperuricaemia, gout and renal ailments. A prospective meta-analysis of six studies estimated 
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the prevalence of chronic kidney disease (CKD) at 24% in the presence of gout (Roughley et 
al. 2015). Another study conducted by Jin and co-workers recorded an increase of gout rate 
from 16% to 35.6% for CKD patients with an estimated high glomerular filtration rate (above 
60 mL/min/17.3m2) (Jing et al. 2014). Overall, the studies indicate that impaired kidney 
function decreases the excretion of urate that results in increased risk of gout. 
Numerous studies suggest an association of cardiovascular diseases with gout (Clarson et 
al. 2015) and thereby depict increased cardiovascular mortalities as a consequence. In a large 
gout cohort, a high cardiovascular mortality rate was found with increased gout severity (Perez-
Ruiz et al. 2014). Experimental studies indicated that hyperuricaemia induces the release of 
potent inflammatory molecules such as cytokines and NF-KB which play an integral part in 
vascular damage and progression to various heart disorders (Shah and Keenan 2010)(Giovine 
et al., 1991; Kanellis et al., 2003). 
An inverse relationship has been suggested between gout and neurological disorders such 
as Parkinson’s disease, Alzheimer’s disease, and dementia (Hong et al. 2015, N Lu et al. 2016, 
Pakpoor et al. 2015). Recently, a study investigated a reduced risk of Parkinson’s disease with 
increased serum urate levels (Weisskopf et al. 2007). Observational studies indicate a protective 
effect of serum urate in neurological disorders but a cause-effect relationship is yet to be 
evaluated. 
 
1.8.1. Mendelian Randomization Studies 
As mentioned before observational and interventional studies show strong correlation 
between exposure and outcome, however, the majority of these  correlations fail to test for 
causality. This indicates the involvement of various confounders (known and unknown) such 
as environmental factors that provide limitation and biases in such studies. To overcome this 
limitation and bias a number of methods, aimed at improving causal inference, have been 
developed. Among these Mendelian randomization is the most successful. In this approach 
genetic variants are selected as instrumental variables (associated with the exposure/risk factor) 
that must not be associated with known and unknown confounders to find their predictive effect 
on the outcome (that is any disease or condition). The Mendelian randomization exploits 
Mendel’s law of independent assortment that states ‘during gamete formation, alleles segregate 
independent to each other and thus associated traits (with these alleles) get equal opportunity 
to occur by chance’. 
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Considering the above observational and experimental studies suggesting a possible 
causal relationship between gout and comorbid conditions, the causal inference between them, 
particularly for inflammatory response, can be tested using the Mendelian randomization 
method. To perform such a study sufficient genetic variants that are not associated with 
comorbid conditions (excluding effect of confounders) can be used as an exposure for gout. 
However, to obtain these genetic variants large genome wide association studies (GWAS) in 
gout are required. Existing gout GWAS are small in sample sizes limiting the ability for 
Mendelian randomization studies in this area. 
Urate-associated loci have been identified to associate with gout confirming 
hyperuricaemia as causal for gout.  In this area of research earlier Mendelian randomization 
studies have been performed to determine the cause-effect relationship between elevated serum 
urate levels and cardiometabolic conditions. These studies used genetic variants that had a very 
strong effect on serum urate as an ‘instrument’ and tested for association of serum urate levels 
with comorbid conditions such as ischaemic heart disease, renal disorder, body mass index 
(BMI) and triglyceride levels but did not evidence a causal relationship between serum urate 
and these phenotypes (Hughes et al. 2014, Lyngdoh et al. 2012, Rasheed et al. 2014). However, 
a reverse causal relationship, whereby increased BMI and triglycerides were causally associated 
with increased serum levels, was identified (Lyngdoh et al. 2012, Rasheed et al. 2014). In 
summary, the paucity of Mendelian randomization studies in this area of research needs more 
consideration to better explain the causality between hyperuricaemia/gout and comorbid 
conditions. 
 
1.9. Treatment of Gout 
The increasing prevalence of gout has brought a renewed interest in its biology, diagnosis 
and treatment and thereby several effective therapeutic strategies and agents are available to 
manage gout. Generally two main categories of therapeutic procedures are currently important 
in gout treatment: 1) using non-steroidal anti-inflammatory drugs to relieve inflammation 
during gout flare and 2) treatment with urate-lowering drugs to reduce the high serum urate 
levels (< 360μmol/L) (D Khanna et al. 2012). Despite recent advances in therapeutic 
procedures, about 90% of people with gout are poorly controlled and continue their life with 
hyperuricaemia and recurrent gout flares (Igel et al. 2017). This may be because of poor 
diagnosis, improper use of drugs, and lack of treatment adherence. Moreover, due to the self-
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limiting nature of gout people do not consider it as a serious chronic ailment (Punzi et al. 2012, 
Spencer et al. 2012). 
 
1.9.1. Anti-Inflammatory Medications 
Management of gout flares requires quick and effective control of the inflammatory 
response (joint pain and swelling) to MSU crystals. The guidelines recommend the use of 
colchicine, non-steroidal anti-inflammatory drugs (NSAID), corticosteroids and interleukin -
1β antagonists. The selection of drugs depends on the comorbidity state of patients, potential 
interaction of drugs and clinical circumstances, provided that these drugs can be used alone or 
in combination (in severe gout flares) (Jordan et al. 2007, D Khanna et al. 2012, W Zhang et 
al. 2006).  
 
a) Colchicine: 
Colchicine is derived from meadow saffron extract and acts through the inhibition of 
microtubules (cytoskeleton) assembly, thus preventing the MSU crystal-induced NLRP3 
inflammasome activation (Cronstein and Terkeltaub 2006, Dubchak and Falasca 2010). 
Colchicine is involved in reducing neutrophil influx by decreasing formation of adhesion 
molecules on immune cells (H. K. Choi et al. 2005).  
 
b) NSAIDS: 
NSAIDs produce anti-inflammatory action through inhibition of the cyclooxygenase 
(COX) enzyme, which is required for the synthesis of, prostacyclin, prostaglandins and 
thromboxane (Schlesinger 2014). The Food and Drug Administration (FDA)-approved 
NSAIDs include naproxen, sulindac and indomethacin, which are recommended to be used for 
the treatment of acute gout attacks with fewer adverse effects. It is recommended to initiate the 
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c) Glucocorticoids: 
Glucocorticoids are considered the most effective and rapidly acting anti-inflammatory 
agents especially for patients with moderate to severe renal insufficiency (Becker et al. 2013). 
Glucocorticoids are useful if one or two joints are affected by gout, however long-term usage 
may cause mood disorders, dysphoria, immune suppression and blood retention (Dalbeth et al. 
2016a, Qaseem et al. 2017).  
 
d) IL-1 blocking agents: 
As the release of inflammatory cytokine IL1β plays a central role in inducing an 
inflammatory response in gout, several novel therapies have been developed recently to control 
inflammatory attacks by blocking the IL1β release. These IL1β blocking agents include 
canakinumab, rilonacept and anakinra, which have been approved for the treatment of various 
auto-inflammatory conditions. However, the treatment with IL1β blockade is restricted to only 
a few gout patients because of its high cost and less availability (Schlesinger et al. 2012, 
Schlesinger et al. 2002, A So et al. 2010, A So et al. 2007). 
 
1.9.2. Urate-Lowering Therapy 
For long-term gout management, urate-lowering therapy is recommended to reduce 
serum urate to a level at which MSU crystals dissolve. In that instance, ACR guidelines suggest 
a target of serum urate less than 6.0mg/dL for patients on urate-lowering therapy to avoid the 
formation of MSU crystals in joints or tissues (D Khanna et al. 2012). Urate-lowering drugs 
are available in three main categories: a) xanthine Oxidase inhibitors: drugs that inhibit the 
production of urate including allopurinol and febuxostat. In particular, these inhibitors impede 
the conversion of hypoxanthine to xanthine and subsequently urate. b) uricosuric drugs: these 
drugs normalize the urate excretion such as benzbromarone, probenecid, losartan and 
sulphinpyrazone by promoting excretion of urate and reducing reuptake of urate via urate 
transporters (URAT1 and GLUT9) and c) drugs that catalyse the conversion of urate into a 
readily water soluble and excretable product like rasburicase and pegloticase (Dalbeth et al. 
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1.9.3. Gout Education and Lifestyle Modifications 
Gout education for patients improves clinical outcomes and the patients' quality of life. 
In a study trial a complex multifaceted intervention was successful at reducing urate over usual 
care including educating patients to improve lifestyle and stick to treatment. However, it was 
not able to demonstrate which parts of the intervention were the successful parts (Rees et al. 
2013). Lifestyle management embraces maintenance of normal body mass index (BMI), dietary 
modifications (consumption of healthy food), cessation of smoking and regular exercise. 
 
1.10. Genetics of Hyperuricaemia and Gout 
Since gout is an outcome of interactions between genetic and environmental factors, 
many people believe that serum urate levels can be controlled by diet. However, a recent study 
by Major et al., (2018) has changed this perception and showed that genetic factors have greater 
control over serum urate levels (Major et al. 2018). In this study, though a significant 
correlation was found between selected food items and urate levels (consistent to previous 
reports), notably these food items could only explain less than 1% of variation in serum urate 
levels. An extended analysis considering several estimates of overall dietary habits also 
explained very little variation ranging from 0.15% to 0.28%. In contrast, genetic variations 
explained substantially more variation in serum urate levels within the study populations as a 
single variant in SLC2A9 gene explained ~4% of the variation in serum urate (X Sun et al. 
2014). And when the whole genome was considered, it explained over 20% in variation. This 
finding has changed the perspective of people relating food with increased serum urate levels 
indicating that genetic factors have a larger influence on serum urate than dietary factors. It is 
also notable that a small proportion of variance ~20% in serum urate  is explained by  genetic 
variants while a considerable proportion is still required to be addressed. Therefore, it is 
important to find ways or methods to explain hidden and missing heritability. In this regard 
researchers have found that gene-environment interaction and identification of uncommon and 
rare variants can also contribute to some extent to address missing heritability. 
 
1.10.1. Serum Urate Genetics 
Until now, the genetic factors that have been convincingly implicated in gout 
pathogenesis are predominately urate transporters. Given that physiology of serum urate levels 
is predominantly controlled by kidneys and hyperuricaemia is a key factor in developing gout, 
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it is unsurprising that the largest GWAS in major populations are dominated by urate 
controlling loci with strong influence. GWAS is an approach used for scanning markers across 
genomes of different people to see if any variant is associated with a trait (mostly common 
single nucleotide polymorphisms). GWAS studies have contributed substantially in the 
discovery of various novel as well as shared loci contributing to hyperuricaemia and gout. Until 
now the largest GWAS have been performed in Europeans (number of individuals in the 
discovery cohort = 110,347), African Americans (number of individuals in the discovery cohort 
= 5,820) and East Asians (number of individuals in the discovery cohort = 51,327) with the 
identification of at least 28 loci, PDZK1, GCKR, SLC2A9, ABCG2, RREB1, SLC17A1, 
SLC16A9, SLC22A11, NRXN2, INHBC, TRIM46, INHBB, SFMBT1, TMEM171, VEGFA, 
BAZ1B, PRKAG2, STC1, HNF4G, A1CF, ATXN2, UBE2Q2, IGF1R, NFAT5, MAF, HLF, 
ACVR1B/ACVRL1, and B3GNT4 conferring risk to develop hyperuricaemia and gout (Köttgen 
et al. 2013, Okada et al. 2012, Tin et al. 2019, Tin et al. 2011). All of them detected the solute 
carrier family 2, member 9 (SLC2A9) and ATP-binding cassette, sub-family G, member 2 
(ABCG2) genes with the strongest influence on serum urate concentration being a single variant 
in the SLC2A9 gene that explains 2-3% variance and ABCG2 that accounts for ~1% variance 
in serum urate levels (Köttgen et al. 2013, Okada et al. 2012). From urate GWAS studies the 
loci with stronger  effect are widely replicated, i.e. SLC2A9, ABCG2, SLC17A1–SLC17A4 (also 
known as NPT1–NPT4) and GCKR, whilst other loci of weaker effect have not yet been 
replicated for association with serum urate levels (Boocock et al. 2019, Chittoor et al. 2017, 
Huffman et al. 2015, Kenny et al. 2011, Son et al. 2017, Voruganti et al. 2013). The serum 
urate GWAS and replication studies have been briefly summarized in a recent review article 
(Major et al. 2018).  
 
Kanai et al., (2018) conducted one of the biggest Asian GWAS of 58 quantitative traits 
in 162,255 Japanese people with incorporation of 32 additional GWAS results for complex 
diseases. They also presented genetic correlations, pleiotropy and cell-type specificity across 
quantitative traits and disorders. This study identified 1,407 trait-associated loci; among those 
679 were novel and provided visualization of results depicting the genetic linkages among 
clinical measurement, complex disorders and related cell-type (specificity). The study traits 
included in this Asian GWAS also covered serum urate clinical measurements under the 
category of kidney-related traits and identified 27 loci associated with serum urate in Japanese 
individuals. Among these loci 10 were newly identified loci (Kanai et al. 2018). Another recent  
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Figure 1.11: Genome-wide Plot Summarizing the Data of Serum Urate GWAS Studies. 
 
The above figure provides the comprehensive detail of serum urate GWAS (until 2018). Genetic variants of 
genome-wide significance in each study have been included in the above plot and are presented in blue circles. 
The circle colour indicates the chromosome location present on the x-axis. An open circle indicates the P-value 
< 1 × 10−6 and a filled circle represents the P-value < 1 × 10−8. The (n) shows the number of individuals included 
in each GWAS study. This diagram is sourced from (Major et al., 2018 and permission to use the image was 
allowed under the licence no. 4666310360665). 
genome-wide meta-analysis in Japanese individuals identified multiple novel loci associated 
with serum urate levels (Nakatochi et al. 2019). After performing meta-analysis a trans meta-
analysis was conducted using Japanese meta-analysis and Global Genetic Urate Consortium 
(Köttgen et al. 2013) that revealed 15 new loci associated with SU. An eQTL mapping analysis 
was also performed. Gene expression level associated with serum urate (SU) SNPs were 
determined. This study identified 71 positive correlated genes and for some genes the allele 
increasing SU also increased the gene expression levels. In particular, 121,745 Japanese 
subjects were included in the genome-wide meta-analysis and identified 8948 variants at 36 
loci of genome-wide significance level (P<5 × 10−8) influencing serum urate levels including 
novel loci (SESN2, PNPLA3, TM4SF4, MXD3-LMAN2, TMEM18, PSORS1C1-PSORS1C2, 
and HNF4A) (Nakatochi et al. 2019). 
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1.10.2. Missing Heritability 
The heritability of gout has been calculated in population- and family-based studies. For 
example a study on familial aggregation of gout and  genetic and environmental contributions 
in a Taiwan population estimated 35.1% heritability in men and 17% in women (Kuo et al., 
2013). In a recent study in a European population (UK Biobank), heritability estimates were 
calculated based on different definitions of gout; cases were defined by self-report of gout, 
defined by urate-lowering therapy (ULT) use and defined by hospital diagnosis with the 
proportion of age, sex and body composition-adjustment that ranged from 0.282 to 0.308. 
GCTA software was used to calculate the heritability estimate that was close to the heritability 
calculated by Köttgen et al (2013) for serum urate 0.27–0.41, adjusted by age and sex. The 
heritability estimates use information from common SNPs under the assumption of additive 
contributions. Therefore, these estimates do not include the contribution of non-additive gene-
by-gene and gene-by-environment interactions, rare genetic variants and copy number 
variations (Cadzow et al., 2017). 
GWAS analysis by genotyping common variants (prevalence >1%) explains a 
considerable proportion of heritability of serum urate levels (45-68%) in Europeans (Köttgen 
et al. 2013). However, a substantial proportion is still to be addressed. Some of the heritability 
can be calculated by additive assumptions (not accounting for gene-environment and gene-gene 
interactions) or it may lie in copy number variants, uncommon and population-specific variants 
which are not assayed by traditional GWAS. 
Some variants with high penetrance that are associated with gout are population-specific. 
These include variants, which are only present in one population and are not shared by other 
populations. For example, dysfunctional ABCG2 rare variants have been identified by 
resequencing studies in diverse ancestral groups with increasing risk of gout in a population- 
dependent manner (Higashino et al. 2017, R Li et al. 2015, Matsuo et al. 2009, Stiburkova et 
al. 2017). The other significant example of population-specific variants (prevalent in European 
populations only) comes from an Icelandic study that reported the strong association of an 
uncommon variant (Pro476Arg) in ALDH16A1 with gout as well as with serum urate in Iceland 
individuals of European ancestry (Sulem et al. 2011) (the role of population-specific variants 
in the disease aetiology has been detailed in the third chapter). 
Given that a large number of common and uncommon genetic variants have been 
identified in serum urate loci, the function of the majority of proteins encoded by these loci is 
currently unclear (Ketharnathan et al. 2018, Leask et al. 2019). Furthermore, most of the genetic 
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variants that are detected by GWAS of complex disorders map to enhancers and insulators 
(regulatory genetic regions) that may be at a distance from the targeted gene (Boyle et al. 2017). 
Often, inter-marker linkage disequilibrium results in association signals that extend across 
multiple genes. These phenomena make detection of a causal variant for a phenotype even more 
challenging. However, the use of expression quantitative trait loci (eQTL) analysis has 
contributed significantly in identifying putative causal genes for traits. This approach is used to 
test association between genetic variation and gene expression level across a large number of 
individuals. The main utility of eQTL analysis includes functional characterization of GWAS 
identified genetic variants without prior knowledge of pathogenic role and become useful in 
understanding basic processes of gene regulation (cis and trans regulation) (Nica and 
Dermitzakis 2013). Moreover, the integration of GWAS and eQTL data is useful to determine 
the mechanism of GWAS loci in disease if the same loci affect the gene expression levels in 
specific tissue types (Hormozdiari et al. 2016). The main concept behind this approach is that 
a GWAS variant affects expression at a nearby gene in some tissues, that the gene and relevant 
tissue might play a role in the disease mechanism. Integration of eQTL and GWAS data 
colocalization is one of the methods that is common in practice. Colocalization can be perfomed 
by using various bioinformatic packages such as “coloc’ in R software (Boocock et al. 2019). 
In the context of serum urate genetics, serum urate-associated variants have been tested for 
association with the level of expression of nearby genes and indicated PDZK1 as nearly a 
definitive causal gene (Ketharnathan et al. 2018). Moreover, many other loci have been 
identified as strong candidate causal genes including GCKR, SLC17A1-4, PRKAG2, MLXIPL, 
RREB1, SLC22A12, IGFR1 and HLF (Boocock et al. 2019)Merriman 2015). 
 
1.10.3. Genetics of Gout 
Since hyperuricaemia is a prerequisite of gout it is expected that most of the serum urate 
associated genetic variants are also associated with gout risk in multiple populations. In most 
of the studies urate-increasing variants are found to increase the risk of gout (Köttgen et al. 
2013, Matsuo et al. 2016, Phipps-Green et al. 2016). It has been observed that in asymptomatic 
individuals with high serum urate levels (7-8.9mg/dl), the annual incidence of gout is found in 
only 0.5% (Campion et al. 1987). Moreover, individuals not possessing high urate levels also 
get gout and sometimes urate levels also drop during a gout attack (Dalbeth et al. 2018b). Such 
evidence directs attention towards the contribution of genetic components that are more likely 
involved in MSU crystal deposition and eliciting innate immune response to these deposited 
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crystals. Gout GWAS are smaller in number and performed in a relatively smaller sample size 
to serum urate GWAS; these evidence associations of non-urate loci with gout susceptibility at 
a genome wide significant level. For example, a GWAS in a Japanese male population 
comprised 945 clinically defined gout patients and 1213 controls identified three non-urate 
transporters loci of GWAS significant level (P<5.0 × 10-8). These included a gene for glucose 
and lipid metabolism (GCKR;rs1260326; P=1.9×10−12; OR=1.36), genes associated with 
diabetes mellitus and cholesterol (MYL2-CUX2;rs2188380; P=1.6×10−23; OR=1.75) and a gene 
involved in regulation of glutamate signalling (CNIH-2;rs4073582; P=6.4×10−9; OR=1.66) 
(Matsuo et al. 2016). A subsequent study from the same group of researchers based on gout 
sub-types GWAS replicated loci that did not reach a genome-wide significant level, instead 
reported novel loci associated with gout (FAM35A, NIPAL1). However, finding the expression 
of FAM35A and NIPAL1 in distal tubules of the kidney may suggest their role is linked to urate 
transportation (Nakayama et al. 2017). A GWAS in Han Chinese male gout participants (cases 
= 4275, controls = 6272 with additional hyperuricaemic (HU) controls = 1,644) detected 
exclusively non-urate loci including KCNQ1 (rs179785, P=1.28 × 10−8), BCAS3 (rs11653176, 
P=1.36 × 10−13) and RFX3 (rs12236871, P=1.48 × 10−10) conferring risk for gout (C Li et al. 
2015). These were localized in inflammatory genes and their association with gout (using HU 
controls versus gout cases) suggested relevance to the progression from hyperuricaemia to gout. 
Another GWAS based study in the Korean gout population by comparing 520 cases with 8314 
controls was used to identify functional associations of cis-regulatory region with gout 
susceptibility. This study conducted genomic regions enrichment analysis to detect such regions 
and detected unique genic regions (with gout susceptibility) from those with urate levels (Shin 
et al. 2012). All of these genome-wide association studies were conducted in Asian populations 
and suggested the substantial involvement of non-urate possibly inflammatory loci in 
conferring gout risk.  
Gout GWAS were performed in European populations and the results were dominated by 
urate loci (ABCG2 and SLC2A9) (Köttgen et al. 2013, Q Yang et al. 2010). The largest 
European GWAS to date was comprised of 7,431 cases and 105,631 controls from combined 
New Zealand (NZ), Eurogout, Ardea Biosciences and UK Biobank groups. This study reported 
additional non-urate TRIM46 (OR=1.15), MLXIPL (OR=1.18) and GCKR (OR=1.24) genetic 
regions with gout at experiment-wide significant level (0.05/234,062; P < 2×10-7) (TR 
Merriman et al. 2017). Furthermore, a gout GWAS in 968 Icelandic gout participants with more 
than 40,000 control subjects detected a population-specific low frequency variant 
(rs150414818; OR=3.1, P= 1.5 × 10−16) in the ALDH16A1 gene in addition to ABCG2 signal 
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(Sulem et al. 2011). This variant was also associated with serum urate levels. Recently a trans-
ancestry GWAS of serum urate in 457,690 individuals was performed and identified 187 loci 
(147 were previously unknown) with an improved prediction of gout in an independent cohort 
of 334,880 individuals. In addition, colocalization of urate associated loci with gene expression 
in 47 tissues implicated liver and kidney as the major target organs and prioritized causal genes 
and variants including HNF1A and HNF4A (transcriptional master regulators) (Tin et al. 2019). 
All of the above GWAS studies undoubtedly support the potential contribution of non-
urate loci in gout pathogenesis, however progression from hyperuricaemia to gout is still a 
caveat. For the solution of this problem a large GWAS using HU controls (not having gout) 
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Table 1.1: Summary of Gout GWAS Studies and Replication Studies across major population (Europeans, Asians and African) 
 Population size (cases; controls) (SNPs (n)) Identified Genes/Locus Reference 
Genome-wide studies 
Asian populations   
China 1,255;1,848 SLC2A9, RFX3, KCNQ1, BCAS3 
Li, C. et al. Genome-wide association analysis identifies 
three new risk loci for gout arthritis in Han Chinese. Nat. 
Comm. 6, 7041 (2015).  
Japan 945; 1,213  GCKR, SLC2A9, ABCG2, MYL2-CUX2, CNIH2 
Matsuo, H. et al. Genome-wide association study of 
clinically defined gout identifies multiple risk loci and its 
association with clinical subtypes. Ann. Rheum. Dis. 75, 
652–659 (2016).  
Korea 520; 8,314  -  
Shin, J., Kim, Y., Kong, M. & Lee, C. Genetic 
architecture for susceptibility to gout in the KARE cohort 
study. J. Hum. Genet. 57, 379–384 (2012).  
European populations   
Europe, UK and USA 2,115; 67,259 SLC2A9, ABCG2, CD14,TLR4,KCNQ1, MC4R,  
Kottgen, A. et al. Genome-wide association analyses 
identify 18 new loci associated with serum urate 
concentrations. Nat. Genet. 45, 145–154 (2013).  
New Zealand, 
Australia, Europe, UK 
and USA 
7,431; 105,631  
PDZK1, TRM46, GCKR, SLC2A9, ABCG2, 
SLC17A cluster, MLXPL, SLC16A9, SLC22A11, 
SLC22A12, CNH2,  
Merriman, T. R. et al. Genome-wide association study of 
gout in people of European ancestry [abstract]. Arthritis 
Rheumatol. 69, S10 (2017).  
Iceland  968; 40,000 SLC2A9, ABCG2, SLC22A11, SLC22A12, CNH2 
Sulem, P. et al. Identification of low-frequency variants 
associated with gout and serum uric acid levels. Nat. 
Genet. 43, 1127–1130 (2011).  
USA and Europe 1,033; 25,982  SLC2A9, ABCG2, SLC22A11, SLC22A12, CNH2 
Yang, Q. O. et al. Multiple genetic loci influence serum 
urate levels and their relationship with gout and 
cardiovascular disease risk factors. Circ. Cardiovasc. 
Genet. 3, 523–530 (2010).  
Replication studies 
African populations   
USA 177; 2,654 (6)  SLC2A9  
Tin, A. et al. Genome-wide association study for serum 
urate concentrations and gout among African Americans 
identifies genomic risk loci and a novel URAT1 loss-of-
function allele. Hum. Mol. Genet. 20, 4056–4068 (2011).  
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Asian populations   
China 582; 4,332 (31) PDZK1, TRM46, GCKR, SLC2A9, ABCG2, 
SLC17A cluster, HNF4G, SLC16A9,  
Dong, Z. et al. Effects of multiple genetic loci on the 
pathogenesis from serum urate to gout. Sci. Rep. 7, 43614 
(2017).  
Korea 109; 102 (9) ABCG2 
Schunkert, H. et al. Large-scale association analysis 
identifies 13 new susceptibility loci for coronary artery 
disease. Nat. Genet. 43, 333–338 (2011).  
China 1,255; 1,848 (2,255) 
GCKR, SLC2A9, ABCG2, SLC17A cluster, 
SLC22A11, SLC22A12, CNH2, MYL2-CUX2, 
BCAS3 
Li, Z. et al. Replication of gout/urate concentrations 
GWAS susceptibility loci associated with gout in a Han 
Chinese population. Sci. Rep. 7, 4094 (2017).  
Japan 1,396; 1,268 (1,961) 
GCKR, SLC2A9, NIPAL1, ABCG2, SLC17A 
cluster, FAM35A, SLC22A11, SLC22A12, CNH2, 
MYL2-CUX2 
Nakayama, A. et al. GWAS of clinically defined gout 
and subtypes identifies multiple susceptibility loci that 
include urate transporter genes. Ann. Rheum. Dis. 76, 
869–877 (2017).  
Japan 153; 532 (11) GCKR, LRP2, SLC2A9, ABCG2, SLC17A cluster, 
SLC22A11, SLC22A12, CNH2 
Urano, W. et al. Effect of genetic polymorphisms on 
development of gout. J. Rheumatol. 40, 1374–1378 
(2013).  
China 110; 110 (9) ABCG2 
Matsuo, H. et al. Common defects of ABCG2, a high-
capacity urate exporter, cause gout: a function-based 
genetic analysis in a Japanese population. Sci. Transl. 
Med. 1, 5ra11 (2009).  
China 139; 309 (47) SLC2A9, ABCG2 
Zhou, Z. W. et al. Polymorphisms in GCKR, SLC17A1 
and SLC22A12 were associated with phenotype gout in 
Han Chinese males: a case-control study. BMC Med. 
Genet. 16, 66 (2015).  
Tibet  299; 314 (47) SLC2A9, ABCG2 
Zhou, Z. W. et al. Polymorphisms in GCKR, SLC17A1 
and SLC22A12 were associated with phenotype gout in 
Han Chinese males: a case-control study. BMC Med. 
Genet. 16, 66 (2015).  
China 163; 187 (5) ABCG2 
Kim, Y. S. et al. Genetic analysis of ABCG2 and SLC2A9 
gene polymorphisms in gouty arthritis in a Korean 
population. Korean J. Intern. Med. 30, 913–920 (2015).  
China 622; 917 (8) GCKR, SLC2A9, SLC17A cluster, SLC22A11, 
SLC22A12, CNH2 
Zheng, C., Yang, H., Wang, Q., Rao, H. & Diao, Y. 
Association analysis of five SNP variants with gout in the 
Minnan population in China. Turk. J. Med. Sci. 46, 361–
367 (2016).  
European populations   
 
 
43 | Page 
UK 2,295; 102,989 (30) 
PDZK1, TRM46, GCKR, MUSTN1, SFMBT1, 
SLC2A9, ABCG2, CD14, RREB1, SLC17A 
cluster, MLXIPL, PRKAG2, HNF4G, SLC16A9, 
FAM35A, SLC22A11, SLC22A12, CNH2, INHBC, 
INHBE, MYL2-CUX2, NRG4, NFAT5, BCAS3 
Cadzow, M., Merriman, T. R. & Dalbeth, N. 
Performance of gout definitions for genetic 
epidemiological studies: analysis of UK Biobank. 
Arthritis Res. Ther. 19, 181 (2017).  
USA and Europe 845; 20,872 (4) SLC2A9, ABCG2, SLC17A cluster  
Dehghan, A. et al. Association of three genetic loci with 
uric acid concentration and risk of gout: a genome-wide 
association study. Lancet 372, 1953–1961 (2008).  
New Zealand 648 ; 1,550 (28) 
PDZK1, GCKR, MUSTN1, SFMBT1, SLC2A9, 
ABCG2, SLC17A cluster, PRKAG2, SLC17A 
cluster, SLC22A11, SLC22A12, CNH2, IGF1R 
Phipps-Green, A. J. et al. Twenty-eight loci that 
influence serum urate levels: analysis of association with 
gout. Ann. Rheum. Dis. 75, 124–130 (2016).  
USA 423; 4,674 (8)  PDZK1, SLC2A9, ABCG2, RREB1,  
Stark. K et al.Common polymorphisms influencing 
serum ric acid levels contribute to susceptibility to gout, 
but not to coronary artery disease. Plos One 4, e7729 
(2009). 
Europe  683; 1,563 (10) SLC2A9, ABCG2  
Zhang, Y. et al. Associations of gout with 
polymorphisms in SLC2A9, WDR1, CLNK, PKD2, and 
ABCG2 Chinese Han and Tibetan populations. Int. J. 
Clin. Exp. Pathol. 9, 7503–7517 (2016).  
USA 569; 15,318 (6) ABCG2 
Tin, A. et al. Genome-wide association study for serum 
urate concentrations and gout among African Americans 
identifies genomic risk loci and a novel URAT1 loss-of-
function allele. Hum. Mol. Genet. 20, 4056–4068 (2011).  
Polynesian population   
New Zealand  888; 1,095 (28) GCKR, MUSTN1, SFMBT1, SLC2A9, ABCG2, 
VEGFA, SLC22A11, SLC22A12, CNH2 
Phipps-Green, A. J. et al. Twenty-eight loci that 
influence serum urate levels: analysis of association with 
gout. Ann. Rheum. Dis. 75, 124–130 (2016).  
The above table represents gout GWAS in European, Asian and African populations with the information of replication studies in these populations. These studies indicate genetic 
variants in urate and non-urate loci for their association with gout in European, Asian and African populations. The table has been adopted from a recent review by Major et al., 
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1.10.3.1. Insights from Gout Candidate Gene Studies 
In addition to GWAS, there are certain gene candidate studies that evidence the role of 
inflammatory loci in gout pathogenesis (W-C Chang et al. 2017, McKinney et al. 2015, 
Rasheed et al. 2016a). Given the absence of large GWAS with gout as outcome, findings from 
candidate gene studies emphasize the importance of activity of the NLRP3 inflammasome in 
causing gout. One such study indicated that Huangshi individuals carrying the GG genotype 
for the rs3806268 in NALP3 had increased risk of primary gout (OR=1.83, P=0.03) when 
compared with AA genotype (Deng et al. 2015). A study conducted by Qing et al., (2013) 
reported the association of the rs2149356 T-allele in the TLR4 gene with increased risk of gout 
(OR=1.88, P=<0.05) and the same allele was also correlated with increased TL4 mRNA and 
IL1β expression (Qing et al. 2013). This TLR4 variant (rs214935) was also successfully 
replicated in the NZ European and Polynesian populations (OR=1.12, P=0.012; OR=0.80, 
P=0.011, respectively) (Rasheed et al. 2016a). The opposite direction of effect sizes in two 
populations can be explained by the hypothesis that rs2149356 is not a causal variant but in LD 
with the causal variant, with a Polynesian-specific ancestral recombination that distinguishes 
the Polynesian haplotypic background from the European background around rs2149356. 
Moreover, the inconsistent effect sizes in two populations may be the result of non-genetic 
interactions (i.e. diet, alcohol and sweet beverages consumption) that were unaccounted for the 
analysis. Other case-control studies evidenced the rs2043211 in CARD8 (encoding Cys10Ter) 
conferring gout risk in multiple populations (Y Chen et al. 2015, McKinney et al. 2015). A 
significant association of the G allele of IL1β;rs1143623 was identified with increasing 
expression of IL1β and IL6 (an effector of IL1β) in response to MSU induced gout 
inflammation (McKinney et al. 2015). Another association study identified an association of 
D4S3243 nearby cGMP-dependent protein kinase II (cGK II) with the development of gout (SJ 
Chang et al. 2009). The Gln allele of Arg265Gln (rs45520937) in PPARGC1B was associated 
with increased risk of gout in Taiwan Han Chinese individuals (OR=1.85, P=6.66×10-9). The 
same allele showed a significant increase in NLRP3 (P=0.044) and IL1β (P=0.006) protein 
levels (W-C Chang et al. 2017). The PPARGC1B;rs45520937 variant replicates in NZ 
Polynesian individuals (details in the second chapter) that suggests the potential contribution 
of this inflammatory regulator (rs45520937) in gout pathogenesis. A genetic association study 
in the Chinese Han male population investigated a SNP (rs1024611; -2518A/G) in CCl2 (CC 
chemokine ligand 2) and found that the -2518G allele was associated with increased risk of 
gout (OR=1.18, P=0.007) (RX Sun et al. 2015). The replication of association of the 
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APOA1;rs670 T-allele with gout (OR=1.53 , P= 4.9×10-6) (Cardona et al. 2005, Rasheed et al. 
2016b) and lack of evidence for association with serum urate (Rasheed et al. 2016b) implicates 
this locus in the aetiology of progression from hyperuricaemia to gout. Although the APOA1 
role is still unclear in gout pathogenesis, APOA1-mediated reduced IL1B production (Hyka et 
al. 2001) and evidence of MSU crystal-bound APOA1 in acute gout (Chiang et al. 2014) 
indicate its pathogenic role in gout inflammation (summarized in a summary Table 1.2).  
By considering the current candidate gene evidence the progression to MSU crystal 
deposition and gout inflammation is still not clearly understood. In this instance a larger, 
ancestrally diverse gout GWAS using HU controls (not having gout) will be of great 
importance. This can shed light on urate loci correlating with the immune response in gout 
inflammation. The analysis may also reveal non-urate loci that initiate inflammatory 
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Table 1.2: Candidate gene and replication studies reporting association of non-urate (predominantly inflammatory loci) with gout in various populations 
TLR4: Toll-like receptor 4, NALP3 (NLRP3): NOD-like receptor (NLR)-Family Pryin Domain Containing 3, CARD8: Caspase Recruitment Domain Family Member 8, CARD14: 
Caspase Recruitment Domain Family Member 14, IL-IB: Interleukin 1 beta, IL23R: Interleukin receptor 23, APOA1: Apolipoprotein-A1, CCl2: CC chemokinase ligand 2 OR: 
Odds ratio, P: Statistical p-value of association. 
Variants Gene 
Population size 
OR P Population References 
Cases Controls 
rs3806268 NALP3 247 247 1.83 0.038 Huangshi  (Deng et al. 2015) 
rs2149356 TLR4 250 318 1.88 <0.05 Han Chinese  (Qing et al. 2013). 
rs2149356 TLR4 (replication) 1614 13005 1.12 0.012 Europeans including NZ European  (Rasheed et al. 2016a) 
rs2043211 CARD8 396 403 0.65 0.006 Chinese  (Y Chen et al. 2015) 
rs2043211 CARD8 (replication) 2357 11972 1.12 0.007 European/NZ Polynesian  (McKinney et al. 2015) 
rs1143623 IL-1β 2357 11972 1.10 0.02 European/NZ Polynesian  (McKinney et al. 2015) 
rs2569190 CARD14 2357 11972 1.08 0.036 European/NZ Polynesian  (McKinney et al. 2015) 
rs45520937 PPARGC1B 250 318 1.85 6.66×10-9 Taiwan Han Chinese (W-C Chang et al. 2017) 
rs102461 CCl2 1109 1034 1.18 0.007 Chinese  (RX Sun et al. 2015) 
rs670 APOA1 2690 2452 1.53 4.9×10-6 NZ Polynesian  (Rasheed et al. 2016b) 
rs7517847 IL23R 400 582 0.82 0.040 Han Chinese  (S Liu et al. 2015) 
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1.11. Aims of the Study 
Given that gout is a complex disorder and various functional and genetic studies evidence 
a significant contribution of urate and non-urate loci in the development of gout, the insight in 
genetic control of gout via inflammatory components is still limited. Thereby, the current 
research has been carried out to add data to the repository of gout and role of inflammatory 
markers in the presence of hyperuricaemia. The broader aim of the research was to fill the gap 
of progression from hyperuricaemia to gout by identifying and testing candidate inflammatory 
and MSU crystallizing loci for their association with gout in European and NZ Polynesian 
populations. The specific aims of the study are based on discrete hypotheses, which have been 
outlined below: 
 
1) To test the association of newly identified loci (NIPAL1, FAM35A, CNIH2 and 
CUX2) with gout susceptibility in NZ populations, which may be indirectly involved 
in the controlling of urate levels. 
2) To evaluate the role of candidate inflammatory loci in gout pathogenesis with the 
relevance to population-specific effect (NZ Polynesian and European). For this 
purpose, common variants in inflammatory genes were selected (IRGM, 
PPARGC1B, IL23R and SERPINA1) that were previously associated with 
inflammatory conditions (i.e. inflammatory bowel disease (Crohn’s disease and 
ulcerative colitis), emphysema and chronic obstructive pulmonary disorder) or 
involved in inflammatory pathways. 
3) The other main objective of the current research was the identification of novel non-
urate (primarily inflammatory) loci associated with gout in a population-dependent 
manner in New Zealand cohorts. These genetic variants could also be causal to gout. 
For the purpose, based on the significance of using high-throughput sequencing 
approaches in the discovery of uncommon population-specific variants, an in-silico 
resequencing analysis was carried out in whole genome sequencing data of gout 
individuals of diverse ancestry (Polynesian, Asian and European). 
4) To discover novel genetic variations in IL37 exon 5 by sequencing this genetic region 
in NZ Polynesian gout individuals. This hypothesis was developed on the basis of 
identification of a genetic variant in IL37 exon 5 that was absent in the European 
population and relatively common in NZ Polynesian. Additionally, it was also 
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significantly associated with gout in the presence of hyperuricaemia in the 
Polynesian population. 
5) Considering the implication of mitochondria in the NLRP3 inflammasome activation 
and evidence of association of reduced mitochondrial DNA copy number associated 
with gout in NZ Māori and Pacific (Polynesian) (Gosling et al. 2018), a genome-
wide association (GWAS) and mitochondrial-wide association analysis (MWAS) 
were conducted in European and NZ Polynesian populations. The reason to perform 
the GWAS and MWAS was to evaluate the cause-effect relationship between 
mitochondrial copy number and gout; based on the hypotheses (i) Identification of 
nuclear loci controlling mtDNA copy number and then test these variants for their 
association with gout. (ii) Identification of mitochondrial genetic variants influencing 
mitochondrial DNA copy number followed by testing their association for gout 
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Chapter 2. Genetics of Gout 
 
  
Chapter 2: Genetics of Gout 
 
 
50 | Page 
Progression from Hyperuricaemia to Inflammation 
A portion of the work presented in this chapter was published in Annals of the Rheumatic 
Diseases in 2017. 
Nakayama A., Nakaoka H., Yamamoto K., Sakiyama M., Shaukat A., Toyoda Y., Okada Y., Kamatani Y., 
Nakamura T., Takada T., et al. (2017). GWAS of clinically defined gout and subtypes identifies multiple 
susceptibility loci that include urate transporter genes. Annals of the Rheumatic Diseases 76(5): 869-877. 
 
2.1. Introduction 
Medical genetics has historically been a specialised area of studying human genetic 
disorders which exploits naturally occurring genetic screens that reveal unexpected genotype–
phenotype relationships (Norrgard 2008). Over the past decade or so, much effort has been 
made to catalogue human genetic variants and their correlation to phenotypic differences. These 
variants are typically referred to as either common or rare based on the frequency of minor 
allele (MAF > 5%, MAF < 0.01%, respectively) in the population. For the last few years the 
common disease common variant hypothesis has been extensively investigated, which posits 
that common traits are associated with common variations of small to moderate effect size, and 
made possible by the existence of a key analysis methodology named the Genome Wide 
Association Study (GWAS) (Sham and Cherny 2011). Genotyping microarrays were developed 
in 1986 (Poustka et al. 1986) and since then microarray technology underlying inexpensive and 
rapid genotyping of multiple single nucleotide polymorphisms (SNPs) has become widely 
available (Hoheisel 2006). Now GWAS is widely used as a contemporary approach to relate 
genetic variations to phenotypic differences through identification of SNPs in the genome 
which influence the phenotype of interest (Frazer et al. 2009). The phenotypic variance 
explained by SNPs within a population is determined by how strongly allelic variants differ in 
their effect size and frequency in the sample (Asimit and Zeggini 2010, Gibson 2012).  
However, some traits possess complex genetic architecture and may provide difficulties 
for GWAS. There are three possibilities; either that trait is controlled by many rare variants 
each with larger effect or alternatively many common variants that explain only a small 
phenotypic effect or a combination of both (Asimit and Zeggini 2010, Gibson 2012). Based on 
these limitations in GWAS other approaches such as whole genome sequencing, exome 
sequencing, deep re-sequencing around known GWAS-associated regions and customized 
genotyping arrays (Eichler et al. 2010, Manolio et al. 2009, Metzker 2010) have been 
introduced for better understanding of the genetic architecture of complex disorders. 
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For molecular insights into the complex disorder it is also necessary to identify the 
specific loci that underlie a phenotype or causal gene or genetic variant that influence the 
phenotype (Hindorff et al. 2009, Lowe and Reddy 2015). Moreover, lead variants that are 
detected by GWAS may map to enhancers and insulators but in some cases these can be at a 
distance from targeted genes (Boyle et al. 2017). Furthermore, extensive inter-marker 
correlations result in association signals that extend across multiple genes. In this scenario, to 
determine causative loci that are connected with phenotypic differences, mapping approaches 
such as expression quantitative trait loci (eQTL) are a powerful tool (Hindorff et al. 2009, Peters 
et al. 2016). Moreover, an approach to integrate eQTL and GWAS data by the colocalization 
method is helpful to determine mechanism of the disease if the same GWAS signal affects the 
gene expression in a specific tissue (Hormozdiari et al. 2016). In this instance, various serum 
urate-associated genetic variants are tested for their association with the level of expression of 
nearby genes and result in the detection of putative causal genes that contribute to urate levels 
(reviewed in (Boocock et al. 2019, TR Merriman 2015). 
Aside from GWAS, candidate gene case-control association studies are also useful to 
identify genetic polymorphisms, particularly those having functional significant effects on the 
gene product while others are simply useful genetic markers (Daly and Day 2001). Candidate 
gene studies have always been at the forefront of association studies, which focus on the 
selection of putative candidate genes that are related to the disease (trait) previously in some 
ways with known genetic functions (Kwon and Goate 2000). 
Association studies rely on the identification of single nucleotide polymorphisms (SNPs) 
through candidate gene studies and on demonstration of association of a particular allele 
associated with the trait (Silverman and Palmer 2000). SNPs associated with functional effects 
are those that influence expression e.g. enhancers and those that cause amino acid substitution 
in a gene product, insertion or deletions which result in a frameshift in the coding region or 
directly affect gene transcription, RNA splicing, or mRNA translation. SNPs that encode 
enzymes involved in drug metabolism and those affecting immunity and inflammation have 
been extensively studied with various biological conditions (S Ahmed et al. 2016, Berno et al. 
2014, Eskdale et al. 1997, Maurer et al. 2000, Mcwilliams et al. 1995, Ober et al. 2000, G 
Smith et al. 1995). A number of such attractive candidates for disease susceptibility have 
prompted a large number of case-control association studies to unravel specific genes involved 
in disease causation, which may lead to the development of new drug treatments. Since 
increasing information on candidate genes and SNPs is available, it is important to consider 
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factors such as study design, functional significance of polymorphisms chosen, methods for 
recruitment of cases and controls and careful statistical analysis of data to ensure genuine 
associations are detected (reviewed in (Daly and Day 2001). Moreover, in polygenic diseases 
such as gout association of many variants with disease does not mean that an individual will 
necessarily develop the disease but rather increase the risk of disease development.  
 
2.1.1. Molecular/Genetic Insights in Gout from Candidate Genes 
Studies 
In the context of the relationship of serum urate with gout, various findings from 
replicated candidate gene studies confirm the potential contribution of genetic variations in 
urate transporters to gout development (S Li et al. 2007, Z Li et al. 2017, TR Merriman et al. 
2017, Phipps-Green et al. 2016, Son et al. 2017, Urano et al. 2013, Vitart et al. 2008, Voruganti 
et al. 2013, Q Yang et al. 2010). However, in contrast little is known about the genetic 
contribution to gout inflammation; that is the progression from hyperuricaemia to gout. Several 
replicated candidate gene studies have been discussed in detail in 1st Chapter of this thesis. 
Based on the fact that there is less information available on candidate genes studies for gout, 
this chapter has been designed to explore the possible genetic contribution (particularly from 
hyperuricaemia to gout) of candidate inflammatory loci in the development of gout.  
 
2.1.2. Genetics of Serum Urate 
Hyperuricaemia is well known as a prerequisite of gout, characterised by elevated serum 
urate concentration in the blood. Therefore, it is important to understand the genetics of serum 
urate levels prior to moving to gout genetics. The first GWAS on serum urate levels was 
conducted in 2007, comprised of 4,305 individuals from Sardinia and Italy, that scanned about 
350,000 SNPs across the whole genome and identified a region SLC2A9 (GLUT9) containing 
38 correlated SNPs significantly associated with serum urate levels (rs6855911;β = -
14.04umolL-1, P = 2.0×10-16) (S Li et al. 2007). That was a novel discovery at the time and 
since then a number of GWAS of serum urate levels have been performed in larger cohorts 
across a wide range of ethnic groups, which explain the genetic heritability of 40-70%. These 
studies have also identified loci involved in the regulation of serum urate levels (Charles et al. 
2011, Dehghan et al. 2008, Giri et al. 2016, Karns et al. 2012, Kolz et al. 2009, Köttgen et al. 
2013, WD Li et al. 2013, Okada et al. 2012, Tin et al. 2011, C Wallace et al. 2008, B Yang et 
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al. 2014). Unsurprisingly, most of these urate-associated loci also associate with increased gout 
risk in multiple populations with the same urate-associated allele increasing the risk of gout (C 
Li et al. 2015, Z Li et al. 2017, Matsuo et al. 2016, Phipps-Green et al. 2016, Urano et al. 2013). 
A detailed description can be found in an introductory chapter under the section “1.10.3. Gout 
Genetics”. Therefore, the initial part of this chapter includes genetic variants in some urate 
transporters (selected from a Japanese GWAS paper (Matsuo et al. 2016)) to test their 
association with gout, especially in NZ populations and this work has also been published 
(Nakayama et al. 2017). 
 
2.1.3. Urate and Non-Urate Transporters in Gout 
2.1.3.1. Urate Transporter Genes 
Hyperuricaemia is key to the development of gout, thus it is important to control serum 
urate levels, tightly regulated by reabsorption and excretion in kidneys encoded by urate 
transporters. Dysfunctional urate transporters can affect renal function and may lead to various 
health states including gout (reviewed in (L Xu et al. 2017). Since it has been evidenced broadly 
that renal under-excretion and over-production of urate are obligatory to the hyperuricaemic 
condition, the under-excretion of serum urate contributes majorly (90%) in developing 
hyperuricaemia (reviewed in (Becker et al. 2014, Riches et al. 2009). The excretion of urate in 
the kidney is carried by urate transporters categorised into a) urate excretory transporters and 
b) urate reabsorption transporters on the basis of their function in renal proximal and distal 
tubules (reviewed in (Mandal and Mount 2015, VanWert et al. 2010). Urate excretory 
transporters can be further categorised into two groups: a group that includes urate transporters 
which contribute to the uptake of urate from the blood into intracellular tubules mainly assisted 
by OAT1, OAT3, and the second group involves urate excretory transporters that account for 
urate secretion from tubular cells to the lumen including MRP4, NPT1 (SLC17A1), NPT4 and 
ABCG2 proteins (VanWert et al. 2010). Urate reabsorption transporters account for only one 
category, which involve GLUT9 (SLC2A9), OAT4, OAT10, UAT and URAT1 proteins 
(reviewed in (Anzai and Endou 2011, Mandal and Mount 2015, L Xu et al. 2017). 
 
Whilst a number of studies have argued the essential role of various urate transporters in 
urate homeostasis, there is a lack of evidence for identifying the possible role of non-urate loci 
in handling urate. In this context a recent GWAS conducted by Matsuo et al., (2016) in a 
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Japanese gout population was a study in which non-urate transporters were identified associated 
with gout risk with a predictive effect on urate handling (a detailed description has been 
provided in following sections). An attempt to replicate these genetic variants has been made 
in New Zealand populations (Polynesian and European): that is one of the hypotheses of this 
chapter. 
 
2.1.3.2. Genetics of Urate Transporters 
2.1.3.2.1. SLC22A12 (URAT1) 
The SLC22A12 gene which encodes the essential urate transporter protein URAT1 
contributes mainly to the absorption of urate in the kidney (Enomoto et al. 2002). It is expressed 
on the apical border of proximal tubules and has a role in the uptake of urate from the lumen in 
exchange for monocarboxylates (Anzai et al. 2007, Enomoto et al. 2002). 
Identification of uncommon loss-of-function variations in the SLC22A12 gene in 
idiopathic renal hypouricaemic patients determined a significant role of SLC22A12 in renal 
urate handling. Several associations between SLC22A12 variants, serum urate and gout have 
been reported (reviewed in (H. K. Choi et al. 2005, Enomoto et al. 2002)). However, a 
genetic analysis study for SLC22A12 was first conducted in 2004 in a Japanese population 
with idiopathic renal hypouricaemia phenotype (Ichida et al. 2004, Komoda et al. 2004). In 
one of these studies the SLC22A12 gene was sequenced in 32 patients with substantially 
reduced levels of serum urate and increased risk of kidney failure (Ichida et al. 2004). 
Another Japanese association study in 2006 reported an intron variant in SLC22A12 
(rs893006) which was significantly associated with serum urate levels in men (β = 350 μmol, 
P = 0.025) (Shima et al. 2006). In a German population, different polymorphisms in the N-
terminus of SLC22A12 including –788T>A in the promoter region, 258C>T in exon 1 and 
426C>T in exon 2 showed a significant association with reduced fractional excretion of urate 
(FEUA) levels (Graessler et al. 2006). A genome-wide association study of 8,868 Japanese 
participants reported association of four urate transporters of a genome wide significant level 
with serum urate but the SLC22A12 variant had the strongest effect explaining 1.5% of the 
variation in serum urate levels (Kamatani et al. 2010). Another serum urate GWAS study in 
East Asians also revealed the stronger effect of SLC22A12-associated variants on serum urate 
than other loci such as SLC2A9 and ABCG2 (Okada et al. 2012). Interestingly, SLC22A12 
variants exhibited a weaker association with serum urate in European and African American 
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genome-wide and whole-exome sequencing association studies (Köttgen et al. 2013, Tin et al. 
2018, Tin et al. 2011) that clearly indicates an ancestry-specific effect of these variants. 
Several studies have reported a causative role of SLC22A12 variants in gout pathogenesis 
(Kamatani et al. 2010, C Li et al. 2014, Phipps-Green et al. 2016, HP Tu et al. 2010, Urano et 
al. 2013) (Table 2.1). SLC22A12 variants showed a significant association with gout in Asian 
and East Asian populations (Chinese and Japanese) correlating with the effect size of serum 
urate (Matsuo et al. 2016, HP Tu et al. 2010). An inconsistent magnitude of effect was found 
in Spanish individuals and in a New Zealand European cohort (rs11231825: T-allele; OR = 
1.63, P = 0.03, rs3825018: G-allele; OR = 1.24, P = 0.02, respectively), whilst other European 
studies did not evidence significant effects for SLC22A12 variants (Phipps-Green et al. 2016, 
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Table 2.1: Published associations of SNPs in SLC22A12 (URAT1) with serum urate levels or gout. 
Study 
Protein 
Allele Serum Urate  Gout 
Population Size 
Reference Population SNP  A1  β Pβ  OR POR 
SLC22A12 (URAT1) 
(Duong et al. 2019) Vietnamese rs11231825 synonymous  C     0.71 0.032 521 
(Nakayama et al. 2017) Japanese (males) rs2285340 intronic  T     1.40 4.61×10-11 4822 
 (C Li et al. 2014) Chinese rs559946 intronic  T     0.70 4.00×10-03 711 
 (Phipps-Green et al. 2016) European rs3825018 5’ UTR  G     1.24 0.01 2,198 
 (Phipps-Green et al. 2016) Polynesian rs3825018 5' UTR  G     1.21 0.03 1,983 
 (F Takeuchi et al. 2013) Japanese rs505802 upstream  C  14.63 2.40×10-50    17,076 
 (Urano et al. 2013) Japanese (males) rs121907892 W258X  A     0.00 0.02 685 
 (Köttgen et al. 2013) European rs478607 intronic  A  -0.047 4.40×10-11  1.03 0.41 110,347 
 (Okada et al. 2012) East Asian rs504915 intronic  T  13.39 3.30×10-63    33,074 
 (Tin et al. 2011) African American rs12800450 G65W  T  -71.97 4.00×10-14  0.26 0.20 14,706 
 (HP Tu et al. 2010) Solomon Island rs7932775 L437  C  27.96 3.00×10-03  1.71 0.09 192 
 (Jang et al. 2008) Korean (males) rs1529909 intronic  T  19.39 0.03    141 
 (CG Li et al. 2010) Chinese rs7932775 L437  C  1.46 3.00×10-03    538 
 (Kamatani et al. 2010) Japanese rs506338 intronic  T  13.62 2.34×10-31    8,868 
SNPs that were tested for an association in either the most recent or largest study for each population are shown. Protein – variant effect on protein composition. Amino acids are 
denoted using the one letter IUPAC code: G – Glycine; W – Tryptophan; X – “Stop”; L – Leucine. A1 – effect allele. β – serum urate beta value relevant to the effect allele in 
μmolL-1; hyperuricaemic (serum urate > 420 μmolL-1) cases were compared to normouricaemic controls (serum urate < 420 μmolL-1) and an odds ratio calculated (dashed 
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2.1.3.3. Loci Indirectly Involved in Urate Handling 
2.1.3.3.1. NIPAL1 
The NIPA-like domain containing-1 (NIPAL1) is also known as NIPA3, a magnesium 
transporter that contains nine transmembrane regions. Non-imprinted in Prader Willi/Angelman 
syndrome subtype 3 (NIPA3) gene expression has been detected in various tissues including 
lung, liver and brain but abundantly found in the kidney (Goytain et al. 2008). Functional 
analyses revealed a potential role of NIPA family members (NIPA2, NIPA3) in magnesium 
metabolism and regulation of magnesium conservation in the kidney (Goytain et al. 2008). 
Magnesium is an essential nutrient and marginal to moderate deficiency could lead to chronic 
inflammatory stress-deficiency that has been found to increase the risk of obesity, diabetes, 
hypertension, atherosclerosis, and other inflammatory disorders. Additionally, a number of 
studies have also revealed a correlation between reduced dietary intake of magnesium and 
increased serum C-reactive protein (biomarker for inflammation) in patients with metabolic and 
inflammatory diseases (Dibaba et al. 2014, King et al. 2007, King et al. 2005, Y Song et al. 
2005, Song et al. 2007). A recent study by Zhang et al., (2018) reported an inverse association 
of serum magnesium with hyperuricaemia (YY Zhang and Qiu 2018) in U.S. adults that is 
consistent with a previous report (S et al. 2013), which suggests a possible relation between 
altered magnesium levels and hyperuricaemia.  
As a novel gout risk locus, NIPAL1 has only been identified for the first time in a recent 
Japanese GWAS of clinical gout subtypes in males (Nakayama et al. 2017), which is also a 
base of generating one of the hypotheses of this study. There is no previous evidence of 
association with serum urate and gout for NIPAL1. Therefore, it would be interesting to test 




A recent Japanese male gout GWAS identified rs11758351 as a ‘top-hit’ of genome wide 
significant level in the HIST1H2BF-HIST1H4E cluster (OR = 1.40, P = 1.63×10-8). Moreover, 
in this GWAS study the HIST1H4E locus was identified to be in LD with SLC17A1 (an 
established serum urate and gout locus). On adjustment of GWAS samples with rs11758351 
the genome wide significance disappeared (P = 0.08) at this locus. Even the same non-
significant effect was found when adjusted with both rs1165176 (SLC17A1) and rs11758351 
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(P = 0.11). To test the association of this variant with gout a replication was attempted in New 
Zealand (NZ) populations (Table 2.2). 
 
2.1.3.3.3. CNIH2 
The cornichon family AMPA receptor auxiliary protein 2 (CNIH2) encodes the 
cornichon-2 protein that regulates glutamate signalling in the mammalian brain. Glutamate is a 
predominant excitatory neurotransmitter which acts on two types of ionotropic receptor 
substrates; N methyl D aspartate (NMDA) and alpha-amino-3 hydroxy-5 methyl-4 isoxazole 
propionic acid (AMPA) receptors (Herring et al. 2013, Schwenk et al. 2009). Cornichons like 
the cornichon-2 and cornichon-3 (CNIH2-3) proteins are intrinsic auxiliary subunits of AMPA 
receptors and participate in regulating glutamatergic neurotransmission in the human central 
nervous system. These proteins promote AMPA receptor trafficking and alter channel gating 
via increasing cell surface expression and markedly slowing AMPAR deactivation and 
desensitization kinetics (Herring et al. 2013, Schwenk et al. 2009). Previously increased 
expression of CNIH2 and CNIH3 mRNA had been detected in patients with schizophrenia that 
suggests its contribution in certain health states (Drummond et al. 2012). 
CNIH2 has been detected as a novel gout locus in the Japanese and Han Chinese 
populations. A genome wide association analysis of 1993 clinically-ascertained Japanese gout 
cases and 2,547 normouricaemic controls reported six loci, significantly associated with gout 
(Matsuo et al. 2016). A subsequent GWAS in the Han Chinese population reported serum 
urate/gout-associated loci including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2 to be 
associated with gout in their cohort of 1255 gout cases and 1848 controls (XF Li et al. 2017). 
Therefore, in the current study the same genetic variant (rs4073582) in CNIH2 was selected 
(Table 2.2) to test its association with gout in NZ European and Polynesian populations. 
 
2.1.3.3.4. CUX2 
Cut-like homeodomain transcription factor family member 2 (CUX2) plays an essential 
role in the regulation of cell cycle and development of neural progenitors. A functional study 
also indicated the contribution of CUX2 in neuroblast development and neuronal differentiation 
by coupling with NeuroD gene Cux2 (Cutl2) that integrates neural progenitor development with 
cell-cycle progression during spinal cord neurogenesis (Iulianella et al. 2008). The NeuroD 
gene potentiates neurogenesis (JE Lee et al. 1995), however, some research groups 
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independently cloned this gene as the beta cell E box transactivator 2 (BETA2) and a class B 
basic helix-loop-helix (bHLH) whose expression was observed in intestine, pancreatic and 
brain cells. The heterodimer of NeuroD/BETA2 with bHLH attains a high affinity to bind with 
the insulin E box complex and regulates transcription of the insulin gene suggesting influence 
on insulin concentration (JE Lee 1997, Madsen et al. 1997, Mutoh et al. 1997, Naya et al. 
1995). In an animal model study, a Neurod/BETA2-deficient mouse was found with a reduced 
number of insulin-producing beta cells and developed severe diabetes (Naya et al. 1997). In 
addition, a genetic study in Japanese patients revealed a loss of function variant (Ala45Thr) in 
the Neurod gene associated with type 1 diabetes (T1D) (P = 0.006) (Iwata et al. 1999). Later a 
study from the Welcome Trust Case Control Consortium also reported an association of CUX2 
variant with T1D (rs1265564, P = 1.6×10-16) (J Huang et al. 2012). Considering a potential 
role of CUX2 in metabolic conditions it could be a target of interest in gout aetiology. 
CUX2 was also identified as a novel gout risk locus in a Japanese GWAS and was 
successfully replicated in a subsequent GWAS in males only (Matsuo et al. 2016, Nakayama 
et al. 2017). In addition, targeted and functional studies (mentioned above) indicate the 
involvement of the CUX2 locus in metabolic mechanisms, which may also confer gout risk. 
Therefore, the rs4766566 in CUX2 was tested for its association with gout in NZ Polynesian 
and European sample sets (Table 2.2). 
 
2.1.3.4. Inflammatory Loci and Gout 
2.1.3.4.1. IRGM 
IRGM is a member of the immunity-related p47guanosine triphosphatases (IRG) family 
and is involved in innate immune-mediated defence against intracellular pathogens. It is well 
known for its role in activation of autophagy to confer organism resistance against infections 
(Singh et al. 2006). 
Several lines of evidence have implicated autophagy in inflammatory signalling and 
inflammasome pathways protecting against infectious, autoimmune and inflammatory 
disorders (Levine and Deretic 2007, Levine et al. 2011, Wildenberg et al. 2012). However, 
impaired autophagy can promote inflammation (Saitoh et al. 2008). Studies have shown that 
defects in autophagy may activate pro-inflammatory elements such as type I IFN (type-I 
interferon), which causes hyperactivation of the inflammasome, a central complex in 
 
 
60 | Page 
inflammation (Bulua et al. 2011, R Zhou et al. 2011). The molecular mechanisms by which 
autophagy regulates inflammasome activation are not well understood yet. 
Among better-established links between autophagy and inflammation are an association 
of genetic polymorphisms in IRGM and ATG16L1 with Crohn’s disease (CD) (rs13361189; C 
allele P = 1.07 × 10-19, OR = 1.34, rs4958847;A allele P = 2.78 × 10-17 OR = 1.31) and 
ulcerative colitis (UC) (rs13361189; P = 0.0069, OR = 1.16; rs4958847 P = 0.014, OR = 
1.13): both conditions occur in chronic inflammation of digestive tract cumulatively known 
as inflammatory bowel disease (IBD) (Palomino-Morales et al. 2009). A genome-wide 
association scan of 1748 CD cases and 2938 controls conducted by the Welcome Trust Case 
Control Consortium (WTCCC) in a European population, identified significant associations 
between IRGM variants (rs13361189; OR = 1.38, P = 2.09 × 10−10 and rs49588847; OR = 
1.36, P = 3.77 × 10−9) and CD with a moderate effect (Parkes et al. 2007). In addition, genetic 
variants rs13361189 and rs4958847 in IRGM were also tested for their association with 
ileocolonic CD in New Zealand Caucasians (of European ancestry) and a signification 
correlation was detected between these variants and ileal CD (OR =1.94, P = 0.001; OR = 
1.76, P = 0.002, respectively) (Roberts et al. 2008). A South Asian study of 752 Indian IBD 
patients and 448 healthy controls also evidenced genetic variants in IRGM (i.e. rs9637876; OR 
= 1.25, P = 0.046) conferring risk for CD (Baskaran et al. 2014). Other emerging links associate 
autophagic inflammation with metabolic disorders, autoimmune conditions i.e. SLE and 
inflammatory lung cystic fibrosis disease (Grossmayer et al. 2005, Levine et al. 2011, Luciani 
et al. 2010, L Yang et al. 2010). Collectively this evidence suggests an inflammatory role of 
the IRGM gene, which may also confer gout susceptibility. Until now, no association study has 
been conducted to explore an inflammatory role of IRGM variants in gout, therefore this study 
will be a valuable resource to identify possible contribution of the IRGM locus in gout 
pathogenesis through testing the association of IRGM (rs13361189) with gout in NZ cohorts. 
Previous evidence of the association of rs13361189 with other phenotypes has been 
documented in Table 2.3. 
 
2.1.3.4.2. PPARGC1B 
The peroxisome proliferator-activated receptor- γ (PPAR-γ), a ligand dependent nuclear 
receptor, potentially contributes both to inflammation and metabolism (Chawla et al. 2001). 
PPAR-γ orchestrates anti-inflammatory signalling in the resolution phase of the inflammatory 
process (Akahoshi et al. 2003, Getting et al. 2006, Rose et al. 2006). Indeed, increased 
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expression of PPAR-γ was found in the MSU crystal-induced inflammatory response 
(Akahoshi et al. 2003). There are two transcriptional co-activators, peroxisome proliferator-
activated receptor- α (PPARGC1A) and peroxisome proliferator-activated receptor- β 
(PPARGC1B), which coordinate with PPAR-γ in stimulating various metabolic and 
inflammatory processes (Finck and Kelly 2006). Among these, PPARGC1B is substantially 
involved in regulating multiple aspects of energy metabolism such as gluconeogenesis, fatty 
acid B oxidation, thermogenesis and more importantly mitochondrial biogenesis (Lehman et 
al. 2000, Puigserver et al. 1998, Vega et al. 2000, Yoon et al. 2001). Emerging evidence of 
PPARC1B involvement in mitochondrial biogenesis opens a new area of debate in an 
inflammatory human disorder. The primary function of PPARGC1B seems to be to co-activate 
PPAR-γ in maintenance and regulation of mitochondrial biogenesis. The PPAR-γ activation 
involves ligand binding and the phosphorylation mechanism, which are catalysed by adenosine 
monophosphate-activated protein kinase (AMPK). AMPK also promotes mitochondrial 
biogenesis through direct activation of PPARGC1B. Alternatively, this protein kinase is also 
recognized as functionally important in limiting MSU crystal-induced inflammation (Yun 
Wang et al. 2014). 
Although these nuclear receptor super family members are negative regulators of 
inflammation, impairment in their function is associated with certain ailments (Finck and Kelly 
2006, J Liu et al. 2015, J-J Zhou et al. 2014). In particular, the association of PPARGC1B has 
been previously reported with inflammation-associated metabolic and immune disorders 
including T2D, obesity, airway hypersensitivity, breast cancer and ankylosing spondylitis 
(Ahmadian et al. 2013, Temesi et al. 2014, Villegas et al. 2014, Wirtenberger et al. 2006). 
Moreover, Ishii and co-workers proposed an active role of PPARGC1B in osteoclastic bone 
resorption by coordinating with mitochondrial biogenesis (Ishii et al. 2009). When it comes to 
gout, established evidence strongly supports an inflammatory role of PPARGC1B in the 
disease. A recent study in a Han Chinese population, typed three correlated variants in 
PPARC1B over 448 gout patients and 943 controls. These variants exhibited significant 
association with gouty arthritis including the missense R265Q (rs45520937) variant (OR = 
1.85, P = 6.66 × 10−9) (SH Chang et al. 2016). The current study also attempted to find 
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2.1.3.4.3. IL23R 
Interleukin 23 (IL23) is a hemopoietic class cytokine. To become functionally active IL23 
needs to bind with biologically-active receptors, thus IL23R pairs with IL-12 subunit IL12Rβ1 
to confer IL23 responsiveness on cells (Parham et al. 2002). Various cells of the immune system 
including activated monocytes, dendritic, natural killer (NK) and T memory cells mainly 
express IL23 receptor on their surfaces (Duerr et al. 2006). This cytokine also promotes 
inflammation by releasing IL-1 and tumour necrosis factor alpha (TNF-α) from activated 
dendritic cells and macrophages (Brombacher et al. 2003, S Liu et al. 2015, S Liu et al. 2013). 
Moreover, IL23R contributes potentially via regulating the T helper 17 (Th17) cell activation 
that highly expresses IL-17 in response to an inflammatory stimulus. The process further 
stimulates the secretion of other inflammatory enhancers and promotes the inflammatory 
response (Sutton et al. 2009). 
Numerous studies have documented the association of IL23R variants with auto- 
inflammatory and auto-immune disorders such as CD, UC, rheumatoid arthritis (RA), 
ankylosing spondylitis (AS), psoriasis arthritis and IBD (Cargill et al. 2007, M Chang et al. 
2008, Chen-Xu et al. 2012, Hollis-Moffatt et al. 2009, Karaderi et al. 2009, Roberts et al. 2007, 
Wellcome Trust Case Control Consortium 2007). One such study constituted a GWAS across 
American populations and found the IL23R rs11209026 (c.1142G>A, p.Arg381Gln) as an 
uncommon variant conferring strong protection against CD in Jewish (OR = 0.26, P = 
5.05×10−9) and non-Jewish individuals (OR = 0.45, P= 3.55×10−11) (Duerr et al. 2006). 
Weersma et al. further confirmed the association of  the IL23R variant rs11209026 with CD 
(OR = 0.14, P = 3.9×10−7) and UC (OR = 0.33, P = 1.4×10−9) in the same direction of effect in 
a Netherlands cohort of 311 CD and 207 UC patients and 893 healthy controls (Weersma et al. 
2008). Furthermore, a study conducted by Roberts et al., (2007) in New Zealand Caucasian 
IBD patients and controlsevidenced association of IL23R rs11209026 variant with CD and UC 
(OR = 0.54, P = 0.002; OR = 0.66, P = 0.037) (Roberts et al. 2007). 
However, only a few genetic studies have assessed the causal effect of IL23R variants for 
gout. For instance, a recent study in Han Chinese males reported an association between the 
IL23R:rs7517847 (G/T) polymorphism and gout (OR = 0.82, P = 0.047) (S Liu et al. 2015). 
This indicates a lack of knowledge on genetic variants in the IL23R gene causal to gout and 
supports further investigation in this area. Thereby, three variants in IL23R (rs7517847, 
rs11209026 and rs11465804) were tested for their association with gout particularly in NZ 
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populations (Polynesian and European). Details of earlier reports on these genetic variants are 
described in the Table 2.3. 
 
2.1.3.4.4. Alpha-1 Antitrypsin Encoded by SERPINA1 
Among immunoregulatory pathways which control innate immune responses, the hepatic 
acute-phase response is one of the crucial contributors. In response to DAMP signals the 
patterns of protein synthesis by the liver become altered; such as increased expression of 
positive acute phase proteins (AAPs) like C-reactive protein (CRP), alpha1-antitrypsin (AAT) 
or alpha1-acid glycoprotein (AGP) and decreased expression of negative AAPs such as 
transthyretin, retinol binding protein, cortisol binding globulin, transferrin and albumin. The 
production of AAPs in hepatocytes is controlled by various cytokines (released during the 
inflammatory response) (Janciauskiene et al. 2013). Alpha anti-trypsin is known as alpha1-
proteinase inhibitor—a historically famous anti-inflammatory marker in the body, which is 
encoded by the SERPINA1 gene. It is a 52-kDa secreted glycoprotein that belongs to the serpin 
protein superfamily, produced by blood monocytes, macrophages, pulmonary alveolar cells, 
and intestinal and corneal epithelium (Geboes et al. 1982, D Perlmutter et al. 1988, Ray et al. 
1982). Expression studies have also detected AAT expression in the kidney, stomach, small 
intestine, pancreas, spleen, thymus ovaries and testes (Kalsheker et al. 2002, Tuder et al. 2010). 
In response to inflammation as an acute-phase reactant, AAT levels increase dramatically 
(3 to 4-fold) in the blood. (BOŠKOVIĆ and TWINING 1997). It has also been evident that 
blood monocytes and alveolar macrophage can enhance tissue AAT levels in response to IL-6, 
IL-1 and TNFα (Knoell et al. 1998, D Perlmutter et al. 1988). Given that neutrophils remain 
key effector cells in inflammatory disorders, AAT is reported as a main inhibitor of neutrophil 
elastases and serine proteases released from activated neutrophils during inflammation (Gettins 
2002). One study reported that the release of serine proteinases by neutrophils is responsible 
for lung damage in the absence of AAT and leads to the progression of COPD and emphysema 
(Hautamaki et al. 1997). AAT deficiency increases neutrophil burden at the inflammatory site 
in response to the chemo attractants (CXCL8) and leukotriene B4 (Woolhouse et al. 2002). One 
of the prominent features of AAT is that it partially regulates the seasonality of the cytokine 
response. The periodicity of AAT is opposite to cytokines (e.g. IL-1β) and highest in summer. 
In a study of more than 800 individuals from the Netherlands, a clear AAT seasonality profile 
had been observed with the peak in summer when the AAT level was low and production of 
IL1β was highest (ter Horst et al. 2016). 
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Since AAT is encoded by the SERPINA1 gene, AAT deficiency (AATD) is one of the 
most common genetic disorders among Europeans caused by mutations in SERPINA1. AATD 
patients coexist with emphysema because of the imbalance between elastase and the anti-
elastase effect of AAT. Many variants in SERPINA1 have been reported to cause AATD 
including the best studied S variant (PIS rs17580) and the Z variant (PIZ rs28929474). 
Common single nucleotide polymorphisms in SERPINA1 have also been detected in early onset 
chronic obstructive pulmonary disease (COPD) in Swiss and Danish cohorts through a GWAS 
of AAT (Thun et al. 2013). Another GWAS of AAT in a Japanese population showed 
associations of metabolic syndrome and SERPINA1 genetic variants with serum AAT levels 
including SERPINA1;rs2896268 (: β = 1.61 mg/dL, P = 2.4×10-4) (Setoh et al. 2015). However, 
there is no evidence of genetic association of SERPINA1 with gout susceptibility. Therefore, 
this study has been designed to test for association of SERPINA1 variants (rs12884390 (surrogate 
of rs2896268) and rs1243160) with gout in NZ cohorts. Here the SERPINA1 rs1243160 was a 
lead blood cis-eQTL signal (Westra et al. 2013). 
 
2.1.4. Aims: 
This chapter aims:  
a) To test the association of genetic loci with gout susceptibility in NZ Polynesian and 
European populations that directly or indirectly contributes to urate handling. 
b) To test the association of genetic variants in inflammatory loci with gout risk in 
sample sets comprised of NZ Polynesian and European people. These loci were 
previously associated with inflammatory or metabolic conditions. 
 
2.2. Genetic Association Analysis Of Urate and 
Inflammatory Loci With Gout In New Zealand Polynesian 
And European Cohorts 
2.2.1. Methods 
2.2.1.1. Selection of Genetic Variants 
In the current study seven SNPs (common genetic variants) have been selected in urate 
related genes based on their association with urate and gout in the literature. Additionally, seven 
SNPs were selected in inflammatory loci (common genetic variants), previously associated with 
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inflammatory and auto-inflammatory disorders. The following tables list these variants, while 
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Table 2.2: List of urate related and inflammatory genetic variants 
SNPs Chromosome Gene Gene associated traits 
Urate-related Loci 
rs1165196 6 SLC17A1 Urate, gout 
rs2285340 11 SLC22A12 Urate, gout 
rs11733284 4 NIPAL1 Novel locus associated with urate and gout 
rs11758351 6 HIST1H4E 
Found in the LD of SLC17A1locus 
associated with urate, gout, various types of 
cancers 
rs7903456 10 FAM35A Novel locus associated with urate and gout 
rs4073582 11 CNIH2 Urate, gout, schizophrenia 
rs4766566 12 CUX2 Urate, gout, T1D 
Inflammatory Loci 
rs13361189 5 IRGM IBD (CD, UC), SLE  
rs45520937 5 PPARGC1B 
Novel locus associated with gout, T2D, 
obesity, airway hypersensitivity, breast 




1 IL23R IBD (CD, UC), rheumatoid arthritis, ankylosing spondylitis 
rs12884390 
rs1243160 14 SERPINA1 AATD, emphysema, COPD 
SNPs: single nucleotide polymorphisms, T1D: Type 1 Diabetes, IBD: Inflammatory Bowel Disease, CD: Crohn’s 
Disease, UC: Ulcerative Colitis, T2D: Type 2 Diabetes, AATD: Alpha-1 Antitrypsin Deficiency, COPD: Chronic 
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Table 2.3: Published association of selected common genetic variants in inflammatory loci with inflammatory 
conditions 
 
IBD: Inflammatory Bowel Disease, CD: Crohn’s Disease, AATD: Alpha-1 Antitrypsin Deficiency, COPD: 
Chronic Obstructive Pulmonary Disease. Effect sizes are odds ratios unless specified. 
 
Reference Population Phenotypes Associated with P-Value Effect Size 
IRGM; rs13361189 
 (Yao et al. 2018) Chinese Grave’s disease 0.027 1.20 
 (Baskaran et al. 2014) Indian CD 0.010 1.33 
 (Parkes et al. 2007) European CD 6.6×10-4 1.38 
 (XC Lu et al. 2013) China CD 5.2×10-10 1.30 
 (Ge et al. 2014) Chinese Glioma 0.028 1.53 
 (DG Yang et al. 2014) Han Chinese Leprosy 0.012 1.49 
 (Roberts et al. 2008) NZ Caucasians CD 0.001 1.94 
PPARGC1B; rs45520937 
 (W-C Chang et al. 2017) Taiwan Han Chinese gout 6.66×10-9 1.85 
IL23R; rs7517847 
 (S Liu et al. 2015) Chinese gout 0.042 χ2=4.20 
 (Xavier et al. 2012) Iranian Bechet’s disease 1.23×10-6 1.48 
 (Zhai et al. 2012) European Rheumatoid arthritis 0.010 1.13 
 (Ferguson et al. 2010) New Zealand CD 0.001 0.42 
IL23R; rs11209026 
 (Oliver et al. 2007) Spanish CD 0.001 0.30 
 (Baptista et al. 2008) Brazilian CD 0.009 0.36 
 (Latiano et al. 2008) Italian CD 0.005 0.62 
(Ferguson et al. 2010) New Zealand CD 0.164 0.64 
 (Hollis-Moffatt et al. 
2009) New Zealand Rheumatoid arthritis 0.86 1.01 
IL23R; rs11465804 
 (Duerr et al. 2006) Jewish and Non-Jewish CD 5.97×10-10 0.47 
(Einarsdottir et al. 2009) Swedish IBD 0.003 0.42 
(Einarsdottir et al. 2009) Swedish UC 0.002 0.42 
SERPINA1;rs12884390 (surrogate of rs2896268, r2=0.968) 
(Setoh et al. 2015) Japanese AAT GWAS 2.4×10-4 β = 1.61 
SERPINA1;rs1243160 
(Westra et al. 2013) European Top signal in blood eQTL 6.25×10-161  
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2.2.1.2. Study Participants 
In the current study, the data of participants from various gout case-control cohorts mainly 
from New Zealand were included to assess association of variants of interest with gout. The 
New Zealand dataset was further subdivided into NZ European (n = 2793) and Polynesian 
(Māori, Cook Islands); n = 2470); subset into Eastern Polynesian (n = 1155) that is further sub-
categorised into EPN (people with higher Polynesian grandparental ancestry; n = 704) and EPZ 
(people with lower Polynesian grandparental ancestry; n = 451), Western Polynesian (Tonga, 
Samoa, Niue, Tokelau); n = 753), admixed group of Polynesian ancestry (EPWP; n = 108) and 
a Māori dataset from Ngāti Porou Hauora NPH (n = 454). Ngāti Porou Hauora operates in the 
tribal territory of rohe, located in the East Coast region (Te Tai Rawhiti). The detailed 
description of NZ datasets can be found in Appendix Section 1.1. The Eastern Polynesian sub-
groups EPN and EPZ were categorised on the basis of calculation of ancestry estimates (self-
reported grandparents ancestry) using STRUCTURE (software) 
https://web.stanford.edu/group/pritchardlab/structure.html. The difference in ancestry levels of 
East Polynesian cases and controls was maintained in the ancestry estimates (average = 0.82 in 
cases and 0.67 in controls, t = 7.8, Pt = 1.8×10-14). The EPN group included EP individuals 
with a higher level of Polynesian ancestry (≥0.67) whereas the EPZ group included individuals 
with lower estimated level of Polynesian ancestry (<0.67). The value of 0.67 is a geometric 
mean of Eastern Polynesian cases and controls. Refer also to last paragraph Section 2.2.1.4. For 
European-specific association analysis, gout cases were also included from two additional 
European cohorts; the European Crystal Network Cohort (EUROGOUT; n = 762) and the 
Arthritis Genomics Recruitment Initiative in Australia Cohort (AGRIA; n= 198)– details in 
Appendix section 1.1. Further a larger European group from the UK Biobank gout cohort that 
consisted of 7341 gout cases and 352487 controls were also included in population (European) 
specific gout association analyses. The demographic and clinical details in each dataset are 




69 | Page 
Table 2.4: Demographic details of the datasets included in the study for gout association analysis 
Population NZ Polynesian  European 
Sub-population EP WP EPWP NPH  NZ European UK Biobank EURO-GOUT AGRIA 










gout Gout Gout 
Baseline Information 
Total 
Participants 475 662 416 337 33 75 267 187  1831 962 7341 352487 762 198 











































































































Comorbidities of Gout 
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Characteristics of Gout 









15.27 -  
48.50± 
16.70 - - - 
45.95 
 (13.87) - 









4.87 -  
4.70 ± 









 (24.10) - 
96 
 (25) - 
11 
 (36.66) - 
8.29 
(10) -  
195 





NZ; New Zealand, EP; East Polynesian, WP; West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngati Porou Hauora, NZ Eur; NZ 
European, UKB; UK Biobank Cohort, EUROGT; European Crystal Network Gout Cohort, AGRIA; Arthritis Genomics Recruitment Initiative in Australia Gout Cohort, BMI; 
Body mass index, n (%); total number (percentage). ^Data are shown as mean ± standard deviation. †Data are shown as percentage reported with comorbidities (who answered 
the question of having comorbidities ‘yes’ (percentage), Data for the comorbidities are self-reported. Data presented as an average for genetic variants genotyped through TaqMan 
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2.2.1.3. Genotype Sources 
The genotyping data were sourced from different platforms either from Illumina chip 
(Illumina CoreExome v24 bead chip array data) (detail in Appendix section A.1.3) or directly 
by TaqMan genotyping. The TaqMan genotyping of variants was conducted over European 
(NZ European, EUROGOUT, AGRIA) and NZ Polynesian sample sets, using TaqMan® SNP 
Genotyping assay (Applied Biosystems, Foster City, USA), following the manufacturer’s 
protocol. TaqMan SNP genotypes were auto-called via reporter dye signal plots on 
Lightcycler® 480 Real- Time Polymerase Chain Reaction (RT-PCR) System (Roche Applied 
Science, Indianapolis, IN, USA). Details about the sources for genotype are presented in the 
Appendix (section A.1.1 and A.1.2). The genotype data were processed manually by visualizing 
plots on the TaqMan machine. These plots distinguish the homozygous major alleles, 
heterozygous and homozygous minor alleles clusters. No error threshold was set to process 
TaqMan genotypes except visualizing genotype data by human eye and failed samples were 
removed. Samples that initially failed were re-genotyped but if they still did not provide 
information for genotype, were excluded from the analysis. 
 
2.2.1.4. Statistical Analysis 
Multivariable adjusted regression analyses were used to assess the association of genetic 
variants with binary response variables such as gout (logistic regression) and with continuous 
response variables such as BMI, number of gout attacks per year etc. (linear regression). 
Logistic and linear regression analyses were done using statistical software R version 3.2.4 (R 
Core, 2016). In the analysis all samples  (case and controls) were pooled and coded with datasets 
they came from. For the analysis a logistic regression model was used where gout (case-control) 
as an outcome was dependent on SNPxdataset. An interaction term was added to regressions to 
test for non-additive interaction between predictor variable (ancestral group) and outcome. 
Individuals with missing data for any variable were excluded from the analyses. Allelic ORs 
for binary response and β-estimates for continuous response were calculated for each SNP by 
adjusting with primary confounders such as age and sex in the regression models. For 
Polynesian individuals, self-reported grandparental (GP) ancestry was added as an additional 
adjustor. Inverse-variance weighted fixed effect meta-analysis was performed using the ‘meta 
package’ within R (http://CRAN.R-project.org/package=meta, 2014) to combine independent 
sample sets and also to increase the overall power of analysis. The inverse variance-weighted 
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average method summarizes effect sizes from multiple independent studies, or in this case 
hypotheses in different ancestral groups, by calculating the weighted mean of the effect sizes 
using the inverse variance of the individual studies/hypotheses as weight. The meta-analysis is 
represented by a Forest plot. The Forest plot is a graphical presentation of meta-analysis in 
which the combined effect of all estimated results for each study can be viewed along with the 
overall result. The Forest plot is commonly presented with two columns; the left hand side 
shows the studies in chronological order and the right hand side presents  measures of estimates. 
The area of each block represents the weighing of each study (measured effect) incorporating 
horizontal lines showing the confidence interval. The overall meta-analysed effect is usually 
represented with a vertical line in the plot and this meta-analysed estimated effect is represented 
as a diamond with vertical lines on both sides showing the confidence interval for this estimate. 
A vertical line representing no effect is also plotted. If the confidence intervals for each study 
overlap with this line, it demonstrates that at the given level of confidence their effect sizes do 
not differ from no effect for the individual study. The same applies for the meta-analysed 
measure of effect; if the lateral points of the diamond overlap the  vertical line of no effect that 
means the overall meta-analysed result cannot be said to differ from no effect at the given level 
of confidence. All NZ Polynesian subgroups were combined by meta-analysis to observe the 
overall effect size and variability across multiple populations. Heterogeneity between combined 
sample sets was determined through the Q-statistic and for variants with significant evidence 
for heterogeneity PHet < 0.05, the fixed-effect model was replaced with a random-effect model.  
Linkage disequilibrium (LD) between some variants (e.g. variants in IL23R and 
SEPINA1) was calculated using information from 1000 Genome database 
(http://browser.1000genomes.org/) for both European and East Asian sample sets (Chinese 
dataset). For visualization, (https://ldlink.nci.nih.gov/?tab=home) was used where r2 ≥ 80 was 
set as the threshold for significant LD.  
Power to detect a POR < 0.05 was calculated in the NZ Polynesian, European and UK 
Biobank data sets following (Johnson et al. 2001) methodology. The power calculation was 
performed in R software (version 3.6.) with a package powerGraph 
(https://rdrr.io/github/MerrimanLab/merrimanR/man/powerGraph.html), followed the Johnson 
et al., (2001) approach, where the number of cases and controls were given for the each study 
ancestral group. Power graphs were plotted in R using the same power package where the allele 
frequency was present on the x-axis and detection power on the y-axis. The broken red line 
illustrates the power based on effect size and frequency.  
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To control for increased false positive discoveries as a result of a large number of tests, 
the false discovery rate (FDR) method was used. The adjusted P value is the smallest family-
wise significance level at which a particular comparison will be declared statistically significant 
as part of multiple comparison testing. A separate adjusted p-value is computed for each 
comparison in a family of comparisons but these values of adjusted p-values depend on the 
entire family (family of comparisons). For adjusting p-values through the FDR method a 
p.adjust function was used in R software that adjusted all significant p-values resulting from 
association analysis. This FDR method is less conservative than the Bonferroni correction 
method and preferred in the case of multiple comparisons as in the current study.  
In the current study, the population stratification effect was controlled by using 
grandparental proportion as adjuster, named as GP ancestry. In the present study different 
ancestral groups were involved such as European and Polynesian where Polynesian were 
categorized into different groups based on their origin and genetic background such as Eastern 
Polynesian,  Western Polynesian, admixed group (EPWP) and NPH. Participants were divided 
into four sample sets according to their self-reported grandparental ancestry; NZ European, 
Eastern Polynesian, Western Polynesian and mixed EP and WP group. These groupings were 
based on previous evidence for genetic heterogeneity between Eastern and Western Polynesia 
found in both genome-wide analyses of population structure in the Pacific (Friedlaender et al., 
2008; Kayser et al., 2006; Wollstein et al., 2010), and more specifically in prior work published 
by the Merriman Laboratory (Phipps-Green et al., 2010). Groups were defined using a 
hierarchy system such as individuals of any Polynesian ancestry being included in their 
respective group first. The individuals who listed no non-European ancestry were included in 
the New Zealand European sample set. The Eastern Polynesian sample set was further split into 
two groups (EPN and EPZ) to compensate the distinct difference in average number of self-
reported grandparents of Polynesian ancestry in cases and controls (average = 3.2 in EP cases 
and 2.5 in controls). To determine which individual should be included in two groups; one with 
high grandparent ancestry level (EPN) and other with low grandparent ancestry level (EPZ) 
estimates of individual Eastern Polynesian ancestry proportions were calculated in 
STRUCTURE by Hollis-Moffat et al. (2011) where 67 bi-allelic ancestry-informative markers 
were obtained through TaqMan or Sequenom genotyping. STRUCTURE ancestry estimates 
were calculated assuming two populations (European and Polynesian). Controls from the 
European dataset were taken as an ancestral reference population for population clustering.  
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Individuals having an ancestry estimate >0.67 were placed in EPN and <0.67 placed into EPZ. 
There was still a possibility that these different ancestral groups produced a population 
stratification effect therefore the association analysis was adjusted with GPancestry in an 
attempt to control for this. However, it is not possible to completely control the population 
stratification effect, for example because of subtle differences in ancestry such as intra-
Polynesian or European. 
The chi-square test for Hardy-Weinberg equilibrium assumes the "null hypothesis" - that 
is, the observed genotype frequencies are not significantly different from those predicted for a 
population in equilibrium. As with any theoretical value, the genotype frequencies predicted by 
the Hardy-Weinberg equilibrium equation almost always differ from the frequencies observed 
in a real population. The problem is to discern when the observed versus expected values differ 
due to chance and when they are truly different. For this region marginally significant 
deviations were not considered strong evidence for a deviation owing to technical reasons (e.g. 
genotyping error). 
 
2.2.1.4.1. Association Analysis Using Hyperuricaemic Controls 
To determine genetic control of the progression from hyperuricaemia to inflammatory 
gout, additional analyses were conducted by splitting controls into hyperuricaemic (serum urate 
(SUA) ≥ 0.41mmolL-1) versus gout cases. This analysis was carried out under a sub-category 
of (HU controls vs gout) of the main cohort of controls in each study population and was 
performed for inflammatory genetic variants (variants in IRGM, PPARGC1B, IL23R and 
SERPINA1) to assess their inflammatory role in gout pathogenesis, in particular during 
progression from hyperuricaemia to gout. For this purpose, a multivariate regression analysis 
was conducted in each sub-category adjusted by age, sex, and grandparental ancestry for 
Polynesian sample sets and in some later analysis with principal components (based on their 
availability by that time). The information about clinical characteristics regarding HU controls 
vs gout cases in each sample set is provided in Table 2.5. The power graphs show that these 
databases are certainly underpowered to detect a moderate effect size (OR =1.5) at frequency 
>0.02.  Even the power was less than 60% to detect moderate effect size at 0.20 allele frequency. 
Power detection of gout association study in the Eastern Polynesian (EP) group was determined 
across a range of effect sizes (OR: 2.0, 1.5, 1.2) and minor allele frequencies. Power 
calculations were performed based on 475 gout cases and 183 non-gout HU controls in EP, 416 
gout cases and 104 non-gout HU controls in WP and 1831 gout cases and 114 HU controls in 
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European. The graph was generated in R version 3.6. The allele frequency is presented on the 
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Power detection of gout association analysis in NZ Polynesian datasets (using HU controls vs gout cases) was 
calculated across range of effect sizes (OR: 1.2, 1.5, 2.0) and minor allele frequencies on the x-axis. The study 
was under-powered (<60%) to detect a moderate size effect (OR = 1.5) for the variants with a minor allele 
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Power detection of gout association analysis in European (NZ European, AGRIA, Eurogout) datasets (using HU 
controls vs gout cases) was calculated across range of effect sizes (OR: 1.2, 1.5, 2.0) and minor allele frequencies 
on the x-axis. The study was under-powered (<60%) to detect a moderate size effect (OR = 1.5) for the variants 
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Table 2.5: Demographic details of the datasets included in the study for gout association analysis using HU controls versus gout cases 
Population NZ Polynesian  European 
Sub-population EP WP EPWP NPH  NZ European UK Biobank EURO-GOUT AGRIA 










controls Gout Gout 
Baseline Information 
Total Participants 475 183 416 104 33 29 267 51  1831 114 7341 - 762 198 





































































































Comorbidities of Gout 













 (6.89) 81 (31.39) 
5 




























(27.92) - - 
205 














 (10.34) 90 (35.01) 
9 






































































 (1.49) - - 
2 




 (4) - -   
Characteristics of Gout 
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48.50± 
16.70 - - - 
45.95 
(13.87) - 









4.87 -  
4.70 ± 









 (24.10) - 96 (25) - 
11 
 (36.66) - 8.29 (10) -  
195 





HU; hyperuricaemic controls, NZ; New Zealand, EP; East Polynesian, WP; West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngāti Porou 
Hauora, NZ Eur; NZ European, UKB; UK Biobank Cohort, EUROGT; European Crystal Network Gout Cohort, AGRIA; Arthritis Genomics Recruitment Initiative in Australia 
Gout Cohort, BMI; Body mass index, n (%); total number (percentage). ̂ Data are shown as mean ± standard deviation. †Data are shown as percentage reported with comorbidities 
(who answered the question of having comorbidities ‘yes’ (percentage), Data for the comorbidities are self-reported. Data presented as an average for genetic variants genotyped 




80 | Page 
 
Each study was differentially powered to detect a moderate effect size (OR =1.5), which has 
been mentioned in the legend of each study power graph. Following are power graphs of all 
study datasets using all controls vs gout cases. 
 
Figure 2.3: A Power graph of NZ Polynesian (EP, WP, EPWP and NPH) datasets. 
 
Power detection of gout association analysis in NZ Polynesian datasets was calculated across range of effect sizes 
(OR: 1.2, 1.5, 2.0) and minor allele frequencies on the x-axis. The study was adequately powered (>80%) to detect 
a moderate size effect (OR = 1.5) for the variants with a minor allele frequency (≥0.04).  
Figure 2.4: A Power graph of Europeans (NZ European, AGRIA, Eurogout) dataset. 
 
Power detection of gout association analysis in the European dataset was calculated across range of effect sizes 
(OR: 1.2, 1.5, 2.0) and minor allele frequencies on the x-axis. The study size was larger than Polynesians therefore 
it was adequately powered (>80%) to detect a moderate size effect (OR = 1.5) for the variants with a minor allele 
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Figure 2.5: A Power graph of the UK Biobank dataset. 
 
Power detection of gout association analysis in the European dataset was calculated across range of effect sizes 
(OR: 1.2, 1.5, 2.0) and minor allele frequencies on the x-axis. The power calculation for UK Biobank suggested 
that it was highly powered (95%) based on the larger sample size to detect a weaker effect of OR =1.2 for the 




2.3.1. Single variant Allelic Associations for Urate transporters 
2.3.1.1. SLC22A12 (rs2285340) 
SLC22A12;rs2285340 was found to be monomorphic in European populations. For the 
Polynesian group the T-allele of rs2285340 revealed significant association with reduced risk 
of gout (OR= 0.44, P0R= 0.004) in Eastern Polynesian of low ancestry (EPZ) sample set after 
adjusting for age, sex and grandparental ancestry (Table 2.6). The association remained 
significant even after adjusting the p-value by the false discovery rate (FDR) method (Padjusted 
= 0.009) to correct for multiple testing. However, non significant associations for the rs2285340 
T-allele with varying effect sizes were observed across other Polynesian  groups. To confirm 
either these ancestral groups e.g. EPZ act differently to each other an interactive analysis was 
performed between SNP and study groups. The interaction between SNP and the EPZ  group 
only showed a significant association between the T-allele and gout (effect size estimate =  -
0.806/OR = 0.44, Pinteraction = 0.001). To increase the power of the study an inverse-variance 
weighted meta-analysis combining all Polynesian sample sets was performed that did not 
evidence significant association between the T allele of rs2285340 and the risk of gout (ORmeta 
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= 0.98, Pmeta = 0.864) (Figure 2.6). Therefore, it appears that a significant association between 
rs2285340 T-allele and gout in one group (EPZ) may be a spurious finding driven by 
stratification. This may be because in the EPZ group the difference in allele frequencies 
detected between cases and controls is because have cases more Polynesian ancestry (because 
gout is more prevalent in Polynesian) therefore we expect a higher prevalence of a gout risk 
variant. Conversely, controls have more European ancestry therefore had a lower prevalence of 
this variant and this may have driven interaction with ancestry in the EPZ. In this particular 
case with the potential complication of stratification it was judged that the conservative 




Table 2.6: Association analysis of urate loci with gout in European and NZ Polynesian populations. 
Gene; SNP Group Genotype Frequencies Allele Freq. 
*Adjusted 
P-value OR (95% CI) PHWE 
SLC22A12; 
rs2285340  CC CT TT T 
   
European 
Cases - - - - 
- - 
- 
Controls - - - - - 
EPN 
Cases 189 (0.663) 88 (0.308) 8 (0.028) 0.182 
0.98 0.99 (0.70, 1.40) 
0.554 
Controls 228 (0.674) 95 (0.281) 15 (0.044) 0.184 0.214 
EPZ 
Cases 100 (0.800) 24 (0.192) 1 (0.008) 0.104 
0.004 0.44 (0.25, 0.77) 
0.735 
Controls 123 (0.594) 72 (0.347) 12 (0.057) 0.231 0.734 
WP 
Cases 288 (0.729) 97 (0.245) 10 (0.025) 0.148 
0.338 1.19 (0.83, 1.73) 
0.594 
Controls 216 (0.779) 56 (0.202) 5 (0.018) 0.119 0.540 
EPWP 
Cases 25 (0.757) 8 (0.242) 0 (0.00) 0.121 
0.535 0.71 (0.23, 2.05) 
0.428 
Controls 47 (0.723) 18 (0.276) 0 (0.00) 0.138 0.195 
NPH 
Cases 196 (0.717) 72 (0.263) 5 (0.018) 0.15 
0.114 1.36 (0.79, 2.29) 
0.150 
Controls 149 (0.776) 42 (0.218) 1 (0.005) 0.114 0.279 
*All values are adjusted for age, sex and grand-parental ancestry (GPancestry) estimates for Polynesian datasets. 
EPN: East Polynesian subjects with high EP ancestry, EPZ: East Polynesian subjects with low EP ancestry, WP: 
West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngāti Porou Hauora, 
EUR; NZ European. OR [95% CI]; Odds ratio [95% confidence interval], P = p-value for ORs, HWE; P values 
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Figure 2.6 : Forest plot of meta-analysis for SLC22A12;rs2285340 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. This variant was monomorphic in the 
European population. 
  
2.3.2. Single Variant Allelic Associations for Non-Urate Transporters 
Indirectly Involved in Urate Transportation 
2.3.2.1. NIPAL1 (rs11733284) 
There was no association of the minor allele (A) of rs11733284 was observed with gout 
risk after including sex and age adjustors in Polynesian and NZ European sample sets (Table 
2.7). Conversely, each additional A allele was found to be associated with a 5% increase 
towards the risk of gout (OR= 1.05, POR = 0.008) in the UK Biobank group. The association 
remained significant (Padjustment = 0.014) after adjusting the p-value through the FDR method to 
control false positive effect.  An opposing but statistical non-significant effect was observed in 
Polynesian groups such as EPN (OR = 0.85, P  = 0.272), WP (OR = 0.94, P  = 0.659) and the 
EPWP group (OR = 0.67, P = 0.341) (Table 2.7). A meta-analysis by combining all Polynesian 
subgroups (Figure 2.7) also did not reveal significant correlation of the variant with gout 
(ORmeta = 0.92, Pmeta= 0.325). 
To determine the likely causal gene at rs11733284 an expression quantitative trait loci 
(eQTL) analysis was also performed. An eQTL is a genomic locus that explain the variation in 
mRNAs levels therefore eQTL sample sets (e.g. GTEx, whole blood) can be used to translate 
identified variants (causal) to affected genes. For the purpose tissue-specific eQTL data from 
liver, pancreas and kidney were sourced from GTEx (http://www.gtexportal.org/). These tissues 
were chosen on the basis of possible involvement in the gout inflammatory process. Most of 
the inflammatory markers (e.g. alpha 1 antitrypsin (AAT)) are released from the liver and it is 
also involved in the production of urate. A significant association with NIPAL1 expression was 
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detected at this locus in the liver (Pos 4_48028097_G_A_b37; beta = 0.59, p = 4.0×10-10) and 
in the pancreas (Pos 4_48028097_G_A_b37; beta = 0.39, p = 5.4×105) (Figure 2.12 a and b). 
However, eQTL data from the kidney (GTEx.v8 (version 8)) did not provide evidence of a 
significant association at this locus for NIPAL expression (Pos 4_48028097_G_A_b38; beta = 
0.12, p = 0.488).  These data support the hypothesis that rs11733284 is likely to be involved in 
gout pathogenesis by influencing the expression of NIPAL1, however, it may not directly 
contribute to urate handling through the kidney but rather effect mechanisms that control urate 
metabolism or influence Mg2+ levels which influence other urate transporters in the kidney. It 
is important to note that a SNP could have association with more than one gene in more than 
one tissue.  For rs11733284 this is the case in that it is associated with NIPAL1 expression in 
the kidney as well as CNGA1 expression in the pancreas. However, it will be useful to add more 
supporting evidence in this regard (for example looking into Kanai et al.,2018 data). Moreover 
the colocalization approach  can be used to identify whether the GWAS and eQTL signals 
overlap. The subset of SNPs look slightly different in Figures 2.12 a and b because the plot was 
generated only using significant SNPs in these tissues.  
  
2.3.2.2. HIST1H4E (rs11758351) 
The minor G allele was significantly associated with gout in the WP (P = 0.042, OR = 0.68) 
and admixed Polynesian EPWP (P = 0.016, OR = 2.65) groups with opposing effect size. The 
FDR adjusted p-value also remained significant for rs11758351 in both groups (Padjusted = 0.044 
and Padjusted = 0.024, respectively). Moreover, the opposite effect size was also found in EP 
subgroups; EPN (OR = 1.11, P = 0.497) and EPZ (OR = 1.32, P = 0.192) (Table 2.7) but was 
statistically non-significant. The G-allele of rs11758351 also did not exhibit significant 
association with gout in the UK Biobank and NZ European datasets (OR = 1.00, POR = 0.940, 
OR = 0.84, POR = 0.073). To consider varying effect sizes in each group an interaction analysis 
was also conducted between SNP (rs11758351) and all datasets used in this study. A significant 
interaction was found between rs11758351 G-allele and EPWP (estimated effect size = 
0.797/OR = 2.21, Pinteraction = 0.031) and the WP  group (estimated effect size = -0.422/OR = 
0.65, Pinteraction = 0.032). In conclusion, these Polynesian groups should be treated as different 




85 | Page 
2.3.2.3. FAM35A (rs7903456) 
The FAM35A variant was selected for study based on a Japanese GWAS that associated 
the variant with gout (Nakayama et al., 2016). The molecular function of FAM35A is not 
known yet. Localisation analysis conducted by Nakayama et al., revealed that cytosolic 
expression was strongly detected in distal tubules which predicts the involvement of FAM35A 
in gout progression through dysfunction in urate handling in the distal nephron. The G-allele of 
the FAM35A;rs7903456 showed a protective association for gout when adjusted with sex and 
age in the UK Biobank (OR = 0.94, POR = 0.001) dataset even after adjusting p-value by the 
FDR method (Padjusted =0.006) . However, it did not exhibit significant association in a NZ 
European sample set (OR = 0.87, POR = 0.070) (Table 2.7). Consistent with this, no evidence 
of significant association of the G-allele was found with gout in any Polynesian groups 
separately (Table 2.7) or in a combined meta-analysis (ORmeta = 0.89, Pmeta = 0.114) (Figure 
2.9).  
 
 The rs7903456 variant identified a new locus for gout in the FAM35 gene that was also 
supported by an eQTL analysis in GTEx data of pancreas tissue (Figure 2.13). This shows that 
FAM35A is likely a causal gene at this locus as found to be a highest association signal at 
FAM35A for rs7903456. However, eQTL data from the kidney tissue did not show an 
association signal at rs7903456 for FAM35A rather was detected as an eQTL for SNCG (Pos 
10_87159562_C_T_b38; beta = -0.56 , p = 7.7×10-4) that indicates FAM35A may not be directly 
involved in gout pathogenesis through urate handling.  
 
2.3.2.4. CNIH2 (rs4073582) 
No association was observed between the rs4073582 C allele and gout in any of the-NZ 
Polynesian and European sample sets (Table 2.7). The association remained non-significant 
after including potential adjustors i.e. sex, age and GPancestry (for Polynesian sample sets) in 
the regression analysis. However, the T-allele showed evidence for protection against gout in 
the UK Biobank cohort (OR = 0.96, POR = 0.016). This association remained significant after 
adjusting the p-value for multiple testing by the FDR method (Padjusted = 0.0249). The rs4073582 
T allele did not exhibit significant association in a meta-analysis of Polynesian sample sets 
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2.3.2.5. CUX2 (rs4766566) 
The T-allele rs4766566 in CUX2 was significantly associated with gout risk with a large 
effect size in the NPH group (OR = 1.75, P = 0.001) as the addition of each T-allele increased 
75% of the gout risk (Table 2.7). The association remained significant after adjusting the p-
value by the FDR method to control false positive results (Padjusted = 0.006). However, the 
rs4766566 T-allele did not show significant association in other Polynesian groups (Table 2.7). 
Similarly, in the meta-analysis of Polynesian groups the CUX2 rs4766566 T-allele also did not 
exhibit significant association with gout (Figure 2.11). An interaction analysis of rs4766566 
was also performed for study ancestral groups where a nominal significant association was 
observed with the NPH group (ORint = 1.39, Pinteraction = 0.050). For European sample sets, the 
T-allele did not exhibit significant association with gout in European groups except for the UK 
Biobank (OR = 0.94, POR = 0.001, Padjusted = 0.006) where the rs4766566 minor allele (T) 
showed protection for gout (Table 2.7). It is also notable that the effect size in European sample 
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Table 2.7: Association analysis of non-urate loci with gout in European and NZ Polynesian populations. 
Gene; SNP Group Genotype Frequencies Allele Freq. 
*Adjusted 
P-value OR (95% CI) PHWE 
NIPAL1; 
rs11733284  AA AG GG A 
   
 
NZ European 
Cases 207 (0.133) 715 (0.460) 632 (0.406) 0.363 
0.486 1.05 (0.92, 1.20) 
0.831 
Controls 113 (0.122) 425 (0.459) 387 (0.459) 0.351 0.824 
 
UK Biobank 
Cases 3344 (0.140) 3344 (0.455) 2963 (0.404) 0.368 
0.008 1.05 (1.01, 1.08) 
0.063 
Controls 45531 (0.129) 162249 (0.46) 144754 (0.411) 0.359 0.843 
        EPN 
Cases 22 (0.070) 102 (0.325) 189 (0.603) 0.233 
0.272 0.85 (0.64, 1.14) 
0.115 
Controls 27 (0.093) 12 (0.446) 133 (0.460) 0.282 0.512 
 
EPZ 
Cases 16 (0.112) 56 (0.387) 71 (0.500) 0.306 
0.963 1.01 (0.69, 1.47) 
0.333 
Controls 12 (0.040) 98 (0.329) 187 (0.629) 0.205 0.592 
 
WP 
Cases 20 (0.050) 138 (0.350) 236 (0.598) 0.225 
0.659 0.94 (0.71, 1.25) 
0.976 
Controls 17 (0.055) 114 (0.375) 173 (0.569) 0.240 0.752 
EPWP 
Cases 1 (0.031) 10 (0.312) 21 (0.656) 0.187 
0.341 0.67 (0.29, 1.54) 
0.884 
Controls 2 (0.026) 35 (0.460) 39 (0.513) 0.256 0.07 
NPH 
Cases 18 (0.066) 110 (0.407) 142 (0.025) 0.270 
0.965 1.01 (0.70, 1.46) 
0.592 
Controls 13 (0.067) 74 (0.385) 105 (0.546) 0.260 0.993 
HIST1H4E; 
rs11758351  GG GT TT G 
   
 
NZ European 
Cases 26 (0.017) 373 (0.249) 1098 (0.733) 0.141 
0.071 0.84 (0.70, 1.02) 
0.376 
Controls 26 (0.028) 232 (0.250) 667 (0.721) 0.153 0.287 
 
UK Biobank 
Cases 126 (0.017) 1654 (0.225) 5560 (0.757) 0.129 
0.936 1.00 (0.95, 1.05) 
0.796 
Controls 5974 (0.016) 79968 (0.227) 266471 (0.756) 0.134 0.777 
 
EP/N 
Cases 24 (0.075) 126 (0.396) 168 (0.528) 0.273 
0.497 1.11 (0.83, 1.47) 
0.955 
Controls 30 (0.078) 146 (0.380) 208 (0.541) 0.268 0.537 
 
EP/Z 
Cases 11 (0.073) 53 (0.353) 86 (0.573) 0.250 
0.192 1.32 (0.87, 2.01) 
0.479 
Controls 12 (0.040) 98 (0.329) 187 (0.629) 0.205 0.850 
 
WP 
Cases 5 (0.012) 74 (0.185) 319 (0.801) 0.105 
0.042 0.68 (0.48, 0.99) 
0.763 
Controls 7 (0.022) 70 (0.229) 228 (0.747) 0.137 0.557 
 
EP/WP 
Cases 3 (0.090) 14 (0.424) 16 (0.484) 0.303 
0.016 2.65 (1.21, 6.08) 
0.980 
Controls 2 (0.026) 19 (0.253) 54 (0.720) 0.153 0.833 
NPH 
Cases 19 (0.069) 88 (0.322) 166 (0.608) 0.230 
0.647 0.92 (0.64, 1.31) 
0.128 
Controls 14 (0.072) 71 (0.369) 107 (0.557) 0.257 0.640 
FAM35A; 
rs7903456  AA AG GG G 
   
 
NZ European 
Cases 807 (0.535) 597 (0.395) 104 (0.068) 0.266 
0.070 0.87 (0.75 1.01) 
0.651 
Controls 460 (0.491) 396 (0.423) 80 (0.085) 0.297 0.687 
 
UK Biobank 
Cases 3866 (0.527) 2921 (0.398) 551 (0.075) 0.044 
0.001 0.94 (0.91, 0.98) 
1.000 
Controls 179953 (0.511) 143626 (0.408) 28774 (0.082) 0.044 0.626 
 Cases 33 (0.104) 130 (0.410) 154 (0.485) 0.69 0.615 0.93 (0.71, 1.22) 0.477 
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EPN Controls 37 (0.094) 151 (0.386) 203 (0.519) 0.712 0.253 
 
EPZ 
Cases 40 (0.268) 67 (0.449) 42 (0.281) 0.506 
0.210 0.80 (0.56, 1.13) 
0.219 
Controls 77 (0.094) 145 (0.386) 80 (0.519) 0.504 0.490 
 
WP 
Cases 43 (0.107) 142 (0.355) 215 (0.537) 0.715 
0.727 0.95 (0.73, 1.24) 
0.009 
Controls 25 (0.081) 126 (0.413) 154 (0.504) 0.711 0.913 
 
EPWP 
Cases 2 (0.060) 12 (0.363) 19 (0.575) 0.757 
0.973 0.99 (0.47,2.09) 
0.954 
Controls 7 (0.094) 29 (0.391) 38 (0.513) 0.709 0.670 
NPH 
Cases 39 (0.142) 137 (0.501) 96 (0.351) 0.604 
0.195 0.79 (0.55,1.13) 
0.376 
Controls 18 (0.094) 86 (0.450) 87 (0.455) 0.680 0.621 
CNIH2; 
rs4073582  TT CT CC C 
   
 
NZ European 
Cases 189 (0.124) 692 (0.454) 642 (0.421) 0.648 
0.455 1.05 (0.92, 1.21) 
0.904 
Controls 126 (0.144) 386 (0.443) 359 (0.412) 0.633 0.180 
 
UK BioBank 
Cases 890 (0.122) 3342 (0.456) 3089 (0.422) 0.349 
0.016 0.96 (0.93, 0.99) 
0.777 
Controls 45301 (0.129) 162147 (0.461) 144226 (0.41) 0.359 0.414 
 
EPN 
Cases 1 (0.003) 20 (0.068) 269 (0.927) 0.962 
0.322 1.40 (0.72, 2.73) 
0.346 
Controls 1 (0.002) 40 (0.111) 319 (0.886) 0.941 0.829 
 
EPZ 
Cases 8 (0.061) 42 (0.320) 81 (0.618) 0.778 
0.549 0.88 (0.57, 1.34) 
0.423 
Controls 22 (0.078) 80 (0.283) 180 (0.638) 0.78 0.003 
 
WP 
Cases 3 (0.007) 55 (0.146) 318 (0.845) 0.918 
0.125 0.68 (0.42, 1.11) 
0.715 
Controls 0 (0.000) 38 (0.126) 262 (0.873) 0.936 0.241 
 
EPWP 
Cases 1 (0.034) 6 (0.206) 22 (0.758) 0.862 
0.375 0.64 (0.24, 1.72) 
0.483 
Controls 2 (0.026) 11 (0.144) 63 (0.828) 0.901 0.104 
NPH 
Cases 3 (0.011) 55 (0.202) 214 (0.786) 0.887 
0.824 1.07 (0.61, 1.85) 
0.798 
Controls 2 (0.010) 31 (0.162) 158 (0.827) 0.908 0.730 
CUX2; 
rs4766566  CC CT TT T 
   
 
NZ European 
Cases 874 (0.576) 538 (0.355) 103 (0.067) 0.245 
0.330 1.08 (0.92, 1.26) 
0.105 
Controls 498 (0.565) 335 (0.380) 47 (0.053) 0.243 0.333 
 
UK BioBank 
Cases 4237 (0.58) 2658 (0.364) 409 (0.056) 0.238 
0.001 0.94 (0.91, 0.98) 
0.796 
Controls 197955 (0.564) 130795 (0.373) 21999 (0.063) 0.249 0.045 
 
EPN 
Cases 57 (0.185) 149 (0.483) 102 (0.331) 0.573 
0.427 1.11 (0.86, 1.43) 
0.841 
Controls 70 (0.185) 195 (0.517) 112 (0.297) 0.555 0.356 
 
EPZ 
Cases 47 (0.345) 66 (0.485) 23 (0.169) 0.411 
0.966 0.99 (0.68, 1.44) 
0.983 
Controls 105 (0.362) 142 (0.489) 43 (0.148) 0.393 0.655 
 
WP 
Cases 28 (0.072) 154 (0.396) 206 (0.53) 0.729 
0.627 0.94 (0.71, 1.23) 
0.915 
Controls 26 (0.085) 106 (0.347) 173 (0.567) 0.74 0.098 
 
EPWP 
Cases 2 (0.060) 16 (0.484) 15 (0.454) 0.696 
0.368 0.72 (0.35, 1.48) 
0.395 
Controls 8 (0.114) 28 (0.400) 34 (0.485) 0.685 0.547 
NPH 
Cases 49 (0.180) 136 (0.501) 86 (0.317) 0.568 
0.001 1.75 (1.24, 2.47) 
0.707 
Controls 58 (0.318) 80 (0.439) 44 (0.241) 0.461 0.118 
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*All values are adjusted for age, sex and grand-parental ancestry (GPancestry) estimates for Polynesian datasets. 
EPN: East Polynesian subjects with high EP ancestry, EPZ: East Polynesian subjects with low EP ancestry, WP: 
West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngāti Porou Hauora, 
EUR; NZ European, EUROGOUT (European Crystal Network Gout Cohort), AGRIA (Arthritis Genomics 
Recruitment Initiative in Australia Gout Cohort) combined, UK Biobank; United Kingdom Biobank Cohort. OR 
[95% CI]; Odds ratio [95% confidence interval], P = p-value for ORs, HWE; P values for Hardy Weinberg 
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Table 2.8 : Association analysis of CNIH2;rs4073582 with gout adjusted by BMI as a confounder. 
Populations 
Association Analysis Adjusted 
with BMI 
P* value OR (95% CI) 
NZ European 0.757 0.97(0.822,1.15) 
EPN 0.42 1.32 (0.66, 2.68) 
EPZ 0.067 0.62 (0.37, 1.03) 
EPWP 0.152 0.43 (0.13, 3.16) 
WP 0.121 0.66 (0.38, 1.10) 
NPH 0.67 1.14 (0.61, 2.09) 
*All values are adjusted for age, sex, BMI (body mass index) and grand-parental ancestry (GPancestry) estimates 
for Polynesian datasets. EPN: East Polynesian subjects with high EP ancestry, EPZ: East Polynesian subjects with 
low EP ancestry, WP: West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from 
Ngāti Porou Hauora. 
 
Figure 2.7 : A Forest plot of meta-analysis for NIPAL1;rs11733284 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
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Figure 2.8: A Forest plot of meta-analysis for HIST1H4E;rs11758351 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH)  
 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. 
 
Figure 2.9: A Forest plot of meta-analysis for FAM35A;rs7903456 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
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Figure 2.10: A Forest plot of meta-analysis for CNIH2;rs4073582 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. 
 
Figure 2.11: A Forest plot of meta-analysis for CUX2 with gout (all controls vs gout) in NZ Polynesian (EPN, 
EPZ, WP, EPWP and NPH)  
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Figure 2.12 (a) : Regional plot from GTEx data showing that the rs11733284 is an eQTL signal of NIPAL1 
gene in liver. This is a candidate causal gene at this locus. (Only significant SNPs are plotted.) 
  
 
Figure 2.12 (b): Regional plot from GTEx data showing that the rs11733284 is an eQTL signal of NIPAL1 
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Figure 2.13 : Regional plot from GTEx data showing that the rs7903456 is an eQTL s of FAM35A gene in a 
pancreas tissue. This is a candidate causal gene at this locus. (Only significant SNPs are plotted.) 
  
The y-axis (left) shows the log10 (P-values) of the variants and the x-axis shows the position on the 
chromosome with the name and location. The y-axis (right) shows the recombination rate. Variants present 
in the hg19 reference panel are indicated in blue, and the index variant in purple. The degree of linkage 
between the index SNP and other variations in the region are colour coded based on r2 values derived from 
1,000 Genome data (Novermber 2014). The top SNP is a variant of interest (index variant) that is 
associated with the gene expression represented on the x-axis.   
 
2.3.3. Single Variant Allelic Associations for Inflammatory Genetic 
Variants 
2.3.3.1. IRGM (rs13361189) 
A deletion in the upstream region of IRGM (tag SNP; rs13361189) showed a 62% 
increase in risk of developing gout with each addition of the C allele (OR = 1.62, POR = 0.012) 
in the NPH dataset (Table 2.9). To control for multiple testing the FDR adjusted p-value also 
remained significant (Padjusted = 0.025). A multivariate adjusted (for age and sex) analysis did 
not reveal significant association of the C allele with gout risk in any other Polynesian sample 
sets (Table 2.9). The association also remained non-significant when Polynesian sample sets 
were combined (ORmeta = 1.09, Pmeta = 0.248) in a meta-analysis (Figure 2.14). The lack of 
association of the C-allele with gout susceptibility was also found in European datasets 
including NZ European (OR = 1.12, POR = 0.384) and the UK Biobank (OR = 0.98, POR = 
0.580) with opposing effect size.  
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A separate regression analysis using HU controls compared to gout cases for the 
rs13361189 C-allele also did not show significant association in any Polynesian and European 
datasets (Table 2.10). 
 
2.3.3.2. PPARGC1B (rs45520937) 
In the admixed Polynesian group (EPWP), the A allele of the rs45520937 variant showed 
strong association with increased gout risk (OR = 3.38, POR = 0.002, Padjusted = 0.009). No 
evidence of association of the A- allele was seen in any other Polynesian and sample sets (Table 
2.9). An interaction analysis of rs45520937 was also performed in Polynesian subgroups to 
determine if rs45520937 was having a different effect in these study populations. A significant 
interaction was only observed between the SNP and the EPWP group (ORint = 1.96, Pinteraction = 
0.042) suggests that the EPWP group is different to other subgroups for rs45520937. In an 
inverse-variance weighted meta-analysis after adjusting with age and sex a significant 
rs45520937 A-allele was also found with gout risk in Polynesian sample sets (ORmeta = 1.18, 
Pmeta = 0.021) (Figure 2.15). This represents a successful replication of the Chang et al. (2017) 
report (W-C Chang et al. 2017). But no evidence for association was detected in Europeans 
including NZ European (OR = 0.93, POR = 0.896) and the UK Biobank (OR = 0.99, POR = 
0.908) datasets.  
In a separate association analysis based on splitting controls into HU vs gout the A-allele 
of rs45520937 showed a consistent association towards gout risk in the admixed group of 
Polynesians (OR = 3.19, POR = 0.021), however the meta-analysis of Polynesian sample sets 
did not show association with gout (ORmeta = 1.06, Pmeta= 0.566).  
 
2.3.3.3. IL23R (rs7517847, rs11209026, rs11465804) 
Before performing TaqMan genotyping the LD among variants was tested using online 
available LDlink database. They were not in close LD (r2 < 0.8) such as the r2 = 0.026 value 
that was detected between rs7517847 and rs11209026 and r2 = 0.045 between rs7517847 and 
rs11465804. Similarly, rs11209026 and rs11465804 were not in high LD (r2 = 0.566). The G-
allele of rs7517847 showed protective association with gout in the Western Polynesian group 
(OR = 0.74, POR = 0.029, Padjusted = 0.034) after including age, sex and GPancestry adjustors. 
There was no evidence found for association of the G-allele of the IL23R variant (rs7517847) 
with gout risk in other NZ Polynesian subsets and European sample sets (Table 2.9). However, 
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the rs7517847 G-allele attained significant protective association with gout in the UK Biobank 
dataset (OR = 0.96, POR = 0.009) even after calculating the p-value by the FDR method (Padjusted 
= 0.023). The combined meta-analysis of Polynesian subsets (Figure 2.16) did not show 
statistically significant association (ORmeta = 0.94, Pmeta= 0.414). Contrary to the rs7517847 
association results, the minor allele of other IL23R variants rs11209026 (A) and rs11465804 
(G) did not show evidence for association with gout in any separate NZ Polynesian and 
European sample sets (Table 2.9), instead showing a significant protective association with 
gout in the UK Biobank only (OR = 0.93, POR = 0.046; OR = 0.92, POR = 0.017, respectively). 
The identified associations in the UK Biobank dataset for the rs11209026 (A) and rs11465804 
(G) alleles remained significant after adjusting the p-value through the FDR method to control 
false positives (Padjusted = 0.046 and Padjusted = 0.025, respectively).  It is also notable that the 
frequency of both of these variants was too low (0.01) in the most Polynesian datasets, therefore 
the analysis was underpowered (< 10%) to detect associations in such subgroups.   
A multivariate adjusted analysis in HU controls vs gout showed a protective association 
from gout for the rs7517847 G-allele in the WP group only (OR= 0.67, POR = 0.041), which 
might predict an exclusive inflammatory role of this IL23R variant in gout (progressing from 
HU to inflammation). 
 
2.3.3.4. SERPINA1 (rs12884390, rs1243160) 
For this part of the study two SERPINA1 variants rs12884390 and rs1243160 were 
selected and before genotyping these were tested for LD and found to have low intermarker LD 
(r2 = 0.012). The rs12884390 variant was a surrogate of rs2896268—a variant significantly 
associated with AAT levels in the Japanese population. It was significantly replicated in the NZ 
European sample (OR = 1.14, POR = 0.041) with adjusted p-value by the FDR method (Padjusted 
= 0.044). However, no evidence of association was found in either the UK Biobank (OR = 1.01, 
POR = 0.626) or Polynesian sample sets (Table 2.9) except the EPWP group (OR = 0.43, POR = 
0.017, Padjusted = 0.024) . In addition, a meta-analysis of Polynesian sample sets (ORmeta= 0.92, 
Pmeta = 0.264) (Figure 2.17) did not show a significant association between the 
SERPINA1;rs12884390 T-allele and gout risk. It is notable that contradictory direction of 
association for the rs12884390 T-allele was detected in Polynesian and European datasets 
(Table 2.9).  
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The other SERPINA1 variant rs1243160, selected on the basis of blood cis-eQTL 
(relevant tissue of this inflammatory marker) (Figure 2.19), was also significantly associated 
with gout susceptibility but only in the NZ European dataset (A-allele; OR = 1.31, POR = 0.023, 
Padjusted = 0.029). The A-allele of rs1243160 also did not exhibit significant association in either 
Polynesian sub-set (Table 2.9). By combining Polynesian groups in a meta-analysis the 
rs1243160 A-allele still showed a lack of association with gout (ORmeta= 1.11, Pmeta= 0.426) 
(Figure 2.18). 
Among the SERPINA1 common variants, the rs12884390 T-allele exhibited a significant 
association towards a gout susceptibility with a strong effect size in the admixed group of 
Polynesian (EPWP) when HU controls were used against gout cases (OR= 3.28, POR = 0.017) 
(Table 2.10). It is notable that the EPWP group is the smallest group and the result could be a 
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Table 2.9: Association analysis of inflammatory variants with gout in European and NZ Polynesian 
populations. 
Gene; SNP Group Genotype Frequencies Allele Freq. 
*Adjusted 
P-value OR (95% CI) PHWE 
IRGM; 
rs13361189  TT CT CC C 
   
 
European 
Cases 1289 (0.841) 233 (0.152) 10 (0.006) 0.082 
0.384 1.12 (0.87, 1.44) 
0.880 
Controls 813 (0.863) 127 (0.134) 2 (0.002) 0.069 0.198 
 
UK Biobank 
Cases 6260 (0.853) 1033 (0.141) 49 (0.007) 0.007 
0.580 0.98 (0.98,1.04) 
0.366 
Controls 299475 (0.849) 50858 (0.144) 2201 (0.006) 0.078 0.407 
 
EPN 
Cases 151 (0.487) 128 (0.412) 31 (0.100) 0.306 
0.271 0.86 (0.65, 1.13) 
0.614 
Controls 173 (0.457) 163 (0.431) 42 (0.111) 0.326 0.699 
 
EPZ 
Cases 97 (0.659) 44 (0.299) 6 (0.040) 0.190 
0.650 0.90 (0.57, 1.41) 
0.721 
Controls 186 (0.639) 96 (0.329) 9 (0.030) 0.195 0.420 
 
WP 
Cases 216 (0.54) 164 (0.41) 20 (0.050) 0.255 
0.609 1.08 (0.81, 1.43) 
0.113 
Controls 179 (0.581) 112 (0.363) 17 (0.055) 0.237 0.924 
 
EPWP 
Cases 160 (0.484) 130 (0.393) 40 (0.121) 0.318 
0.576 1.25 (0.58, 2.69) 
0.596 
Controls 38 (0.513) 34 (0.459) 2 (0.027) 0.256 0.079 
NPH 
Cases 133 (0.488) 116 (0.426) 23 (0.008) 0.297 
0.012 1.62 (1.19, 2.20) 
0.745 
Controls 108 (0.562) 76 (0.395) 8 (0.041) 0.239 0.231 
PPARGC1B; 
rs45520937  AA AG GG A 
   
 
European 
Cases 9 (0.005) 160 (0.106) 1333 (0.880) 0.058 
0.896 0.93 (0.30, 2.90) 
0.084 
Controls 14 (0.015) 67 (0.075) 803 (0.906) 0.055 0.000 
 
UK Biobank 
Cases 12(0.002) 632(0.086) 6698(0.912) 0.086 0.908 0.99 (0.91, 1.07) 0.583 
 Controls 714(0.002) 30152(0.086) 321668(0.912) 0.086   0.782 
 
EPN 
Cases 77(0.253) 133(0.437) 94(0.309) 0.472 0.225  1.16 (0.91,1.47) 0.583 
Controls 79(0.207) 160(0.421) 141(0.371) 0.418 0.782 
 
        EPZ 
Cases 7(0.060) 37(0.321) 71(0.617) 0.221 0.733 0.93 (0.60, 1.44) 0.033 
Controls 5(0.039) 53(0.420) 68(0.539) 0.250 0.033 
WP 
Cases 97(0.244) 206(0.520) 93(0.234) 0.505 0.188 1.21 (0.95, 1.55) 0.513 
Controls 75(0.242) 135(0.436) 99(0.320) 0.461 0.434 
EPWP 
Cases 8(0.250) 17 (0.531) 7(0.218) 0.515 
0.002 3.38 (1.57, 8.00) 
0.420 
Controls 8(0.106) 34 (0.453) 33 (0.440) 0.333 0.033 
NPH 
Cases 37 (0.136) 126(0.463) 109(0.400) 0.367 
0.533 1.11 (0.78, 1.59) 
0.719 
Controls 21(0.109) 91 (0.476) 79 (0.413) 0.348 0.862 
IL23R; 
rs7517847  TT GT GG G 
   
European 
Cases 448 (0.363) 714 (0.4860 306 (0.19) 0.451 
0.402 0.94 (0.84, 1.06) 
0.488 
Controls 260 (0.274) 489 (0.515) 199 (0.209) 0.467 0.214 
UK Biobank 
Cases 2376 (0.324) 3562 (0.485) 1404 (0.191) 0.433 
0.009 0.96 (0.93, 0.99) 
0.295 
Controls 109002 (0.309) 174006 (0.494) 69526 (0.197) 0.444 0.861 
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EPN 
Cases 43 (0.152) 114 (0.404) 125 (0.443) 0.645 
0.939 0.99 (0.75, 1.28) 
0.049 
Controls 37 (0.103) 165 (0.459) 157 (0.437) 0.667 0.509 
EPZ 
Cases 26 (0.204) 58 (0.456) 43 (0.338) 0.566 
0.457 1.14 (0.80, 1.62) 
0.430 
Controls 50 (0.190) 131 (0.5) 81 (0.309) 0.559 0.818 
WP 
Cases 78 (0.203) 187 (0.488) 118 (0.308) 0.552 
0.029 0.74 (0.57, 0.96) 
0.803 
Controls 51 (0.195) 118 (0.452) 92 (0.352) 0.578 0.238 
EPWP 
Cases 1 (0.030) 17 (0.515) 15 (0.454) 0.712 
0.665 1.20 (0.53, 2.73) 
0.140 
Controls 6 (0.092) 37 (0.569) 22 (0.338) 0.623 0.087 
NPH 
Cases 30 (0.113) 137 (0.516) 98 (0.369) 0.628 
0.678 1.07 (0.76, 1.52) 
0.564 
Controls 29 (0.153) 95 (0.502) 65 (0.343) 0.595 0.601 
IL23R; 
rs11209026  AA AG GG A 
   
NZ European 
Cases 4 (0.002) 179 (0.116) 1329 (0.878) 0.062 
0.981 1.00 (0.76, 1.31) 
0.429 
Controls 4 (0.004) 110 (0.114) 848 (0.881) 0.061 0.324 
UK Biobank 
Cases 34 (0.005) 859 (0.117) 6449 (0.878) 0.063 
0.046 0.93 (0.87, 0.99) 
0.602 
Controls 1558 (0.004) 44048 (0.125) 306928 (0.871) 0.066 0.593 
EP/N Cases 0 (0.000) 5 (0.017) 280 (0.982) 0.008 - - - 
 Controls 0 (0.000) 2 (0.005) 359 (0.994) 0.002   - 
EP/Z Cases 0 (0.000) 6 (0.046) 122 (0.953) 0.023 0.403 0.62 (0.20,1.91) 0.785 
 Controls 0 (0.000) 24 (0.089) 244 (0.910) 0.044   0.442 
WP Cases 0 (0.000) 4 (0.009) 400 (0.990) 0.004 - - - 
 Controls 0 (0.000) 2 (0.006) 298 (0.993) 0.003   - 
EP/WP Cases 0 (0.000) 0 (0.000) 34 (1.000) 0.000 - - - 
 Controls 0 (0.000) 3 (0.040) 72 (0.960) 0.020   - 
NPH Cases 0 (0.000) 7 (0.018) 19 (0.492) 0.134 0.334 0.50 (0.13, 2.02) 0.427 
 Controls 0 (0.000) 7 (0.018) 183 (0.471)) 0.018 - - 0.795 
IL23R; 
rs11465804  TT GT GG G 
   
European 
Cases 1350 (0.891) 161 (0.106) 3 (0.001) 0.055 
0.601 0.93 (0.70, 1.23) 
0.428 
Controls 842 (0.880) 111 (0.116) 3 (0.003) 0.061 0.736 
UK Biobank 
Cases 6503 (0.886) 808 (0.11) 31 (0.004) 0.059 
0.017 0.92 (0.86, 0.98) 
0.293 
Controls 309114 (0.877) 41981 (0.119) 1439 (0.004) 0.063 0.734 
EPN Cases 277 (0.968) 8 (0.027) 1 (0.003) 0.017 - - - 
 Controls 357 (0.986) 5 (0.013) 0 (0.000) 0.006   - 
EPZ Cases 120 (0.937) 8 (0.062) 0 (0.000) 0.031 0.827 0.89 (0.33, 2.45) 0.940 
 Controls 246 (0.921) 21 (0.078) 0 (0.000) 0.039   0.534 
WP Cases 399 (0.992) 3 (0.007) 0 (0.000) 0.003 - - - 
 Controls 285 (0.982) 5 (0.017) 0 (0.000) 0.008   - 
EPWP Cases 34 (1.000) 0 (0.000) 0 (0.000) 0.000 - - - 
 Controls 72 (0.972) 2 (0.027) 0 (0.000) 0.013   - 
NPH Cases 90 (0.321) 2 (0.007) 0 (0.000) 0.021 0.096 0.12 (0.01, 1.54) 0.916 
 Controls 184 (0.657) 4 (0.014) 0 (0.000) 0.022   0.882 
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SERPINA1; 
rs12884390  CC CT TT C 
   
European 
Cases 340 (0.233) 754 (0.516) 365 (0.250) 0.508 
0.041 1.14 (1.01, 1.30) 
0.195 
Controls 215 (0.256) 412 (0.491) 211 (0.251) 0.497 0.629 
UK BioBank 
Cases 584 (0.243) 1165 (0.485) 653 (0.271) 0.485 
0.626 1.01 (0.96, 1.08) 
0.403 
Controls 24345 (0.239) 50569 (0.497) 26748 (0.263) 0.488 0.402 
EPN 
Cases 47 (0.174) 137 (0.511) 84 (0.312) 0.568 
0.584 0.93 (0.71, 1.21) 
0.489 
Controls 64 (0.187) 149 (0.436) 128 (0.375) 0.593 0.081 
EPZ 
Cases 27 (0.221) 60 (0.491) 35 (0.286) 0.532 
0.869 0.97 (0.68, 1.39) 
0.509 
Controls 45 (0.217) 82 (0.396) 80 (0.386) 0.584 0.007 
WP 
Cases 100 (0.268) 184 (0.494) 88 (0.236) 0.483 
0.431 0.90 (0.70, 1.16) 
0.851 
Controls 60 (0.209) 153 (0.533) 74 (0.257) 0.524 0.244 
EPWP 
Cases 8 (0.235) 21 (0.617) 5 (0.147) 0.455 
0.017 0.43 (0.21, 0.86) 
0.153 
Controls 11 (0.161) 28 (0.411) 29 (0.426) 0.632 0.345 
NPH 
Cases 34 (0.236) 64 (0.444) 46 (0.319) 0.541 
0.401 1.24 (0.75, 2.03) 
0.208 
Controls 14 (0.215) 32 (0.492) 19 (0.292) 0.538 0.938 
SERPINA1; 
rs1243160  AA AG GG A    
European 
Cases 26 (0.012) 337 (0.167) 663 (0.329) 0.189 
0.023 1.31 (1.04, 1.64) 
0.027 
Controls 34 (0.016) 275 (0.136) 680 (0.329) 0.173 0.344 
UK Biobank 
Cases 259 (0.035) 2326 (0.317) 4757 (0.648) 0.193 
0.426 1.02 (0.98, 1.06) 
0.231 
Controls 12749 (0.05) 10893 (0.043) 230853 (0.907) 0.190 0.471 
EPN 
Cases 2 (0.003) 45 (0.073) 215 (0.349) 0.093 
0.901 1.03 (0.64, 1.64) 
0.832 
Controls 3 (0.004) 64 (0.103) 287 (0.465) 0.098 0.783 
EPZ 
Cases 1 (0.003) 36 (0.108) 84 (0.253) 0.157 
0.546 1.19 (0.67, 2.10) 
0.173 
Controls 4 (0.012) 51 (0.153) 156 (0.469) 0.139 0.943 
WP 
Cases 5 (0.006) 82 (0.112) 302 (0.414) 0.118 
0.430 1.16 (0.80, 1.68) 
0.830 
Controls 2 (0.002) 77 (0.105) 261 (0.358) 0.119 0.144 
EPWP 
Cases 1 (0.009) 7 (0.063) 28 (0.254) 0.125 
0.066 3.40 (0.92, 12.52) 
0.504 
Controls 1 (0.009) 11 (0.100) 62 (0.563) 0.087 0.533 
NPH 
Cases 5 (0.010) 56 (0.120) 210 (0.453) 0.121 
0.487 0.77 (0.36, 1.62) 
0.577 
Controls 1 (0.002) 51 (0.110) 140 (0.302) 0.138 0.106 
*All values are adjusted for age, sex and grand-parental ancestry (GPancestry) estimates for Polynesian datasets. 
EPN: East Polynesian subjects with high EP ancestry, EPZ: East Polynesian subjects with low EP ancestry, WP: 
West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngāti Porou Hauora, 
EUR; NZ European, EUROGOUT (European Crystal Network Gout Cohort), AGRIA (Arthritis Genomics 
Recruitment Initiative in Australia Gout Cohort) combined, UK Biobank; United Kingdom Biobank Cohort. OR 
[95% CI]; Odds ratio [95% confidence interval], P = p-value for ORs, HWE; P values for Hardy Weinberg 
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Table 2.10: Association analysis of inflammatory variants with gout in European and NZ Polynesian 
populations using HU controls. 
Gene; SNP Group Genotype Frequencies Allele Freq. 
*Adjusted 
Gout versus HU Controls 
P-value OR (95% CI) PHWE 
IRGM; 
rs13361189  TT CT CC C 
   
European 
Cases 1289 (0.841) 233 (0.152) 10 (0.006) 0.082 
0.570 0.85 (0.52, 1.49) 
0.880 
HU Controls 84 (0.831) 16 (0.158) 1 (0.009) 0.089 0.632 
EPN 
Cases 151 (0.487) 128 (0.412) 31 (0.1) 0.306 
0.886 1.03 (0.68,1.56) 
0.614 
HU Controls 35 (0.479) 30 (0.410) 8 (0.109) 0.315 0.682 
EPZ 
Cases 97 (0.659) 44 (0.299) 6 (0.040) 0.190 
0.462 0.78 (0.40, 1.52) 
0.721 
HU Controls 26 (0.619) 14 (0.333) 2 (0.047) 0.214 0.947 
WP 
Cases 216 (0.540) 164 (0.41) 20 (0.050) 0.255 
0.420 1.18 (0.79, 1.81) 
0.113 
HU Controls 57 (0.587) 36 (0.371) 4 (0.041) 0.226 0.566 
EPWP 
Cases 160 (0.484) 130 (0.393) 40 (0.121) 0.318 
0.673 0.84 (0.37, 1.87) 
0.596 
HU Controls 9 (0.321) 16 (0.571) 3 (0.107) 0.392 0.295 
NPH 
Cases 133 (0.488) 116 (0.426) 23 (0.008) 0.297 
0.145 1.49 (0.88, 2.60) 
0.745 
HU Controls 28 (0.528) 22 (0.415) 3 (0.056) 0.264 0.621 
PPARGC1B; 
rs45520937  AA AG GG A 
   
European 
Cases 9 (0.005) 160 (0.106) 1333 (0.880) 0.058 
0.515 0.85 (0.53, 1.43) 
0.084 
HU Controls 7 (0.070) 3 (0.030) 92 (0.901) 0.083 0.000 
EPN 
Cases 77 (0.253) 133 (0.437) 94 (0.309) 0.472 
0.626 0.91 (0.64, 1.30) 
0.033 
HU Controls 21 (0.283) 26 (0.351) 27 (0.364) 0.459 0.011 
EPZ 
Cases 10 (0.071) 49 (0.352) 80 (0.575) 0.248 
0.660 1.16 (0.58, 2.35) 
0.513 
HU Controls 1 (0.024) 18 (0.439) 22 (0.53) 0.243 0.222 
WP 
Cases 97 (0.244) 206 (0.520) 93 (0.234) 0.505 
0.665 1.07 (0.76, 1.52) 
0.420 
HU Controls 25 (0.255) 48 (0.489) 25 (0.255) 0.500 0.839 
EPWP 
Cases 8 (0.250 17 (0.531) 7 (0.218) 0.515 
0.021 3.19 (1.26, 9.43) 
0.719 
HU Controls 1 (0.037) 15 (0.555) 11 (0.407) 0.314 0.134 
NPH 
Cases 37 (0.136) 126 (0.463) 109 (0.400) 0.367 
0.881 1.03 (0.63, 1.72) 
0.951 
HU Controls 8 (0.150) 25 (0.471) 20 (0.377) 0.386 0.967 
IL23R; 
rs7517847  TT GT GG G 
   
European 
Cases 448 (0.363) 714 (0.4860 306 (0.19) 0.451 
0.684 1.06 (0.79, 1.41) 
0.488 
HU Controls 30 (0.297) 53 (0.524) 18 (0.178) 0.440 0.516 
EPN 
Cases 43 (0.152) 114 (0.404) 125 (0.443) 0.645 
0.920 0.98 (0.66, 1.44) 
0.049 
HU Controls 9 (0.121) 32 (0.432) 33 (0.445) 0.662 0.773 
EPZ 
Cases 26 (0.204) 58 (0.456) 43 (0.338) 0.566 
0.734 1.09 (0.63, 1.89) 
0.430 
HU Controls 9 (0.214) 16 (0.380) 17 (0.404) 0.595 0.174 
WP Cases 78 (0.203) 187 (0.488) 118 (0.308) 0.552 0.041 0.67 (0.46, 0.97) 0.803 
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HU Controls 14 (0.179) 34 (0.435) 30 (0.384) 0.602 0.427 
EPWP 
Cases 1 (0.030) 17 (0.515) 15 (0.454) 0.712 
0.170 2.06 (0.74, 6.14) 
0.140 
HU Controls 5 (0.208) 13 (0.541) 6 (0.250) 0.520 0.676 
NPH 
Cases 30 (0.113) 137 (0.516) 98 (0.369) 0.628 
0.748 1.08 (0.64, 1.83) 
0.564 
HU Controls 6 (0.117) 27 (0.529) 18 (0.352) 0.617 0.388 
IL23R; 
rs11209026  AA AG GG A 
   
European 
Cases 4 (0.002) 179 (0.116) 1329 (0.878) 0.062 
0.698 0.89 (0.51, 1.65) 
0.429 
HU Controls 0 (0.000) 14 (0.137) 88 (0.862) 0.068 0.456 
EP/N Cases 0 (0.000) 5 (0.017) 280 (0.982) 0.008 - - - 
 HU Controls 0 (0.000) 1 (0.013) 73 (0.986) 0.006   - 
EP/Z Cases 0 (0.000) 6 (0.046) 122 (0.953) 0.023 0.703 0.70 (0.12, 4.65) 0.785 
 HU Controls 0 (0.000) 3 (0.071) 39 (0.928) 0.035   0.810 
WP Cases 0 (0.000) 4 (0.009) 400 (0.990) 0.004 - - - 
 HU Controls 0 (0.000) 0 (0.000) 99 (1.000) 0.000   - 
EP/WP Cases 0 (0.000) 0 (0.000) 34 (1.000) 0.000 - - - 
 HU Controls 0 (0.000) 1 (0.037) 26 (0.962) 0.018   - 
NPH Cases 0 (0.000) 7 (0.018) 19 (0.492) 0.134 0.423 2.64 (0.322, 57.39) 0.427 
 HU Controls 0 (0.000) 1 (0.019) 51 (0.980) 0.009   0.944 
IL23R; 
rs11465804  TT GT GG G 
   
European 
Cases 1350 (0.891) 161 (0.106) 3 (0.001) 0.055 
0.987 0.99 (0.54, 1.99) 
0.428 
HU Controls 91 (0.892) 11 (0.107) 0 (0.000) 0.053 0.564 
EPN Cases 277 (0.968) 8 (0.027) 1 (0.003) 0.017 - - - 
 HU Controls 73 (0.986) 1 (0.013) 0 (0.000) 0.006   - 
EPZ Cases 120 (0.937) 8 (0.062) 0 (0.000) 0.031 0.417 2.15 (0.38, 18.24) 0.940 
 HU Controls 40 (0.952) 2 (0.047) 0 (0.000) 0.023   0.874 
WP Cases 399 (0.992) 3 (0.007) 0 (0.000) 0.003 - - - 
 HU Controls 96 (1.000) 0 (0.000) 0 (0.000) 0.000   - 
EPWP Cases 34 (1.000) 0 (0.000) 0 (0.000) 0.000 - - - 
 HU Controls 27 (1.000) 0 (0.000) 0 (0.000) 0.000   - 
NPH Cases 90 (0.321)) 2 (0.007) 0 (0.000 0.021 0.808 0.53 (0.08, 29.37) 0.916 
 HU Controls 51 (0.962) 2 (0.037) 0 (0.000) 0.018   0.886 
SERPINA1; 
rs12884390  CC CT TT C 
   
European 
Cases 340 (0.233) 754 (0.516) 365 (0.250) 0.508 
0.186 0.82 (0.61, 1.09) 
0.195 
HU Controls 32 (0.310) 48 (0.466) 23 (0.223) 0.495 0.537 
EPN 
Cases 47 (0.174) 137 (0.511) 84 (0.312) 0.568 
0.138 0.75 (0.52, 1.09) 
0.489 
HU Controls 22 (0.247) 41 (0.460) 26 (0.292) 0.477 0.468 
EPZ 
Cases 27 (0.221) 60 (0.491) 35 (0.286) 0.532 
0.907 1.03 (0.57, 1.85) 
0.509 
HU Controls 8 (0.186) 21 (0.488) 14 (0.325) 0.430 0.979 
WP Cases 100 (0.268) 184 (0.494) 88 (0.236) 0.483 0.319 1.17 (0.85, 1.62) 0.851 
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HU Controls 20 (0.190) 56 (0.533) 29 (0.276) 0.457 0.444 
EPWP 
Cases 8 (0.235) 21 (0.617) 5 (0.147) 0.455 
0.017 3.28 (1.30, 9.59) 
0.153 
HU Controls 2 (0.068) 11 (0.379) 16 (0.551) 0.258 0.953 
NPH 
Cases 34 (0.236) 64 (0.444) 46 (0.319) 0.541 
0.942 0.97 (0.42, 2.24) 
0.208 
HU Controls 3 (0.200) 7 (0.466) 5 (0.333) 0.433 0.847 
SERPINA1; 
rs1243160  AA AG GG A    
European 
Cases 26 (0.012) 337 (0.167) 663 (0.329) 0.189 
0.083 1.29 (0.97, 1.73) 
0.027 
HU Controls 5 (0.020) 56 (0.226) 186 (0.753) 0.133 0.745 
EPN 
Cases 2 (0.003) 45 (0.073) 215 (0.349) 0.093 
0.345 0.73 (0.39, 1.42) 
0.832 
HU Controls 1 (0.013) 15 (0.208) 56 (0.777) 0.118 0.996 
EPZ 
Cases 1 (0.003) 36 (0.108) 84 (0.253) 0.157 
0.340 1.54 (0.64, 3.89) 
0.173 
HU Controls 1 (0.023) 7 (0.166) 34 (0.809) 0.107 0.403 
WP 
Cases 5 (0.006) 82 (0.112) 302 (0.414) 0.118 
0.828 1.05 (0.63, 1.81) 
0.830 
HU Controls 1 (0.009) 25 (0.242) 77 (0.747) 0.131 0.505 
EPWP 
Cases 1 (0.009) 7 (0.063) 28 (0.254) 0.125 
0.311 2.51 (0.51, 2.06) 
0.504 
HU Controls 0 (0.000) 2 (0.071) 26 (0.92) 0.057 0.844 
NPH 
Cases 5 (0.010) 56 (0.120) 210 (0.453) 0.121 
0.723 1.28 (0.36, 6.29) 
0.577 
HU Controls 0 (0.000) 14 (0.264) 39 (0.735) 0.132 0.267 
*All values are adjusted for age, sex and grand-parental ancestry (GPancestry) estimates for Polynesian datasets. 
EPN: East Polynesian subjects with high EP ancestry, EPZ: East Polynesian subjects with low EP ancestry, WP: 
West Polynesian, EPWP; Mixture of East and West Polynesian, NPH; Māori cohort from Ngāti Porou Hauora, 
EUR; NZ European, EUROGOUT (European Crystal Network Gout Cohort), AGRIA (Arthritis Genomics 
Recruitment Initiative in Australia Gout Cohort) combined, UK Biobank; United Kingdom Biobank Cohort. OR 
[95% CI]; Odds ratio [95% confidence interval], P = p-value for ORs, HWE; P values for Hardy Weinberg 
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Figure 2.14 :  A Forest plot of meta-analysis for IRGM;rs13361189 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. 
 
 Figure 2.15 : A Forest plot of meta-analysis for PPARGC1B;rs45520937 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
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 Figure 2.16 : A Forest plot of meta-analysis for IL23R;rs7517847 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. 
 
Figure 2.17 : A Forest plot of meta-analysis for SERPINA1;rs12884390 with gout (all controls vs gout) in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH) 
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Figure 2.18: A Forest plots of meta-analysis for SERPINA1;rs1243160 with gout (all controls vs gout)in NZ 
Polynesian (EPN, EPZ, WP, EPWP and NPH)  
 
 
Overall effect (OR), p for overall effect and heterogeneity p are shown. 
 
Figure 2.19 : Regional plot from a blood cis-eQTL data (Westra et al. 2013) showing that the rs1243160 is an 
eQTL signal of SERPINA1 gene. That is a causal gene at this locus. 
 
The y-axis (left) shows the log10 (P-values) of the variants and the x-axis shows the position on the 
chromosome with the name and location. The y-axis (right) shows the recombination rate. Variants present 
in the hg19 reference panel are indicated in blue, and the index variant in purple. The degree of linkage 
between the index SNP and other variations in the region are colour coded based on r2 values derived from 
1,000 Genome data (November 2014). The top SNP is a variant of interest (index variant) that is associated 
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2.4. Discussion 
2.4.1. Association of Genetic Variants in Urate Transporters with 
Gout 
This study tested for association between gout and genetic variants in urate transporters 
(e.g. SLC22A12), previously reported widely for their well-established role in hyperuricaemia 
and gout development in multiple populations with ancestral-specific patterns. The selected 




The SLC22A12;rs2285340 variant selected for the current study was sourced from a 
GWAS of clinically-defined gout and its subtypes in a Japanese male cohort (Nakayama et al. 
2017). The T- allele reduced the risk of gout in individual NZ Polynesian low ancestry group 
(EPZ) (OR = 0.44, P = 0.004). The direction of effect was inconsistent to what was found in a 
Japanese dataset (OR = 1.44, P = 8.79×10-10): this may be because of the haplotype-specific 
different risk allele. No significant association was found when Polynesian groups were 
combined by meta-analysis (OR = 1.06, P = 0.105). Interestingly, this SLC22A12 variant was 
monomorphic in European populations and thereby a novel candidate variant to test for 
association with gout in a population-specific manner. Dysfunctional variations in SLC22A12 
have been widely reported associated with  hypouricaemia thus indicating a physiological role 
of SLC22A12 in regulation of serum urate in humans (Jang et al. 2008, Kamatani et al. 2010, 
Köttgen et al. 2013, CG Li et al. 2010, Okada et al. 2012, F Takeuchi et al. 2013, Tin et al. 
2011). For example recently Tin et al., (2018) also reported two novel uncommon missense 
variants rs150255373 (exclusive to European ancestry) and rs147647315 in SLC22A12 
associated with hypouricaemia (T-allele; β = -1.11mg/dL , P = 1.3×10-10 , A-allele; β = -
0.74mg/dL , P = 1.1×10-10, respectively) (Tin et al. 2018). In addition, previously SLC22A12 
has also been recognised for its well-established role in gout pathogenesis in different 
populations including New Zealand European and Polynesian (Flynn et al. 2013, C Li et al. 
2014, Phipps-Green et al. 2016, Urano et al. 2013). In the current study it is notable that the 
significant association for the rs2285340 T-allele was only detected in the EPZ group that 
predicted this association was likely driven by admixture of European ancestry. This conclusion 
was made based on finding a variant that was monomorphic in Europeans but which exhibited 
a significant association with gout in the EPZ dataset, which is a highly admixed European 
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ancestry group. Moreover, inconsistent direction of effect sizes for rs22853340 across study 
populations (represented by a forest plot of meta-analysis across all ancestral groups) shows 
that population stratification effects have not been adequately controlled even though the 
analysis was adjusted by grandparental proportions. Population stratification would be driven 
in the EPZ group where cases have got more Polynesian ancestry (because gout is more 
prevalent in Polynesian) therefore we expect a higher prevalence of this variant. However, 
controls have more European ancestry (because gout is less prevalent in European) therefore 
lower prevalence of this variant. 
 
2.4.2. Association of Genetic Variants of Non-Urate Transporters 
with Gout 
2.4.2.1. NIPAL1 
The findings of this study did not report significant association of a selected novel 
candidate variant in NIPAL1 with gout in either NZ Polynesian or European datasets. However, 
in the UK Biobank dataset of European ancestry the A allele of rs11733284 secured a 
significant level of association with gout (OR = 1.05, P = 0.008) which was concordant with 
what was detected in the gout GWAS of a Japanese sample set (OR = 1.34, P = 1.13 ×10-8) 
(Nakayama et al. 2017). This GWAS study first tested the association of NIPAL1;rs11733284 
with gout susceptibility (as a novel locus) in a renal under-excretion gout subtype cohort 
without prior evidence for gout and then was successfully replicated in a European cohort (UK 
Biobank) (Table 2.7). For NIPAL1;rs11733284 the effect size was consistent in European 
populations, however it had significant association with gout risk only in the UK Biobank 
dataset. This is because the UK Biobank sample set is large enough to derive the significant p-
value (increasing the chance of rejecting the null hypothesis). However, the NZ European 
dataset is relatively smaller in size with a wider confidence interval (CI) and is not adequately 
powered to detect a moderate effect with OR = 1.5 at frequency of > 0.1. It is also notable that 
the direction of association of rs11733284 was consistent in Europeans and the Polynesian 
group having a high admixture of European ancestry (EPZ). However the effect size for 
rs11733284 was in an opposite direction in other Polynesian groups (EPN, WP, EPWP and 
NPH) but was statistically non-significant. Failure of replication of rs11733284 in NZ European 
and Polynesian groups can be explained by the following reasons (discussed in more detail in 
Appendix A.4); one possible explanation may be the smaller study sample size of the NZ 
participants (as mentioned above). The power of the study may not have been enough to detect 
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the weak effect size exerted by the rs11733284. The second possibility of inconsistent direction 
of association between Polynesian and European is that these populations have different LD 
patterns representing haplotypic heterogeneity among the studied populations (Beaty et al. 
2005). Finally, the variant is not causal but in LD with the causal variant that is inherited 
together. Therefore, further replication in a larger NZ dataset and / or in other ancestral groups 
should be carried out with adjustment for non-genetic risk factors. 
NIPAL1 is reportedly expressed on the membrane of distal tubules in kidneys and thought 
to be a magnesium transporter (Goytain et al. 2008). Integrating this evidence of NIPAL1 
localization with the association with gout in the renal under-excretion gout GWAS, this study 
proposed a possible role of NIPAL1 in urate handling using the Xenopus oocyte expression 
system with high potassium buffer and buffer without magnesium for NIPAL1;rs11733284 in 
the same study (Nakayama et al. 2017). This work did not support this hypothesis, rather 
suggested indirect involvement of this locus in urate handling.  Nevertheless, studies have found 
association between abnormal serum magnesium levels and hyperuricaemia (Kuroczycka-
Saniutycz et al. 2015, C Zeng et al. 2015). Together with such reports it can be hypothesized 
that there could be some relation between gout and magnesium handling through magnesium 
transporters such as NIPAL1 (Nakayama et al. 2017).   
 
2.4.2.2. HIST1H4E 
The minor G-allele of  HIST1H4E;rs11758351 that was selected from a Japanese GWAS 
of gout subtypes (Nakayama et al. 2017),  was significantly associated with gout in WP (P = 
0.042, OR = 0.68) and admixed Polynesian EPWP (P = 0.016, OR = 2.65) groups with opposing 
effect size. The opposing statistically non-significant effect size was also observed in EP 
subgroups; EPN (OR = 1.11, P = 0.497) and EPZ (OR = 1.32, P = 0.192) and the NPH group 
(OR = 0.92, P=0.647).  The possible explanation of inconsistent effect sizes in different 
ancestral groups is due to differences in LD patterns in these subgroups and that the variant is 
not causal but in LD with the causal variant. This is supported by a recent Japanese report 
(Nakayama et al. 2017) where rs1175835 has been found in strong LD with a known urate 
transporter SLC17A1—an established serum urate and gout locus (Chiba et al. 2015, Hollis-
Moffatt et al. 2012). There is a possibility that SLC17A1;rs1165176 is a causal variant and  
rs11758351 is a surrogate marker. In addition, non-genetic factors (i.e. environmental factors) 
were also not accounted for in the analysis that may influence association in each group. To 
consider varying effect sizes in each group an interaction analysis was also conducted between 
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the SNP (rs11758351) and all datasets used in this study. The significant associations were 
found in an interaction between rs11758351 G-allele and EPWP (estimated effect size = 
0.797/OR = 2.21, Pinteraction = 0.031) and the WP group (estimated effect size = -0.422,/OR =0.65 
Pinteraction = 0.032). In conclusion, these Polynesian groups should be treated as different 
ancestral groups for measuring the effect of this variant (rs11758351) on gout risk. However in 
these groups cases and controls have almost equal Polynesian ancestry levels (i.e. not as 
stratified as EPZ) and therefore the population stratification effect was less of an issue.  
The effect size produced by the G-allele of rs11758351 in the EPWP group is very strong 
compared to other ancestral groups. This is an admixed group of individuals with EP and WP 
ancestry. It is also important to notice that this group is the smallest group compared to other 
study groups and the variability in effect increases in smallest groups. Moreover, because of 
the smaller size and admixed ancestry group it is hard to interpret whether this is a real signal 
or a result of population stratification. Compared to the admixed EPWP group the WP group is 
adequately powered to detect association with gout although effect size was opposing in 
direction. Overall, the HIST1H4E (rs11758351) being in LD with SLC17A1 is not contributing 
independently, instead is a surrogate marker involved in a  gout pathogenesis.  
 
2.4.2.3. FAM35A 
The FAM35A rs7903456 variant evidenced significant association with gout risk in the 
UK Biobank dataset (OR = 0.94, P = 0.001). This association is consistent with Nakayama et 
al. (2017) GWAS findings in a Japanese male population but with an opposite effect allele (A-
allele, OR = 1.34, P = 4.29×10-8) (Nakayama et al. 2017). The significant p-value in the UK 
Biobank is clearly because of the large sample size of the UK Biobank sample set. For the 
FAM35A variant, the same direction of effect was found in the NZ European sample set, 
however it was likely non-significant because of its relatively small sample size. The same 
direction of association in two European groups indicates that it is likely a genuine signal. The 
rs7903456 variant was identified as a new locus for gout in the FAM35A gene that was also 
supported by an eQTL analysis in GTEx data of pancreas tissue (Figure 2.13). However, eQTL 
data from the relevant tissue (kidney) did not show an association signal at rs7903456 for 
FAM35A (described in the result section) that suggests FAM35A may not be directly involved 
in gout pathogenesis through controlling urate homeostasis. In addition, Nakayama et al. 2017 
also reported that genes nearby FAM35A may have some relationship with gout. For example, 
SNPs in GLUD1 (glutamate dehydrogenase 1) were found in mild LD with FAM35A and this 
 
 
111 | Page 
gene encodes glutamate hydrogenase that induces insulin secretion and mutations in GLUD1 
which are also known to cause hyperinsulinism (Luczkowska et al. 2020). Because 
hyperinsulinemia is correlated to serum urate (inversely associated with fractional excretion of 
urate) (Muscelli et al. 1996), therefore GLUD1 could be causal to gout. However, further 
functional analysis e.g. using mouse model and performing gene knock out experiment can 
confirm this hypothesis.      
FAM35A is ubiquitously expressed in the kidney and a collaborative Japanese study also 
revealed cytosolic expression of the FAM35A protein in distal tubules but also weakly detected 
in collecting ducts (Nakayama et al. 2017) (Figure 2.20). However, the molecular function of 
FAM35A is still unknown. Taken together FAM35A may possibly contribute in developing 
gout pathogenesis but not through urate handling or be involved in regulating expression of the 
other loci (e.g. GLUD1) that influences urate homeostasis.   
 
Figure 2.20 : Renal expression of identified genes in Nakayama et al. 2017 GWAS of gout subtypes in proximal 
and distal nephron. 
 
This illustration shows expression of four urate transporters, SLC22A12, SLC2A9, SLC17A1 and ABCG2, in 
proximal tubules of the human kidney. In Nakayama et al. 2017 (a collaborative study with our NZ study (includes 
my work)), NIPAL1 (a magnesium transporter gene) and FAM35A are revealed to be associated with gout and to 
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2.4.2.4. CNIH2 
This study could not successfully replicate association of a CNIH2 splice variant 
rs4073582 in Polynesian groups, where the C allele of rs4073582 conferred gout risk at genome 
wide significant level (OR = 1.44, P = 3.56×10-8) in the Japanese population. Conversely, a 
protective effect of the CNIH-2;rs4073582 C allele was seen in the individual UK Biobank 
dataset of European ancestry (OR = 0.96, P = 0.016). 
The genetic association of rs4073582 in CNIH2 with gout was first reported by Matsuo 
and co-workers (Matsuo et al. 2016) in the Japanese population (OR = 1.66, P = 6.4×10-9). 
Later a gout study in a Han Chinese population also evidenced nominal association at 
rs801733 (OR = 0.42, P = 0.026), in strong LD with rs4073582 (r2 = 0.96) (Z Li et al. 2017). 
The disparate OR’s for these two high LD variants is because of the given effect size belongs 
to different reference alleles e.g. the effect showed in the thesis for rs4073582 was relevant to 
the C-allele where for rs801733 the OR is relevant to the (alternate) T-allele. The rs801733 
variant was previously detected in the PASC1 locus nearby CNIH2 that was found to be 
associated with severe obesity (Wheeler et al. 2013). To consider this evidence, in the current 
study, the regression models for gout association were also designed with and without the 
adjustment of body mass index as a possible confounder but did not produce significant 
association in any study cohorts (Table 2.7 and Table 2.8). Previously, the rs4073582 variant 
has been reported to be located within the CNIH2 gene by Matsuo et al. (2016). Moreover, this 
is a splice region variant that may affect the splicing of mRNA by retaining large segments 
of intronic DNA by the mRNA, or to entire exons being spliced out of the mRNA resulting in 
a production of dysfunctional protein. In addition, Haploreg 4v.1 suggests that rs4073582 is 
situated in a region of the genome showing enriched levels of chromatin modifications such as 
enhancer histone marks (H3K4me1 and H3k27ac) and promoter histone marks (H3k4me3) 
observed in PBMCs. These chromatin modifications are commonly associated with the gene 
enhancers, higher activation of transcription and gene regulation where H3k4me3 activates the 
transcription of nearby genes (Barski et al. 2007, Creyghton et al. 2010, Rada-Iglesias 2018, 
Sims et al. 2003). Thus, it is possible that this variant influences mRNA stability and 
transcription and/or translation efficiency that leads to production of an abnormal protein. 
Online available eQTL data from GTEx were also analysed to confirm the causal gene at 
rs4073582 but that did not show association at CNIH2 for rs407358. However, it is notable 
that this variant was also in high LD with the rs801733 variant located in PASC1 therefore it 
is possible that rs4073582 is not a causal locus but in LD with the causal variant. Thereby, 
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additional genetic and expression analyses will be required to determine whether and how 
CNIH2 or either PASC1 play a causal role in gout pathogenesis at this locus. 
 
2.4.2.5. CUX2 
This study reports association of rs4766566 at the CUX2 locus with gout in the Māori– 
NPH group (OR = 1.75, P = 0.001). A consistent direction of  non-significant association was 
found in the EPN group (OR = 1.11, P = 0.427) but with a relatively small effect size, this group 
is also dominated by people of Māori ancestry. However, non-significant association of the 
rs4766566 T-allele in the opposing direction was observed in other Polynesian groups (EPZ, 
EPWP and WP) with a weak effect. It is also noteworthy that an effect size in opposing direction 
was detected in the European sample sets; UK Biobank (OR = 0.94, P = 0.001) and European 
(OR = 1.08, P = 0.330). The difference in magnitude of effects in the Polynesian and European 
UK Biobank datasets may represent a difference in genetic background. The difference in LD 
patterns in these populations could be a reason of disparity of OR’s  therefore it is possible that 
rs4766566 may not be causal but in LD with the causal variant, with Polynesian-specific 
ancestral recombination that distinguishes the Polynesian haplotypic background from the 
European background around the  rs4766566 variant. The opposing effect of rs4766566 with 
gout in the NZ European and UK Biobank datasets may reflect the contribution of different 
gene-environmental interactions or differences between the gout classification criteria used in 
the UK Biobank and NZ European cohorts. The ascertainment of gout cases for the New 
Zealand Gout Case-Control Cohort was performed by GPs according to the American College 
of Rheumatology classification criteria (ACR) (Wallace et al., 1977) while the diagnosis of 
gout cases for the UK Biobank dataset was based on a combination of self-reported reporting, 
hospital diagnoses, ULT (Colhoun et al., 2003; Dalbeth et al., 2016b; Köttgen et al., 2013) and 
Winnard-defined criteria (Cadzow et al., 2017; Winnard et al., 2012). The opposing effect size 
could also be due to inadequacy of the smaller sample size of the NZ European cohort compared 
to the UK Biobank dataset to detect the modest effect size of the risk variant.  
Previously a functional study indicated the contribution of CUX2 in neuroblast 
development and neuronal differentiation by coupling with NeuroD gene Cux2 (Cutl2) that 
integrates neural progenitor development with cell-cycle progression during spinal cord 
neurogenesis (Iulianella et al. 2008). The NeuroD gene potentiates neurogenesis (JE Lee et al. 
1995), however, some research groups independently cloned this gene as the beta cell E box 
transactivator 2 (BETA2) and a class B basic helix-loop-helix (bHLH) whose expression was 
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observed in intestine, pancreatic and brain cells. The heterodimer of NeuroD/BETA2 with 
bHLH attains a high affinity to bind with the insulin E box complex and regulates transcription 
of the insulin gene suggesting influence on insulin concentration (JE Lee 1997, Madsen et al. 
1997, Mutoh et al. 1997, Naya et al. 1995). In an animal model study, a Neurod/BETA2-
deficient mouse was found with a reduced number of insulin-producing beta cells and 
developed severe diabetes (Naya et al. 1997). The rs4766566 variant is located in the intronic 
region, meaning it could influence gout progression by affecting the function of CUX2 protein 
through alteration of splicing efficiency or disrupting the splicing motifs (Wang and Cooper, 
2007). Furthermore, investigation of the functional impact of this variant using Haploreg v4.1 
and RegulomeDB showed that this variant was present in the region of the genome showing a 
high proportion of chromatin modification such as enhancer histone marks (H3K4me1 and 
H3k27ac), which could thereby influence transcription efficiency (Barski et al. 2007, 
Creyghton et al. 2010, Rada-Iglesias 2018, Sims et al. 2003). However, further work in other 
ancestral populations with larger sample sizes is required to confirm this association. Moreover, 
experimental studies in animal models can unravel the functional effect of the variant. For 
example a CUX2 knockout mouse could be created and then injected with MSU crystals. This 
could determine the effect in the absence or presence of  the variant in response to MSU crystals.  
In an ex vivo experiment, for instance, isolate macrophages from gout patients carrying the 
rs4766566 variant and then stimulate these with MSU crystals. The immune response to  
injected crystals can be measured and compared to the control group  (isolate macrophages 
from gout patients not carrying the variant of interest (rs4766566)).    
2.4.3. Association of Genetic Variants in Inflammatory Loci with 
Gout 
2.4.3.1. IRGM 
A common polymorphism rs13361189 in the upstream region of the IRGM gene was 
associated with gout only in the NPH group of Māori individuals (OR = 1.62, P = 0.012). 
However, the C-allele of rs13361189 did not exhibit significant association in the same cohort 
when an analysis was conducted using HU controls against gout cases (OR = 1.83, P = 0.145). 
There can be two ways to explain these results for the rs13361189 variant; one, this variant 
might play an inflammatory role but through influencing urate levels or second, the lack of 
association using HU controls was produced because of the smaller size of the sample set 
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2.4.3.2. PPARGC1B 
PPARGC1B exhibits an anti-inflammatory effect. In the current study, the relationship of 
the gene with the auto-inflammatory disorder gout was investigated. Rs45520937 (p. R265Q) 
is a missense variant in exon 5 of the gene. A significant association was found between the A-
allele of rs45520937 and gout in combined Polynesian groups (ORmeta = 1.18, Pmeta = 0.021). 
The result is consistent with a recent study in which the R265Q variant exhibited strong 
association with gout in the Taiwan Han Chinese population (OR = 1.85, P = 6.66×10-9) (SH 
Chang et al. 2016). It is noteworthy that the effect size is consistent in Polynesian datasets, 
however, weak and opposite in direction in European sample sets. These opposing direction of 
associations detected between PPARGC1B;rs45520937 and gout susceptibility in the European 
and Polynesian individuals could be explained as Polynesian-specific ancestral recombination 
event distinguishing the Polynesian haplotypic background around rs45520937 from European, 
resulting in the (A) allele of rs45520937 being on the Polynesian risk haplotype. It is also 
noticeable that a statistically significant association of the rs45520937 A-allele with strong 
effect size was only detected in the EPWP group, which is the smallest group. This association 
could be due to population stratification as well as the smaller study sample size. To confirm 
the risk-conferring role of rs45520397 in gout an additional replication with a larger NZ (e.g. 
the EPWP group) sample set is required. A significant association of the rs45520937 A-allele 
with gout susceptibility was also detected in the WP group using HU controls against gout 
(Table 2.9) which suggests this variant may be involved in progression from hyperuricaemia to 
gout. In the context of functional characterization for this PPARGC1B missense variant 
(rs45520937), experiments were performed by Chang et al. (2016) in their study and reported 
that rs45520937 mediated NLRP3 activation in MSU crystal stimulated TH1P, peripheral blood 
mononuclear and synovial cells from gout patients. This study particularly showed the up-
regulation of PPARGC1B and IL1β expression upon MSU crystal stimulation in macrophage 
cell lines, where the protein product acted as a transcriptional repressor of NLRP3. The genetic 
and functional evidence supports the idea that the PPARGC1B 265Q amino acid change may 
impact on NLRP3 inflammasome activation and influence gout risk (SH Chang et al. 2016). 
Taking into account the anti-inflammatory attributes of PPARGC1B, variation in 
PPARC1B could possibly predispose to certain inflammatory phenotypes. Earlier lines of 
evidence have reported association of PPARGC1B variations with certain metabolic and 
immune disorders including type II diabetes, obesity, airway hypersensitivity, breast cancer and 
ankylosing spondylitis (Ahmadian et al. 2013, Temesi et al. 2014, Villegas et al. 2014, 
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Wirtenberger et al. 2006). Moreover, Ishii and co-workers (2009) proposed the active role of 
PPARGC1B in osteoclastic bone resorption by coordinating with mitochondrial biogenesis 
(Ishii et al. 2009). One of the recent candidate-gene based studies also revealed the association 
of PPARGC1B;rs7379457 with ankylosing spondylitis in Han Chinese patients (J Liu et al. 
2015). Functional studies also confirmed up-regulated PGC-1B levels with increased NF-κB 
activity in rheumatoid arthritis fibroblast-like synoviocytes. This up-regulation of PPARGC1B 
also induced increased expression of tumour necrosis factor-α (TNFα), IL6, IL-8, matrix 
metalloproteinases-3 (MMp-3), MMP-13 and receptor activator of nuclear factor kappa-B 
ligand, which are key regulators of driving inflammatory mechanisms (RANKL) (J-J Zhou et 
al. 2014). 
Being a transcriptional co-factor of the nuclear receptor PPAR-γ, the primary function of 
PPARGC1B seems to be regulating multiple energy metabolic processes such as 
gluconeogenesis, fatty acid B oxidation, thermogenesis and more importantly mitochondrial 
biogenesis by co-activating with PPAR-γ (Lehman et al. 2000, Puigserver et al. 1998, Vega et 
al. 2000, Yoon et al. 2001). In the context of mitochondrial biogenesis PPAR-γ is also activated 
by adenosine monophosphate-activated protein kinase (AMPK), the enzyme which also 
orchestrates anti-inflammatory reactions, serving as a key inhibitor of MSU crystal-induced 
inflammation by effecting NF-KB and NLRP3 inflammasome activation along with promoting 
M2 anti-inflammatory macrophage polarization (Y. Wang et al. 2016). Thereby, it is possible 
that changes in PPARGC1B, PPAR-γ and AMPK expression could lead to mitochondrial 
dysfunctionality that in turn is causal for mitochondrial dysfunction-associated phenotypes. 
Gout could be one supported by a recent study by Gosling et al., (2018) that detected reduced 
mitochondrial copy number in gout patients (Gosling et al. 2018). Moreover, in some 
inflammatory disease models altered mitochondrial function induced NLRP3 inflammasome 
activation. Taken together, these findings collectively demonstrate PPARGC1B as one of the 
several inducible nodes that work in a complex regulatory network for damping NLRP3 




In the current study IL23R (rs7517847, rs11209026 and rs11465804) common variants 
were tested for their association with gout in NZ Polynesian and European sample sets. The 
rs7517847 variant is in intron 6 of the IL23R gene (S Liu et al. 2015). Earlier, this variant has 
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been widely reported for its association with CD, UC, ankylosing spondylitis, RA and systemic 
autoimmune diseases (Dong et al. 2013, Einarsdottir et al. 2009, Y Li et al. 2010, Zhai et al. 
2012). One of the New Zealand genetic studies also revealed the protective effect of the 
rs7517847 G allele for CD in individuals of European ancestry (OR = 0.42, P = 0.001) 
(Ferguson et al. 2010). In terms of implication of the role of the IL23R intron (rs7517847) 
variant for gout pathogenicity, a study by Liu and the colleagues in 2015 from a Han Chinese 
group including 982 males documented a protective association between the G allele and gout 
(OR = 0.82, P=0.04) (S Liu et al. 2015). My finding is consistent with this gout study and also 
with other immune-related diseases for the IL23R rs7517847 variant and successfully reports 
the same pattern of association with gout in the WP (G-allele; OR = 0.74, P = 0.029) and in the 
European UK Biobank cohort (OR = 0.96, P = 0.009). The associations remained significant 
(however, the significance level dropped after adjustment) after adjusting  p-values for 
controlling false positives ( Padjusted = 0.034, ( Padjusted = 0.023)) via the FDR method. A non-
significant effect was observed in EPZ , EPWP and NPH datasets. An opposite direction of 
association was identified in European datasets with weak effect size, however, it was 
significant in the UK Biobank. This is likely because of the larger sample size of UK Biobank 
compared to other European datasets. Several reasons can also explain this difference in effect 
sizes in Polynesian and European ancestral groups. First, the failure of replication in Polynesian 
datasets (EPN, EPZ, EPWP and NPH) may be because of the limitation of the smaller sample 
size of the NZ cohorts to detect the modest effect size of the rs7517847 variant. Secondly, these 
inconsistencies in direction of effect are subject to the population stratification effect. For 
instance this IL23R variant produced a large effect in the EPZ group that possesses a high 
admixture of European ancestry, opposite to the effect size observed in European populations. 
Finally, the variant is present in an intronic region and may not be causal but rather in high LD 
with the causal variant. Fourth, the difference in effect sizes may due to difference in LD 
patterns for rs7517847 in different ancestral groups. There is also evidence of a significant 
association for the IL23R; rs7517847 G-allele with gout that was found upon using HU controls 
versus gout cases (WP; OR = 0.67, P = 0.041) that predicts its inflammatory role in gout 
pathogenesis in the presence of hyperuricaemia. 
Regarding the functional implication of rs7517847 in gout, it is located in the intronic 
region, meaning it can influence gout progression by affecting IL23R function through 
alteration of splicing efficiency or disrupting the splicing motifs. Additionally, rs7517847 is an 
expression QTL for  IL23R in peripheral blood CD4+ lymphocytes (P = 0.0003) (Murphy et 
al., 2010). Furthermore, it is likely to affect gene expression as it  has been associated with high 
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levels of chromatin modification, including H3K4me1 and H3K27ac that are associated with 
gene enhancers and active transcription, respectively (Barski et al. 2007, Creyghton et al. 2010, 
Rada-Iglesias 2018, Sims et al. 2003).  
Among other selected IL23R variants, rs11209026 is a missense variant in IL23R 
(c.1142G>A, p.Arg381Gln) (Duerr et al. 2006). An earlier study suggested a protective 
association of the A-allele with IBD, UC and CD (OR = 0.19, CI = 0.10-0.37, P = 6.6×10-9; CD 
OR = 0.14, CI = 0.06-0.37, P = 3.9×10-6 and UC OR = 0.33, CI = 0.15-0.73, P = 1.4×10-3). 
Later many studies replicated the association of rs11209026 with CD in multiple populations 
(Baptista et al. 2008, Latiano et al. 2008, Oliver et al. 2007) including NZ European (A-allele; 
OR = 0.58, P = 0.015), AS (Rueda et al. 2008), psoriasis (Cargill et al. 2007). However, some 
studies also reported lack of association for the IL23R;rs11209026 minor allele with 
inflammatory phenotypes i.e. IBD (particularly CD) (Borgiani et al. 2007, Tremelling et al. 
2007) and RA (Hollis-Moffatt et al. 2009). This discrepancy in results in different populations 
directs attention towards ancestral differences that influence the genetic predisposition of 
diseases in a particular population. And it could also mean that rs11209026 only associates with 
some auto-inflammatory conditions. The mixed trend of association was also observed in the 
current genotype-phenotype association study for gout where the rs11209026 A allele 
conferred a lack of association in NZ Polynesian individuals (Table 2.9). However, the 
Arg381Gln A allele exhibited significant protective association with gout phenotype in the UK 
Biobank with a weak effect size (OR = 0.93, P = 0.047), also after adjusting p-value through 
the FDR method (Padjusted = 0.046). The difference in significance levels and effect size in some 
Polynesian subgroups may reflect the increased power of large sample size (i.e. UK Biobank) 
and different genetic backgrounds for two populations, respectively. It is important to consider 
that the frequency of rs11209026 in the most Polynesian groups was too low (< 1%) meaning 
that these datasets were underpowered to detect an association.  
The final selected IL23R;rs11465804 variant for this study is intronic (Duerr et al. 2006, 
McGovern et al. 2010). A study conducted by Duerr et al (2006) (Duerr et al. 2006) revealed 
the protective effect of the rs11465804 G-allele against CD in non-Jewish and Jewish sample 
sets (OR= 0.30, P = 7.52×10-7, OR= 0.47, P = 1.39×10-5). A replication study (Einarsdottir et 
al. 2009) also reported a significant correlation between the G-allele of rs11465804 with IBD 
(OR = 1.38, P = 0.009) in Swedish people and with celiac disease (P = 0.00006) and psoriasis 
(P = 0.03) in the Finnish population. However, this study does not suggest the successful 
replication of the IL23R;rs11465804 in either NZ Polynesian and European sample sets. Also 
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due to the low frequency of the rs11465804 in Polynesian groups, the data was underpowered 
to detect associations in these groups.  
In conclusion, this study attempted the replication of three IL23R variants 
(rs7517847, rs11209026 and rs11465804) with gout in NZ Polynesian and European 
populations. The study identified a significant association of the rs7517847 variant with 
gout in the WP and UK Biobank datasets, but not in the other European and Polynesian 
datasets. For clarification, the observed association should be replicated in other ancestral 
cohorts (i.e Asian and other Pacific cohorts) and functional studies such as gene expression 
assay in vitro or in vivo are required to delineate the biological implications of this IL23R 
variant. Such as using ex-vivo method peripheral blood monocytes or macrophages from 
gout patients carrying rs7517847 G-allele could be be isolated and then be stimulated with 
MSU crystals to evaluate the effect of the variant in inflammation. To compare the effect 
of the variant a control group is required by isolating macrophages from gout patients not 
carrying the rs7517847 variant. For the other two low frequency variants (rs11209026 and 
rs11465804) larger sample sets of adequate power are required to detect an effect at low 
frequency < 0.01.                                                                                                                
 
2.4.3.4. SERPINA1 
In addition to investigating the putative role of known or susceptible inflammatory loci 
in gout pathophysiology another inflammatory candidate locus SERPINA1– the alpha 1 
antitrypsin (AAT) encoding gene was included in this study. Human AAT is a 52KD 
glycoprotein in the blood (DH Perlmutter and Punsal 1988), and has anti-inflammatory, 
immune regulatory and cytoprotective characteristics (Hunt and Tuder 2012, Miyamoto et al. 
2000) as previously demonstrated in various disease models including aging, emphysema, 
arthritis, type 1 diabetes, stroke and liver disorders (Grimstein et al. 2011, Lomas 1994, Y Lu 
et al. 2006, Ma et al. 2010, Moldthan et al. 2014, Poller et al. 1993, Yuan et al. 2018). 
Previously genetic variants in AAT encoded by the SERPINA1 gene have been discovered as 
causative variants of alpha1 anti-trypsin deficiency and emphysema and early onset chronic 
obstructive pulmonary disorders (Thun et al. 2013, Zorzetto et al. 2008). SERPINA1 variants 
(rs12884390 and rs1243160) included in the current study have previously been identified as 
top-signals in an AAT GWAS in a Japanese population and a blood cis-eQTL study (Figure 
2.19) (Setoh et al. 2015, Westra et al. 2013). 
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The SERPINA1;rs12884390 variant (in LD with Japanese GWAS variant rs2896268—r2 
=0.968) C–allele exhibited a significant association with gout but only in European including 
NZ European individuals (OR = 1.14, P = 0.041). However, opposing and statistically non-
significant effect sizes were observed in Polynesian groups. A relatively large effect size was 
detected in NZ European and UK Biobank, however a weak effect size was detected in 
Polynesian subgroups (except NPH). There are several possible reasons that might explain the 
failure of replication in the NZ European dataset alone, and in the NZ Polynesian datasets. One 
possible explanation may be the smaller study sample size of the NZ participants. The power 
of the study was not adequate (less than 80%) to detect the weak effect size exerted by the 
rs12884390 in Polynesian groups such as in the EPN group the power was only 8% to detect 
the effect size of 0.93 at the allele frequency of 0.568. The second possible reason for this could 
be the presence of haplotypic heterogeneity among the studied populations (Beaty et al. 2005) 
as in different populations this variant may operate in different pathways that lead to the disease. 
It is also possible that this variant is not causal but in LD with the causal variant.  
For SERPINA1;rs1243160 the direction of effect size of the A-allele is consistent across 
all ancestral groups except the NPH group. A statistically significant effect size was determined 
in the NZ European group only (OR = 1.31, P =0.023). However, a large but non-significant 
effect size was observed in the EPWP group which is a very small group of people of admixed 
ancestry of EP and WP. Therefore, there is a possibility that the effect may be produced by 
stratification effect even though it was attempted to control by adjusting analysis with PCs in 
the current study.  
The rs12884390 variant is located in the 5.8kb 5’UTR of SERPINA1 and affects the gene 
expression as it has been detected in a chromatin region of the transcriptionally-active domain, 
(H3K4me1, H3K27ac and H3K4me3). This locus was also identified as an expression 
quantitative trait locus (eQTL) of SERPINA1 in whole blood cells (P = 8.557 ×10-134). The other 
SERPINA1 variant (rs1243160) is an intronic variant that could alter the expression of 
SERPINA1 by influencing the splicing process (e.g. altering splicing motifs). Further, 
functional investigation through the Haploreg 4v.1 and RegulomeDB platforms demonstrate 
association of this variant with high levels of chromatin modification such as enhancer histone 
marks (H3K4me1 and H3K27ac) and promoter histone marks (H3K4me3). These histone 
modifications could affect gene transcription (Barski et al. 2007, Creyghton et al. 2010, Rada-
Iglesias 2018, Sims et al. 2003) and result in production of dysfunctional protein. Further, to 
determine a causal gene at this locus an eQTL dataset of whole blood was utilized where the 
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highest association signal was observed at SERPINA1 for rs1243160 (P = 6.252 ×10-61) (Westra 
et al., 2013). The AAT protein that is a acute-phase protein, releases into blood (majorly 
produced by the liver) on an inflammatory response. Therefore, blood is a relevant tissue to test 
for eQTLs for study loci rs12884390 and rs1243160.   
Functional analyses using several animal models have indicated a remarkable effect of 
AAT on blocking or delaying the inflammatory process or alleviating symptoms for various 
inflammatory diseases including arthritis. One of these studies was performed using a mouse 
model of gout arthritis and introduced recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc 
fusion protein (AAT-Fc) that suppressed inflammation via reducing IL1β expression— a key 
cytokine that induces inflammation (Joosten et al. 2016). The same group published other 
findings early in the same year and reported for the first time the seasonal variation of AAT. It 
was observed that AAT levels were high in February (a cold month in Europe) and lowest in 
summer thus indicating that the periodicity of AAT is opposite to the periodicity of cytokines 
that are high in summer (i.e. IL1β). For this study, an experimental model of gout was used to 
explore the impact of AAT on cytokine response, a condition caused by MSU crystal + C16 
stimulations in mouse joints. Injecting AAT (prolastin C) plasma-derived proteins significantly 
reduced the joint swelling and also inhibited the expression of IL1β (ter Horst et al. 2016). 
Further, to demonstrate clinical relevance of their findings they analysed plasma for AAT and 
IL1β levels in 800 people from the Netherlands. Indeed, retrospective assessment clearly 
identified a reverse correlation between plasma AAT and plasma IL-1β in people with gout 
during summer, where the concentration of IL1β was found to be high. Other studies also 
showed an anti-inflammatory effect of AAT in both Drosophila and human cell lines through 
down-regulating activation of NF-KB (Pott et al. 2009, Yuan et al. 2018). All of this gives the 
impression that AAT either directly or indirectly interacts with a highly conserved mechanism 
that plays a central role in controlling inflammation. 
Taken together this genetic study with reported functional effect of AAT in 
inflammatory mechanisms, particularly its response to MSU crystals in gout using animal and 
cell models suggest implication of AAT encoded by SERPINA1 variants in gout pathogenesis. 
The selected SERPINA1 variants showed association with susceptibility to gout in the 
European datasets. However, it will be worth replicating these variants in larger Polynesian 
sample sets. In addition, these two variants are likely to be functional. Thus, their effects in 
the process of gout inflammation are likely to be significant. The association analysis using 
HU controls versus gout cases for the SERPINA1 genetic variant (rs12884390) also predicts 
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its inflammatory role progressing from hyperuricaemia to the development of gout, however, 
larger sample sizes are required to confirm these associations. 
 
2.5. Strengths and Limitations of the Study 
The current study provides evidence of successful replication of previously known urate 
loci and newly discovered non-urate loci (indirectly involved in urate handling) from a Japanese 
GWAS in the NZ Polynesian and European populations. This study for the first time reports 
direct association of variants in inflammatory loci with gout such as IRGM, IL23R, and 
SERPINA1, which have previously been associated with certain immune-related conditions 
(inflammatory, auto-immune and metabolic). It is also important to note that some variants 
showed significant associations with gout exclusively either in European or NZ Polynesian 
subgroups. This may be because of the limited power in these individual groups or may be due 
to genetic differences in background of different populations. This study also evidences a 
successful replication of PPARGC1B (rs45520937) with gout in Polynesians with the same 
direction of effect that was detected by Chang et al., (2017) in a Han Chinese population (W-C 
Chang et al. 2017). The present study is also an attempt to fill the gap of progression from 
hyperuricaemia to gout by using HU controls versus gout cases. Altogether findings of this 
study provide a valuable addition to the knowledge to determine contribution of novel (non-
urate, inflammatory) loci in developing gout progressing from hyperuricaemia in different 
populations but has certain limitations. Datasets used in the current study had adequate power 
to determine the moderate effects of common variants at a minor allele frequency (>0.05). 
However, the study is limited by detection of lower effect in smaller Polynesian subsets. Lower 
powered studies are biased as they inflate the effect size and more likely to produce false 
negative results with an inflated effect size. Furthermore, the present study is substantially 
limited by smaller size and underpowered datasets including HU controls vs gout cases (30-
40% power to detect variants with minor allele frequency >0.04 in the NZ Polynesian and 
European sample sets). Larger sample sets consisting of HU controls vs gout cases are required 
to confirm exclusive inflammatory effects of the study including genetic variants (particularly 
variants in inflammatory loci). However, the UK Biobank cohort included in this study was 
highly powered (95%) to detect a weaker effect (OR = 1.2) for variants with minor allele 
prevalence > 0.02 (Figure 2.5) whereas NZ European and NZ Polynesian datasets were 
adequately powered (> 80%) to detect intermediate effect (OR = 1.5) for those variants at minor 
allele frequency > 0.05. This disparity in sample size may bias the results, however, cohorts of 
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almost equal sizes are required to eradicate possible biasness and minimize false negative 
results. To minimise false positive associations as a result of multiple testing a FDR method 
was applied. Finally, although it was attempted to control the population structure by adjusting 
with proportion of Polynesian grandparental ancestry and PCs, however there will likely still 
be inaccuracy inherent in studying admixed populations such as EP and WPEP. 
 
2.6. Conclusion and Future Direction 
In conclusion the current study presents genetic effects of previously known urate loci, 
novel non-urate loci through controlling urate levels and inflammatory genes increasing or 
decreasing gout risk in European and NZ Polynesian populations. Possibilities that have arisen 
through these findings will be worth further investigation in future research and are detailed 
below. 
 
§ The current study evidences successful replication of urate (SLC22A12) and non- 
urate loci (FAM35A, NIPAL1, CNIH2 and CUX2) in New Zealand population 
groups, previously identified with gout risk in the Japanese population. However, for 
a more convincing conclusion regarding the role of these genetic variants in gout 
pathogenesis, association analysis should be repeated in independent datasets as large 
in size as the UK Biobank sample set.  
 
§ To further determine or confirm the causal genes at newly identified loci (FAM35A; 
rs7903456, NIPAL1;rs11733284, CUX2;rs4766566 and CNIH2; rs4073582) in the 
Japanese gout GWAS, colocalization of these GWAS with gene expression i.e. eQTL 
will be useful. However, an attempt was made to find causal genes at a newly 
identified locus for gout using GTEx (eQTL) dataset. However to provide evidence 
for causality at these loci may require additional eQTL datasets, particularly those 
from a relevant tissue (single-tissue eQTL). Colocalization (a method to integrate 
GWAS data with eQTL data) is a better approach to detect casual genes at new loci. 
This method has been applied in a recent study, where trans-ancestral meta-analysis 
was conducted across serum urate GWAS in European and East Asian populations 
and then identified new serum urate loci of biological significance through 
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colocalization of GWAS data with available cis and trans eQTL data (Boocock et al. 
2019).  
 
§ This study is also a significant effort to detect the contribution of genetic variants in 
inflammatory genes PPARCGC1B, SERPINA1, and IL23R in the development of 
gout particularly in NZ Polynesian and European individuals. This part of the study 
hypothesis was designed based on available inadequate genetic knowledge for 
determining the potential role of inflammatory loci in gout pathogenesis. Since 
positive associations of these inflammatory components were identified with gout 
risk in study populations, further functional studies (gene expression experiments 
and mammalian models of gout) that determine whether predicted functional 
consequences of these variants align with actual function are necessary. For example, 
to determine the functional effect of IL23R and SERPINA1 missense variants in gout, 
peripheral blood mononuclear cells/macrophages can be isolated from gout patients 
carrying the allele of variants of interest and measure for differential expression of 
these IL23R and SERPINA1 using real time qPCR by designing primers. It will also 
be useful to measure the protein activity of such variants. The other way to delineate 
the role of a protein (encoded by the gene of interest) is by designing an experiment 
through generating a genetically modified knockout mouse. In such a mouse model, 
genes of interest can themselves be knocked out or existing DNA can be replaced by 
the DNA construct with a modified genetic variation to explore what that gene does 
normally. In this way the biological role of a genetic allele of the gene of interest can 
also be determined. 
 
§ Furthermore, the current study is a significant contribution towards addressing an 
important step of gout pathogenesis, which is about explaining the genetic control of 
progression from hyperuricaemia to gout. For this purpose, the selected 
inflammatory loci were tested for their association with gout in the presence of 
hyperuricaemia by using HU controls against gout cases. However, the sample size 
of study cohorts was relatively small so a large-scale study based on asymptomatic 
hyperuricaemic controls and gout cases to detect gout specific loci (excluding serum-
urate loci) would be worth-while. 
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RESEQUENCING—AN IMPORTANT TECHNIQUE 
TO UNCOVER POTENTIAL POPULATION 
SPECIFIC GENETIC VARIANTS 
A portion of the work presented in this chapter has been published at Annals of Rheumatic 
Diseases. 
Klück V., van Deuren R.C., Cavalli G., Shaukat A., Arts P., Cleophas M.C., Crisan T.O., Tausche A.K., Riches 
P., Dalbeth N., Stamp L.K., Hindmarsh J.H., Jansen T.L., Janssen M., Steehouwer M., Lelieveld S., van de Vorst 
M., Gilissen C., van de Veerdonk F.L., Eisenmesser E.Z., Kim S., Merriman T.R., Hoischen A., Netea M.G., 
Dinarello C.A. and Joosten L.A.B. (2020). Rare genetic variants in Interleukin-37 link this anti-inflammatory 
cytokine to the pathogenesis and treatment of gout. Annals of Rheumatic Diseases, 79(4), 536–544. 
 
3.1. Introduction 
Discovering the genetic basis of complex traits has been a central focus for many decades. 
Complex disorders are not caused by a single mutated gene, but by the combination of 
numerous genetic and environmental factors. Genome wide association studies (GWAS) have 
contributed to understanding of the complex pattern of various disorders but thus far are only 
focused on identifying disease-associated common single nucleotide polymorphisms (SNPs) 
(minor allele frequency > 0.05). The majority of these SNPs that have small effect sizes explain 
less than half of the apparent heritability leaving a large proportion unexplained or missing 
referred to as ‘missing heritability’. Additionally, being in non-coding regions most of these 
variants have not been tracked to their functional effects. Moreover, there are unique genetic 
signatures only present in one population but monomorphic in others that can explain more than 
50% of trait variability in such populations (Hartford et al. 2009, Young 2019). Therefore, there 
is a need to search for non-synonymous or other essential genomic components that confer 
additional population risk for disease. Significant progress has been driven by high throughput 
sequencing and microarray technologies to address this issue of inadequate coverage of genetic 
variations in GWA studies (Ku et al. 2010). These technologies cover whole genome, exome 
sequencing, deep re-sequencing around known GWAS-associated regions and customized 
genotyping arrays (Eichler et al. 2010, Manolio et al. 2009, Martinez-Hernandez et al. 2019, 
Metzker 2010). 
There are several possible ways to resolve the mystery of missing heritability - one can 
be through identifying low frequency or rare variants. Another possible way is to co-analyse all 
polymorphisms being genotyped in a GWAS rather than considering only significant signals 
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with strong or moderate effects. Moreover, missing heritability could also be explained by 
identifying all causal variants including population-specific genetic signatures and measuring 
how much trait variation they explain (reviewed in (Sadee et al. 2014, Young 2019)). 
Nonetheless, recent advances in high-throughput sequencing have provided significant insights 
to resolve such ‘missing heritability’ challenges by looking into all possible culprits e.g. 
structural variations, rare and low frequency variants and population-specific genetic 
determinants. Utilising the advantages of high-throughput sequencing technologies, the present 
study has been designed to develop and apply the in-silico resequencing approach to capture 
functional variants (including population-specific variants) that contribute to gout risk. 
 
3.1.1. Advent of Sequencing Technologies 
The development of massively parallel sequencing technologies alternatively known as 
next generation sequencing (NGS), has transformed the field of human genetics and enables 
researchers to explain some of the missing heritability through identifying putative disease-
causing variants. These sequencing technologies are explained in detail in the following 
paragraphs. 
 
a) Whole genome sequencing (WGS) 
Whole genome sequencing, also known as full genome sequencing or complete genome 
sequencing, is a process to determine the complete DNA sequences of an organism’s genome 
at a particular time. This includes the sequencing of all organisms’ chromosomal DNA as well 
as mitochondrial DNA. The WGS approach can be used to gain essential information on a gene, 
genetic variants and gene function for biological, medical and clinical studies (Bentley 2006). 
Since WGS offers a single test that captures almost all genetic variations (single nucleotide 
variations (SNVs), indels, copy number variations, structural variations, intronic SNVs) in an 
unbiased and accurate manner, its utility in clinical diagnosis and gene discovery is merging 
(Posey et al. 2017, Stavropoulos et al. 2016). Previously, the sequencing of an entire genome 
was prohibitively expensive, particularly for regular use in clinical practice (National Human 
Genome Research Institute, 2017). However, introduction of cost-effective sequencing 
methods (WGS, WES, low-depth WGS and targeted re-sequencing) has made biological and 
medical research more feasible and accurate for clinical implications (S Davies 2017, Y Li et 
al. 2011, Pasaniuc et al. 2012, YP Yang et al. 2014). For example, recently, researchers at the 
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Rady Children's Institute for Genomic Medicine in the USA determined that rapid whole 
genome sequencing (rWGS) can diagnose genetic orders in time in ill infants to change medical 
management (clinical utility) with improved outcomes. They reported a retrospective cohort 
study of ill infants . In this study forty-two families received rWGS for the diagnosis of genetic 
disorders and researchers identified the higher rate of clinically utility of rWGS (31%, 13 in 42 
infants) compared to standard genetic tests (2%, P =0.001) (Farnaes et al. 2018). Another study 
provided strong evidence for increased clinical utility of singleton WGS (as a first-tier 
sequencing test) in the diagnosis of suspected monogenic disorders in infants from an 
Australian children’s hospital (Z Stark et al. 2016).  
 
b) Exome Sequencing 
This particular approach aims to sequence the 1-2% coding region of the genome and can 
be effective to identify novel and disease causal variants (Bamshad et al. 2011, Ng et al. 2010b, 
Posey et al. 2017). Causal variants have been identified for various Mendelian disorders via 
exome sequencing at less cost relative to WGS (Ng et al. 2010a, Ng et al. 2010b). Now it is 
also increasingly being used to identify disease-associated causal genetic variants, particularly 
those associated with complex traits (Bilguvar et al. 2010, J Cai et al. 2015, Snape et al. 2012, 
Toledo et al. 2016, Worthey et al. 2011). For example, the UK10K project has sequenced the 
exomes of 6000 people suffering from obesity and neurological disorders to understand the 
genetic basis of these biological conditions (Rivas et al. 2011). Another exome sequencing 
study discovered disease susceptible rare and low frequency variants in PLD3 (phospholipase 
D family member 3) associated with late-onset Alzheimer disorder (Cruchaga et al. 2014). The 
only limitation of this sequencing technique is that it leverages genetic information across the 
exome and ignores non-coding variants (~98% of the genome), which play an essential role in 
complex trait genetics (Elgar and Vavouri 2008).  
 
c) Capture/Targeted Sequencing 
This sequencing approach allows many individuals to be sequenced for particular regions 
of interest (of high priority) at low cost and in a short time. It yields greater sensitivity for 
detection compared to WGS. This technique has been increasingly used to detect rare causal 
variants associated with complex diseases, which are usually unidentified by genome-wide 
scans. As an example, Rivas et al. sequenced 56 candidate genes and identified many low–
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frequency variants for Crohn’s disease (Rivas et al. 2011). Recently Pulignani et al. (2018) 
tested targeted NGS of a specific gene panel in non-syndromic congenital heart disease patients 
and identified 20 missense variants in 9 genes: among those 14 were present in publicly-
available databases with rare frequency and the remaining six variants in four genes (TBX1, 
NKX2-5, GATA4N, OTCH1) were detected as novel mutations (Pulignani et al. 2018). 
Therefore, targeted sequencing is a powerful and easy procedure that allows sequencing of 
many genes at a single time.  
 
3.1.2. Why Resequencing? 
Resequencing is one of the most popular applications of NGS, which is used to determine 
genomic sequence variations in a sample in relation to the common reference sequence. 
Aligning of resultant generated short sequences (50-400bp) to a reference genome provides 
information for SNPs, CNVs, genomic rearrangements, and indels. NGS platforms for 
sequencing also produce sequencing errors but these can be rectified using suitable statistical 
tools (Anand et al. 2016, H. Li and Homer 2010, Pirooznia et al. 2014, Salojärvi 2018). 
Targeted resequencing is a type of resequencing that is increasingly being used to detect causal 
genetic variations in various disorders (Cuyvers et al. 2015, Decker et al. 2019, Franca et al. 
2018, Hildebrand et al. 2016, Rizvi et al. 2018, Y Xu et al. 2018). This approach also provides 
cost effective and rapid generation of high-quality sequences with an average depth of 50X or 
higher. With respect to the discovery of a wider range of genetic variations, until now, 
resequencing studies have identified several hundred thousand short indels, copy number 
variations and other structural variations in the human genome. The innovation of these ‘newer 
types’ of genetic variations has broadened the implication of a vast number of genetic signatures 
in genetic studies to reveal mechanistic pathways relevant to disease pathogenicity (Cuyvers et 
al. 2015, Decker et al. 2019, FitzPatrick 2017, J Zhang et al. 2011). Moreover, genotyping by 
resequencing becomes a standard approach to address geographical population genomics 
through estimating SNP diversity and explaining different haplotype structure. Based on the 
emerging popularity of the resequencing approach it is now being applied in the area of ‘rare 
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3.1.3. Sequencing Analysis for the Discovery of Variants 
A plethora of new technologies are expediting discovery of variants underpinning 
complex human disorders with the growing popularity of massive parallel i.e. whole-genome 
and whole-exome sequencing. However, the choice of sequencing experiment solely depends 
on the population under investigation and research questions being addressed. Comprehensive 
resequencing of the human genome is now feasible to reveal the entire genetic make-up of each 
individual, allowing identification and discovery of causal disease-associated variants. 
Irrespective of the sequencing methodologies used, the principles of sequencing analysis are 
similar and are described below. 
 
3.1.3.1. Alignment to The Reference Sequences 
The first step in the analysis process comprises aligning of the sequencing output to the 
human reference assembly, to allow identification of differences with the ‘normal’ sequences 
and to determine the location of these variations, either present in either gene exon, intron or 
intergenic regions. The commonly used reference genomes are the human genome consortium 
database (GRCh37; http:/grch37.ensembl.org/). 
 
3.1.3.2. Classification of Variants Based on Functional Consequences 
Further to this, there is the need to determine the class of variants on the basis of 
functional consequences, which encodes the alteration in regulatory regions. The information 
is useful to categorize variants into synonymous, insertions and deletions (indels), frameshift, 
splicing and most critically non-synonymous (missense and nonsense) variants—due to having 
a diverse range of functional effects. Missense variants being present in critical residues can 
have deleterious effects on both protein structure and function. Given that in vitro studies using 
animal models, human cell culture and CRISPR/Cas9 digestion are potential methods to 
elucidate the functional consequence of individual variants, it is impractical to apply these 
methods for a large number of investigated variants thus it is necessary to develop alternative 
strategies. Thereby, functional predictor tools can be a significant source to infer pathogenicity 
of variants where there is lack of experimental elucidation data. These functional annotation 
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Table 3.1: List of tools used in Functional Annotation of Genetic Variations 
  
Tools Description Website References 
SIFT It is known as scale-invariant feature transform (SIFT) which predicts 
whether an amino acid substitution affects protein function based on the 
degree of conservation of amino acid residues in sequence alignments 
derived from closely related sequences 
http://sift.jcvi.org/  (P Kumar et al. 2009) 
CADD CADD is an abbreviation of combined annotation dependent depletion, that 
integrates multiple annotations into one metric by contrasting variants that 
survived natural selection with simulated mutations 
http://cadd.gs.washington.edu/  (Kircher et al. 2014)  
ENCODE Encyclopaedia of DNA elements (ENCODE) is a platform that provides 
information based on annotation of potential functional elements (for 
example, histone tail modifications) in several cell lines 
https://www.encodeproject.org/  (GTEx Consortium 2017) 
  
PolyPhen-2 Polymorphism Phenotyping version 2 (PolyPhen2) is a tool that predicts the 
possible impact of an amino acid substitution on the structure and function 
of a human protein using straightforward physical and comparative 
considerations 
http://genetics.bwh.harvard.edu/pph2/  (Adzhubei et al. 2010)  
Phen-Gen Method that combines patients' disease symptoms and sequencing data with 
prior domain knowledge to identify the causative genes for rare disorders 
http://phen-gen.org/about.htm  (Javed et al. 2014) 
VEP Variant effect predictor (VEP) determines the effect of given variants 
(SNPs, insertions, deletions, CNVs or structural variants) on genes, 
transcripts and protein sequence, as well as regulatory elements. 
http://useast.ensembl.org/info/docs/tools/vep
/index.html?redirect=no 
 (McLaren et al. 2010)  
HaploReg v1-v4 This tool is used for visualization of DNA polymorphisms along with their 
predicted chromatin state, their sequence conservation across mammals, 
and their effect on regulatory motifs 
http://www.broadinstitute.org/mammals/ 
haploreg/haploreg.php 
 (Ward and Kellis 2012)  
Epigenomics 
Roadmap 
Epigenomics Roadmap is tool for annotation of potential functional 
elements (for example, DNase I hypersensitive sites) in various human 
tissues and primary cells 
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3.1.3.3. Comparison with Population Databases 
The discovery of functionally-predicted variations in the genome is then followed by 
comparison to publicly-available online databases to assess whether these variants are novel or 
have been previously reported and what the frequency is of such variants in different 
populations. This can be done using dbSNP, 1000G, gnomAD, TOPMed, and Exon Sequencing 
Project (ESP) databases. Nonetheless, measuring the distribution of allele frequencies across 
the global population groups is also essential to determine commonality or rarity of short-listed 
genetic variants. 
 
3.1.3.4. Determination of Regulatory Genes (Gene-Specific Information) 
Subsequent variant discovery requires mapping to regulatory regions of the genome 
(enhancers, insulators etc.), as in some cases, the detected variants can be found at a 
considerable distance from targeted genes. Moreover, the complex inter-marker correlations 
also limit the identification of causal variants influencing phenotypes. This is because often 
many co-inherited genetic variants are in linkage disequilibrium (LD) with the most significant 
disease-associated variant forming a haplotype (Gabriel et al. 2002). Such variants in strong 
LD within a haplotype often have significant indistinguishable associations with disease risk 
(Gallagher and Chen-Plotkin 2018). Undoubtedly, the knowledge of function and expression 
quantitative loci (eQTL) analysis has resolved this enigma to some extent by testing discovery 
variants for the association with the level of expression of nearby genes. Expression QTL 
mapping was established in 2001 with the introduction of the concept of ‘genetical genomics’, 
used to evaluate which genes are regulated by genetic variations via correlating variations with 
gene expression (transcriptome levels) or protein levels (Jansen and Nap 2001). The eQTL then 
entails the information of heritable (58%-85%) variations of transcript levels within and across 
individuals for a wide variety of tissues and cell types thus enabling identification of tissue/cell 
specific gene expression of trait-associated variants (YQ Chen et al. 2008, Emilsson et al. 2008, 
Goring et al. 2007, Guo et al. 2018, WD Li et al. 2019, Moreno et al. 2018, Qiu et al. 2018). A 
variety of eQTL databases are in practice now to extract gene or tissue specific information 
such as the Genotype-Tissue Expression (GTEx) database and the blood eQTL dataset (Westra 
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Figure 3.1: A flow chart showing essential steps for DNA sequencing analysis. 
 
WGS: whole genome sequencing; TOPMed: Trans-Omics for Precision Medicine; eQTL: expression quantitative 
trait loci; QTL: quantitative tool loci. 
 
3.1.3.5. Validation of Discovered Signals 
This is an important phase in order to validate identified genetic variants. These variants 
could affect protein structure, gene expression and regulation or may have no detectable effect 
at all. There are possibilities to infer identified variants as ‘real signals’ and their contribution 
to confer disease susceptibility; one is to test these variants for association with the same trait 
but in an independent cohort of un-related individuals (that should be ancestrally related). 
There are two ways to replicate identified variants; one is through designing sequencing-
based strategies, which represent a locus-based (resequencing of whole region) validation. This 
strategy enables researchers to magnify regions of interest by avoiding irrelevant regions of the 
genomes. The other method to validate the identified signals is variant-based where genotyping 
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of discovery variants over the samples (population of interest) has been performed through 
TaqMan. 
 
3.1.4. Role Of Resequencing In Determining Population-Specific 
Genetic Variants OR Determining the Role of Population-Specific 
Genetic Variants 
In the era of high-throughput sequencing technologies, it is possible to estimate variant 
frequencies in control populations using larger datasets and some of these differ considerably 
across different populations. Recent large-scale population genomic projects evidence 
differences in allelic frequencies in polymorphic variants that are distinct in respective 
populations. Consistent to this extensive variability, surveys in European populations show an 
obvious correspondence between genetic and geographic distances. The first large population 
scale sequencing dataset was established by the 1000 Genomes Project, where a genome-wide 
map of variants was generated across 2504 individuals of European, African, American and 
Asian ancestry (Altshuler et al. 2010). Another ‘Exome Sequencing Project’ was launched by 
the National Heart, Lung and Blood Institute, in which 6500 African and European samples 
were exome sequenced (Tennessen et al. 2012). Moreover, the Exome Aggregation Consortium 
(ExAC) combines sequence data of 60,000 unrelated individuals from different parts of the 
world (Lek et al. 2016). These large sequencing projects clearly indicate that a significant 
proportion (~85%) of variants are population-specific (Bamshad et al. 2003). Thereby, several 
initiatives have produced more local datasets to closely interpret the role of ancestry-specific 
markers corresponding to genetic and geographic structure of such populations. For example 
the UK10K project has been created that contains 4000 genomes from UK individuals along 
with 6000 exomes with selected extreme phenotypes (UK10K, http://www.uk10k.org [June-
2015]. A study based on a collection of 3000 Finnish Exomes revealed more loss of function 
variants in Finnish Europeans than non-Finnish Europeans (Lim et al. 2014). Furthermore, 
relatively smaller studies such as a WGS study of 100 Malayans (LP Wong et al. 2013) and 
250 trio-families in the Netherlands also reported genetic variations (Genome of the 
Netherlands 2014) private to these populations. Another initiative for generating a local dataset 
is based on 2636 Icelandic genomes (Gudbjartsson et al. 2015). The Icelandic population, being 
isolated from other populations, could have a high frequency of deleterious variants (unique 
only to this population) compared to other global populations. A difference in allelic 
distribution of variants across multiple populations also affects their susceptibility to complex 
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and rare diseases (Adeyemo and Rotimi 2010). For example, a study of exome sequencing in 
267 Spanish individuals revealed significant differences in allele frequencies of variants 
associated with several degenerative retinal dystrophies in Spanish people compared to other 
populations (compared with frequencies of 1000 Genome data). For variants associated with 
autosomal dominant cone dystrophy, 4 heterozygotes were detected in 267 Spanish people 
while it was absent in the 1000 Genome database (Dopazo et al. 2016). Another study reported 
a lack of correlation in allele frequencies between Europeans and non-Europeans for variants 
associated with 26 complex disorders including type 2 diabetes, various cancers, mental 
disorders, neurodegenerative disorders and systemic autoimmune disease (Adeyemo and 
Rotimi 2010). Contribution of a specific variant toward susceptibility of the disease in a given 
population may result from genetic drift, selection and gene flow. Thereby it is essential to 
generate local genetic maps to interpret population-specific variant frequencies of clinical 
relevance. 
 
3.2. Aim of the Study 
The main aim of this chapter is the identification of functional variants in inflammatory 
genetic regions, either common or less frequent (low-frequency or rare), that may be causal to 
gout. Given the potential role of genetic variants located in inflammatory loci in the 
development of various auto-inflammatory and inflammatory conditions, it is reasonable to 
investigate their causality with gout inflammation. Nowadays, various high-throughput 
sequencing technologies are commonly used to investigate such loci for their causality in 
various clinical conditions, therefore in the current study the resequencing approach has been 
used with in-silico (computational) application to interrogate potential genetic associations in 
inflammatory regions with gout in Polynesian and European sample sets. Further, to validate 
resultant signals as genuine, genotyping and basic sequencing (Sanger sequencing) approaches 
were used in NZ Polynesian and European sample sets. 
 
3.3. Methodology 
Taking into account the contribution especially of uncommon and population-specific 
variants to heritability (Agarwala et al. 2013, Speed et al. 2012) along with the lack of evidence 
for such variants (particularly located in inflammatory genetic regions) in gout pathogenesis, 
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this study has been designed to capture such genetic variants conferring gout risk in the NZ 
Polynesian and European populations. 
The majority of the chapter consists of developing a strategy (designing an 
approach/analysis) to assess human functional sequence variations underpinning gout 
pathogenesis.  
 
3.3.1. Generation of Inflammatory Loci List— A literature based 
approach 
The substantial portion of the identification of inflammatory loci for in-silico 
resequencing was comprised of a ‘literature survey’ which is based on the following 
considerations: 
a) Database searching for genetic associations/loci involved in the development of 
common auto-inflammatory conditions. 
b) Monogenic auto-inflammatory genes 
c) Top signals from GWAS for immune-mediated conditions conducted in two main 
population divisions; Europeans and East Asian such as: 
- Inflammatory Bowel Disease (IBD [Crohn’s disease, UC]) 
- Systemic Lupus Erythematosus (SLE) 
- Systemic sclerosis 
- Rheumatoid Arthritis 
- Ankylosing Spondylitis 
- Gout 
d) Exploiting the above approach but in the latest meta-analysis of association studies 
in large cohorts with an inflammatory phenotype in European and East Asian sample 
sets 
e) Candidate inflammatory genes from targeted association studies 
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Figure 3.2: Schematic View of In-Silico Resequencing Study Design. 
 
Above is the comprehensive description of the literature survey with subsequent computational analysis for the in-
silico resequencing analysis. IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; RA: 
Rheumatoid arthritis; SLE: systemic lupus erythematous; WGS; whole genome sequencing. 
 
3.3.1.1. The Analysis Methodology 
After an extensive literature survey, the next step was to design an analytical approach to 
extract genomic features from the loci of interest for further genetic analyses. The following 
methodology has been evolved, to generate a list of genomic regions to be analysed through 
sequences of gout individuals with detection of novel or uncommon disease associated genetic 
variations. 
 
3.3.1.1.1. Input Data 
The original vision was to use GWAS and large meta-analysis studies summary statistics 
data to identify windows of maximal association and through these genomic windows define 
the boundaries for selection of genes and relevant genomic features. However, GWAS and 
meta-analysis study summary datasets are not always available; in this situation SNP extraction 
from selected publications (manual creation of a list of SNPs) is a robust alternative. Thus, the 
analysis catered for two input data sources; meta-analysis and GWA study summary data and 
selected SNPs (lead SNPs); these files were merged into a single dataset to avoid any 
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complexity during the processing process. The input data files must adhere to a very specific 
data format, details below; 
 
3.3.1.1.2. GWAS Summary Format 
All GWAS summary files must have the following four columns: 
- Chromosome number 
- SNP name (e.g. rsID/dbSNP identifier) 
- P value (level of association) 
- POS (base pair position) 
 
In addition, there must be a separate input file for each population of interest. One of the 
key requirements for this analysis was to extract the top 20 GWAS loci per immune phenotype 
per population. Thus, by necessity the analysis must treat each population independently while 
selecting loci. For example, in GWAS summary data for IBD present in both European and 




The population abbreviations follow the nomenclature of the 1000 Genomes project such 
as European (eur), East Asian (eas), South Asian (sas), African (afr), America (amr). 
 
3.3.1.1.3. SNP Input Format 
The format of the SNP files was much simpler, and only required CHR and RSID 
columns. SNP positions were not required in the input file (as these were not present in any  
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3.3.1.1.4. For a Lead SNP 
The data (from the literature) that was lacking locus-wide or genome-wide summary 
statistics information instead had a single SNP (lead SNP) details: the association boundary 
(genetic regions associated with the single SNP) was defined on the basis of linkage 
disequilibrium (LD) with the lead SNP. For the purpose an appropriate 1000 Genome 
population panel (www.browser.1000genomes.org) was used to define LD with the lead SNP 
in the appropriate population (European and East Asian). This was performed because the 
genomic regions present at 500kb+/- from the genomic region associated with the lead SNP 
could be of interest and play an important role in gout pathogenesis. 
 
3.3.1.2. Windows of Maximal Association 
In designing this analysis, a few objectives were taken into account: 
a) Developing an automated rigorous and reproducible method. 
b) Removing the burden of manually trawling through large data files. 
 
Thus, the process of finding 'regions' or association in GWAS/meta-analysis summary 
data was broken into a number of parts: 
1) Filter the GWAS hits (default parameter filters out p-value > 0.0001) to make the 
data easier to handle and to artificially generate 'low-density' regions in the data. 
2) Use a density-based clustering algorithm (dbscan) to pick up 'high-density' regions 
on each chromosome. 
3) Each region was scored (or window, we use this term interchangeably) based on the 
minimum p-value (used default setting). 
4) Rank the regions by their score and select the first K (e.g. the top 20 regions). 
5) For each of the top 20 regions, record the top 3 SNPs (by p-value). These SNPs will 
become the reference SNP (with two alternate SNPs) for the calculation of LD. 
 
Each of these steps relies heavily on the data.table package in R. 
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3.3.1.3. Selection of Candidate Genes 
In general, those genes were selected which lay within the region of association or in the 
immediately flanking region of 50kb. The exact numbers of flanking genes were somewhat 
arbitrary but mainly dependent on how gene-rich these regions were and how interesting they 
potentially were. Thus, the selection of genes was facilitated through an interactive interface 
using R and Shiny package within R software. For each region: 
1) 1000 Genomes data was downloaded 
2) LD within this region was calculated 
3) Relevant genes were queried from UCSC (an online genome browser hosted by the 
University of California, Santa Cruz) 
4) The pattern of LD and genes was visualised in R software to select interactively. 
 
Regional plots were generated by the Shiny R package to visualize top SNPs (the 
information obtained was based on the LD matrix that was sourced from 1000 Genome data) 
and surrounding genomic regions, the top SNP in the plot was found strongly correlated with 
signal of association seen in GWAS p-values. This top SNP lay in the genetic region that was 
then selected along with genes in the flanking region of 50kb.  
 
3.3.1.4. Extraction of Genomic Features 
Information on genomic regions for selected candidate loci was extracted from the 
reference dataset available in the background of UCSC browser using various bioinformatics 
tools (mentioned below at the end of this section). For each of the final genes: 
1) Entrez ids were found (by linking gene symbols and UCSC IDs) 
2) Transcripts were identified 
3) For each transcript, the exons, promoters, 3' and 5' UTR were queried from Biomart 
4) Each of these was reduced to remove duplicate sequences 
5) The generated loci selection app also displayed a summary of the sizes of these by 
feature type as well as a total summary 
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This part of the analysis relied heavily on the GenomicRanges package from R's 
Bioconductor repository with additional TxDb.Hsapiens.UCSC.hg19.knownGene and 
VariantAnnotations packages. 
 
3.3.1.5. Loci Selection App (LSA) 
To aid this analysis, an interactive interface using R and Shiny app. was developed. The 
primary motivation for this was due to the somewhat flexible criteria for the selection of genes. 
The loci selection app provides the most flexibility and allows users to adjust their selection 
criteria as necessary. The app has three main parts: 
1) The instructions page has basic user instructions and is where the user sets up the 
project settings 
2) The visualisation page is the main area where users may navigate through the loci 
and select genes 
3) The summary page displays a summary of the final resequencing regions and the 
total size. 
The interface has been designed using a modified 3-tiered architecture with a presentation 
layer (ui.r), a logic layer (server.r) and a data access layer (lsa_logic.r). This app. was designed 
with the help of lab employee Nick Burns. To view this app. docker software would be required 
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Figure 3.3: Schematic View Of In-Silico Resequencing Analysis (methodology). 
 
This illustration briefly explains the methodology steps used in the in-silico resequencing analysis, LD: linkage 
disequilibrium; UTRs: Untranslated regions, regional plots are representing the lead SNP and surrogate markers 
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3.3.2. Study Cohorts 
3.3.2.1. Discovery Phase 
The following sections describe the data which have been used initially to discover 
genetic variants in inflammatory loci associated with gout. 
 
3.3.2.1.1. Whole Genome Sequence (WGS) Data 
For the discovery and prioritizing of genetic variations a whole genome sequence dataset 
of gout patients was utilized, recruited from USA, Japan, Australia and New Zealand. An 
American based pharmaceutical company (Ardea Biosciences) recruited people of ancestral 
groups European (n= 780), Asian (n=135) and Polynesian (n=55) which were further processed 
by the Merriman laboratory group who also organized whole genome sequencing of these 
samples. The phenotype data collated with the sequence information from the same individuals 
were also collected. The genomes were sequenced at the Garvan Institute of Medical Research 
| Kinghorn Cancer Centre, 370 Victoria St., New South Wales, Australia. The platform used 
for WGS was 30x WGS (TruSeq Nano) v2.5. 
 
3.3.2.1.1.1. Processing of WGS data through a Bioinformatics Pipeline 
The bioinformatics processing of raw sequencing data was run through a pipeline 
customized by James Boocock and Murray Cadzow, with some up-grading from Matt Bixley. 
The detailed process is described below. 
The FASTQ format files of sequences were aligned to the human reference genome 
(GRCH37/hg19) using Burrow’s Wheeler Aligner (BWA) tool, where a maximal exact matches 
(MEM) command was used for quality alignment. The local realignment was performed using 
the Genome Analysis Toolkit’s (GATK v 3.6.0) outlined by (McKenna et al. 2010) and 
resultant BAM files indexed by another tool called SAMtools (v0.1.19). All of these 
programming jobs were run through GNU parallel—a shell tool to execute multiple jobs at the 
same time, introduced by Tange (2011) for  improving and reducing the run time and sequential 
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3.3.2.1.1.2. Variant Calling and Filtering 
Single nucleotide polymorphisms and insertion deletions (indels) were detected using the 
GATK HaplotypeCaller (v3.4.0.) for which sample ‘-ploidy’ option was set to 2. Various filters 
were used for quality control (QC) and to harmonize the data. The only variants included were 
those which followed the standard criteria of QC such as heterozygosity= 0.001, 
indel_heterozygosity = 1.25×10-4, genotype quality (GQ) >10, mapping quality (MQ) > 30 and  
those which had high coverage of reads and genotype quality (~ > 90). In addition, various 
bioinformatics tools were applied to confirm accuracy and high quality of data, for example a 
variant recalibrator (VQSRT) in GATK command-line with the Apply Recalibration tool was 
used to assign well-calibrated quality to each variant call in an input call set. This calibration 
of variant calling was sourced from ‘gold standard’ databases connected through VQSRT. 
SnpEff (v4.3t) software conjoining with bcftools commands was used to annotate SNPs 
and indels in the VCF file. This software contains the reference genome GRCh37.75 and links 
to other databases including gnomAD genome and exome, so that it contributes to calculating 
the relative allele frequencies of each variant in these sourced datasets. The data were also run 
through another variant annotation tool dbNSFP 
(http://varianttools.sourceforge.net/Annotation/DbNSFP), an annotation database for non-
synonymous SNPs assembled by Xiaoming Liu (XM Liu et al. 2011), which predicted the 
functional consequences of the variants.  
 
3.3.2.1.2. In-Silico Analysis Using WGS Database 
The outcome from initial data processing and analysis, comprised of promoters, DHS 
regions, exons and 3’/5’UTRs genetic information was then subjected to another customized 
pipeline along with WGS data. This whole analytical part resulted in a variant call format (VCF) 
file containing information on genetic variations in gout patients including rare and low 
frequency variants (synonymous and non-synonymous). The resultant VCF file was then 
processed to transform into a readable file with required information using bioinformatics tools 
like vcf and bcf tools, PLINK. The reference datasets (gnomAD, exomAD) for the annotation 
of genetic variants were also downloaded to support this bioinformatics pipeline and placed in 
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3.3.2.2. Replication Phase 
3.3.2.2.1. Validation of Discovery Variants 
Subsequent association analysis of discovered and distinct variants was undertaken in a 
replication cohort comprised of NZ Polynesian and European sample sets (details are presented 
in the following section named as cohorts for validation). This replication of variants was 
carried out because of the following reason: 
To confirm and validate the potential genetic variations identified in the discovery 
phase that could be regions of interest for future studies in terms of identifying their 
functional role in gout pathogenesis. 
 
3.3.2.2.2. Prioritizations of Genetic Variants 
Genetic variations found in the discovery phase were first prioritized prior to being 
replicated in the replication cohort. The prioritization was based on the following criteria: 
1) Calculating the frequency of variants in individual ancestral groups (European, 
Polynesian and Asian). 
2) Frequency-based: certain thresholds were set across diverse groups of the population 
based on the allele frequency spectrum and also compared to the reference database 
of gnomAD (European ancestry). For example, variants were chosen which were 
common in the Polynesian group (AF>0.05) and had low or rare frequency in 
Europeans and vice versa.  
3) Population-specificity: Population-specific variants (based on an allele frequency 
spectrum) were prevalent (AF>0.05) in one population while absent or rare 
(AF<0.0005) in other populations.  
 
3.3.2.2.3. Cohorts for Validation 
To validate and confirm the sequencing findings, two categories of sample sets were used. 
These two divisions of sample sets have overlapped samples; the difference is one was used for 
TaqMan genotyping (an allelic discrimination assay) and the other (with additional samples) 
used genotyping data available from the using Illumina CoreExome Chip. One of the validation 
cohorts (used for TaqMan genotyping) consisted of gout patients and controls from different 
parts of New Zealand, Australia and Europe. For the selection of samples, New Zealand data 
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sets were divided into three groups based on ancestry: European cases (n=1011) and controls 
(n=1033), East Polynesian (New Zealand Māori, Cook Islands) cases (n=739) and controls 
(n=850), West Polynesian (Samoa, Tonga, Tuvalu, Tokelau and Niue) cases (n=452) and 
controls (n=412). The European ancestry data set comprised samples from various European 
regions (Dresden, Germany; Utrecht, the Netherlands; Nijmegen, the Netherlands; Edinburgh, 
United Kingdom, Australia and New Zealand). A group of East Polynesian ancestry Māori 
individuals (n=458) from the rohe (area) of Ngāti Porou was also included (details are provided 
in section 2.2 and Appendix). The clinical table entailing the information regarding necessary 
clinical parameters has been documented in a detail in Chapter 2.2.1 Methods. 
Human CoreExome Illumina chipped (genotype) data comes under the second category 
of cohorts, used for the validation of some of the discovery-phase genetic variations (a 
description can be found in Section 4.2 and Appendix section 1.3). These data are comprised 
of Eastern Polynesian (EP; n = 1340; cases = 647, controls = 693), West Polynesian (WP; n = 
816; cases = 445, controls = 371) and Europeans (n = 4579; cases = 3557, controls = 1022). 
The New Zealand Eastern Polynesian are New Zealand and Cook Island Māori individuals, 
whereas Western Polynesian belong to the Tonga, Samoa, Niue, and Tokelau regions. The 
European cohort includes data from NZ European, European Crystal Network Cohort 
(EUROGOUT), the Arthritis Genomics Recruitment Initiative in Australia Cohort (AGRIA) 
and Ardea Biosciences from America (detail is presented in Appendix section 1.1 and 1.3).  
 
3.3.2.2.3.1. Genotyping by TaqMan 
Genotyping of p.N182S (rs752113534) in IL37 and rs78635115 in ALDH16A1was 
performed by a TaqMan® SNP Genotyping assay (C_2215549_20; Applied Biosystems, Foster 
City, USA) according to the instructions provided in the manufacturer’s protocol. The TaqMan 
SNP genotypes were auto-called via reporter dye signal plots on Lightcycler® 480 Real- Time 
Polymerase Chain Reaction (RT-PCR) System (Roche Applied Science, Indianapolis, IN, 
USA). TaqMan genotyping was conducted in all aforementioned NZ Polynesian (EP, WP and 




148 | Page 
3.3.2.2.3.2. Statistical Analysis 
For both TaqMan and Illumina CoreExome Chip genotyped data a multivariate-adjusted 
regression analysis approach was used to measure the association of selected missense variants 
including TaqMan genotyped IL37;rs752113534 and ALDH16A1;rs78635115 missense variant 
(explanatory variables) with gout (binary response variable). The association analysis was 
conducted through statistical software R version 3.3.2 (RCore, 2016). Any participant with 
missing data for any variable was excluded from the various analyses. Allelic odd ratios (ORs) 
calculated for study variants were adjusted with age, sex, first 10 principal components (PCs) 
described in the methodology section of Chapter 4 (methodology section 4.3.3) for Europeans 
and the first 4 PCs (significantly affected the analysis in terms of producing population 
stratification effect) in Polynesian analyses. These PCs account for population stratification and 
cryptic relatedness. All association analyses were also adjusted with QC batches (quality 
control batches). This is because the NZ Polynesian and European samples were sent at 
different times to be genotyped on the Illumina CoreExome chip. The data were also sent back 
at different times and processed accordingly. This could provide false positive results if not 
adjusted as a confounder (batch effect). Therefore, a logistic regression model was designed 
including variables that gave batch information. Next, to test for association of selected genetic 
variants with gout in the presence of hyperuricaemia, hyperuricaemic controls (serum urate ≥ 
0.41mmol/L) were used (detailed description is presented in section 2.2). NZ Polynesian 
subgroups were also combined in a meta-analysis using the Meta package within R 
(http://CRAN.R-project.org/package=meta, 2014) using a fixed-effect model to increase the 
power of the study. 
A false discovery rate (FDR) method was used to correct significant p-values to remove 
artefacts of a large number of multiple testings such as false positives. It was calculated in R 
software (version 3.6.) using the p.adjustment function that adjusted all significant p-values in 
the association analysis. 
An interaction analysis was also performed between the ALDH16A1 rs78635115 
variant and SLC2A9 variants rs6449144 and rs2280205. Gene-gene interaction, also 
called epistasis, is a potential approach to enlighten missing heritability (Zuk et al., 
2012). It has been reported that gene-gene interaction can influence the heritability 
calculation of complex traits (Cordell, et al., 2009; Diamond and Moore, 2011; He al., 
2015; Jamshidi et al., 2015). The current method of interaction used  proposes to cluster 
genotype combinations at multiple loci into subgroups to account for the variation caused 
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by the genetic interactions (Jung et al., 2003). The method starts with all 3 × 3 genotypic 
combinations for two SNPs (e.g. rs78635115 and rs6449144). The genotypic p value is 
related to the interaction of genotype combinations while the allelic interaction  
represents the interaction of the minor allele of a SNP with the minor allele of the other 
SNP. The interaction analysis was performed in R software for pairs of variants in a 
combination of the genotypes. The tests were adjusted for sex and age and 1-10 PCs in 
the EP and WP groups. The Bonferroni corrected significance threshold was determined 
for a number of interaction analyses performed in each Polynesian group. For genotypic 
interaction analysis, if a Bonferroni-correction factor of 9 (two-locus genotype 
combinations of the two testing variants) was used, then the threshold for significance 
level would be 0.006. 
 
3.3.2.2.3.3. Power of the Association Study 
The present study has adequate power > 80% to detect moderate effect at minor allele 
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Figure 3.4: Association detection power in the Polynesian dataset across a range of odds ratios with minor 
allele frequency > 0.01. 
 
Dotted red line indicates an adequate detection power ≥ 80%. 
 
Figure 3.5: Association detection power in the European dataset across a range of odds ratios with minor allele 
frequency > 0.01. 
 




151 | Page 
3.3.2.2.4. Polymerase Chain Reaction (PCR) Protocol for the Detection of 
Variations in IL37 (Exon 5) Genetic Region in Polynesians (EP and WP) 
This methodology represents the part of sequencing analysis used for further validation 
of discovery-phase variants. This is a protocol of standard Sanger sequencing that is comprised 
of designing primers for the targeted region (IL37-exon5) PCR for optimization, preparation of 
DNA samples for sequencing and Sanger sequencing. In addition, the sequences were 
interpreted using bioinformatics tools. 
 
3.3.2.2.4.1. Materials and Reagents 
- TaqMan buffer with KCl 
- dNTPs (4mM) 
- IL37 exon (5) region forward primer 
- IL37 exon (5) region reverse primer 
- MgCl2 (25mM) 
- Taq DNA Polymerase 
- DMSO 
- Template DNA (40ng/ul) 
- Distilled Water 
- Exo-SAP (for DNA purification)  
- T.E buffer  
 
3.3.2.2.4.2. Preparation of DNA Template 
DNA extracted from 131 Polynesian (EP; n = 81, WP; n = 50) blood samples was used 
40ng/ul per sample. This dilution was prepared with T.E buffer. Blood samples used in the 
current study were from Polynesian gout patients. 
 
3.3.2.2.4.3. Selection of Optimal Mg2+ Titration 
A serial titration was conducted based on varying the quantity of experimental reagents 
(25mM MgCl2 and distilled water). It ranged from 1mM to 4mM MgCl2. At the end 4mM was 
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3.3.2.2.4.4. Primer Design 
An online software tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to 
design primers. Primers were selected using the following parameters. 
1) Melting temperature between 57°C to 63°C 
2)  (G+C) content between 50-60% 
3) Length between 20-24 
For the PCR reaction, primers (both forward and reverse) were diluted to 500ng/ul with 
T.E buffer.  
Forward Primer: ACATGTGCTGTGTTTTCCTCC 
Reverse Primer:             CCAATGACAGAAAGTTTAGTGAGC 
 
The product length was 401 base pairs (the length of the genomic region (IL37:exon 5) 
for the primers that were designed). 
 
3.3.2.2.4.5. 10X PCR Reaction Mixture 
For optimal 4mM magnesium-based titration the following reagents were used in defined 
measurements  
- 10XTaq buffer with KCl (includes 100mM Tris-HCl, 500mM KCl and 0.8% (v/v) 
Nonidet P40 (1.5ul) 
- 4mM dNTPs (0.75ul) 
- Fwd. primer (307.5ug/nmol) (307.5ug (1.125ul) 
- Rev. primer (305.4ug/nmol) (1.125ul) 
- 25mM MgCl2 (2.4ul) 
- Taq DNA Polymerase (1U/ul) (0.375ul) 
- Distilled water (1.974ul) 
- Dimethyl sulfoxide (DMSO) (5-10% v/v) (0.75ul) 
- And then add 5ul of Polynesian DNA (40ng/ul) to make a stock solution of 15ul 
 
3.3.2.2.4.6. Determination of Annealing Temperature 
Melting temperature (Tm) of primers can be calculated by the formula:  
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Tm = [ (Number of A + T residues) x 2] + [ (Number of G + C residues) x 4] °C. 
 
The optimal annealing temperatures are determined experimentally for a certain 
primer/template combination. Temperature gradient PCR is often a way to finalize an optimal 
annealing temperature. In the PCR reactions an optimized Tm-59°C was used with 32 cycles 
run. 
 
3.3.2.2.4.7. Agarose Gel Electrophoresis 
The PCR products were electrophoresed on a 4% agarose gel (4g of agarose in ml 100ml 
T.E buffer) for an hour at 120V. The loading dye and marker were used to determine the correct 
size of the designed PCR, which was 401 base pairs in the current experiment. DNA bands 
were visualized under UV light on a transilluminator and a digital photograph was generated. 
 
3.3.2.2.4.8. Quantification 
The PCR product was cleaned using EXOSAP before doing quantification. For the 
purpose 5ul of the PCR product of each sample was separated in a separate PCR plate and 2ul 
of EXOSAP was added in each well. 
DNA was quantified by applying the following Beer-Lambert equation relating 
absorbance and extinction co-efficient to DNA concentration. Absorbance readings were 





c is the concentration of attenuating species 
3.3.2.2.5. Sanger Sequencing 
After optimizing primers, the stock solution was prepared for further sequencing for 131 
EP and WP gout samples. The stock contained the following components: 
1) 1/25 dilution of EXOSAP-IT DNA samples (for each DNA sample). Use the 
calculated volume for each sample. 
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2) In the sequencing tube then add reverse primer (3.2pmol)  
3) Then add relative amount of ddH2O to get the required amount of DNA (4ng/ul) for 
Sanger sequencing. Sanger sequencing of Polynesian gout samples was performed by 
Genetic Analysis Services at Otago, Lindo Ferguson Building, 270 Great King Street, 
Dunedin, New Zealand. 
The following is the sequencing protocol that is used by Genetic Analysis Services at The 
University of Otago, Dunedin, New Zealand. 
Sequencing Reaction Protocol 
Each sample of 10µl should contain the following volumes of components:  
5 x Sequencing Buffer    1.75µl 
Big Dye Terminator        0.5µl 
Primer (3.2µM)               1µl 
Template                         0.5µl - 4µl* 
Distilled Water              to bring total up to 10µl 
* In a 10µl reaction use the following quantities of template 
PCR product.                  1ng/100bp 
Recommended cycling conditions for sequencing reaction 
96°C  10s                              
50°C 10s 
60°C 60s* 
Repeat for 25 cycles 
Hold at 4°C 
* For 1000bp fragments (the extension time can be decreased or increased depending on the size 
of the product).  
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Sequencing Reaction Clean-Up Protocol 
This is a post-sequencing reaction purification. 
The following is a method that is used to clean up the sequencing reaction. The Sephadex resin 
is comprised of small beads that contain small holes. Big molecules such as sequencing products 
cannot fit into the holes and so they go around the beads and move quickly through the column 
on applying pressure (centrifugal force). Small molecules (dNTPs) fit into the holes in the beads 
and they move very slowly through the column and get retained. When the column is spun at 
low relative centrifugal force for a short time, only the pure sequencing product is eluted and 
the dNTPs stay in the resin (Zoon RA 1987). 
To prepare resin 
1. Weigh 25g Sephadex G-50 
2. Add 500ml ddH2O 
3. Mix well and stand about 10 minutes 
4. Suck cloudy water off to ~ 1cm above resin 
5. Refill with ddH2O 
6. Go back to step 3 and repeat until upper ddH2O layer is clear 
7. Store in the fridge 
To use resin 
1. Suck water down to 1cm or so 
2. Mix resin well (no stir bars) 
Protocol 
1. Set up two Whatman Unifilter plates with deep well collection plates underneath: one 
for clean-up and one for balance 
2. In one plate, aliquot 500µl of Sephadex resin in the number of wells required (using a 
cut-off tip). In the other plate, aliquot equivalent weight in water 
3. Spin at 750xg for 5 mins 
4. Flick the water off the collection plates, rebalance, and spin again at 750xg for 3 mins 
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5. Flick the water off the collection plates then add 250µl Sephadex resin on top of the 
500µl resin in the wells 
6. Rebalance and spin at 750xg for 5 mins 
7. Flick the water off the collection plates 
8. Replace the deep-well collection plate with an empty PCR plate and spin at 750xg for 
1min 
9. Check the PCR plate. Some water should be present but not too much (<5ul per well). 
This shows that the resin in the plates isn't too wet or dry 
10. Quickly spin down the 10µl sequencing reaction and then add 10µl of ddH20 to each 
sample (a better elution is achieved with 20µl sample volume) 
11. Apply sample to the Sephadex column (ideally, watch the sample "drop" onto the 
column: don't let it slip down the side and/or ram the pipette tip into the column) 
12. Replace the collection plate with a clean PCR plate for collecting the sample 
13. Balance and spin at 750xg for 5 mins 
14. Check the plate to ensure that the samples are collecting satisfactorily and then spin at 
750xg for a further 3 mins 
15. Check that the volume is close to 20µl (if not, bring it up to 20µl) 
16. Seal the plate and wrap in tinfoil. 
 
3.3.2.2.6. Interpretation and Annotation of Sequences 
The resultant sequences from Sanger sequencing were then uploaded in Geneious Prime 
version 2019.2.1 build 2019-06-17 11:03 (www.geneious.com) to visualize sequence 
variations. The variation at the nucleotide level was then related with encoded amino acids 
using the following websites 
(https://i.pinimg.com/originals/2c/09/44/2c0944772f1ecbcc0e2068f342d5aa90.jpg) and 
(https://www.dnabaser.com/articles/IUPAC%20ambiguity%20codes.html.). Detected 
variations at different positions were annotated using a script generated by Murray Cadzow 
(Merriman lab) sourced from 
(https://github.com/murraycadzow/phd_thesis/tree/master/src/scripts). Here again the 
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Bioconductor packages were used including VariantAnnotation, GenomicRanges, 
TxDb.Hsapiens.UCSC.hg19.knowGene, dplyr and org.Hs.eg.db). The R packages include 
human genome reference data from UCSC genome browser to interpret genetic variations 
especially with known rsIDs. Additionally Kaviar online software was also used to annotate 
sequence changes (http://db.systemsbiology.net/kaviar/cgi-pub/Kaviar.pl). This was also 
useful to compare frequency of identified variants (already known) with global databases. 
 
3.4. Results 
3.4.1. In-Silico Resequencing—Discovery Phase 
WGS was carried out in gout individuals of various ancestral groups, mainly categorised 
into European, Asian and Polynesian. As a part of in-silico resequencing that has been described 
in the previous section (Methodology), genetic regions were extracted and markers’ frequencies 
were compared among study populations (Polynesian, European and Asian) and also with 
publicly-available databases (e.g. gnomAD and ExAC). 
 
3.4.1.1. Frequency Based Analysis 
The initial assessment resulted in the generation of frequency-based population-stratified 
data files. The allelic distribution of protein-coding genetic variants in each population 
(European, Asian and Polynesian) was calculated and recorded using PLINK 1.9.v2. Various 
cut-off values were applied to explore population-specific common (allele frequency (AF) > 
0.05) and low frequency or rare variants for Polynesian (AF < 0.01) and for other populations; 
European and Asian (AF < 0.0005). Given the variation in population size in the current study 
(European = 780, Polynesian = 55, Asian = 135) the resultant variants were further investigated 
by comparing their allelic distribution in online available sequence databases. The resultant 
files were then merged and produced a list of annotated genetic variants accompanied by 
essential information of allelic distribution across study populations and publicly-available 
database gnomAD (Genome Aggregation Database) (Figure 3.6). The gnomAD database 
contains information from 125,748 exome sequences and 15,708 genome sequences 
(https://gnomad.broadinstitute.org) and was obtained from 141,456 individuals who were 
sequenced as a part of disease-specific and population studies.  
Consideration of discrete allelic frequency distribution among study ancestral groups, 
European, Polynesian and Asian, led to the prioritization of the coding and non-coding variants. 
 
 
158 | Page 
The output file contained a total of 584 genetic variants including upstream, downstream, 
intergenic, 3 and 5 prime UTRs and missense/ nonsense and splice variants. From this file, 25 
missense variants, which can directly influence protein function by altering amino acids, were 




Figure 3.6: Schematic view of selection of genetic variants across Europea and Asian populations based on the 
threshold ranged between allele frequencies (AF > 0.05 and AF < 0.0005) while (AF > 0.05 and AF < 0.01) in 
Polynesians. 
 
The above flow chart briefly explains the selection criteria of genetic variants as the result of in-silico resequencing 
based on the threshold range of allele frequencies differing across populations and then the resultant frequencies 
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Table 3.2: List of missense variants selected on the basis of distinct allelic distribution across populations 






















Overall AF: average allele frequency of variants across WGS European, Polynesian and Asian populations, MAF: 












gnomAD Polynesian European Asian 
rs104895509 NLRP7 0.008 0.0004 0.0002 0.136 0 0.011 
rs1059542 HLA-A 0.881 0.882 0.862 0 0.143 0.014 
rs114820168 IRAK4 0.004 0.0002 0.0002 0.090 0 0.007 
rs115700798 RAB38 0.004 0.0006 0.0006 0.063 0.0005 0.011 
rs115724324 FFAR4 0.007 0.006 0.007 0.054 0.0005 0.029 
rs13374149 CACNA1S 0.066 0.060 0.110 0 0.076 0.003 
rs199943004 SNAPC4 0.008 0.0005 0.0005 0.132 0.0005 0.011 
rs201030657 SNAPC4 0.008 0.0005 0.0003 0.132 0.0005 0.011 
rs201808826 SDCCAG3 0.009 0.0005 0.0003 0.163 0.0005 0.011 
rs202214079 MASP2 0.004 0.0001 0.0001 0.1 0.0005 0 
rs2071471 TAP2 0.015 0.008 0.005 0.127 0.0005 0.077 
rs2228139 IL1R1 0.052 0.056 0.061 0 0.063 0.0036 
rs2229699 LTB 0.005 0.004 0.001 0.090 0.0005 0.007 
rs2275272 ALDH18A1 0.098 0.105 0.140 0 0.111 0.047 
rs2708943 IL37 0.081 0.068 0.101 0 0.096 0.014 
rs2708947 IL37 0.081 0.068 0.100 0 0.096 0.014 
rs2723183 IL37 0.081 0.068 0.100 0 0.096 0.014 
rs2723187 IL37 0.080 0.068 0.100 0 0.095 0.014 
rs2723192 IL37 0.080 0.067 0.100 0 0.095 0.014 
rs28374506 KANK1 0.047 0.036 0.090 0 0.052 0.011 
rs3087374 POLG 0.058 0.062 0.068 0 0.069 0.003 
rs35060588 IRAK2 0.051 0.050 0.051 0 0.059 0.011 
rs36111323 TRPC6 0.087 0.096 0.084 0 0.098 0.066 
rs752113534 IL37 0.00002 0.00002 0.00001 0.063 0 0 
rs78635115 ALDH16A1 0.00037 0.0003 0.0005 0.236 0.0005 0.018 
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3.4.2. Validation of Discovered Genetic Variations– Association 
Analysis 
The prioritized non-synonymous variants (missense variants) displaying varied allelic 
distribution in each population were selected for association analysis in NZ datasets. Only those 
variants where genotypes were available from CoreExome chip data were used for the 
association analysis, however, for two population (Polynesian) specific missense genetic 
variants (IL37;rs752113534 and ALDH16A1;rs78635115) TaqMan genotyping was conducted 
in NZ sample sets. Among variants sourced from chip data, only CACNA1S;rs13374149 and 
TAP2;rs2071471 were successfully replicated for gout in adequately powered NZ Polynesian 
data. The T-allele of rs13374149 and the A-allele of TAP2; rs2071471 were significantly 
associated with gout risk (OR = 2.56, P = 0.003, OR = 0.69, P = 0.030, respectively) in the EP 
group. These associations remained significant after adjusting the p-value using the FDR 
method (Padjusted = 0.006, Padjusted = 0.030, respectively). The meta-analysis of Polynesian 
subgroups also indicated a susceptible association of the T-allele of rs13374149 (ORmeta = 2.52, 
Pmeta = 0.002) and the A allele of rs2071471 (ORmeta = 0.72, Pmeta = 0.008) towards gout risk 
(Figure 3.7Figure 3.8). No evidence of significant associations was found for these variants in 
other Polynesian ancestral groups (WP) (rs13374149; OR = 2.21, P = 0.387, rs2071471; OR = 
0.76, P = 0.123) and European (Table 3.3). Similarly, the TAP2 rs2071471 variant was not 
successfully replicated in other Polynesian subgroups or European datasets (Table 3.3). 
Interestingly, the rs13374149 variant existed as an uncommon variant with a T-allele frequency 
of 2% in the EP sub-set sourced from CoreExome chip data that was comprised of 1340 
individuals, however, it was not detected in Polynesians of the WGS data that was comprised 
of only 55 individuals. Based on the allele frequency calculated (0.02) with the CoreExome 
Polynesian data set, we would expect 1 in 50 people to have the variant allele. Due to the sample 
size of 55, it could be possible that none of the individuals in the WGS data set had the variant 
of interest. The CACNA1S rs13374149 variant was also found as a rare variant in the WP dataset 
(MAF = 0.002). The TAP2 variant was found as a common variant in Polynesian groups with 
a frequency ranging from 7-10% but was rare in the European group (Table 3.3). None of the 
other variants showed any significant association in any study group (Table 3.3).  
Analysing HU controls vs gout, the only association for the T allele of rs13374149 with 
gout was in the EP (OR = 10.03, P = 0.033) sample set (Table 3.4) This is possibly because of 
the smaller sample size, however, the replication of rs13374149 in a larger dataset could clarify 
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Table 3.3: Association analysis of selected missense variants from in-silico resequencing data with gout in Polynesian (EP, WP) and European (gout cases vs all controls) 
CHR SNP Ref Allele 
Gout Association Analysis (All Controls vs Gout Cases) 

























19 rs104895509 T 0.084 0.083 0.401 0.89  (0.67, 1.18) 0.093 0.089 0.839 
1.04 
 (0.72, 1.5) 0.0001 0.0004 0.306 
0.06 
 (0.00, 13.26) 
12 rs114820168 T 0.052 0.055 0.96 0.99  (0.69, 1.43) 0.138 0.114 0.838 
0.97 
 (0.7, 1.33) 0.0002 - - - 
11 rs115700798 A 0.084 0.075 0.892 0.98  (0.73, 1.32) 0.049 0.044 0.929 
1.02 
 (0.65, 1.61) 0.0007 - - - 
10 rs115724324 G 0.051 0.042 0.555 1.12  (0.77, 1.64) 0.132 0.107 0.203 
0.81 
 (0.59, 1.12) 0.0002 0.0004 0.972 
1.07 
 (0.01, 61.98) 
1 rs13374149 T 0.021 0.016 0.003 2.56  (1.38, 4.75) 0.002 0.002 0.387 
2.21 
 (0.37,13.36) 0.046 0.049 0.406 
0.88 
 (0.67, 1.17) 
9 rs199943004 T 0.132 0.125 0.764 0.96  (0.76, 1.23) 0.164 0.197 0.22 
0.84 
 (0.63, 1.11) 0.0004 0.001 0.274 
0.21 
 (0.01, 3.36) 
9 rs201030657 T 0.132 0.125 0.714 0.96  (0.75, 1.22) 0.165 0.199 0.191 
0.83 
 (0.62, 1.1) 0.0004 0.001 0.142 
0.14 
 (0.01, 1.9) 
9 rs201808826 A 0.132 0.110 0.987 1.00  (0.78, 1.28) 0.173 0.199 0.345 
1.15 
 (0.86, 1.52) 0.0004 0.001 0.272 
0.21 
 (0.01, 3.35) 
6 rs2071471 A 0.069 0.075 0.030 0.69  (0.17, 0.49) 0.101 0.105 0.123 
0.76 
 (0.53, 1.07) 0.0005 0 - - 
2 rs2228139 G 0.014 0.017 0.968 1.01  (0.51, 2) 0.003 0.004 0.270 
0.46 
 (0.11, 1.84) 0.07 0.07 0.563 
0.93 
 (0.73, 1.18) 
6 rs2229699 A 0.065 0.055 0.782 1.05  (0.74, 1.48) 0.042 0.043 0.329 
0.77 
 (0.45, 1.3) 0.0001 0.0009 0.25 
0.08 
 (0.001, 5.71) 
10 rs2275272 A 0.033 0.044 0.832 1.05  (0.68, 1.62) 0.008 0.007 0.613 
1.35 
 (0.42, 4.37) 0.133 0.128 0.949 1 (0.84, 1.2) 
2 rs2708947 C 0.026 0.024 0.216 0.43  (0.12, 1.63) - - - - - - - - 
2 rs2723183 G 0.019 0.027 0.776 1.09  (0.61, 1.94) 0.006 0.015 0.918 
1.06 
 (0.34, 3.34) 0.08 0.077 0.295 
1.12 
 (0.89, 1.41) 
2 rs2723187 T 0.018 0.027 0.820 1.07  (0.6, 1.92) 0.006 0.015 0.918 
1.06 
 (0.34, 3.34) 0.08 0.077 0.353 
1.11 
 (0.88, 1.39) 
2 rs2723192 A 0.018 0.027 0.820 0.93  (0.52, 1.67) 0.006 0.015 0.918 
0.94 
 (0.3, 2.96) 0.08 0.077 0.353 
1.11 
 (0.88, 1.39) 
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CHR: chromosome; SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value and odd ratio are adjusted with sex, age, 










9 rs28374506 G 0.002 0.004 0.945 0.95  (0.21, 4.36) 0.001 0 - - 0.006 0.003 0.547 
1.31 
 (0.53, 3.21) 
15 rs3087374 A 0.024 0.030 0.607 1.15  (0.68, 1.94) 0.004 0.005 0.642 
1.37 
 (0.36, 5.2) 0.078 0.083 0.503 
0.92 
 (0.74, 1.15) 
3 rs35060588 G 0.015 0.020 0.718 0.89  (0.46, 1.7) 0.003 0.007 0.153 
0.36 
 (0.09, 1.46) 0.065 0.062 0.359 
1.12 
 (0.87, 1.44) 
11 rs36111323 A 0.034 0.037 0.533 0.87  (0.55, 1.36) 0.007 0.008 0.779 
1.17 
 (0.4, 3.41) 0.122 0.116 0.263 
1.11 
 (0.92, 1.34) 
6 rs3800381 T 0.072 0.067 0.548 1.1  (0.8, 1.53) 0.057 0.105 0.983 
1.00 
 (0.65, 1.54) 0.0001 0.0004 0.524 
0.31 
 (0.01, 10.75) 
9 rs7860464 A 0.002 0.005 0.622 1.46  (0.32, 6.57) 0.002 0 - - 0.008 0.004 0.551 
1.28 
 (0.55, 2.97) 
19 rs78635115 C 0.240 0.218 0.779 0.97  (0.8, 1.18) 0.28 0.31 0.592 
1.07 
 (0.84, 1.37) 0.0001 0.0009 0.598 
0.42 
 (0.01, 10.24) 
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Table 3.4: Association Analysis of selected missense variants from in-silico resequencing data with gout in Polynesian (EP, WP) and European (Gout cases vs HU controls). 
CHR SNP Ref Allele 
Gout Association Analysis (HU Controls vs Gout Cases) 
Eastern Polynesian Western Polynesian European 


























19 rs104895509 T 0.084 0.111 0.285 0.78  (0.49, 1.23) 0.093 0.092 0.476 
1.22 
 (0.71, 2.1) 0.0001 0.000 - - 
12 rs114820168 T 0.052 0.055 0.518 1.22  (0.67, 2.23) 0.138 0.112 0.425 
0.83 
 (0.52, 1.32) 0.0002 0.000 - - 
11 rs115700798 A 0.084 0.077 0.059 0.6  (0.35, 1.02) 0.049 0.056 0.115 
1.67 
 (0.88, 3.18) 0.0007 0.000 - - 
10 rs115724324 G 0.051 0.046 0.778 1.09  (0.59, 2.03) 0.132 0.096 0.899 
0.97 
 (0.59, 1.59) 0.0002 0.0005 0.964 
1.09 
 (0.02, 58.34) 
1 rs13374149 T 0.021 0.003 0.033 10.03  (1.2, 83.93) 0.002 0.004 0.962 
0.94 
 (0.08, 11.52) 0.046 0.048 0.376 
0.87 
 (0.64, 1.18) 
9 rs199943004 T 0.132 0.114 0.125 1.38  (0.91, 2.1) 0.164 0.229 0.433 
0.85 
 (0.57, 1.28) 0.0004 0.000 - - 
9 rs201030657 T 0.132 0.115 0.127 1.38  (0.91, 2.1) 0.165 0.231 0.401 
0.84 
 (0.56, 1.26) 0.0004 0.000 - - 
9 rs201808826 A 0.132 0.109 0.112 0.71  (0.47, 1.08) 0.173 0.225 0.829 
1.05 
 (0.69, 1.58) 0.0004 0.000 - - 
6 rs2071471 A 0.069 0.095 0.168 0.68  (0.40, 1.17) 0.101 0.092 0.482 
0.84 
 (0.51, 1.36) 0.0005 0.0005 0.97 
1.05 
 (0.06, 17.13) 
2 rs2228139 G 0.014 0.009 0.583 0.7  (0.19, 2.52) 0.003 0.000 - - 0.07 0.069 0.518 
0.91 
 (0.70, 1.19) 
6 rs2229699 A 0.065 0.086 0.155 1.49  (0.86, 2.59) 0.042 0.044 0.97 
0.99 
 (0.49, 2) 0.0001 0 - - 
10 rs2275272 A 0.033 0.04 0.675 0.85  (0.39, 1.83) 0.008 0.004 0.144 
3.87 
 (0.63, 23.87) 0.133 0.126 0.803 
1.02 
 (0.84, 1.24) 
2 rs2708947 C 0.026 0.017 0.274 0.26  (0.02, 2.91) - 0.000 - - 0.08 0.088 - - 
2 rs2723183 G 0.019 0.012 0.274 1.79  (0.63, 5.06) 0.006 0.02 0.157 
3.3 
 (0.63, 17.33) 0.08 0.078 0.464 
1.09 
 (0.85, 1.39) 
2 rs2723187 T 0.018 0.012 0.262 1.81  (0.64, 5.15) 0.006 0.02 0.157 
3.3 
 (0.63, 17.33) 0.08 0.078 - - 
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2 rs2723192 A 0.018 0.012 0.262 0.55  (0.19, 1.56) 0.006 0.02 0.157 
0.3 
 (0.06, 1.59) 0.08 0.078 - - 
9 rs28374506 G 0.002 0.000 - - 0.001 0.000 - - 0.006 0.004 - - 
15 rs3087374 A 0.024 0.018 0.326 0.59  (0.21, 1.68) 0.004 0.000 - - 0.078 0.083 - - 
3 rs35060588 G 0.015 0.012 0.579 1.41  (0.42, 4.74) 0.003 0.012 0.133 
0.21 
 (0.03, 1.6) 0.065 0.064 0.571 
1.08 
 (0.82, 1.41) 
11 rs36111323 A 0.034 0.015 0.047 0.37  (0.14, 0.99) 0.007 0.008 0.541 
1.67 
 (0.32, 8.68) 0.122 0.117 0.212 
1.13 
 (0.92, 1.39) 
6 rs3800381 T 0.072 0.074 0.686 1.12  (0.65, 1.94) 0.057 0.136 0.653 
1.15 
 (0.63, 2.09) 0.0001 0.000 - - 
9 rs7860464 A 0.002 0.000 - - 0.002 0.000 - - 0.008 0.004 - - 
19 rs78635115 C 0.240 0.219 0.56 0.9  (0.64, 1.27) 0.28 0.384 0.512 
1.13 
 (0.79, 1.62) 0.000 0.0005 - - 
CHR: chromosome; SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value and odd ratio are adjusted with sex, age, 
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Figure 3.7: Forest plot of meta-analysis for CACNA1S;rs13374149 with gout (all controls vs gout) in NZ 
Polynesian (EP and WP) 
 
Overall effect is presented by (OR), P (overall effect) = 0.002 and P (heterogeneity) = 0.879. 
 
Figure 3.8: Forest plots of meta-analysis for TAP2;rs2071471 with gout (all controls vs gout) in NZ Polynesian 
(EP and WP) 
 
The overall effect is presented by (OR), P (overall effect) = 0.008 and P (heterogeneity) = 0.693. 
 
3.4.3. Association Analysis for Population-Specific Variants 
Two missense variants (IL37 rs752113534 and ALDH16A1 rs78635115) were selected 
for TaqMan genotyping in the current study sample sets (NZ Polynesian and European) on the 
basis of their high prevalence in Polynesian subgroups while very uncommon in other 
populations. Moreover, these genetic variants were not present on the Illumina CoreExome 
Chip. The other reason for the selection of rs78635115 in ALDH16A1was the occurrence of 
this variant in a separate dataset of urate resequencing generated by the Merriman lab (apart 
from the current in-silico analysis). This resequencing dataset targeted predominantly urate-
transporter genes that were sequenced over 374 Māori and Pacific individuals (of extreme 
phenotypes e.g. gout, hyperuricaemia and normouricaemic). Cases were defined 
hyperuricaemic with serum urate levels ≥410µmolL-1 irrespective of gout status and urate 
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lowering therapy while controls had the lower serum urate levels ≤370µmolL-1 with a self-
report of no gout history. 
 
3.4.3.1. IL37;rs752113534 
The IL37;rs1752113534 p. (N182S).G-allele was prevalent in Polynesian ancestral 
groups, exhibiting 5% frequency as compared to European groups. The rs1752113534 variant 
was monomorphic in the European population. In the current study, the rs1752113534 minor 
allele (G) did not exhibit significant association with gout in either Polynesian groups; EP (OR 
= 1.41, P = 0.116) and WP (OR= 1.19, P = 0.538) (Table 3.5). The rs1752113534 G-allele was 
associated with gout with the same direction of effect when HU controls were used in EP (OR 
= 1.89, P = 0.069) and WP (OR = 1.68, P = 0.243) sample sets (Table 3.6).  Inverse-variance 
weighted meta-analysis combining all Polynesian datasets using HU controls versus gout cases 
produced significant association between the rs1752113534 G allele and gout risk (OR= 1.81, 
P = 0.031) (Figure 3.10). 
For IL37;rs752113534 the difference in gout rate between populations (EP and WP) can 
be explained by the population attributable fraction (PAF) that quantifies the contribution of a 
risk factor to a disease and death. It is a proportional reduction in a population burden of disease 
that would occur if exposure to a risk factor is reduced to an alternative ideal exposure scenario 
(e.g. no use of tobacco).  Gout is caused by multiple factors where individual risk factors may 
interact in their impact on overall risk of disease. The PAF calculated for rs752113534 risk 
allele (T-allele) in  EP is 0.016 and in WP is 0.009. Thus this variant accounts for ~1% of PAF, 
an effect not present in other populations. 
Further statistical analysis was conducted to find the genetic effect of IL37;rs1752113534 
in different conditions (available data in Merriman laboratory) alongside gout (Table 3.7). In 
the analysis individuals carrying the risk allele G (AG and GG) were compared to individuals 
without the risk allele (A) on p. (N182S) stratifying by available clinical parameters. This 
evaluation showed that patients with the p. (N182S) G-allele developed gout at an earlier age 
compared to non-carrier patients with gout (P-value = 0.005 and P-value = 0.018 for the EP and 
WP sample sets, respectively) (Table 3.7), consistent with the data when this was tested using 
a regression model (in EP (carriers n=76; non-carriers n=640; p-value=0.014; ß=−4.309 
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In an international collaboration in which I was involved Klück et al., (2020) found rare 
variants in IL37 exon 5 in Dutch gout patients. Considering the Polynesian-specific effect of 
rs1752113534 the IL37 exon 5 region was selected for Sanger sequencing in Polynesian. There 
is a possibility that this genetic region may contain various other potential loss of function, 
missense and nonsense population specific variants, which could be causal to gout. Therefore, 
for the Sanger sequencing 131 EP gout patients were selected (based on gout status) to validate 
the rs1752113534 findings as well as to identify novel variants (if any exist) in NZ Polynesian 
gout individuals. This ended up with the identification of the following genetic variants (next 
paragraph). Among these variants, some non-synonymous variants have already been reported 
in publicly-available sequence databases (gnomAD, gnomAD exome, ESP and TOPMED), 
however were uncommon outside the sequenced populations. 
The identified missense variants in the present study that were also present in the publicly-
available databases include rs536123660 (G-allele = 0.001 in South East Asian) and 
rs752113534 (G-allele = 0.0002 in East Asian). Note that the frequencies for variants were 
extracted from publicly-available databases, detailed in (Table 3.8). Furthermore, in the current 
sequencing study the rs536123660 variant was detected in 3 Polynesian individuals 
(chromatograms are provided in the Appendix, Section 3). The rs752113534 sequence variation 
was identified in 11 individuals (5 WP and 6 EP). The variant call of G was also detected in an 
EP individual (chromatograms have been included in the Appendix, Section 3). At rs75211353 
most people (57) had a TT genotype, some (28) had were heterozygous, and one had a GG 
genotype. These sequencing results for the rs752113534 variant were aligned with the TaqMan 
results, that again validate the discovery of this variant in Polynesian individuals. Three novel 
sequence variations were also detected at positions 2:113676219, 2:113676298 and 
2:113676374 (sequence traces are presented in the appendix section 3) with allele frequencies 
AF = 0.022, AF = 0.122 and AF = 0.114, respectively. Among these novel variants the latter 
two were relatively prevalent in Polynesians. In some individuals at position 2:113676374-5 
the genotype change from GG to AT was observed (chromatograms are provided in the 
Appendix, Section 3). It is also notable that some of the variant calls were not of high quality 
and perhaps need confirming by other methods. All of these genetic variants were detected in 
exon 5 of IL37 in NZ Polynesian (EP and WP) gout samples and are not genotyped on the 
Illumina CoreExome chip. Therefore it will be worth-while to test associations of these variants 
with gout in a larger cohort of Polynesian gout case and control datasets using TaqMan 
genotyping methodology, particularly for those identified for the first time and which show 
convincing sequence variations in the traces (i.e. : 2:113676298 and 2:113676374). 
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The protein alteration of rs1251554057 (p.Glu215_Val216delinsAspIle) is near to the C-
terminus where it may alter protein function. IL37 broadly reduces inflammation and exists in 
a monomer/dimer equilibrium. IL37 binds to its receptor IL-18Rα and the orphaned IL-1R8 
receptor and inhibits proinflammatory cytokine secretion. The IL-37 dimer must dissociate with 
the IL-37 monomer to interact with IL-18Rα (Eisenmesser et al., 2019). A recent study 
demonstrated that the alteration in either the N-terminal or the C-terminal residues leads to no 
measurable change to (LPS-induced) IL-1β secretion, yet the removal of both termini led to a 
recombinant form with slightly reduced activity compared with WT IL-37. There is a possibility 
that the C-terminus is critical for specific interaction for specific  receptors. Conversely, it may 
cause non-specific interactions that dampening of its anti-inflammatory activities (Eisenmesser 
et al., 2019).  
 
3.4.3.2. ALDH16A1;rs78635115 
The missense variant rs78635115 encoding p.Ser178Pro in ALDH16A1 was tested for its 
association with gout in NZ Polynesian and European populations. This is an uncommon 
variant with < 1% frequency in East Asian populations while monomorphic in European 
populations. 
An association analysis of the rs78635115 C-allele did not exhibit significant association 
to gout in either Polynesian group (EP and WP) using all controls versus gout cases (Table 3.5). 
A consistent outcome was found for the minor (C) allele of rs78635115 when HU controls were 
used (Table 3.6). Similarly, meta-analysis of Polynesian subsets also did not demonstrate 
association for rs78635115 C-allele with gout using all controls as well as HU controls (Figure 
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Table 3.5: Association analysis of population-specific variants with gout in European and NZ Polynesian 
populations (gout cases vs all controls) 
Gene;SNP Group Genotype Frequencies MAF 
*Adjusted 
P Value OR (95% CI) PHWE 
IL37; 






















4 (0.006) 0.057 
0.116 
1.41 














1 (0.002) 0.056 
0.538 
1.19 






0 (0.000) 0.050 0.275 
ALDH16A1; 






























































SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value 
and odds ratio are adjusted with sex, age, first 4 principle components account for Polynesian ancestral variations 
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Table 3.6: Association analysis of population-specific variants with gout in European and NZ Polynesian 
populations (gout cases vs HU controls) 
Gene;SNP Group Genotype Frequencies MAF 
*Adjusted 
P Value OR (95% CI) PHWE 
IL37; 




















































 (0.88, 5.00) 
0.874 






































































SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value 
and odd ratio are adjusted with sex, age, first 4 principle components account for Polynesian ancestral variations 
and QC batches; PHWE = P for Hardy Weinberg 
 
Figure 3.9: Forest plots of meta-analysis for IL37;rs1752113534 with gout (all controls vs gout) in NZ 
Polynesian (EP and WP) 
 
The overall effect is presented by (OR), P (overall effect) = 0.281 and P (heterogeneity) = 0.631. 
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Figure 3.10: Forest plots of meta-analysis for IL37;rs1752113534 with gout (HU controls vs gout) in NZ 
Polynesian (EP and WP) 
 
The overall effect is presented by (OR), P (overall effect) = 0.031 and P (heterogeneity) = 0.836. 
 
Figure 3.11: Forest plots of meta-analysis for ALDH16A1;rs78635115 with gout (all controls vs gout) in NZ 
Polynesian (EP and WP) and European (NZ European, Eurogout and AGRIA) 
 
The overall effect is presented by (OR), P (overall effect) = 0.690 and P (heterogeneity) = 0.787. 
 
Figure 3.12: Forest plots of meta-analysis for ALDH16A1;rs78635115with gout (HU controls vs gout) in NZ 
Polynesian (EP and WP) and European (NZ European, Eurogout and AGRIA) 
 
The overall effect is presented by (OR), P (for overall effect) = 0.946 and P (heterogeneity) = 0.208. 
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Comorbidities of Gout 



































































































































































In the above table individuals carrying the risk allele G (AG and GG) are compared to individuals without the risk 
allele (A) of p. (N182) (rs1752113534) in different categories of clinical parameters. FEUA; Fractional excretion 
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Table 3.8: Interpretation of sequences of EP and WP gout samples for IL37 exon (5) region with identification of known and novel variants 
SNP Base Position 
Nucleotide Change 
(N individuals with 
change) 
AF in Polynesian 
cohort 
Functional 
Effect Variant Type 
rsID and AF from the 
literature 










T = 0.001, G= 0.0019 
G=0.0001 (1/125568, TOPMED) 
G= 0.000 (1/5008, 1000G) 
rs2708947 113676219 
Y=3 

















G= 0.00002 (4/251388, gnomAD) 
G=0.00002 (3/125568, TOPMED) 
G = 0.00002 (3/121370, ExAC) 
2:113676298 113676298 
Y= 16 




Missense   
2:113676374 113676374 
K=15 




Missense   
The table provides details of annotated sequences of EP and WP gout samples for IL37-exon5. A total of 131 EP and WP samples were sequenced by Sanger sequencing. The 
column showing nucleotide code (change in a nucleotide sequence predicts the change of amino acids (encoded by nucleotides), the data is present in this column on the basis of 
information provided by following diagrams (a standard format for interpretation of nucleotide sequence changes; sourced from 
https://www.genome.jp/kegg/catalog/codes1.html); the numbers are representing individuals carrying those nucleotide sequence changes, the frequencies of sequence variations 
are also compared with globally present sequencing databases e.g. gnomAD: Genome aggregating database, TOPMED; Trans-omics for precision medicine; ExAC: Exome 
aggregation consortium, GO-ESP: Exome sequencing Project. 
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Considering the possible epistatic effect of this variant an interaction analysis was 
conducted between ALDH16A1;rs78635115 and ABCC4;rs4148500 and 22 SLC2A9 genetic 
variants already genotyped in NZ Polynesian groups. This is because there is evidence that 
ALDH16A1 (enzymatically inactive) interacts with other proteins including those involved in 
urate transport (i.e. SLC17A3, SLC2A4) to produce its functional effect (Charkoftaki et al. 
2017, Kerrien et al. 2012). Considering the evidence of interaction of ALDH16A1 with 
SLC2A4 (which) belongs to a transport family to which SLC2A9 (a well-known locus for serum 
urate) also belongs), it would be interesting to test if ALDH16A1 also interacts with SLC2A9 
for its role in handling urate homeostasis. The selection of the ABCC4;rs4148500 variant for 
the interaction analysis was based on a mouse model study where Aldh16a1 knockdown 
resulted in increased expression of Abcc4 and Slc16a9 (Charkoftaki et al. 2017). 
Among selected SLC2A9 variants for the analysis, only rs6449144 significantly 
interacted with the ALDH16A1 rs78635115 variant (Table 3.9). The genotypic effects were also 
tested among study variants and provided evidence of genotypic combinations of ALDH16A1 
rs78635115 with SLC2A9 rs6449144 (TT (homozygous major for rs78635115))/TT 
(homozygous minor for rs6449144), CT (heterozygous for rs78635115)/TT and CC 
(homozygous minor for rs78635115)/TT (homozygous minor for rs6449144) OR = 0.04, P = 
0.009, OR = 0.06, P = 0.031 and OR = 2.21, P = 0.008, respectively) in the EP cohort. 
Interestingly, the first two genotypic combinations of rs78635115 (ALDH16A1) with 
rs6449144 (SLC2A9) displayed a significant protection from gout risk, but the direction of 
effect was found in the opposite direction with the CC/TT genotypic combination. Overall the 
genotypic interaction analysis between the two variants showed a significant association 
towards gout risk (OR = 1.84, P = 0.004) in the EP group only. No evidence of significant 
associations for genotypic combinations between rs78635115 (ALDH16A1) and rs6449144 
(SLC2A9) was observed in the WP group (Table 3.9). 
There was another variant in the SLC2A9 locus rs2280205 that showed a mixed trend of 
association of different genotypic combinations with gout risk in the EP group only when an 
interaction analysis was conducted between this variant (rs2280205) and the ALDH16A1 
rs78635115 variant. The genotypic combinations TT (homozygous major for rs78635115) /AA 
(homozygous minor for rs2280205) and CC (homozygous minor for rs78635115)/GG 
(homozygous major for rs2280205) were found to protect from gout risk (OR = 0.17, P = 0.036, 
OR = 0.08, P = 0.018, respectively) in the EP group. Whilst the TT (homozygous major for 
rs78635115)/GG (homozygous major for rs2280205) genotypic combination was associated 
 
 
176 | Page 
with increased risk of gout ( OR = 9.46, P = 0.037) in the same population (EP). Similarly, 
none of the genotypic combinations between rs78635115 and rs2280205 showed significant 
associations in the WP cohort. In addition, the overall genotypic interaction analysis between 
these two variants also did not provide significant outcome for gout in either population (Table 
3.9). The overall outcome of the interaction analysis thus indicates a significant interaction 
between ALDH16A1 rs78635115 and SLC2A9 rs6449144 (OR = 1.84, P = 0.004) that was 
significant according to the Bonferroni corrected p-value of 0.006. But overall, it could be 
suggested that ALDH16A1 locus may produce its effect in interaction with other proteins (i.e. 
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Table 3.9: Interaction analysis of ALDH16A1 variant with variants in SLC2A9 with gout susceptibility in NZ 
Polynesian 
 
ALDH16A1: Aldehyde dehydrogenase family 16 member A1, SLC2A9: Solute carrier family 2, facilitated glucose 
transporter member 9, OR: Odds Ratio, 95% CI: 95 confidence intervals, P: The probability of finding the observed 
results when the null hypothesis (HO) is true, the analysis was adjusted by age, sex and first 4 principle components 




East Polynesian (EP) West Polynesian (WP) 
Cases Controls OR (95% CI) P Cases Controls OR (95% CI) P 
rs78635115-rs6449144 (ALDH16A1-SLC2A9) 
TT/GG 65 (0.225) 130 (0.233) 2.40  (0.47, 1.91) 0.336 49 (0.219) 72 (0.129) 
0.58 
 (0.21, 1.55) 0.286 
TT/GT 92 (0.318) 168 (0.302) 0.61  (0.062, 4.32) 0.640 50 (0.223) 50 (0.09) 
2.06 
 (0.51, 8.43) 0.306 
TT/TT 22 (0.076) 43 (0.077) 0.04  (0.002, 0.39) 0.009 8 (0.036) 10 (0.018) 
3.66 
 (0.42, 3.21) 0.234 
CT/GG 28 (0.097) 77 (0.138) 1.24  (0.23, 1.01) 0.811 52 (0.232) 74 (0.133) 
0.61 
 (0.22, 1.62) 0.329 
CT/GT 51 (0.176) 82 (0.147) 1.01  (0.09, 7.60) 0.990 34 (0.152) 50 (0.09) 
1.49 
 (0.36, 6.14) 0.575 
CT/TT 10 (0.035) 28 (0.05) 0.06  (0.004, 0.68) 0.031 2 (0.009) 7 (0.013) 
0.63 
 (0.05, 6.62) 0.705 
CC/GG 4 (0.014) 10 (0.018) Alt - 13 (0.058) 12 (0.022) alt - 
CC/GT 8 (0.028) 16 (0.029) 1.95  (0.29, 1.83) 0.512 12 (0.054) 13 (0.023) 
0.58 
 (0.16, 2.04) 0.405 
CC/TT 9 (0.031) 3 (0.005) 2.21  (2.54, 2.83) 0.008 4 (0.018) 4 (0.007) 
0.47 




- - 1.84  (1.21, 2.81) 0.004 - - 
0.79 
 (0.49, 1.28) 0.349 
rs78635115-rs2280205 (ALDH16A1-SLC2A9) 
TT/GG 59 (0.207) 133 (0.239) 9.46  (1.22, 8.79) 0.037 38 (0.171) 48 (0.086) 
0.40 
 (0.05, 2.79) 0.358 
TT/GA 94 (0.33) 155 (0.278) 5.70  (0.86, 4.45) 0.079 57 (0.257) 61 (0.11) 
1.25 
 (0.19, 8.16) 0.809 
TT/AA 22 (0.077) 56 (0.101) 0.17  (0.02, 0.83) 0.036 11 (0.05) 16 (0.029) 
1.15 
 (0.23, 5.69) 0.856 
CT/GG 32 (0.112) 71 (0.127) 4.86  (0.56, 4.95) 0.161 43 (0.194) 60 (0.108) 
0.81 
 (0.11, 5.94) 0.836 
CT/GA 45 (0.158) 93 (0.167) 1.93  (0.25, 1.67) 0.529 38 (0.171) 60 (0.108) 
2.39 
 (0.35, 1.66) 0.370 
CT/AA 12 (0.042) 23 (0.041) 0.27  (0.04, 1.47) 0.148 6 (0.027) 13 (0.023) 
0.51 
 (0.09, 2.61) 0.421 
CC/GG 6 (0.021) 13 (0.023) 0.08  (0.010, 0.60) 0.018 12 (0.054) 8 (0.014) 
2.44 
 (0.46, 1.31) 0.290 
CC/GA 8 (0.028) 13 (0.023) 0.26  (0.03, 1.55) 0.156 11 (0.05) 16 (0.029) 
0.80 
 (0.16, 3.93) 0.784 




- - 1.46  (0.97, 2.18) 0.067 - - 
0.86 
 (0.54, 1.35) 0.519 
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3.5. Discussion 
It is possible now to detect disease causal or susceptible variants including rare, low 
frequency and population-specific variants via sequencing, deep re-sequencing and genotyping 
approaches (Eichler et al. 2010, Manolio et al. 2009, Metzker 2010). Likewise, in the current 
study in-silico resequencing was performed on a WGS gout dataset with a subsequent 
replication-phase association analysis in NZ Polynesian and European cohorts. The initial 
analysis produced functional variants by analysing WGS data obtained from individuals of 
different ancestral groups (mainly of European and Polynesian) suffering from gout. Based on 
set criteria, prioritized missense genetic variants including CACNA1S;rs13374149, 
TAP2;rs2071471 and IL37;rs752113534 were successfully replicated in NZ datasets. To 
replicate signals from the outcome of in-silico resequencing, two types of genotyped datasets 
were utilized. In this regard, the first dataset used to investigate associations of selected variants 
was genotyped using a Illumina CoreExome chip, while the other SNPs were genotyped in the 
NZ case-control samples using the TaqMan assay. All missense variants identified in the 
resequencing analysis had variable allele frequency distribution across the study as well other 
global populations. Some variants (i.e. rs1752113534) were prevalent in Polynesian however 
were found with low frequency or monomorphic in other populations. In addition, in the present 
study, an extended sequencing of NZ gout samples was also performed for IL37 exon 5 on the 
basis of significant association of rs1752113534 with gout in Polynesian only when HU 
controls were included in the analysis, whilst this variant was monomorphic in European 
populations (detailed below). 
Among variants sourced from CoreExome array data, only CACNA1S;rs13374149 and 
TAP2;rs2071471showed a significant association with gout risk in NZ Polynesian (the EP 
group). The CACNA1S;rs13374149 variant is reported as a common variant in European and 
African populations with T-allele frequency = 6% and 29%, respectively as compared to East 
Asian populations (T-allele = 0%) but interestingly has been identified with 2% frequency (as 
an uncommon variant) in Polynesians (T-allele = 0.021) sourced from CoreExome data. It 
should be noted that rs13374149 was found to be uncommon in Polynesian (0 in genomes) and 
was likely only present in the larger EP and WP sample sets owing to admixture with 
Europeans. That it did not associate at all with gout in European suggests that it may be a false 
positive, with the EP association driven by population stratification (despite adjusting for PCs1-
10 or being less than FDR p-value of 0.006). However, if this is a real signal then validation or 
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replication is required in Polynesian and other ancestral groups through other genotyping 
methods like Taqman.   
Previously, CACNA1S was reported as associated with two phenotypes: malignant 
hyperthermia (MH) and hypokalaemic periodic paralysis (Carpenter et al. 2009, Richards et al. 
2015). MH is an inherited skeletal muscle disorder, which is caused by an elevated release of 
calcium from muscle sarcoplasmic reticulum (Maclennan and Phillips 1992) as a result of 
uncoupling of receptors involved in Ca2+ homeostasis. The dihydropyridine receptor (DHPR) 
plays an essential role in the process of excitation-contraction (E-C) coupling to control Ca2+ 
homeostasis whose α subunit is encoded by the CACNA1S gene (Monnier et al. 1997, Weiss et 
al. 2004). In the MH study, Carpenter et al., 2009 found rs772226819 (CACNA1S) is a missense 
variant (p.Arg174Trp) and the domain of this amino acid is in the S4 segment domain of the 
DHPR thought to function as a voltage sensor. Thus a change in charge may alter cellular Ca2+ 
homoeostasis. They also detected non-synonymous changes of rs13374149 in 5 MH patients 
with performing CACNA1S cDNA sequencing in 50 MH patients but did not find significant 
association with MH in replication (Carpenter et al. 2009). The present study does not provide 
convincing evidence for the association of the rs13374149 variant with gout in NZ Polynesian 
thus suggesting it is not a gout locus. 
 The other apparent successfully replicated selected variant rs2071471 in this study is 
monomorphic in European populations but common in East Asian in 1000 Genome, gnomAD 
exomes and gnomAD genomes. Thereby, the prevalence of this variant in Polynesian with 
evidence of being common in East Asian suggests a close proximity between Polynesian and 
East Asian ancestry that can be explained by evolutionary history and migratory patterns of 
these populations (Blench and Dendo 2006, Soares et al. 2011, Summerhayes et al. 2010). The 
A-allele of rs2071471 revealed a protective association towards gout risk in the EP group only 
(Table 3.3). Again, the significant association was only detected in the EP group with no 
evidence in the European dataset. The EP group has admixture with European ancestry 
therefore it is likely driven by the population stratification effect despite being adjusted with 
first 10 PCs. To ensure either it is a real association further follow up and validation is necessary 
in larger Polynesian datasets along with other ancestral groups (e.g. Han Chinese and Japanese 
populations).   
The non-synonymous rs2071471 variant is within the transporter associated with antigen 
processing 2 (TAP2) gene. The TAP2 gene encodes the membrane bound protein transporter 2 
ATP-binding cassette, subfamily B (MDR/TAP), which is a major histocompatibility complex 
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(MHC) gene localized between the HLA-DP and HLA-DQ (HLA class II regions) (Powis et 
al. 1993). It is involved in antigen presentation and transports peptides of the HLA class 1 
molecule across the endoplasmic reticulum in an ATP-dependent manner (Robertson 1991). 
Thus the requirement of the TAP proteins for normal class I expression and location in the class 
II region, in combination with linkage disequilibrium with the HLA complex, provide a possible 
connection between class II association with insulin dependent diabetes mellitus (IDDM), 
rheumatoid arthritis (RA) and suggestive importance of class 1 expression with disease. 
Therefore, TAP2 has been suggested to play an essential role in HLA-associated diseases and 
immune response (Bauer and Tampe 2002). In this regard, association of TAP2 polymorphisms 
with RA has been studied in many populations and among these Ile379Val, Thr655Ala and 
Ala565Thr are most studied (Hillarby et al. 1996, Marsal et al. 1994, Wordsworth et al. 1993, 
MC Yu et al. 2004, SL Zhang et al. 2002). However, in the current study the association result 
of TAP2; rs2071471 for gout is not convincing that suggests it may not be a genuine gout locus.      
Following is the detail of the remained selected resequencing genetic variants, which have been 
found to be rare and monomorphic across global populations including European, American 
African, African, and East Asian populations (in 1000 Genome, gnomAD exomes and gnomAD 
genomes datasets) but interestingly were prevalent in Polynesian only. 
 
3.5.1. Polynesian-Specific Genetic Variants 
Genetic as well as clinical trials demonstrate ancestry-specific differences in outcome 
among individuals suffering with various clinical conditions (Children's Oncology et al. 2006, 
Hofman et al. 2015, Sekeres et al. 2004). Therefore, in the current study such variants have 
been detected, at a relatively high frequency in Polynesians only in comparison to their 
occurrence in other populations. Details of these variants haare discussed in following 
paragraphs. 
 
3.5.1.1. Interleukin-37 (IL37) 
It is well established that inappropriate release of IL1β is a key factor involved in 
initiating and amplifying an inflammatory process in gout (Charles A Dinarello 2010, 
Terkeltaub et al. 2009). In addition to IL1β, there are other cytokines from the IL-1 family that 
equally contribute to inflammation, but not have been studied extensively. Among these, IL37 
is a IL-1 family member, which exerts potent anti-inflammatory effects by suppressing 
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unwanted release of IL1β and other pro-inflammatory cytokines (Nold et al. 2010). For human 
IL37, five transcripts have been identified (IL37a-e), of which IL37b is the largest isoform, 
abundantly found in vivo and which has received most attention (Boraschi et al. 2011). It has 
been mentioned before (in the introduction section) that IL37 acts through both intra and 
extracellular mechanisms: intracellular IL37 undergoes proteolytic cleavage and translocates to 
the nucleus where it suppresses the transcription of pro-inflammatory cytokines (Sharma et al. 
2008); and extracellular IL37 through binding to the α-chain of the IL-18 receptor recruits IL-
1R8 that leads to the activation of anti-inflammatory pathways while suppressing release of 
pro-inflammatory cytokines (Cavalli and Dinarello 2018, Lunding et al. 2015) (Figure 3.13). 
The anti-inflammatory properties of IL37 have been extensively demonstrated in various 
disease models. For example, expression of human IL37 protected transgenic mice from LPS-
induced shock, colitis, hepatitis, cardiac ischaemia, metabolic syndrome and inflammation-
induced fatigue (Ballak et al. 2018, Ballak et al. 2014, McNamee et al. 2011, Nold et al. 2010, 
Q Zeng et al. 2017). Notably, studies also documented that administration of recombinant IL37 
was effective for the treatment of experimental arthritis (Cavalli et al. 2016, S Li et al. 2015, 
Lunding et al. 2015, Moretti et al. 2014, B Wu et al. 2014, Ye et al. 2014), and MSU crystal-
induced inflammation both in vitro and in vivo in mouse peritonitis and foot pad models (L Liu 
et al. 2016, M Zeng et al. 2016). Moreover, the anti-inflammatory role of IL37 was also 
observed in metabolic conditions such as a study that documented an increased level of IL37 
associated with reduced adipose tissue inflammation and enhanced insulin sensitivity (Ballak 
et al. 2014). Therefore, it is unsurprising to find IL37 as a potential mediator in the 
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Figure 3.13: Extracellular binding of IL37 with IL-1R8 to suppress release of pro-inflammatory cytokines (an 
important property of IL37). 
 
Extracellular IL37 binds to the α-chain of the IL-18 receptor (IL-18Rα) and recruits the IL-1R8, leading to 
activation of anti-inflammatory- and suppression of pro-inflammatory pathways. 
 
To date, no association studies have been conducted between IL37 genetic (both common 
and rare) variants and gout, however SNP rs3811047 in IL37 was found to be a risk factor for 
coronary artery disease and M. tuberculosis infection (H Liu et al. 2017, Yin et al. 2017). 
Considering the lack of association studies for IL37 in inflammatory conditions along with its 
significant anti-inflammatory role, the current study was designed to test association of the 
genetic variant in this gene (detected primarily by resequencing in Leo Joosten’s lab | Nijmegen, 
and then also from current in-silico resequencing analysis) with inflammatory gout in NZ 
Polynesian and European populations. 
Interestingly the IL37 genetic variant p. (N182S) was not found in European populations, 
while the prevalence was found to be as high as 5% in NZ Polynesian groups that suggests a 
population-specific role. The p. (N182S) variant is only reported in the Genome Aggregation 
Database (gnomAD) with an allele frequency of 0 in European Non-Finnish and 0.0002 in 
South East Asian reference populations. Notably, this variant was first recognized as a rare 
genetic variant in a Dutch (the Netherlands) gout cohort (only found in one self-reported 
European individual). But following up on this person indicated that he was of Indonesian 
origin. When IL37p. (N182S) was tested for association with gout in NZ populations, the 
genetic analysis only revealed a significant association between IL37;rs1752113534 (G-allele) 
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and gout risk in a meta-analysis combining Polynesian cases- HU controls dataset (ORmeta = 
1.81, Pmeta = 0.031). This finding suggests an inflammatory role of the IL37 variant, with 
progression from hyperuricaemia to gout. Additional evaluation of available clinical data of 
these individuals also showed earlier onset of gout in patients carrying p. (N182S) as compared 
to non-carrier patients with gout (P = 0.005 and P = 0.018 in EP and WP, respectively) (Table 
3.7). It was observed that the average age was 42 years for EP and 36 years for WP people who 
have this variant and get gout. 
The effect of IL37 p. (N182S) variant on protein function was also determined in the 
Netherlands (Klück et al. 2019) at Radboud University Medical Center, where a tolerance 
landscape of IL37 was generated by MetaDome. MetaDome is a web browser 
(https://stuart.radboudumc.nl/metadome/) that analyses mutation tolerance at each position in a 
human protein. This platform collects data from gnomAD and Clinvar and provides a tolerance 
landscape of the gene of interest. The IL37 p. (N182S) variant was localized in the functional 
PF00340 domain that is also shared by many other genes of the IL1-family. On the calculation 
of mutational tolerance of a genomic position, the p. (N182S) variant possessed a lower 
tolerance to genetic variation with predicted mild functional effect on amino acid residues. 
However, existence of this variant in the functional domain at the start of the protein predicts 
that it is likely to affect the structure of protein and thus influence protein function.  
Furthermore, to evaluate whether administration of recombinant IL37 (being a potential 
therapeutic) could be useful to individuals carrying p. (N182S) variant, they isolated peripheral 
monocytes from the Dutch patient carrying this variant. Upon treatment with recombinant 
IL37b the MSU crystal-induced ROS generation and IL-8 release were remarkably reduced in 
these cells (Klück et al. 2019). 
The functional investigation of IL37;rs1752113534 showed that this variant was 
associated with chemical modifications, such as modifications (e.g. methylation and acylation) 
to the histone proteins present in chromatin that influence gene expression by changing how 
accessible the chromatin is to transcription. A specific modification of a specific histone protein 
is called a histone mark. This genetic variant shows the levels of enrichment of the H3K27Ac 
histone mark across the genome as determined by a ChIP-seq assay. The H3K27Ac histone 
mark is acetylation of lysine 27 of the H3 histone protein, and enhances transcription possibly 
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Figure 3.14: Protein prediction of rare variants in IL37 identified in patients with gout in the Netherlands. 
 
This picture has been adapted from a paper by (Klück et al. 2019). In this diagram the study group has modelled 
3D protein structure in Yasara View (Krieger and Vriend 2014). The figure shows the wildtype IL-37b protein in 
the centre, with four identified rare variants highlighted in red, and zoomed in on their alterations on protein 
structure. The variant in p.H172 causes a frameshift which results in an altered amino acid sequence from p.(G174) 
on (highlighted in yellow), which results in a premature stop-codon. The position of p. (N182S) shows the 
conformational change in IL37 protein structure that can affects protein function. 
 
Considering the genetic outcome of IL37 variant rs1752113534 (p.N182S) in the NZ gout 
cohort with the evidence of occurrence in the Netherlands gout cohort and a functional 
characterization provided by Viola Klück and colleagues in the Netherlands, it was further 
hypothesized that there may be other variants of interest present in this region which could be 
causal to gout. For this a traditional Sanger sequencing approach was used to detect functional 
variants in IL37-exon5, which may also implicate a population-specific effect in 131 Polynesian 
(EP and WP) gout samples. The sequencing output identifying four missense variants including 
the above tested missense variant (rs752113534), rs536123660 and three novel variants at 
positions 2:113676219, 2:113676298 and 2:113676374 . These variants were prevalent in 
Polynesians including those that were uncommon (rs752113534 and rs536123660) in 
publicaly-available databases (description presented in Table 3.8). The functional investigation 
of such variants provides little information regarding their functional effects except 
rs536123660. For this variant the SIFT score was 0.02 that indicates that  is deleterious. The 
 
 
185 | Page 
PolyPhen and CADD scores were detected as 0.403 and 13, respectively. These are online 
available tools that are designed to provide a prediction score with a cut-off value that indicates 
if a variant may be functional or not such as if the variant is deleterious or neutral for a change 
in protein. The online platforms used to assess the scores are; CADD 
(www.cadd.gs.washington.edu: score ≥ 10 indicates deleteriousness), SIFT (www.sift.jcvi.org: 
score ≤ 0.05 indicates damaging affect), PolyPhen-2 (www.genetics.bwh.harvard.edu: score ≥ 
0.43 indicates damaging affect) and PROVEAN (www.provean.jcvi.org: score ≤ -2.5 is 
deleterious). Nevertheless, for the validation of these signals as genuine apart from 
rs1752113534 (already tested in NZ Polynesian cohort), a replication study is required in a 
larger gout cohort of Polynesian ancestry. 
In conclusion, by identifying and validating the p. (N182S) variant in IL37 in individuals 
with gout, particularly in the presence of hyperuricaemia, suggests its inflammatory role in gout 
pathogenesis progressing from hyperuricaemia to gout. Moreover, identification of p. (N182S) 
and three novel genetic variants (2:113676219, 2:113676298 and 2:113676374) only in 
Polynesian people with gout indicates their potential contribution to the development of gout 
in a population-dependent manner. 
 
3.5.1.2. Aldehyde Dehydrogenase family 16 member A1 (ALDH16A1) 
The other variant selected from the in-silico resequencing analysis was rs78635115, 
within the ALDH16A1 gene. This variant was identified as monomorphic in European and rare 
in East Asian populations (gnomAD exomes and gnomAD genomes East Asians) with 0% and 
0.005% frequency, respectively, whilst it was found to be relatively common in Polynesian 
populations only, occupying a frequency of 23% in the EP group and 31% in the WP group. 
ALDH16A1 rs78635115 was tested for association with gout in NZ Polynesian and European 
sample sets but did not evidence significant association in either group. 
ALDH16A1 is a novel and unique member of aldehyde dehydrogenase (ALDH) 
superfamily (in relation to its gene and protein structure) that exists in the enzymatically 
inactive form. It is highly expressed in kidneys, which indicates its involvement in kidney 
function (Charkoftaki et al. 2017, Vasiliou et al. 2013). ALDH16A1, being enzymatically 
inactive, interacts with other proteins to exert its function. Earlier reports on ALDH16A1 have 
reported its interaction with maspardin protein (responsible for Mast syndrome) (Hanna and 
Blackstone 2009), S-phase kinase associated protein 1 (SKIP-1) (Foster et al. 2006), protein 
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kinase, AMP-activated, γ-2 non-catalytic subunit (PRKAG2) and GLUT4 (SLC2A4) 
(Behrends et al. 2010).  
Previously a variant (rs150414818) in ALDH16A1 was associated with serum urate 
(beta = 0.36, P = 4.5×10-21) and gout (OR = 3.12, P = 1.5×10-16) in an Icelandic population and 
identified as a potential locus of gout (Sulem et al. 2011). Taking into account the genetic 
association of this ALDH16A1 variant with gout in Iceland together with finding ALDH16A1; 
rs78635115 in WGS data of gout as a result of in-silico sequencing, prompted testing this 
variant for association with gout in NZ populations. However, the non-significant results 
suggest that it is not a gout locus in either NZ Polynesian or European groups. This also 
indicates a difference in genetic backgrounds of two different populations (Icelandic and New 
Zealand populations). In addition, the finding of the current study also supports the existence 
of ALDH16A1 in an enzymatically inactive form that requires interaction with other proteins 
to modulate its functional effect. In this regard an interaction analysis was conducted   between 
ALDH16A1; rs78635115 and available data of ABCC4 and SLC2A9 genetic variants in the NZ 
European and Polynesian population. Notably, ALDH16A1 rs78635115 and SLC2A9 
rs6449144 showed evidence for non-additive interaction in the risk of gout  in the EP group 
only (OR = 1.84, P = 0.004). This significant interaction may explain the enzymatic effect of 
ALDH16A1 in gout pathogenesis with regulating the expression of SLC2A9, which is a known 
locus for developing hyperuricaemia and gout. This might further propose a susceptible role of 
ALDH16A1 in conferring gout risk via influencing urate homeostasis in the kidney by 
interacting with urate transporters such as SLC2A9. The finding is consistent with a functional 
study that explored altered expression of kidney transporters Slc16a9, Abcc4 (upregulated) and 
Slc17a3 (downregulated) known to influence urate homeostasis in Aldh16a1 knockdown mice 
(Charkoftaki et al. 2017).  
 
3.6. Conclusion and Future Directions 
This section of the thesis provides a detailed description of population-specific genetic 
variants (prevalent in one population while found to be rare or without any evidence in other 
populations). An in-silico resequencing approach was applied using WGS gout data to filter 
missense variants, which were then followed up for association analysis in a larger data set 
sourced from Illumina CoreExome Chip and TaqMan genotyping. Genetic variants identified 
in the current study were prevalent in Polynesians, while absent or uncommon in other 
populations. Among these rs752113534 was localized in the relatively newly identified IL-1 
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family member; IL37 (exon 5) that showed a significant susceptibility to gout in the presence 
of hyperuricaemia (association analysis HU controls versus gout cases). Based on this finding 
it has been functionally evaluated for a role in gout in the Netherlands collaborating laboratory. 
Furthermore, emerging as an interesting locus in Polynesian gout individuals, IL37 exon 5 was 
also sequenced via Sanger sequencing in a sample set of 131 EP and WP gout patients. 
Consequently, missense variants were detected, some of which were quite rare across global 
sequenced populations. The current study did not provide evidence for association between 
ALDH16A1 rs78635115 and gout. 
The current study is a contribution to a better understanding of gout pathogenesis in the 
context of identification of inflammatory and population-specific genetic variants that may be 
causal to gout. A few suggestions to extend this research are detailed below: 
 
§ That variants in CACNA1S, TAP associated with gout only in the EP group shows 
that these could be false positives. This may be because the EP group has European 
ancestry admixture while a non-significant evidence of association was found in 
European datasets therefore the association in the EP group may be driven by 
population stratification. A further genetic association analysis in relatively larger 
gout cohorts including controlling for population stratification in different ancestral 
groups will be beneficial to confirm if these loci are genuine and to confirm their 
population-specific role in gout. 
 
§ Functional studies such as gene expression assays, mammalian models of gout and 
human cell lines will also be useful to confirm and decipher the underlying 
mechanisms of effects for these genetic variants in gout aetiology. There are various 
ways to do this: one example of such assays is culturing THP-1 cells (human acute 
monocyte leukaemia cells) and incubating them with MSU crystals of different 
concentrations transfecting these cells with plasmids containing the cDNA of a gene 
of interest containing a sequence variant (e.g. CACNA1S and TAP2 (if real)). Then 
measuring the expression of the transfected gene through RNA extraction and real 
time qPCR. Expression levels can then be compared between MSU crystal 
concentration treatments to assess whether the variant within the gene changes 
expression levels in response to MSU crystal stimulation. This would aid in 
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determining whether changes in expression of these genes contributes to the 
development of gout. 
 
§ Genetic variants (particularly novel variants) detected in the IL37 exon 5 through 
Sanger sequencing in the Polynesian group should be tested for association with gout 
in a larger NZ Polynesian gout case-control cohort. 
 
§ Since in this study an in-silico resequencing approach was used to detect genes of 
interest in inflammatory gout using WGS (of gout individuals) dataset, an in-silico 
targeted resequencing study in Polynesians will be of great worth for the 
identification of non-urate, particularly inflammatory loci that may be causal to gout 
in Polynesians only. Such loci could be significant regions of interest to address 
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Mitochondrial Genome Wide Association Study 
in New Zealand Populations 
4.1. Introduction 
Benda in 1898 introduced the word “mitochondrion” which originates from the Greek 
"mitos" (thread) and "chondros" (granule), because of the appearance of these structures during 
spermatogenesis (Benda 1898). Mitochondria are semi-autonomous subcellular organelles 
present in all cells. They are comprised of functionally distinct double membranes i.e. outer 
membrane and inner folded membrane, separated by inter-membrane space, which encapsulates 
the matrix compartment. Mitochondrial DNA (mtDNA) is organised into a structure known as 
the nucleoid that resides in a matrix (Lecrenier et al. 1997, Tiranti et al. 1997). Mitochondria 
are key players in a wide range of cellular processes, such as pyruvate oxidation, the Krebs 
cycle, metabolism of amino acids and fatty acids, apoptosis induction, haem biosynthesis and 
calcium homeostasis. However, they are most importantly involved in generating energy from 
adenosine triphosphate (ATP) through oxidative phosphorylation and the electron-transport 
chain (electron transport chain) (Chinnery 2015, Koopman et al. 2013, Koopman et al. 2012, 
Vafai and Mootha 2012) (Figure 4.1).  
Since mtDNA is an integral part of a mitochondrion, its contents and function vary 
according to physiological changes and various other factors inside a body. Substantially, 
mtDNA function depends on the integrity of mtDNA molecular structure and mtDNA copy 
number inside the cell. Different studies report a correlation of high mtDNA content in 
peripheral blood with a low metabolic score, increased production of inflammatory mediators 
and high neutrophil to lymphocyte ratio in various physiological conditions (Knez et al. 2017, 
Tranah et al. 2011). This indicates that an imbalance in systemic metabolism and immune 
responses can change mtDNA susceptibility to oxidative stress and energy homeostasis. 
Thereby, perturbed mtDNA function based on increased oxidative stress, imbalanced energy 
homeostasis and altered mtDNA copy number have  been observed in many inflammatory 
conditions including various types of cancers (Bonifacio et al. 2012, Giromini et al. 2016, T 





191 | Page 
Figure 4.1: Mitochondrial Structure. 
 
Illustration of a mitochondrion. The right part of the figure shows a detailed process of OXPHOS and electron 
transport chain in generating ATP. Left: A mitochondrion consists of outer and inner membranes, the cristae, and 
the matrix. Fat and sugar enter the mitochondria through channels of the outer membrane. Right: The citric acid 
cycle feeds the chain of respiratory complexes I through IV that generate an electrical and proton (H+) gradient 
(electromotive force), across the inner membrane. ATP synthase utilizes the electromotive force to generate ATP 
from ADP and inorganic phosphate (Pi) (reviewed in Bartolak-Suki et al., 2017). 
 
4.1.1. Role of Mitochondrion in Inflammation and Innate Immunity 
Considering the fundamental role of mitochondria in cellular physiology and organismal 
health, it is not surprising that altered mitochondrial dynamics has emerged as an essential 
factor in a wide range of disorders including neurodegenerative, metabolic and inflammatory 
conditions (Cho et al. 2010, Kraytsberg et al. 2006, Shirendeb et al. 2012, Ylikallio and 
Suomalainen 2012). A number of studies have evidenced involvement of mitochondria in 
cellular defence and the innate immune response by sensing danger signals; danger associated 
molecular patterns (DAMPS) and inducing inflammation (Cloonan and Choi 2013, Lotze et al. 
2007, Q Zhang et al. 2010). Therefore increasing attention has been devoted to mitochondrial 
derived DAMPs (Krysko et al. 2011). The degenerated mitochondria secrete N-formyl peptides 
at the site of tissue damage, which may attract inflammatory cells including neutrophils and 
amplify the inflammatory process (Carp 1982). The mitochondrion is also a major source of 
radical oxygen species (ROS) production including superoxides and hydrogen oxides. The 
electron transport chain in the inner mitochondrial membrane contributes potentially in the 
generation of energy and ROS, while breakdown of the electron transport chain can cause 
abnormal ROS accumulation within cells (either by inducing apoptosis or inflammasome 
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activation), which might lead to mitochondrial dysfunction and consequent diseases (Fleury et 
al. 2002, Tschopp and Schroder 2010, R Zhou et al. 2011). The dysfunctional or damaged 
mitochondria cause reduction in extra-cellular ATP production, alteration in intracellular NAD+ 
levels, potassium efflux and aberrant calcium mobilization. These changes have also been 
reported to be involved in NLRP3 inflammasome activation that is central in gout pathogenesis. 
Additionally, several studies have reported aberrant mitochondrial-induced NLRP3 activation 
in a variety of inflammatory disorders (underlying various pathways including those above) 
(Akira et al. 2013, Misawa et al. 2013, Sadatomi et al. 2017, Z Zhong et al. 2016, R Zhou et 
al. 2011). Even though these involved pathways act as individual separate pathways, they may 
interconnect with each other and might not be mutually exclusive (Gurung et al. 2015). The 
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Figure 4.2: Mitochondrial involvement in NLRP3 inflammasome activation. 
 
The NLRP3 inflammasome is activated by a myriad of stimuli ranging from PAMPs (virus, bacteria, and fungi) 
to DAMPs such as ATP, nigericin, and MSU crystals. Once activated, NLRP3 forms a complex with associated 
speck-like protein containing a caspase activation and recruitment domain (CARD; ASC) and caspase-1 (CASP1) 
collectively termed the inflammasome. Activated Caspase-1 cleaves pro-IL-1β (pro-interleukin-1β) and pro-IL-18 
into their bioactive mature forms. Mitochondria are key regulators of the NLRP3 inflammasome activation. 
Mitochondrial reactive oxygen species (ROS), Ca2+ overload, reduced NAD+, cardiolipin, mitofusin, 
mitochondrial antiviral signalling protein (MAVS), and mitochondrial DNA (mtDNA) have all been shown to 
promote NLRP3 inflammasome activation. Damaged mitochondria are cleared by nucleotide-binding 
oligomerization domain containing 2 (NOD2)/receptor interacting protein kinase 2 (RIPK2)-dependent mitophagy 
and microtubule-associated protein 1 light chain 3B (LC3B)/Beclin 1-mediated autophagy, thus negatively 
regulating NLRP3 inflammasome activation. This diagram has been sourced from (Gurung et al., (2014) and 
permission to use the image was allowed under the licence number: 4652750336673. 
 
4.1.1.1. Mitochondrial DNA (mtDNA) 
Mitochondrial DNA has increasingly been recognised as an agonist of the innate 
inflammatory system which is released upon opening of mitochondrial transition pores in 
response to the intrinsic cell death and damage, resulting in inflammation (Patrushev et al. 2006, 
Q Zhang et al. 2010). Entering the cytoplasm, mtDNA can be recognised by multiple pattern-
recognition receptors to trigger pro-inflammatory responses. Growing evidence suggests a 
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direct relation between mtDNA release in the cytoplasm and NLRP3 inflammasome activation. 
In this instance, one of the studies reported damaged mitochondria associated with ROS caused 
the release of mtDNA that in turn activated the NLRP3 inflammasome (Figure 4.2). In 
accordance with this  study, oxidised mtDNA was secreted during programmed cell death, and 
appeared to activate the NLRP3 inflammasome with subsequent release of IL1β (Shimada et 
al. 2012). Consistent with these observations, cells lacking mtDNA after treatment with 
ethidium bromide were unable to provoke NLRP3 inflammasome activation (Nakahira et al. 
2011). Mounting evidence suggests that mtDNA might act in a positive feedback scenario to 
potentiate NLRP3 inflammasome activation, further bridging mitochondrial components with 
NLRP3 inflammasome activation. 
All of the above evidence suggests a robust connection between aberrant mitochondrial 
function and NLRP3 inflammasome activation that may equally contribute in gout pathogenesis 
(the related pathways were discussed at the end of the introduction section). 
 
4.1.2. Mitophagy and Mitochondrial Biogenesis 
Mitochondria are dynamic organelles of cells, which maintain their integrity, or 
homeostasis by undergoing inter-related fission and fusion processes-mitophagy and 
mitochondrial biosynthesis, respectively. Mitophagy is an essential process that selectively 
removes the degraded and unnecessary mitochondria using macro-autophagy machinery 
(Youle and Narendra 2011). There are several mechanisms by which cells execute mitophagy 
in which mitochondria are targeted at the autophagosome – a double membrane structure that 
encapsulates mitochondria. The best understood pathway is the PINK1/Parkin partnership that 
facilitates the turnover of depolarized mitochondria (Pickrell and Youle 2015) and the stress-
induced BCL2-interacting protein 3 like (BNIP3), NIX and FUN14 domain containing 1 
(FUNDC1) molecular adaptor that interacts directly with LC3 to promote mitophagy 
(Chourasia et al. 2015). Mitophagy is essential for regulating mitochondria, especially removal 
of those that become dysfunctional, and inversely correlates with inflammation (Nakahira et al. 
2011). However, if mitophagy breaks down and is unable to dispose of dysfunctional 
mitochondria, the organism may be susceptible to inappropriate NLRP3 inflammasome 
activation and propagation of inflammatory processes (Lazarou 2015, Nakahira et al. 2011). 
Like mitophagy, mitochondrial biogenesis is equally important to maintain cell 
homeostasis, particularly to replace old or dysfunctional mitochondria. Various genes including 
 
 
195 | Page 
nuclear-encoded loci such as peroxisome proliferator-activated receptor gamma coactivator 
alpha-1 (PPARGC1A) and beta (PPARGC1B) regulate transcription of mitochondria (Scarpulla 
2011), also the mitochondrial transcription factor A (TFAM) is involved in packaging and 
transcribing mtDNA (Hallberg and Larsson 2011). Genetic variants in these genes have been 
found to be associated with metabolic disorders including type 2 diabetes risk, insulin 
resistance, altered lipid profiles and neurodegenerative diseases (Ek et al. 2001, Gauthier et al. 
2009, K Hara et al. 2002, YL Muller et al. 2003, Oka et al. 2016, Suarez et al. 2008). These 
variations may contribute to reduced turnover of mitochondria thus contributing to 
susceptibility to inflammation. 
Given the altered expression of PPARG (PPARGC1A and PPARGC1B) co-activators in 
metabolic conditions, the increased expression of PPARGC1B has also been detected in gout  
via inducing NLRP3 inflammasome activation (SH Chang et al. 2016). Moreover, their 
contribution in mitochondrial processes may be interpreted that altered expression of these 
genes may reduce mitochondrial turnover, which results in the accumulation of dysfunctional 
mitochondria, and leads to the development of metabolic as well as inflammatory conditions 
such as gout.  
 
4.1.3. Mitochondrial Genetics 
The human mitochondrial genome is much smaller than the nuclear genome. The 
mitochondrial genome is a circular, multicopy, dsDNA molecule underlying the dual genetic 
control of nuclear DNA and its own genome. The mitochondrial genome consists of 16.6kb of 
DNA encoding 13 polypeptides of the oxidative phosphorylation system and 24 necessary RNA 
components of the mitochondrial translational machinery (2rRNA and 22tRNA) (Kato et al. 
2004, McBride et al. 2006, Schon et al. 2012). The 13 mRNAs encode proteins of the electron 
transport chain (complex I, III, IV and V) that are involved in producing ATP through oxidative 
phosphorylation (Figure 4.3). Some of these genes, NADH dehydrogenase; MT-ND1, MT-
ND2, MT-ND3, MT-ND4, MT-ND5 and MT-ND6 encode electron transport chain complex-1 
(comprises of seven subunits) and the cytochrome-b (MT-CYB) gene encodes complex III. The 
cytochrome C oxidase gene family (MT-CO1, MT-CO2 and MT-CO3) encodes subunits of the 
electron transport chain complex IV and the MT-ATP6 and MT-ATP8 genes encode subunits 
(two) of the electron transport chain complex V (Chabi et al. 2005, Gu et al. 2013, Iborra et al. 
2004, Satoh and Kuroiwa 1991, DC Wallace and Fan 2010) (Figure 4.3). The remaining protein 
components required for the respiratory-chain formation and maintaining mtDNA complex are 
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nuclear-encoded. The tightly packed mitochondrial genetic material does not contain any 
introns while intergenic sequences are limited to a few bases. Moreover, in some cases, 
mitochondrial genes (MT-ATP8/MT-ATP6 and MT-ND4L/MTNDA) also overlap (Schon et 
al. 2012). The number of organelles within a cell varies and so does the amount of mtDNA in 
each organelle based on energetic cellular requirements and oxidative stress (Satoh and 
Kuroiwa 1991). 
 
Figure 4.3: Mitochondrial Genetics. 
 
The map of human mitochondrial DNA contains 22 tRNA, 2 rRNA and 13 protein-encoded regions that are 




Although mitochondria contain 37 genes an additional 1500 genes encoded by the nuclear 
genome are also responsible for mtDNA replication, transcription and translation. These 
nuclear-encoded proteins (described in more detail in the following paragraphs of section 
4.1.3.3) dictate a strong link between organelle and nucleus, important for mitochondrial 
biogenesis and functionality (Horan and Cooper 2014, Michel et al. 2012). Moreover, the 
majority of the mitochondrial proteins are synthesized by nuclear factors and transported to 
mitochondrial chambers, however some electron transport chain enzymes are controlled by 
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mitochondrial genes themselves (Chacinska et al. 2009). Therefore, it is essential to understand 
the complex integrated processes involved in mtDNA replication and transcription in terms of 
the development of mitochondrial variations or mutations and their biochemical consequences. 
 
4.1.3.1. Mitochondrial Haplogroups 
mtDNA is exclusively maternally inherited as a haplotype (DC Wallace et al. 1980). On 
the basis of phylogenetic relationships haplotypes are categorised into sub-haplogroups, and 
haplogroup clusters, characterised by a specific set of polymorphisms. The mtDNA haplotype 
analysis has enabled the creation of a human migration map that traces human origin to Africa. 
This is a part of the world where the most ancient and variable lineages occurred such as L0, 
L1, L2 and L3 which evolved into macrohaplogroups M and N and subsequently colonized 
Eurasia. In Europe, nine mtDNA lineages are prevalent; H, I, J, K, T, U, V, W and X, where 
the H haplogroup is the common one in spite of being relatively evolutionarily young (Loogvali 
et al. 2004) (Figure 4.4). The distribution of haplogroups on Earth indicates highly specific 
regional variations that are thought to be explained by founder effects. 
 
Figure 4.4: Distributions of Mitochondrial DNA Lineages with Migratory Patterns Across the World. 
 
The map shows the migratory patterns of people across variant parts of the world, traced out with the identification 
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In the Pacific, the current mitochondrial lineages were introduced approximately 49,000 
years ago by the original colonists (Summerhayes et al. 2010) and include M27, M28, M29, P 
and Q haplogroups (Duggan et al. 2014, Friedlaender et al. 2007, Kayser et al. 2006). However, 
Austronesian-speaking colonists introduced recent Asian-derived lineages. In Polynesia, the 
mtDNA macrohaplogroup range is limited and predominantly belongs to Asian–derived B4 
lineages (where B4a1a1 is the most common haplotype and also known as the ‘Polynesia 
motif’) (Duggan et al. 2014, Kayser et al. 2006, Redd et al. 1995). This indicates the limited 
genetic diversity in the region and also supports the underlying specific regional genetic 
variations – though voyaging and frequent contact would have reduced these effects. 
The ancient adaptive mtDNA haplogroups still affect individual predisposition to a 
variety of common disorders. However, the first evidence of this came from the discovery of 
increased penetrance of a rare disease: Leber’s hereditary optic neuropathy (LHON) mutations 
in a European haplogroup J (Brown et al. 2002, Brown et al. 1997, Brown et al. 1995). This 
haplogroup has also been found associated with increased risk of diabetes in certain European 
descendants (Crispim et al. 2006, Saxena et al. 2006). Haplogroup U has been associated with 
high serum IgE levels (Raby et al. 2007), while haplogroup H is protective against sepsis 
(Baudouin et al. 2006). Association of several haplogroups has also been found with altered 
risk of particular cancers (Bai et al. 2007, Booker et al. 2006, M Brandon et al. 2006, Darvishi 
et al. 2007). The mtDNA variants that affect mitochondrial function are also correlated with 
haplogroups such as missense variants of macrohaplogroup N, ND3 np 10398 A115T and 
ATP6 np 8701 A59T that affect Complex I activity and Ca2+ regulation (Kazuno et al. 2006). 
Moreover, a variant 295 C>T in haplogroup J has been found to increase L-strand transcription 
with double the amount of mtDNA copy number (Suissa et al. 2009). 
 
4.1.3.2. Mitochondrial Mutations and Variations 
Despite the diminutive size of mitochondrial genetic material, mitochondrial variations 
are an important factor in causing various inherited disorders. The polyploid nature of the 
mitochondria give rise to unique mitochondrial genetic features. Homoplasmy: having identical 
copies of all mitochondrial genomes and heteroplasmy: a combination of two or more 
mitochondrial genotypes. Based on these features mtDNA mutations are being categorised into 
homoplasmic mutations—which affect all copies of the mitochondrial genome, and 
heteroplasmic mutations —which only affect some copies of the mitochondrial genome. In the 
heteroplasmy situation the threshold level of mutation is important for the appearance of clinical 
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signs and for biochemical defects (Taylor and Turnbull 2005). Available evidence indicates 
that in most heteroplasmic diseases mtDNA constantly undergoes mutation, with clonal 
expansion (although the level of individual mutation is usually extremely low) or loss of point 
mutations or deletions (Coller et al. 2001, Taylor et al. 2003). There is also evidence for mtDNA 
susceptibility polymorphisms and haplotypes in complex diseases, including gout (Anderson et 
al. 2011, Arning et al. 2010, Gosling et al. 2018, Mancuso et al. 2008, SanGiovanni et al. 2009, 
Santoro et al. 2010, Sequeira et al. 2012). 
Changes to the mitochondrial sequence affecting mitochondrial efficiency may lead to 
the development of certain medical conditions: such variations in mtDNA have been reported 
in various metabolic and neurological disorders. For example, mitochondrial control region 
sequence variants e.g. T414G have been found to associate with reduced mtDNA copy number 
in Alzheimer’s disease (Coskun et al. 2004). Mitochondrial DNA variants in protein-coding 
regions are correlated with autism spectrum disorder, such as three variants; m.3308T >C, 
m.3394T>C and m.3397A in the mitochondrially-encoded NADH dehydrogenase 1 (MT-ND1) 
gene were associated with autism spectrum disorder (Alvarez-Iglesias et al. 2011, Guevara-
Campos et al. 2013). Another mitochondrial variation in m.3591G>A was associated with 
autism spectrum disorder, muscle hypotonic and bilateral inguinal hernia (Alvarez-Iglesias et 
al. 2011, Legido et al. 2013, Palmieri and Persico 2010). Furthermore, m.9237G>A in 
mitochondrially-encoded cytochrome c oxidase III (MT-CO3) was identified in mitochondrial 
encephalopathy and epilepsy (Bacalhau et al. 2017). 
Some of the previous studies have also investigated individual mtDNA SNPs in relation 
to developing metabolic traits but yielded inconsistent results because of genetically diverse 
populations having different mitochondrial haplotypes. For instance, Saxena et al., (2006) did 
not identify common mtDNA variants associated with type 2 diabetes, body mass index, blood 
pressure and cholesterol across 6608 white subjects recruited from North America, Poland and 
Scandinavia (Saxena et al. 2006). However, previously, Poulton et al., (1998) had identified an 
association between T16189C (common mtDNA variant) and type 2 diabetes in 251 white 
individuals (Poulton et al. 1998). In addition, an uncommon non-synonymous mitochondrial 
variant 5913G > A (Asp4Asn) in the complex IV cytochrome c oxidase subunit 1 was found 
associated with high blood pressure and fasting blood glucose levels (P = 0.05) (CY Liu et al. 
2012). In the same study, another non-synonymous SNP 3316G > A (Ala4Thr) in MT-ND1 (in 
complex I) was associated with higher fasting blood glucose (P = 0.01) (CY Liu et al. 2012). 
Notably, in a recent report Gosling et al., (2018) identified an association of mitochondrial 
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heteroplasmic genetic variants in the region of 16179-16183 with increased risk of gout in 
Māori and Pacific people (Gosling et al. 2018), evidence for the  role of mitochondrial 
variations in gout pathogenesis.  
 
4.1.3.3. Control of Mitochondrial Function by Nuclear-Encoded Genes 
It is known that more than 1500 nuclear-encoded genes are required for mitochondrial 
function. They include RNA polymerases, transcription factors, endonucleases for RNA 
processing, aminoacyl-tRNA synthetase, translation factors, factors necessary for 
mitochondrial biogenesis and other auxiliary factors. This indicates an inter-genomic 
communication between the nuclear and mitochondrial genomes, mandatory for optimal 
mitochondrial functions and indeed, for the cell itself (Pearce et al. 2017). Since it has been 
discovered that mitochondria are dependent on the nuclear genome for maintaining and 
replicating mtDNA and the oxidative phosphorylation system, there is increasing evidence of 
mitochondrial variation influencing the expression of genes involved in metabolism and innate 
immunity. Lee et al., (2015) identified a short open reading frame in mtDNA-encoded 16 
amino-acid peptide named MOTS-c regulating insulin sensitivity and metabolic homeostasis , 
consistent with the finding that MOTS-c treatment protected mice from age related disorders, 
fat-induced insulin resistance and obesity (C Lee et al. 2015). Considering the involvement of 
the nuclear genome controlling mtDNA mechanisms, a host of studies (mentioned below in 
detail) reported correlation of common variations in nuclear-encoded genes with impaired 
mitochondrial function manifesting various metabolic conditions. For instance, a Gly482Ser 
variation in the transcriptional co-activator PGC-1alpha, involved in mitochondrial biogenesis, 
was found to be associated with suppressed insulin secretion in type 2 diabetic patients (Ling 
et al. 2008). Furthermore, a nuclear encoded oxidative phosphorylation gene NADH: 
ubiquinone oxidoreductase subunit B6 (NDUFB6) variation rs540467 (tag SNP) conferred an 
increased risk of type 2 diabetes in a Scandinavian case-control cohort (OR = 2.06, P = 0.03) 
(Ling et al. 2007). Reduced expression of two key mitochondrial biogenesis regulators TFAM 
and the nuclear respiratory factor-1 (NRF1) was also associated with obesity (Niemann et al. 
2011). Such evidence of association of nuclear-encoded genes controlling mitochondria with 
metabolic disorders may support an argument for involvement of these variations in the 
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4.1.4. Mitochondrial Variations’ Predisposition to Complex Traits 
There has been increasing interest in evaluating how mtDNA variations might predispose 
to common disorders based on earlier known associations of mitochondrial variations with 
diabetes, Parkinson disease, Alzheimer’s disease and other aging-related disorders (Lowell and 
Shulmanz 2005, Ross et al. 2003, DC Wallace 1992). A most common approach which involves 
identifying candidate pathogenic mtDNA variations is comparing mtDNA sequences between 
control and cases (patients). However, the outcome is limited by a high mtDNA mutation rate 
that results in high frequency of rare variants (Herrnstadt et al. 2002). Some of these variants 
are more common than others e.g. 16189T and have been associated with various phenotypes 
(low birth weight, type 2 diabetes (T2D), and cardiomyopathy, schizophrenia) (Khogali et al. 
2001, Poulton et al. 2002). Mitochondrial variations can also be detected by the haplogroup 
analysis approach in which control and disease groups containing mtDNA sequences are 
assigned to haplogroups and their distribution is compared. Specific SNPs in each haplogroup 
reflect mtDNA variations that are accumulated by discrete maternal lineages. The approach has 
been implicated in various complex diseases to elucidate the role of mtDNA mutations in such 
diseases (Chagnon et al. 1999, Lowell and Shulmanz 2005, van der Walt et al. 2003). 
Considering the potential role of mtDNA genetic variations in a wide range of metabolic and 
inflammatory disorders, it is not surprising to postulate their contribution to developing 
inflammatory gout. Indeed, gout and metabolic conditions (e.g. T2D) often present as 
comorbidities (Kim et al. 2015, Rho et al. 2016). A detailed description of mitochondrial 
variations in conferring metabolic and inflammatory conditions is outlined in the following 
paragraphs, which supports one of the hypotheses of this chapter (mitochondrial variations 
through copy number may confer susceptibility to gout in Polynesian groups). 
 
4.1.4.1. Mitochondrial Variation and Metabolic Disorders 
Given that insulin secretion from pancreatic cells is modulated in response to ATP 
metabolism, interrupting insulin action by a mitochondrial oxidative phosphorylation 
metabolite has led researchers to consider mtDNA itself as a causal genomic locus for T2D 
susceptibility. A first example comes from a study, which reported association of an A to G 
substitution at position 3243 of mitochondrial tRNA encoding leucine amino acid with T2D 
(Kadowaki et al. 1994). Even at low heteroplasmy, this point mutation was thought to 
contribute to pathogenicity in 2% (2 persons in 100 individuals with insulin dependent diabetes 
mellitus) of T2D cases. This finding, in combination with other biochemical and population 
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genetics studies, also motivated the search for homoplasmic mtDNA variations predisposing to 
metabolic syndromes. For instance, a study was conducted by Wilson et al., (2004), in which a 
clear significant segregation of a homoplasmic mtDNA tRNA mutation substituting cystidine 
for uridine was reported associated with metabolic conditions (FH Wilson et al. 2004). Other 
studies also evidence association of  a common mtDNA sequence variant T16189C with low 
birth weight, metabolic syndrome, and glucose intolerance in Asian and European populations 
(Liou et al. 2007, KS Park et al. 2008, Poulton et al. 2002, Saldana-Rivera et al. 2018). The 
population-specific effects arise because of a diverse heterogeneity of mitochondrial 
haplogroups across global populations. 
Further to this, two D haplogroup mtDNA variants including T16189C were found to be 
associated with obesity in a European cohort of obese children and adolescents followed by a 
replication study in the Korean population (Knoll et al. 2014). A recent study also indicated the 
association of the IWX haplogroup with increased risk of obesity (48%) in a North American 
population (Veronese et al. 2018). Additionally, a haplogroup association study across 
Southern Italian participants (cases=500, controls = 216) described the association of the 
mitochondrial T haplogroup in morbid obesity (Nardelli et al. 2013). 
Considering the above findings, one can suggest a potential contribution of mtDNA 
sequence variations contained by population-specific haplotypes in the progression of certain 
metabolic disorders and as these metabolic conditions are essential comorbidities of gout risk, 
these mitochondrial variations could also be causal to gout pathogenicity. 
 
4.1.4.2. Mitochondrial Variations and Inflammatory Conditions 
As well as confirming the involvement of mitochondrial genomic variations in a wide 
range of metabolic and neurodegenerative disorders (as previously described), several studies 
have also highlighted their implication in the development of various inflammatory conditions, 
especially multiple cancer types. Cancerous cells are characterized by a high amount of 
proliferation thus require a high amount of energy, meaning mitochondria may play a vital role 
in its progression. 
While mitochondrial genic regions are logical targets (being majorly involved in energy 
production) to assess cancer mutations, most of the well-studied mtDNA cancer-associated 
variants have been discovered in a large proportion of control region displacement (D) loop (a 
non-coding genic area in a control region). Given the association between the control region 
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and mitochondrial replication and transcription, the regulation of mitochondria (including copy 
number) may be influenced by D-loop mutations (Nicholls and Minczuk 2014). The D-loop 
mutations are susceptibility factors to various cancers including, breast, colon and gastric etc. 
(HC Lee et al. 2014, Salgado et al. 2008, Skonieczna et al. 2012). Besides D-loop mtDNA 
variations, mutations in other mitochondrial genomic regions have also been reported in 
prostate cancer in a North American cohort study (Booker et al. 2006). In addition, Webb and 
colleagues examined common variants (excluding hypervariable D-loop) in association with 
colorectal cancer in 2854 patients compared to 2822 healthy subjects and identified a significant 
association at A5657G (P=<0.05) (Webb et al. 2008). 
Discovery of oncogenes mediating mitochondrial biosynthesis through the PPAR-
gamma coactivator family brings the concept of nDNA-mtDNA interaction into a cancer 
picture. A well-known oncogene—c-Myc has been reported to regulate mitochondrial 
biosynthesis through PGC1B (F Li et al. 2005). P53, which is a tumour suppressor nuclear-
encoded gene that negatively regulates mitochondrial biogenesis, also indicates a connection 
between cancer and mitochondrial functionality (Kamp et al. 2016). 
Besides cancer, for the past few years, osteoarthritis (OA) has also been included in the 
list of inflammatory disorders that are linked to the mitochondrial genomic variations. Several 
studies report associations between mtDNA haplogroups and OA prevalence and progression 
across different world populations (HZ Fang et al. 2014, Fernandez-Moreno et al. 2017a, 
Fernandez-Moreno et al. 2017b, Shen et al. 2014, Soto-Hermida et al. 2014). 
A previously established mitochondrial role in inducing NLRP3 inflammasome 
activation along with mediating other inflammatory signalling (resulting from mitochondrial or 
nuclear-encoded mitochondrial genetic variations) in the development of certain metabolic and 
inflammatory conditions may suggest its pivotal contribution in gout pathogenesis following 
the same or shared signalling pathways. 
 
4.1.5. Mitochondrial Copy Number and Inflammation 
It is already well established that mitochondria act as a hub of various metabolic processes 
that are necessary to maintain cell integrity by taking part in homeostasis; oxidative 
phosphorylation, redox signalling and macromolecule synthesis etc (Clayton 1991). To fulfil 
these roles mitochondria require adequate mitochondrial biogenesis, transcription and 
particularly mtDNA replication that is monitored by a single mtDNA control region known as 
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the D-loop. Ablated genetics of the D-loop region also result in altered binding affinities of 
nuclear proteins involved in mtDNA replication and transcription that lead to the depletion of 
mtDNA content (Modica-Napolitano and Singh 2002, Parisi and Clayton 1991). Thus the 
affected mtDNA replication and transcription may alter mtDNA copy number and such 
alteration has been implicated in a wide range of human diseases, including type 2 diabetes (J 
Wong et al. 2009), multiple cancer types (HC Lee et al. 2005, Y. Wang et al. 2006, CW Wu et 
al. 2005), neurodegenerative diseases (Baron et al. 2007, Turner and Schapira 2001) and late-
onset age related states (Cree et al. 2008, Mengel-From et al. 2014). 
By looking at the morphology of mitochondrion, mitochondrial DNA coated by specific 
mitochondrial proteins forms complex nucleoid structures, that are firmly attached at regular 
intervals on the inner mitochondrial membrane and alter their shape with correspondence to an 
increased or decreased mtDNA copy number inside (XJ Chen and Butow 2005). This shows 
that mitochondria are mobile entities through ongoing processes of fission, fusion, and 
changing their shapes and sizes (Figure 4.5) (Youle and van der Bliek 2012). There are 
supporting studies in this notion, for example Ylikallio et al., (2010) reported enlarged 
nucleoids-containing a high mtDNA copy number corresponding with defective transcription 
(Ylikallio et al. 2010). Moreover, mitochondria, thus mtDNA also vary between tissues based 
on energy requirements. For instance, the oocyte contains a high number of mitochondria 
numbered at more than 50,000 (Reynier et al. 2001). Human blood cells may also contain a 
different number of mitochondria i.e. neutrophils have been reported possessing less 
mitochondrion. Therefore, the mitochondrial copy number in different tissues is a range not a 
set figure. Moreover, the mitochondria number also varies according to the physiological state 
(Figure 4.5), for example Stringer et al. (2013) found a varied ratio of mtDNA:nDNA from 
753-7762 among study controls (Stringer et al. 2013). Moreover, reduced mtDNA along with 
increasing age is also normal, as lower amounts of mtDNA have been reported in healthy 
elderly people. However, altered mtDNA levels that are identified in pathological conditions 
clearly reflect its pathogenic role. These conditions may be a consequence of extreme mtDNA 
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Figure 4.5: Mitochondrial Copy Number. 
 
Mitochondrial nucleoid structure contains mtDNA (also enzymes are involved in mtDNA replication and 
transcription and produce multiple mtDNA copies). Mitochondria DNA copy number varies from 100-1000 per 
cell. Their number also varies in different tissues dependent on energy requirements. Alteration of the mtDNA 
copy number has also been reported in various pathological conditions. 
 
Regulation of mtDNA copy number is a complex phenomenon. In addition to 
mitochondrial genes, nuclear encoded proteins including mtDNA-binding protein transcription 
factor A (TFAM), B1 (TFB1M) and B2 (TFB2M), PGC1α, and β, nuclear receptor co-repressor-
1 (NCOR1) and associated co-activators have been implicated as mtDNA copy number 
regulators through affecting mitochondrial biogenesis (Shokolenko and Alexeyev 2015). 
Genetic variations in these genes have previously been reported in certain pathological 
conditions (detailed in the discussion section of this chapter). Moreover, there have been studies 
reported that deletion of nuclear-encoded genes also resulted in depletion of mtDNA in human 
cell lines (H Zhang and Singh 2014). Collectively the above information suggests a significant 
role of a range of nuclear genes contribute to maintain mtDNA copy number. 
There has been some indication of association of mtDNA variation with altered mtDNA 
copy number. In this instance, Liou et al., in 2010 reported that the mtDNA 16189C variant 
was associated with reduced the mtDNA copy number in obese Han Taiwanese adults (Liou et 
al. 2010). However this research era had started in 1998 when Lee et al. identified reduced 
mtDNA content in peripheral blood mononuclear cells in T2D patients (HK Lee et al. 1998). 
In this notion, most research has been done on cancers. The first study came from Lee and co-
workers, who found a significant reduction in the mtDNA copy number of 60.5% in patients 
with hepatoma, especially in those who had mutations in the D-loop (HC Lee et al. 2004) and 
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this was followed by various cancerous studies (Ellinger et al. 2009, Jiang et al. 2005, 
Mizumachi et al. 2008). 
Given the substantial effect of the mtDNA copy number variations on disease 
pathogenesis, the underlying discrete mechanisms are not yet fully understood, which suggests 
the possibility that these mechanisms perturbing the mtDNA copy number may either 
contribute, or possibly result from disease susceptibility. 
 
4.1.6. Mitochondrial Connection with Inflammatory Gout: Proposed 
mechanisms 
Given that gout is a prototype disease of dysregulated urate metabolism and inflammatory 
response mediated by MSU crystal-mediated stimulation, mechanisms linked to these could be 
regulators of disease susceptibility. In this regard, several lines of evidence have supported 
mitochondrial dysfunctionality as a key element in gout pathophysiology. One such study 
evidenced increased urate concentration resulting from impaired mitochondrial respiration 
(switching from oxidative phosphorylation to aerobic glycolysis) during inflammation (Wen et 
al. 2012). The other relevant study demonstrated changes in urate levels, which were induced 
by dysfunction in oxidative respiration in hepatic mitochondria (Kristal et al. 1999). 
The other possible framework, which fits mitochondrial dysregulation (via damaged 
mtDNA) in conferring gout risk, is the stimulation of the NLRP3 inflammasome by 
dysfunctional mitochondria. Mitochondria act as a signal-integrating organelle for NLRP3 
inflammasome activation, which has been explained in detail in the introductory part of this 
chapter. In this context, DAMPs (including MSU crystals in gout) either directly or via 
alteration of cellular metabolism induce mitochondrial dysfunction that is accompanied with 
the release of ROS and mtDNA. Increased levels of ROS and mtDNA have been associated 
with impaired NLRP3 inflammasome activation (Nakahira et al. 2011, R Zhou et al. 2011). 
Furthermore, establishing a mechanism that reveals the co-localization of ASC and 
NLRP3 inflammasome to induce inflammasome activation (Misawa et al. 2013, Subramanian 
et al. 2013, R Zhou et al. 2011) also supports the direct role of mitochondria in NLRP3 
inflammation generation (Figure 4.6). Evidence suggests that ASC is present on mitochondria, 
while the NLRP3 inflammasome is localized on the endoplasmic reticulum (Misawa et al. 2013, 
R Zhou et al. 2011). When NLRP3 inducers stimulate activation, mitochondria approach the 
endoplasmic reticulum and get closer to the NLRP3 inflammasome, resulting in the co-
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localisation of ASC and NLRP3 inflammasome that in turn activate caspase-1 with the release 
of IL1β (Figure 4.6). The overall process seems to be mediated by acetylated-alpha tubulin in 
microtubules, resulting from inactivation of sirtuin 2 (SIRT2) (a tubulin deacetylase which is 
sensitive to change in the mitochondrial NAD+ gradient) (Misawa et al. 2013). There is still an 
emerging debate on how mitochondria approach the ER and what triggers this co-localization 
to induce NLRP3 inflammasome activation. However, some studies evidenced that the 
inactivation of SIRT2 and mitochondrial derived ROS, respectively, can be proximal 
stimulators of this co-localization (Misawa et al. 2013, R Zhou et al. 2011). Moreover, Park et 
al., 2013 also reported a viral-mediated NLRP3 inflammasome activation through co-
localization of ASC and NLRP3 by mitochondrial antiviral signalling protein (S Park et al. 
2013). 
 
Figure 4.6: A pathway connecting mitochondrial regulated NLRP3 inflammasome activation. 
 
Mitochondrial damage resulting in reduction of NAD+ levels and inactivation of SIRT2 (the NAD+ dependent 
alpha tubulin deacetylase). Accumulation of acetylated alpha tubulin promotes transportation of mitochondria on 
microtubules. Thus, spatial rearrangement induces proximity of ASC on mitochondria to NLRP3 inflammasome 
on ER and promotes inflammasome activation. The diagram is sourced from Akira et al., 2013 and permission for 
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Impaired mitochondrial biosynthesis reflecting altered mtDNA copy number can also be 
a factor leading to gout. PPARGC1B encodes a protein that plays an important part in 
mitochondrial biogenesis and in this way could influence mtDNA copy number. Recently, a 
missense variant (rs45520937) in PPARGC1B was reported in gout patients that was associated 
with increased NLRP3 inflammasome activation and IL1β secretion in response to MSU 
crystals (SH Chang et al. 2016) that may lend credence to impaired mitochondrial biosynthesis 
inducing gout inflammation. Furthermore, there are compelling studies on the subject of 
telomere dysfunction and mitochondrial impairment, whereas the telomerase shortening reverse 
transcriptase was also discovered with gout (shortening telomeres) (Haendeler et al. 2009, 
Kovalenko et al. 2010, Sahin et al. 2011, Vazirpanah et al. 2017). This evidence suggests a 
connection between dysfunctional mitochondria and gout. 
In this context a significant finding supporting the contribution of mitochondrial copy 
number in developing gout in New Zealand Māori and Pacific populations has been recently 
published (Gosling et al. 2018), which is central in generating the hypothesis of this chapter. In 
this study both heteroplasmy and reduced mitochondrial copy number were associated with 
gout in the New Zealand Polynesian population. For the purpose whole mitochondrial genome 
sequencing was undertaken in 437 Polynesian (Māori and Pacific) individuals and investigated 
for mitochondrial copy number variations. Replication of the study finding was done in an 
independent cohort of 1159 Polynesians. 
In this study 35 mitochondrial haplogroups were identified in whole mitochondrial 
genome sequencing data of Polynesians. Association analysis of heteroplasmy with gout 
revealed association of heteroplasmic variants in the region 16179-16183 was tested with the 
risk of gout. These variants were localized near the 16189C variant that is a B 
macrohaplogroup-defining variant, which may indicate a strong influence of B-haplogroup- 
specific variations on gout in the Pacific region. When B4a1a- derived lineages (prevalent in 
Polynesians) were exclusively investigated, the association between gout and heteroplasmic 
allelic fraction in the region was maintained. Moreover, a high correlation (Pearson’s 
correlation = 0.81, P < 2.2×10-16) between the 16183C heteroplasmic variant and a 16189 
variant that altered the length of a poly C tract indicated that presence of 16189C may directly 
contribute to poly-cytosine tract and therefore to the heteroplasmy. 
Furthermore, in this study an in-silico analysis using whole mitochondrial genomes and 
urate locus resequencing in Polynesians datasets showed a reduced mtDNA copy number 
associated with an increased risk of gout. Each increase of 10 copies of mtDNA was associated 
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with 13% and 9% decrease in gout susceptibility in whole mitochondrial genome (OR = 0.87, 
P = 0.003) and urate resequencing (OR = 0.91, P = 0.003) sample sets, respectively. The 
calculation of the mitochondrial copy number was a relative estimate of mtDNA copy number 
rather than an actual measurement inside cells. On the basis of this finding, it was hypothesized 
that mtDNA being a marker of mitochondrial dysfunction can increase the activation of NLRP3 
inflammasome in the presence of hyperuricaemia. Therefore, mtDNA copy number association 
was tested using hyperuricaemic controls and association was maintained in two datasets (OR 
= 0.89, P =0.007 and OR = 0.90, P = 0.002, respectively). The finding was also supported by 
qPCR in a non-overlapped cohort of Polynesian individuals (OR = 0.76, P = 0.03). 
Interestingly, in the same study, testing for association of the mtDNA copy number with 
gout flare frequency in people with gout evidenced a strong association between an increased 
mtDNA copy number and higher risk of gout flare (β = 0.003, P = 7.1×10-7) (Gosling et al. 
2018). This is counterinituitive to the association of reduced copy number with prevalent gout 
– Gosling et al. stated that this finding was difficult to interpret. The Gosling et al. (2018) study 
provides a significant contribution in detecting the potential role of mtDNA genetic variation 
in gout pathogenesis via influencing the mtDNA copy number, possibly in a population-specific 
manner as susceptible mitochondrial variations were predominantly detected in B4-
haplogroups (prevalent in Polynesians). However, this study did not provide evidence for 
association of mtDNA allelic variation with gout, thus leaving a question of a cause and effect 
relationship between the mtDNA copy number and gout. 
Given that causality in genetics is still probabilistic and rarely a deterministic certainty, 
it is possible to detect disease-causing variants particularly those exerting a large effect size and 
exhibiting high penetrance. Methodologies, which are common in practice currently in genetics 
are large scale genome wide association scan (GWAS) with a replication approach in different 
populations the candidate gene approach and Mendelian randomization. Most of the GWAS 
signals associated with certain phenotypes are further tested for their causality for a disease 
through Mendelian randomization approach. Mendelian randomization is an approach to 
investigate causal relations between a modifiable risk factor and a health outcome in 
observational data. Generally, it is an analytical method that uses genetic variants as 
instrumental variables for modifiable (risk) factors that affect population health with removal 
of unmeasured confounders affecting the interpretation (Davey Smith and Hemani 2014, NM 
Davies et al. 2018, GD Smith and Ebrahim 2005). Thereby, considering the gap in Gosling et 
al. (2018) study for cause and effect relationship for mitochondrial copy number with gout, this 
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thesis chapter has been designed to conduct a GWAS for mtDNA copy number and then test 
variants for association with gout in NZ Polynesian as well as in European populations. Then 
this cause and effect question could be clarified through Mendelian randomisation analysis 
where nuclear variants associated with the mtDNA copy number could be tested for association 
with gout. 
 
4.1.7. Population Specific Role of Mitochondrial Variation in Disease 
Susceptibility in Pacific people 
Given the fact that mitochondrial genetic variants influence susceptibility to metabolic 
and inflammatory disorders, their prevalence also varies among different populations. Though 
inheritance of mtDNA is strictly through the maternal line, major alterations to mitochondrial 
genome outpace new phylogenetic lineages. Therefore, different ancestral groups have distinct 
mitochondrial haplotypes resulting from accumulation of these sequential variations (Cann et 
al. 1987, Pakendorf and Stoneking 2005). Some of the haplotypes are more vulnerable to 
complex diseases while others may protect from them. Indeed, genetic variations belonging to 
distinct haplotypes may be responsible for subtle biochemical differences among haplotypes. 
For instance, it has been postulated that haplotypes favouring loose coupling between 
phosphorylation and oxidation (generating a surplus of heat) may have favoured the settlement 
of human populations in colder environments (Ruiz-Pesini et al. 2004, C Sun et al. 2007). This 
adaptive selection of mtDNA variations in different environments indicates the plasticity of the 
mitochondrial genome for adapting to new environments or adverse conditions (Ruiz-Pesini 
and Wallace 2006). Disparity in metabolic rates between mitochondrial haplogroups in various 
populations may ensue from the consensus of adaptation to new environments. This might be 
the case in Pacific Island groups that are predominated by B4-derived lineages and have a high 
prevalence of metabolic conditions. Previously mitochondrial variations in these lineages have 
been reported with various metabolic disorders. For instance, T16189C, C16261T, and 
T16519C have been found to be associated with type 2 diabetes, abdominal obesity, and 
hypertension in various populations (Liou et al. 2007, KS Park et al. 2008, Poulton et al. 2002). 
Gout is also prevalent in the Polynesian region: together with previous information it can be 
suggested that genetic variations limited to B macrohaplogroup could also be causal to gout 
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4.1.8. Mitochondrial Copy Number GWAS 
Great efforts have been made to determine the role of mtDNA common variations in the 
development of metabolic conditions, i.e. type 2 diabetes (Poulton et al. 1998, Poulton et al. 
2002). Hence, there is a lack of evidence for GWAS accounting for the mtDNA copy number 
variation contributing to inflammatory and auto-inflammatory conditions. To date, only a few 
genome-wide scans of mtDNA copy number have been published. These include a very recent 
study in which a mtDNA copy number GWAS was performed in ~14,000 participants from the 
UK based Avon Longitudinal Study of Parents and Children (ALSPAC) and the UK Blood 
Service (UKBS) cohorts and this reported significant association between nuclear encoded 
TFAM, MED24 and ABHD8 variations and mtDNA copy number (Guyatt et al. 2019). The 
other mtDNA genome wide and candidate association study, but in a smaller cohort of 471 
placental abruption mothers, identified SNPs in the nuclear genome associated with varied 
mtDNA copy numbers (Workalemahu et al. 2017). A similar small sized study was conducted 
in 21 Spanish families comprised of 386 subjects under an Idiopathic Thrombophilia (GAIT) 
Project and found variations in nuclear DNA genes (i.e. PARK2¾rs708928; P = 3.33×10-06 in 
females only and MRPL37¾rs10888838; P = 4.01×10-06 in males only) associated with 
mtDNA copy number (López et al. 2014). Another mtDNA copy number study was carried out 
by Asher et al., (2015) and reported an inverse association of mtDNA copy number with aging 
and frailty in a white population from The Atherosclerosis Risk in Communities (ARIC) and 
Cardiovascular Health study (CHS) (Ashar et al. 2015). 
 
4.2. Hypothesis 
Given that altered mitochondrial function based on mitochondrial copy number variation 
influences other metabolic and inflammatory phenotypes, it may also influence gout 
pathogenesis. Recently, a significant relationship between mitochondrial copy number and gout 
in Māori and Pacific (Polynesian) individuals was found (Gosling et al. 2018). Here I present 
an extended analysis to investigate the cause-effect relationship between mitochondrial 
variation and gout. To assess this cause-effect relationship, a genome-wide association analysis 
of mitochondrial DNA copy number was conducted, including a larger cohort of Polynesian 
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§ If mtDNA copy number is causal of gout then nuclear genetic variants associated 
with mtDNA copy number would also associate with gout. 
 
Broadly, the rationale to conduct a mtDNA copy number GWAS with a subsequent gout 
association analysis is based on the following scenarios, which have also been raised in Gosling 
et al. (2018). 
a) The change in mitochondrial CN associated with disease may be caused by the 
disease itself and can be considered as a disease marker. 
b) Alteration in mitochondrial CN may contribute to susceptibility to disease, perhaps 
through disrupting mitochondrial biogenesis and mitophagy. 
c) Mitochondrial CN may not affect disease status directly but rather be related to 
confounding factors that contribute to the development of gout such as increased 
body mass index (known as being causal of gout) (Gosling et al. 2018). 
 
4.3. Methods 
Two approaches were used to assess the cause-effect relationship between mitochondrial 
variation and gout; 1) a genome wide association study (GWAS) for mtDNA copy number to 
scan the entire human genome to find either mitochondrial variations themselves or nuclear 
variants (known to control mitochondrial replication and transcription), 2) and mitochondrial 
wide association studies (MWAS) across mitochondrial sequences obtained from Polynesian 
people (EP and WP) to detect potential mitochondrial variants that may contribute to 
developing gout. To determine the role of identified genetic variants significantly associated 
with the mtDNA copy number (as a result of GWAS and MWAS) in gout pathogenesis they 
were further tested for association with gout in NZ Polynesian and European gout cohorts. 
 
4.3.1. Study Cohorts/participants 
For mtDNA copy number GWAS, data sourced from Illumina CoreExome v24 array chip 
were used. The CoreExome data were produced by the Merriman laboratory, and were 
comprised of NZ Polynesian and European samples (gout cases and controls) recruited from 
various parts of New Zealand, U.S.A and Europe (described previously in Chapter 3 under 
Methodology Section). These data consisted of a total of 1,340 Eastern Polynesian (EP), 816 
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Western Polynesian (WP) and 4,579 European (Eurogout, Ardea Biosciences, Australian) gout 
and non-gout individuals. These data were processed by Merriman laboratory co-workers: 
Marilyn Merriman, Tanya Major, Ruth Topless, Mandy Phipps Green and Murray Cadzow. 
The Illumina CoreExome chip captured 343 mitochondrial SNPs. For mitochondrial-wide 
association analysis (MWAS), data comprised of whole mitochondrial genome sequences of a 
total of 601 Polynesian people with symptoms of gout were used (details are present in the 
following section). 
For the next part of the analyses—single association analysis, both Illumina CoreExome 
genotyped data and mitochondrial genomes datasets were used. The targeted analysis was 
performed in the same ancestral groups categorised into EP, WP and European with an equal 
number of individuals, previously separated into GWAS and MWAS (Figure 4.7). 
 
Figure 4.7: Schematic flow of methodology used in mtDNA copy number GWAS followed by gout association 
analysis. 
 
This particular flow chart represents a methodology adapted from Ashar et al., 2015 to perform mtDNA copy 
number genome wide association studies across Polynesian and European sample sets, followed by gout 
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4.3.2. Mitogenomes Sample Selection 
Because the CoreExome chip used for the mtDNA copy number estimations does not 
contain a wide range of mitochondrial variants present on Pacific mitochondrial lineages, a 
separate dataset was required to explore the potential association between Pacific mitochondrial 
variants and the mtDNA copy number. This is an example of ascertainment bias and is an 
inherent problem when working with the genetics of minority groups whose genotypes were 
often not used to help design genetic assays. 
Complete mitochondrial sequences were previously generated for 437 Māori and Pacific 
people (Gosling et al. 2018). This cohort was selected on the basis of BMI, rather than gout 
status, meaning that there are relatively few healthy controls in this dataset (327 gout cases vs 
110 controls). The mitochondrial genomes were produced by the amplification of 2 to 4 long-
range PCR products including HUM-LR1, HUM-LR2, Mit15041F, Mit15499R, Mit3435F and 
Mit3957R. The final PCR product was sequenced in study samples and sequencing was done 
on an Illumina MiSeq Instrument in a 2× 250 base paired-end run with V2 chemistry. The 
resultant sequence reads in FASTQ format were aligned to human reference genome build 
GRCh37/hg19 via the maximal exact matches command of Burrow’s Wheeler aligner (BWA) 
version V.0.7.13 (Heng Li 2013). Duplicates were removed using Picard’s MarkDuplicates 
(V.1.114) (http://broadinstitute.github.io/picard/). Picard’s AddOrReplaceGroups software was 
used to add read groups and then reads mapping to the mitochondrial reference sequence were 
extracted. For the local realignment Genome Analysis Tool-kit’s (GATK version V.3.4.0) was 
used (McKenna et al. 2010). IndelRealigner accounting the set of mitochondrial insertions and 
deletions (indels) were annotated in HmtDB (Rubino et al. 2012) and Mitomap (MC Brandon 
et al. 2005) and resultant realigned BAM files were then sorted and indexed using SAMtools 
version V.0.1.19 (H. Li et al. 2009). Mitochondrial SNPs and indels were detected by 
GATKHaplotpeCaller (V.3.4.0) (DePristo et al. 2011) software with setting –ploidy is equal to 
1. This is because although a cell contains many mitochondrial copies, however, mostly only 
one dominant lineage is inherited. The resultant variant calling format files were then split into 
two files with one containing bi-allelic mitochondrial SNPs while the other contained all other 
SNPs and indels. Filters were also applied at sample level to remove SNPs having read depth 
< 10, mapping quality < 30, genotype quality < 30 and Phred scaled P value for Fisher’s exact 
test > 60. The above data were processed by Anna Gosling with the help of James Boocock. 
To increase the power of the MWAS an additional dataset of mitochondrial sequences 
was included. These complete mitochondrial sequences were generated for 576 Māori and 
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Pacific people by the Diabetes Mellitus Targeted Resequencing project (affiliated with Maurice 
Wilkins Centre, Auckland, NZ). Again, these study participants were selected on the basis of 
BMI and diabetes status, again meaning that relatively few gout-free individuals were included. 
The 200ng/μl DNA concentration of the study samples was sent for sequencing at the 
McDonnell Genome Institute at Washington University U.S.A. Custom capture sequencing was 
performed using Nimblegen 5.0Mb probe set on a HISeq4000 panel. Sequencing data were 
provided in SAM format so the initial step was to convert these files back into FASTQ files (a 
file format that contains sequence from clusters that passes filters of quality control). Processing 
and interpretation of resultant files were done in the similar way that has been described 
previously with reference to Gosling et al., (2018) by GATK best practice recommendations. 
FASTQ files were aligned to the human reference genome (GRCh37 decoy reference genome) 
using BWA (v0.7.12 r1039). Further, Picard (v 1.114) was used to mark read duplications 
followed by indels realignment and base calibration using GATK (v3.3) 
(https://www.broadinstitute.org/gatk/download/). GATK HaplotypeCaller along with GNU 
Parallel (v20140422) (Tange 2011) were used for genomic variant calling. The resultant variant 
calling files were then passed through variant calling filtering using VQSR for variant quality 
score recalibration utility taking quality by read depth, mapping quality, Fisher score and truth 
sensitivity were recommended by GATK practice. This pipeline was adapted from a paper by 
(Tanner et al. 2017) with minor changes by Matt Bixley and Murray Cadzow and processing 
was done by Murray Cadzow. 
There was substantial overlap between these two sequenced datasets, and a resulting 
dataset of 601 individuals was used in the subsequent analysis. The skewing of the cases and 
controls, and the limited number of participants represented in this dataset do somewhat limit 
the downstream analyses. 
The final dataset of 601 individuals was comprised of 298 Eastern Polynesians, 287 
Western Polynesians, 14 mixed East/West Polynesians and 4 Europeans. The characteristics of 
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Table 4.1: Demographic details of the datasets included in the MWAS. 
Sub-population Eastern Polynesian (EP) Western Polynesian (WP) *Admixed Ancestry Polynesians 
Sex Groups Male Female Male Female Male Female 
Group Case Control Case Control Case Control Case Control Case Control Case Control 
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4.3.3. Calculation of mtDNA Copy Number from Microarray 
Intensities 
The methodology for the determination of the mitochondrial copy number was adapted 
from a study published by (Ashar et al. 2015). Existing Illumina CoreExome v24 array chip 
data from individuals belonging to various ancestral groups (EP, WP and European) were 
utilised. This array chip contains 343 mitochondrial SNPs. The probe intensities from the chip 
data were used to relatively estimate the mtDNA copy number. For a SNP with genotype AA, 
probe intensity related to the A allele was considered the true signal and probe intensity 
belonging to the B allele was considered background. An absolute difference of the probe 
intensities of the two alleles (|A-B|) was calculated, accounting for overall signal intensity. The 
median of such probe intensity differences across all mitochondrial SNPs was taken as a 
measure of the mitochondrial DNA copy number. Further, principal components (PCs) 
generated from the probe intensities of an additional 10,000 randomly selected autosomal 
SNPs, aimed to correct technical artefacts including plate and batch effects. These PCs were 
generated in R software (V.3.6.0.) using the prcomp function. For both purposes (calculating 
mtDNA copy number and generating PCs) two files x and y representing probe intensities of 
one allele in one file (x) and probe intensities of the other allele in the second file (y) of SNPs 
were generated. These files included probe intensities (representing alleles) of mitochondrial as 
well as autosomal SNPs which were then further separated into two files auto.x and auto.y 
representing one allele probe intensity of autosomal SNPs in auto.x file and probe intensities 
for the second allele in auto.y file. The absolute median for autosomal SNPs was then calculated 
using both files (auto.x and auto.y). The resultant file was then passed through a prcomp 
function in R with rotation of 10,000 (representing selection of random 10,000 autosomal 
SNPs) to generate PCs accounting for intensity variations across all Illumina CoreExome 
genotyped batches. Our laboratory co-worker Matt Bixley contributed significantly to 
calculating the mtDNA copy number for the chip data. 
Additionally, for the correction of the population structure effect another set of 10 PCs 
was generated from genotype calls for 3,000 independent autosomal SNPs.  Principal 
components vectors were calculated using a sub-set of 3000 ancestry-informative markers set 
(identified by the Illumina) extracted from the CoreExome whole genome genotypes. The 
SmartPCA (EIGENSOFT v6.0.1 www.hsph.harvard.edu/alkes-price/software/) software was 
used to generate eigenvectors without population size limit and removing any outliers. In the 
analysis data from Polynesian as well as from non-Polynesian individuals were included. Ten 
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eigenvectors were considered; however, the first four vectors were plotted against each other 
to view clustering of included ancestral groups which also explained 97.1% of the variability 
within sample sets (Krishnan et al. 2018).	The following plot (Figure 4.8) has been generated 
using shiny app in the R software (version 3.6.) between PC2 and PC3 that differentiates 
ancestral groups involved in the current analysis. 
 
Figure 4.8: A plot between PC2 and PC3 representing the clustering of different ancestral groups included in 















4.3.4. Statistical Analysis 
As mentioned before, two types of statistical analyses were performed comprising both 
large-scale analyses to targeted analysis. A genome-wide association scan was conducted 
across Polynesian and European sample sets (including all previously mentioned datasets) 
using PLINK 1.9.v2, adjusted with two sets of PCs (mentioned above), age, sex and gout 
affection status (comprised of gout cases and non-gout controls). To ensure that the results from 
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the GWAS were meaningful, a number of quality control thresholds were employed. Things 
like missing data can skew GWAS results and give false positive results. For this reason, 
variants with a minor allele frequency (MAF) less than 0.01 were excluded, and variant calls 
missing 5% of data across the entire dataset were filtered out. Moreover, this analysis was also 
adjusted with study QC batches (as explained in Chapter 3 in the methodology section). An 
inverse weighted meta-analysis was also performed to combine Eastern and Western 
Polynesian groups. Consequently, experiment-wide top signals were further subjected to 
targeted association analysis with gout. Allelic ORs were calculated for each selected variant 
in R program of version 3.2.2. using a regression model with the addition of primary adjustors 
sex, age and the first 10 PCs in the model. 
Mitochondrial wide association analysis (MWAS) was also conducted with and without 
adjustment against confounders including sex, age, gout (affection status) and the first 10 
genome-wide genotype PCs accounting for ancestral variations across the study populations. 
 
4.3.5. Power of the Study 
The power of the mtDNA copy number GWAS in Polynesian and European populations 
was calculated in R based on the outcome (continuous variable) (Goncalo 2010). The mtDNA 
copy number genome wide heritability estimates were calculated using the Genome-wide 
Complex Trait Analysis tool v1.91.7beta (Yang et al. 2011), adjusting the genetic relatedness 
matrix with a cryptic relatedness threshold of 0.025. These heritability estimates were 0.469 for 
the EP, 0.648 for WP and 0.076 for the European population. Given the sample sizes of 1,340 
(EP), 816 (WP) and 4,579 (European) all groups had > 80% power to detect a significant effect 
P< 1x10-7. 
The power of gout association analysis for selected nuclear and mitochondrial variants 
was calculated in R version 3.6.0. software using merrimanR package (powerGraph) 
(https://github.com/MerrimanLab/merrimanR.git) (Figure 4.9, Figure 4.10, Figure 4.11). The 
power graphs indicate the power of the study in Polynesian and European cohorts to detect 






220 | Page 
 
 
Figure 4.9: Association detection power in the Eastern Polynesian dataset across a range of odd ratios and 
altered frequencies (usually minor allele frequencies). 
 
The dotted red line indicates an adequate detection power ≥ 80%. 
 
Figure 4.10: Association detection power in the Western Polynesian dataset across a range of odd ratios and 
altered frequencies (usually minor allele frequencies). 
 









Figure 4.11: Association detection power in the European dataset across a range of odd ratios and altered 
frequencies (usually minor allele frequencies). 
 
The dotted red line indicates an adequate detection power ≥ 80%. 
 
4.4. Results 
4.4.1. Association Analysis between mtDNA copy number and gout 
in NZ Polynesian and European groups 
Before conducting the mtDNA copy number GWAS an association analysis was 
conducted to test for association between mtDNA copy number and gout in all three study 
populations (EP, WP and European). For this analysis CoreExome data were used. The mtDNA 
copy number was negatively associated with gout in the Polynesian sample sets (ß = -2.81, P = 
2.9x10-6 for Eastern Polynesian and ß = -8.11, P = 3.6x10-16 for Western Polynesian). However, 
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4.4.2. Mitochondrial DNA Copy Number GWAS 
A mtDNA copy number GWAS was conducted in Eastern Polynesian, Western 
Polynesian and European cohorts separately, adjusted by confounders including sex, age, gout 
affection status, two types of PCs (description is presented in the methodology section) and QC 
batches. For the Eastern Polynesian cohort, the FCRL6 missense variant rs149132393 T-allele 
was associated with increased mitochondrial CN close to an experiment-wide ((1.9x10-7) level 
of significance (ß = 0.048, P = 2.09x10-7) (Figure 4.12) (  
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Table 4.2). The ß does not have units because it is a ratio of the mitochondrial genome to 
the nuclear genome. No variants in either nuclear or mitochondrial genomes reached an 
experimental-wide significance level (1.9x10-7 (P value divided by number of genetic variants 
included in the analysis)) in the Western Polynesian cohort (Figure 4.13) (Table 4.3). Notably, 
there were no nuclear variants significantly associated with the mtDNA copy number in 
European sample sets, instead mitochondrial SNPs exhibited highly significant association with 
increased mtDNA copy number (Table 4.4) including a ‘top hit’ (rs2854128; ß=0.018, P = 
1.75x10-32) (Figure 4.14). Figure 4.16, Figure 4.17 and Figure 4.18 shows a Q-Q plot from the 
mtDNA copy number GWAS in the EP, WP and European populations, respectively. The Q-Q 
plot is a graphical representation of deviation of observed p-value from the null hypothesis: the 
observed p-value is plotted against the expected p-value from a theoretical X2 distribution. If 
the observed values correspond to the expected values, then all points are on or near the middle 
line between x and y-axes (null hypothesis: red line in the graphs). A good fit as was seen in 
the Q-Q plot of mtDNA copy number GWAS in WP and European groups. In these plots some 
observed p-values deviated from the mid-line, representing more significant p-values than 
expected. However, the Q-Q plot in the EP group represents an early separation of the expected 
from observed p-values and the deviating black line indicates general signal amplification 
possibly due to residual stratification owing to admixture.  
 
4.4.3. Mitochondrial Wide Copy Number Association Analysis in 
Polynesians 
Mitogenomes of Polynesian people (EP and WP) were used to perform mitochondrial 
wide copy number association analysis (MWAS) to test whether mitochondrial genetic 
variations associate with mtDNA copy number (Table 4.5), particularly in Polynesian 
individuals. Consistent with the previous mtDNA copy number GWAS, the MWAS was also 
adjusted against confounders sex, age, gout affection status, PCs (to account for ancestral 
variations) and QC batches (QC batch 2 and 6, dominated by data from EP and WP individuals), 
setting the same threshold of quality controls. The MWAS produced data comprised of only 73 
mitochondrial variants with the majority having low frequency (<0.05) (Table 4.5). None of the 
mitochondrial genetic variants reached an experiment wide significance level (1.08x10-4 (P 
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4.4.4. Meta-Analysis of mtDNA copy number GWAS 
PLINK 1.9.v2 was used to do meta-analysis of mtDNA copy number GWAS by 
combining Polynesian cohorts; the EP and WP groups. Neither of the nuclear and mitochondrial 
variants approached a genome-wide significant level in the combined meta-analysis of 
Polynesian sample sets (Table 4.6 and Figure 4.15). In the meta-analysis, on the basis of overall 
effect size I2 describes the magnitude of heterogeneity (i.e., “how much” heterogeneity) across 
effect size measured in each study group, whereas the Q represents the Cochrane value, that is 
used to test homogeneity of effect size calculated in different populations for the same 
parameter and combined by meta-analysis. If it is non-significant (e.g. Q (4) = 2.58, p =0.67) it 
suggests that studies are estimating the same population parameter, however if the p-value is 
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Figure 4.12: Manhattan plot of mtDNA copy number GWAS in the Eastern Polynesian population. 
 
Here the red line is showing the global threshold of GWAS that is 5×10-08 and the blue line represents the 
experimental wide threshold that is 1.9×10-07. Only one signal (rs149132393) is approaching experimental wide 
significance. 
 
Figure 4.13: Manhattan plot of mtDNA copy number GWAS in the Western Polynesian population. 
 
Here the red line is showing the global threshold of GWAS that is 5×10-08 and the blue line represents the 
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Figure 4.14: Manhattan plot of mtDNA copy number GWAS in Europeans. 
 
Here the red line is showing the global threshold of GWAS that is 5×10-08 and the blue line represents the 
experimental wide threshold that is 1.9×10-07. Exclusively mitochondrial variants are showing high significant 
association with mtDNA copy number even crossing the standard GWAS significance threshold. 
 
Figure 4.15: Manhattan plot of meta-analysis of mtDNA copy number GWAS in Polynesians. 
 
This is a Manhattan plot of meta-analysis of Polynesian sample sets by combining EP and WP cohorts. The red 
line is showing the global threshold of GWAS that is 5×10-08 and the blue line represents the experimental wide 
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Figure 4.16: Quantile-Quantile (Q-Q) plot of mtDNA copy number GWAS in the Eastern Polynesian cohort. 
 
The negative logarithm of the observed P-value (Y-axis).is plotted against expected P-value (X-axis) for genetic 
variants (black dots) included in mtDNA copy number GWAS conducted in the Eastern Polynesian sample set 
under the null hypothesis of no true association which is represented by red line. The allelic P-values in the above 
plot have come from a linear regression between genetic variants and mtDNA copy number. The deviating black 
line indicates general signal amplification probably due to residual stratification owing to admixture. 
Figure 4.17: The Q-Q plot of mtDNA copy number GWAS in the Western Polynesian cohort. 
 
The negative logarithm of the observed P-value (Y-axis).is plotted against expected P-value (X-axis) for genetic 
variants (black dots) included in mtDNA copy number GWAS conducted in the Western Polynesian sample set 
under the null hypothesis of no true association which is represented by red line. The allelic P-values in the above 
plot have come from a linear regression between genetic variants and mtDNA copy number. There is a good fit 
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Figure 4.18: The Q-Q plot of mtDNA copy number GWAS in Europeans. 
 
The negative logarithm of the observed P-value (Y-axis).is plotted against expected P-value (X-axis) for genetic 
variants (black dots) included in mtDNA copy number GWAS conducted in the European cohort under the null 
hypothesis of no true association which is represented by red line. The allelic P-values in the above plot have come 
from a linear regression between genetic variants and mtDNA copy number. There is a good fit between observed 
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Table 4.2: Top 20 signals of mtDNA copy number GWAS in Eastern Polynesian 
CHR SNP Gene/ Gene Nearby BP 
Affect 
Allele b (95% CI) P 
1 rs149132393 FCRL6 159785345 T 0.048 (0.030, 0.066) 2.09× 10-07 
13 rs1334226 Intergenic 67877199 T 0.050 (0.030, 0.071) 1.49× 10-06 
3 rs17006968 intergenic nearby CNTN4 2104048 A 0.025 (0.014, 0.036) 3.460-06 
4 rs12502309 intergenic nearby KIT and KDR 55867442 A 0.010 (0.005, 0.014) 4.91× 10-06 
7 rs4363139 CADPS2 122238571 A 0.044 (0.025, 0.064) 5.74× 10-06 
8 rs7820557 TMEM74 109735830 T 0.011 (0.006, 0.016) 9.12× 10-06 
5 rs10942945 CKMT2 80535187 C 0.021 (0.011, 0.031) 1.37× 10-05 
6 rs147798585 RNU5E-1 116784682 C -0.019 (-0.028, -0.010) 1.41× 10-05 
2 rs10520368 CKMT2-AS1 83660960 C 0.013 (0.007, 0.019) 1.46× 10-05 
2 rs13407412 intergenic nearby FUNDC2P2 83731825 C 0.013 (0.007, 0.019) 1.46× 10-05 
2 rs13420115 intergenic nearby FUNDC2P2 83740166 C 0.013 (0.007, 0.019) 1.56× 10-05 
16 rs1541698 USP10 84794632 A 0.009 (0.005, 0.013) 1.76× 10-05 
2 rs10497530 intergenic nearby SESTD1 andCCDC141 179924203 G 0.035 (0.019, 0.051) 1.84× 10-05 
20 rs2325900 USP10 2677566 C -0.013 (-0.019, -0.007) 2.29× 10-05 
1 rs12063142 intergenic nearby PAX7 and TAS1R2 19139517 T 0.011 (0.005, 0.016) 2.31× 10-05 
16 rs9928897 EBF4 13605058 T 0.013 (0.007, 0.020) 2.36× 10-05 
20 rs17268666 POFUT1 30818850 T 0.045 (0.024, 0.066) 2.50× 10-05 
15 rs3825885 NTRK3 88602841 C 0.009 (0.005, 0.014) 2.59× 10-05 
2 rs4578863 ZC3H6 113090047 T -0.009 (-0.014, -0.005) 2.68× 10-05 
13 rs2408987 Intergenic 54659312 C 0.015 (0.008, 0.022) 2.93× 10-05 
CHR: chromosome number; SNP: single nucleotide polymorphism; BP: base position; CI (95%): confidence 
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b (95% CI) P 
6 rs9482558 NKAIN2 124744006 T 0.038 (0.023, 0.053) 4.47× 10-07 
20 rs7266699 PHACTR3 58253438 C 0.045 (0.027, 0.062) 5.04× 10-07 
11 rs11023813 SOX6 16007047 T 0.038 (0.023, 0.054) 1.27× 10-06 
6 rs9491154 NKAIN2 124712739 C 0.035 (0.021, 0.050) 1.57× 10-06 
11 rs10840257 
intergenic nearby 
WEE1 and ZNF143 








108759480 T  0.016 (0.009, 0.024) 9.91× 10-06 
9 rs4977826 
intergenic nearby 
DMRTA1 and ELAVL2 
23127562 T 0.016 (0.006, 0.022) 1.60× 10-05 
11 rs1459658 NCAM1 112565534 T 0.011 (0.006, 0.016) 1.63× 10-05 
18 rs7235783 SPIRE1 12490502 T 0.045 (0.025, 0.066) 1.71× 10-05 
15 rs558290 PRTG 55927698 C -0.011 (-0.017, -0.006) 2.13× 10-05 




14735509 C 0.012 (0.006, 0.017) 2.91× 10-05 
19 rs12974044 RPS19 42368629 G 0.022 (0.011, 0.032) 3.72× 10-05 
6 rs2284923 RNF8 37348920 C 0.012 (0.006, 0.018) 4.05× 10-05 
2 rs10495822 
intergenic nearby 
MYADML and CRIM1 
34672921 T 0.044 (0.023, 0.065) 4.18× 10-05 
4 rs12501359 KCNIP4 21361701 A 0.045 (0.023, 0.067) 4.37× 10-05 
2 rs12472885 lincRNA 52479251 A -0.011 (-0.017, -0.006) 4.53× 10-05 
5 rs7708548 
intergenic nearby 
SPINK13 and SPINK6 
147638851 A 0.048 (0.025, 0.072) 4.64× 10-05 
8 rs2279590 CLU 27456253 T 0.014 (0.008, 0.021) 4.89× 10-05 
CHR: chromosome number; SNP: single nucleotide polymorphism; BP: base position; CI (95%): confidence 
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Table 4.4: Top 20 signals of mtDNA copy number GWAS in European 
CHR SNP BP 
Affect 
Allele 
b (95% CI) P 
MT rs2854128 2706 A 0.018 (0.015, 0.022) 1.75× 10-32 
MT rs3928306 3010 A 0.021 (0.017, 0.024) 5.53× 10-31 
MT rs2853498 12308 G -0.018 (-0.022, -0.015) 3.36× 10-23 
MT rs2853493 11467 G -0.018 (-0.022, -0.014) 2.42× 10-22 
MT rs2853510 15924 G -0.028 (-0.035, -0.021) 4.34× 10-15 
MT rs28358576 1811 G -0.017 (-0.022, -0.012) 2.50× 10-13 
MT rs28358577 1888 A -0.018 (-0.023, -0.012) 6.56× 10-12 
MT rs527236198 15928 A -0.017 (-0.022, -0.012) 1.22× 10-11 
MT rs28357980 4917 G -0.017 (-0.022, -0.012) 1.87× 10-11 
MT rs147903261 16068 T 0.016 (0.011, 0.022) 2.19× 10-10 
MT rs28358279 10463 C -0.015 (-0.020, -0.010) 9.16× 10-10 
MT rs28358280 10550 G -0.017 (-0.023, -0.011) 5.31× 10-09 
MT rs34301918 16391 A -0.027 (-0.037, -0.018) 2.10× 10-08 
MT Mito G15044A 15043 A -0.021 (-0.029, -0.014) 2.66× 10-08 
MT rs267606893 12705 T -0.016 (-0.021, -0.010) 3.06× 10-08 
MT rs41347846 10034 C -0.027 (-0.037, -0.017) 4.37× 10-08 
MT rs41323649 228 A 0.018 (0.011, 0.024) 5.48× 10-08 
MT rs2854131 3197 C -0.014 (-0.020, -0.009) 6.47× 10-08 
MT rs28359178 13708 A 0.012 (0.008, 0.017) 1.22× 10-07 
MT rs2853825 9477 A -0.014 (-0.019, -0.008) 1.71× 10-07 
CHR: chromosome number; MT: Mitochondrial genome; SNP: single nucleotide polymorphism; BP: base 
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b (95% CI) P 
4117 C 0.026 -0.051 (-0.100, -0.002) 0.039 
16126 C 0.037 0.045 (0.001, 0.088) 0.042 
11914 A 0.017 0.061 (0.001, 0.121) 0.044 
9540 C 0.035 -0.043 (-0.085, -0.001) 0.044 
10873 C 0.034 -0.041 (-0.085, 0.001) 0.057 
16223 T 0.034 -0.041 (-0.084, 0.001) 0.058 
10400 T 0.034 -0.041 (-0.085, 0.001) 0.059 
12705 T 0.034 -0.041 (-0.085, 0.001) 0.059 
14783 C 0.034 -0.041 (-0.085, 0.001) 0.059 
15301 A 0.034 -0.041 (-0.085, 0.001) 0.059 
8701 G 0.034 -0.041 (-0.085, 0.001) 0.059 
489 C 0.035 -0.041 (-0.084, 0.001) 0.059 
10398 G 0.037 -0.040 (-0.082, 0.001) 0.061 
16241 G 0.024 -0.044 (-0.095, 0.006) 0.088 
13500 C 0.024 -0.044 (-0.094, 0.006) 0.089 
5843 G 0.024 -0.044 (-0.094, 0.006) 0.089 
15043 A 0.035 -0.035 (-0.077, 0.006) 0.100 
16092 C 0.016 0.051 (-0.010, 0.113) 0.105 
16261 C 0.071 -0.025 (-0.057, 0.006) 0.112 
16311 C 0.042 -0.032 (-0.071, 0.007) 0.115 
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Table 4.6: Top 20 signals of meta-analysis of mtDNA copy number GWAS in Polynesian (EP, WP) populations. 
CHR SNP BP 
Affect 
Allele 
b P Q I 
18 rs7235783 12490502 T 0.025 1.89× 10-06 0.0236 80.47 
5 rs6866864 71006645 T -0.008 2.57× 10-06 0.626 0 
1 rs12063142 19139517 T 0.009 7.19× 10-06 0.262 20.25 
2 rs10520368 83660960 C 0.010 7.82× 10-06 0.116 59.41 
1 rs149132393 159785345 T 0.031 8.57× 10-06 0.004 87.45 
11 rs11218323 98951110 C -0.008 8.73× 10-06 0.862 0 
2 rs13407412 83731825 C 0.010 1.21× 10-05 0.094 64.31 
2 rs13420115 83740166 C 0.01 1.38× 10-05 0.092 64.75 
17 rs12600452 45054564 A 0.010 1.40× 10-05 0.436 0 
5 rs638191 17183851 A -0.009 1.56× 10-05 0.322 0 
13 rs9572892 72700026 T 0.012 1.73× 10-05 0.112 60.37 
1 rs7521204 19138295 T 0.007 2.90× 10-05 0.325 0 
5 rs10066275 10069158 G 0.014 3.19× 10-05 0.432 0 
6 rs9346224 69294401 G -0.007 4.08× 10-05 0.371 0 
8 rs1532278 27466315 T 0.011 4.40× 10-05 0.212 35.67 
2 rs9631074 83741398 T 0.008 4.52× 10-05 0.207 37.19 
2 rs1384925 52812988 A 0.007 4.68× 10-05 0.796 0 
7 rs2011310 142152369 C 0.008 5.01× 10-05 0.702 0 
2 rs4675077 227238030 C -0.012 5.16× 10-05 0.790 0 
1 rs4950826 202077927 A 0.009 5.16× 10-05 0.721 0 
CHR: chromosome number; SNP: single nucleotide polymorphism; BP: base position; b: effect size; Q: classical 
measure of heterogeneity also known as Cochran’s Q, calculated as weighted sum of squared difference between 
individual study effects and pooled effects across studies ; I: usually measure as I2 describes the percentage of 
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Table 4.7: Top mitochondrial DNA copy number GWAS signals in each population and across meta-analysis of Polynesians 
 
    
Effect size in EP 
mtDNA copy 
numberGWAS 
Effect size in WP 
mtDNA copy 
numberGWAS 
Effect size in Euro 
mtDNA copy 
numberGWAS 
Effect size in meta-
analysis of Polynesian 
CHR SNP Top 
GWAS 
signals 
A1 ß P ß P ß P ß P 
1 rs149132393 EP T 0.048 2.09× 10-07 0.007  0.539  -- -- 0.028  0.170  
13 rs1334226 EP T 0.050 1.49× 10-06 -- -- 0.003  0.238  -- -- 
3 rs17006968 EP A 0.025 3.460-06 0.000  0.922  -0.004  0.101 0.013  0.306  
4 rs12502309 EP A 0.010 4.91× 10-06 -0.002  0.607  0.0006  0.628 0.005  0.451  
7 rs4363139 EP A 0.044 5.74× 10-06 -- -- -0.004  0.059 -- -- 































-- -- 0.011 2.58× 10-06 
 
 






















0.922 -- -- 
2 rs10497530 EP G 0.035 1.84× 10-05 -- -- -0.0009 
 
0.639 -- -- 
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20 rs17268666 EP T 0.045 2.50× 10-05 -- -- 0.001 
 
0.629 -- -- 



























            
    Effect size in WP 
mtDNA copy 
numberGWAS 
Effect size in EP 
mtDNA copy 
numberGWAS 
Effect size in Euro 
mtDNA copy 
numberGWAS 
Effect size in meta-
analysis of Polynesian 
6 rs9482558 WP T 0.038 4.47× 10-07 -- -- -- -- -- -- 
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0.005 -- -- 
5 rs7708548 WP A 0.048 4.64× 10-05 -- -- -- -- -- -- 







    Effect size in Euro 
mtDNA copy 
numberGWAS 
Effect size in EP 
mtDNA copy 
numberGWAS 
Effect size in WP 
mtDNA copy 
numberGWAS 
Effect size in meta-
analysis of Polynesian 
MT rs2854128 Euro A 0.018 1.75× 10-32 0.009  0.310 -0.023  0.121 -0.007  0.703  
MT rs3928306 Euro A 0.021 
  
5.53× 10-31 0.026  0.036 -- -- -- -- 
MT rs2853498 Euro G -0.018 
  
3.36× 10-23 -0.010  0.473 -- -- -- -- 
MT rs2853493 Euro G -0.018 2.42× 10-22 -0.007  0.613 -- -- -- -- 
MT rs2853510 Euro G -0.028 4.34× 10-15 -- -- -- -- -- -- 
MT rs28358576 Euro G -0.017 2.50× 10-13 -- -- -- -- -- -- 
MT rs28358577 Euro A -0.018 6.56× 10-12 -0.013  0.389 -- -- -- -- 
MT rs527236198 Euro A -0.017 1.22× 10-11 -0.013  0.387 -- -- -- -- 
MT rs28357980 Euro G -0.017 1.87× 10-11 -0.013  0.387 -- -- -- -- 
MT rs147903261 Euro T 0.016 2.19× 10-10 -- -- -- -- -- -- 
MT rs28358279 Euro C -0.015 9.16× 10-10 -0.013  0.387 -- -- -- -- 
MT rs28358280 Euro G -0.017 5.31× 10-09 -- -- -- -- -- -- 
MT rs34301918 Euro A -0.027 2.10× 10-08 -- -- -- -- -- -- 
MT Mito 
G15044A 
Euro A -0.021 2.66× 10-08 -- -- -- -- -- -- 








MT rs41347846 Euro C -0.027 4.37× 10-08 -- -- -- -- -- -- 
MT rs41323649 Euro A 0.018 5.48× 10-08 -- -- 0.007 
 
0.621 -- -- 
MT rs2854131 Euro C -0.014 6.47× 10-08 -- -- -- -- -- -- 
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MT rs28359178 Euro A 0.012 1.22× 10-07 -- -- -- -- -- -- 
MT rs2853825 Euro A -0.014 1.71× 10-07 -- -- -- -- -- -- 
 
CHR: chromosome; MT: Mitochondrial genome SNP: single nucleotide polymorphism; EP: Eastern Polynesian; WP: Western Polynesian; Euro: European; mtDNA CN: 
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4.4.5. Gout Association Analysis 
Gout association analysis accounts for the second part of this chapter. After achieving 
GWAS and MWAS outcomes, the ‘top-hits’ of each genome- and mitochondrial-wide 
association analysis were tested for their association with gout in each study population (i.e. 
Eastern Polynesian, Western Polynesian and European). This was to evaluate whether such 
variants contribute to gout pathogenesis via controlling the mtDNA copy number. 
The EP GWAS FCRL6;rs149132393 variant is uncommon. It was monomorphic in 
Europeans, but present in the Polynesian groups at an overall allele frequency of ~1-2%. The 
T-allele of this variant did not exhibit significant association with gout risk in either the EP (OR 
= 1.87, P = 0.110) or WP (OR = 0.41, P =0.053) sample sets. 
The mtDNA copy numberGWAS in Western Polynesians did not detect any significant 
association between nuclear variants and mtDNA copy number at an experimental-wide 
significance level (P = 1.9×10-07), so no variants from this GWAS were used to test for potential 
associations with gout. However, the European GWAS identified the mitochondrial variant 
rs2854128 altered allele (A-allele), which associated with mtDNA copy numberat genome-
wide significance. When a regression was performed to predict whether this variant may 
contribute to gout risk among Eastern or Western Polynesians, it was found to be nominally 
significantly associated with an increasing risk of gout among Eastern Polynesians only (OR = 
2.16, P = 0.043) (Table 4.8). It is unclear why this variant is associated with gout in EP but not 
in European. It is possible that population stratification drove the association in EP and / or that 
the effect size was low in European and power was insufficient to detect association.  
To determine if either GWAS nuclear or mitochondrial loci contribute exclusively as 
inflammatory loci, an analysis was conducted using hyperuricaemic controls versus gout cases 
(detailed in method section in Chapter 2) in each of the sample sets. The T-allele of EP GWAS 
hit signal rs149132393 in the FCRL6 gene did not associate with gout risk among the EP 
hyperuricaemic subset, however it was found to significantly associate with gout among the 
WP hyperuricaemic subset (OR = 0.18, P = 0.003). Hyperuricaemic West Polynesian people 
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None of the European mtDNA copy numbe rGWAS hit signals exhibited significant 
association with gout in any of the hyperuricaemic study cohorts (Table 4.10). Moreover, the 
frequency of these mitochondrial genetic variants (present in the CoreExome data (genotyped 
on the Illumina CoreExome chip)) was found to be very low (less than 1%) in all study case-
control cohorts. Possibly owing to lower power some of these did not show any association 
with gout in all cohorts. The other possibility for not showing association is small size sample 
sets (gout association analysis using HU controls), also limiting power of the analysis. 
Based on the hypothesis that genetic variants in nuclear loci may confer gout risk via 
controlling mtDNA copy number, nuclear loci POLG, POLG2, TFB1M, TFB2M, NRF-1, NRF-
2, PARK2, MRPL37, FOXA3, THRBMED24, TFAM and ABHD8 (Bornstein et al. 2008, 
Carling et al. 2011, Chiaratti et al. 2011, Guyatt et al. 2019, Harvey et al. 2011, López et al. 
2014, Oskoui et al. 2006, Spinazzola et al. 2009, Tyynismaa et al. 2009, Workalemahu et al. 
2017) previously reported to influence mtDNA copy number in different populations mainly of 
European ancestry (details have been provided in the discussion section) were also tested for 
their association with the mtDNA copy number and gout in the current study of mtDNA copy 
number GWAS , CoreExome and UK Biobank databases. Among these loci only the PRKCA 
gene was associated with mtDNA copy number and gout in the European cohort included in 
the present study, however, they were not significantly associated with gout in the UK Biobank 
GWAS (rs8069696; A allele frequency = 17% , β = 2.1×10-5, Pβ = 0.006, ORCoreExome = 0.84, 
PCoreExome = 0.021, ORUK biobank, = 1.00 , PUK biobank = 0.940 and rs6504459; G allele frequency = 
3% , β = 6.0×10-4, Pβ = 0.023, ORCoreExome = 1.94, PCoreExome = 0.001, ORUK biobank, = 1.04 , PUK 
biobank = 0.424) (Table 4.11). 
Gout association analysis using mitogenomes did not evidence convincing results. Only 
four mitochondrial variants at positions 709, 5460, 195 and 16189 were found significantly 
associated with gout (having low frequency (< 5%) except the 16189 variant (6%) (OR = 0.24, 
P = 0.023; OR = 0.32, P = 0.023; OR = 0.25, P = 0.034; OR = 0.45, P = 0.045, respectively) 
(Table 4.10). However, these variants were not significantly associated with mtDNA copy 
number (β = -0.031, Pβ = 0.262; β =-0.008, Pβ =0.703 ; β = -0.020, Pβ = 0.438; β = -0.001, Pβ = 
0.926, respectively). Notably, all of these mitochondrial genetic variants define a B-haplogroup 
such as 709 defines B4ab1a2f, 5460 belongs to B4a1a1ad, 195 has been identified in 
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Table 4.8: Association analysis of selected ‘top-signals’ of mtDNA copy number GWAS in study populations with gout in the same study groups 
CHR SNP Ref Allele 
Gout Association Analysis (All Controls vs Gout Cases) 


















Value OR* (95%CI) 
mtDNA copy number GWAS Hit in Eastern Polynesian 
1 rs149132393 T 0.017 0.010 0.110 1.87 (0.87, 4.05) 0.011 0.019 0.050 0.41 (0.17, 1.01) - - - - 
mtDNA copy number GWAS Hits in European 
MT rs2854128 A 0.032 0.034 0.043 2.16(1.02,4.57) - - - - 0.439 0.429 0.726 0.97 (0.81, 1.15) 
MT rs3928306 A 0.017 0.018 0.248 1.83 (0.65,5.12) 0.004 0.002 0.172 7.92 (0.40, 154.5) 0.242 0.258 0.145 0.86 (0.70, 1.05) 
MT rs2853498 G 0.010 0.018 0.890 1.08 (0.32,3.59) 0.002 0 - - 0.218 0.236 0.982 1.00 (0.81, 1.22) 
MT rs2853493 G 0.009 0.017 0.894 1.08 (0.32,3.63) 0.002 0 - - 0.212 0.233 0.952 0.99 (0.80, 1.22) 
MT rs2853510 G 0.004 0.002 0.425 2.71 (0.23,31.61) 0.002 0.002 - - 0.051 0.051 0.914 0.97 (0.65, 1.45) 
MT rs28358576 G 0.007 0.011 0.943 0.94 (0.22, 4.08) 0.002 0 - - 0.126 0.130 0.710 1.05 (0.81, 1.35) 
MT rs28358577 A 0.006 0.018 0.666 0.74 (0.19, 2.83) 0.002 0 - - 0.104 0.095 0.893 1.02 (0.76, 1.36) 
MT rs527236198 A 0.006 0.018 0.672 0.74 (0.19, 2.85) 0.002 0 - - 0.104 0.093 0.638 1.073 (0.79, 1.44) 
MT rs28357980 G 0.006 0.018 0.667 0.74 (0.19, 2.83) 0.002 0 - - 0.103 0.092 0.641 1.07 (0.79, 1.44) 
MT rs147903261 T 0.006 0.010 0.505 1.68 (0.36, 7.80) 0 0 - - 0.094 0.116 0.617 0.93 (0.70, 1.23) 
MT rs28358279 C 0.006 0.018 0.667 0.74 (0.19, 2.83) 0.002 0.003 - - 0.110 0.096 0.538 1.09 (0.82, 1.45) 
MT rs28358280 G 0.004 0.008 0.628 0.64 (0.10, 3.88) 0.002 0 - - 0.076 0.076 0.336 1.17 (0.84, 1.61) 
MT rs34301918 A 0 0 - - 0 0 - - 0.025 0.026 0.873 0.95 (0.55, 1.65) 
MT Mito G15044A A 0.023 0.012 0.106 2.25 (0.83, 6.07) 0.045 0.032 - - 0.043 0.042 0.931 0.98 (0.63, 1.51) 
MT rs267606893 T 0.020 0.012 0.188 1.98 (0.71, 5.51) 0.045 0.030 - - 0.086 0.064 0.380 1.16 (0.82, 1.64) 
MT rs41347846 C 0 0 - - 0 0 - - 0.024 0.027 0.755 0.91 (0.53, 1.58) 
MT rs41323649 A 0.007 0.007 0.253 2.58 (0.50, 13.14) 0.013 0.021 0.154 0.37 (0.09, 1.44) 0.054 0.073 0.358 0.85 (0.60, 1.20) 
 
 
241 | Page 
MT rs2854131 C 0.003 0.007 0.733 1.41 (0.18,10.61) 0 0 - - 0.087 0.107 0.504 0.90 (0.68, 1.20) 
MT rs28359178 A 0.007 0.011 0.390 1.82 (0.46,7.14) 0 0.008 - - 0.118 0.142 0.342 0.88 (0.68, 1.13) 
MT rs2853825 A 0.003 0.007 0.733 1.41 (0.18,10.61) 0 0 - - 0.090 0.103 0.716 0.94 (0.71, 1.26) 
CHR: chromosome; SNP: single nucleotide polymorphism; MT: mitochondrial genome; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value and odd ratio 















242 | Page 
Table 4.9: Association analysis of selected ‘top-signals’ of mtDNA copy number GWAS in study populations with gout using HU Controls in the same study groups. 
CHR SNP Ref Allele 
Gout Association Analysis (HU Controls vs Gout Cases) 



















Value OR* (95%CI) 
mtDNA copy number GWAS Hit in Eastern Polynesian 
1 rs149132393 T 0.018 0.009 0.079 3.43 (0.86, 13.61) 0.009 0.036 0.004 0.20 (0.06, 0.61) - - - - 
mtDNA copy number GWAS Hits in European 
MT rs2854128 A 0.032 0.030 0.497 1.46 (0.48, 4.35) - - - - 0.4395 0.434 0.904 0.98 (0.82, 1.19) 
MT rs3928306 A 0.017 0.012 0.510 1.71 (0.34, 8.46) 0.004 0.002 0.991 - 0.2425 0.252 0.451 0.92 (0.74, 1.14) 
MT rs2853498 G 0.010 0.012 0.784 1.26 (0.23, 6.99) 0.002 0 - - 0.2186 0.240 0.567 0.93 (0.75, 1.16) 
MT rs2853493 G 0.009 0.012 0.878 1.14 (0.20, 6.54) 0.002 0 - - 0.2125 0.237 0.536 0.93 (0.75, 1.16) 
MT rs2853510 G 0.004 0 - - 0.002 0.002 0.994 - 0.05146 0.055 0.528 0.87 (0.57, 1.32) 
MT rs28358576 G 0.007 0.006 0.732 1.48 (0.15, 14.19) 0.002 0 - - 0.1265 0.131 0.904 1.01 (0.77, 1.33) 
MT rs28358577 A 0.006 0.012 0.811 0.79 (0.12, 5.20) 0.002 0 - - 0.1042 0.092 0.691 1.06 (0.77, 1.46) 
MT rs527236198 A 0.006 0.012 0.824 0.80 (0.12, 5.29) 0.002 0 - - 0.1047 0.091 0.515 1.11 (0.80, 1.53) 
MT rs28357980 G 0.006 0.012 0.820 0.80 (0.12, 5.27) 0.002 0 - - 0.1039 0.091 0.538 1.10 (0.80, 1.52) 
MT rs147903261 T 0.006 0 - - 0 0 - - 0.09472 0.113 0.820 0.96 (0.71, 1.30) 
MT rs28358279 C 0.006 0.012 0.820 0.80 (0.12, 5.27) 0.002 0.002 - - 0.1101 0.092 0.271 1.192 (0.8716, 1.631) 
MT rs28358280 G 0.004 0.006 0.994 0.99 (0.09, 10.76) 0.002 0 - - 0.07694 0.077 0.508 1.12 (0.79, 1.57) 
MT rs34301918 A 0 0 - - 0 0 - - 0.02584 0.028 0.534 0.83 (0.46, 1.48) 
MT Mito G15044A A 0.023 0.018 0.450 1.68 (0.43, 6.49) 0.045 0.032 0.486 1.55 (0.44, 5.41) 0.04343 0.044 0.590 0.88 (0.55, 1.39) 
MT rs267606893 T 0.020 0.018 0.530 1.55 (0.39, 6.13) 0.045 0.029 0.486 1.55 (0.44, 5.41) 0.08608 0.062 0.259 1.24 (0.85, 1.80) 
MT rs41347846 C 0 0 - - 0 0 - - 0.02469 0.028 0.641 0.87 (0.49, 1.55) 
MT rs41323649 A 0.007 0 - - 0.013 0.021 0.939 0.91 (0.08, 9.3) 0.05499 0.070 0.594 0.90 (0.62, 1.31) 
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MT rs2854131 C 0.003 0.006 0.997 1.00 (0.07, 14.07) 0 0 - - 0.08745 0.108 - - 
MT rs28359178 A 0.007 0 - - 0 - - - 0.1186 0.139 0.406 0.89 (0.67, 1.16) 
MT rs2853825 A 0.003 0.006 0.997 1.00 (0.071, 14.07) 0 0 - - 0.09013 0.105 0.365 0.86 (0.63, 1.17) 
CHR: chromosome; MT: Mitochondrial genome SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odd ratio; P: P value; * = both P value and odd ratio 
are adjusted with sex, age, first 10 principal components account ancestral variation and QC batches.  
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Table 4.10: Association analysis of selected ‘top-signals’ of MWAS with gout in Polynesian. 




(Controls) P* Value OR (95%CI) 
4117 C 0.025 0.032 0.171 0.48 (0.17, 1.38) 
16126 C 0.028 0.048 0.248 0.53 (0.18, 1.56) 
11914 A 0.022 0.016 0.629 1.45 (0.32, 6.45) 
9540 C 0.031 0.048 0.057 0.41 (0.16, 1.03) 
10873 C 0.031 0.044 0.112 0.47 (0.18, 1.19) 
16223 T 0.031 0.044 0.113 0.47 (0.18, 1.2) 
10400 T 0.031 0.044 0.114 0.47 (0.18, 1.2) 
12705 T 0.031 0.044 0.114 0.47 (0.18, 1.2) 
14783 C 0.031 0.044 0.114 0.47 (0.18, 1.2) 
15301 A 0.031 0.044 0.114 0.47 (0.18, 1.2) 
8701 G 0.031 0.044 0.114 0.47 (0.18, 1.2) 
489 C 0.031 0.044 0.113 0.47 (0.18, 1.2) 
10398 G 0.034 0.044 0.195 0.54 (0.22, 1.36) 
16241 G 0.022 0.032 0.136 0.44 (0.15, 1.3) 
13500 C 0.022 0.032 0.136 0.44 (0.15, 1.3) 
5843 G 0.022 0.032 0.136 0.44 (0.15, 1.3) 
15043 A 0.034 0.044 0.159 0.52 (0.21, 1.29) 
16092 C 0.022 0.012 0.294 2.49 (0.45, 13.73) 
16261 C 0.068 0.081 0.345 0.70 (0.33, 1.47) 
16311 C 0.043 0.044 0.428 0.70 (0.29, 1.7) 
Significant Associations 
709 A 0.018 0.032 0.023 0.24 (0.07, 0.82) 
5460 A 0.024 0.056 0.023 0.32 (0.12, 0.85) 
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195 C 0.012 0.044 0.034 0.25 (0.06, 0.90) 
16189 C 0.049 0.084 0.046 2.22 (1.02, 5.00) 
BP: Base position MAF: minor allele frequency; OR: odd ratio; P: P value; both P value and odd ratio are not adjusted (unadjusted) with sex, age, first 10 principal components 
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Table 4.11: Look up in Pattero et al of genetic variants in loci previously associated with mtDNA copy number or influencing mtDNA copy number in various European 
populations in the current mtDNA copy number GWAS and gout association analysis in Europeans (from CoreExome and UK Biobank GWAS). 
SNP A1 
mtDNA Copy Number GWAS Gout Association Analysis   
Europeans CoreExome UK Biobank CoreExome UK Biobank  
β 
 (95% CI) P 
OR 
 (95% CI) P 
OR 
 (95% CI) P 
Pc Pc 
Gene; ABHD8 
rs3745186 T -0.0011 (-0.0035, 0.0013) 0.777 1.14 (0.89, 1.45) 0.301 0.97 (0.91, 1.03) 0.306 - -  
rs4808616 A 0.0032 (-0.0018, 0.0082) 0.773 0.93 (0.81, 1.06) 0.260 1.00 (0.96, 1.03) 0.855 - -  
Gene; FOXA3 
rs11669442 C 0.0011 (-0.0016, 0.0038) 0.546 0.96 (0.84, 1.09) 0.489 1.04 (1.01, 1.08) 0.020 - 0.035  
Gene;  MED24 
rs11555255 T 0.0014 (-0.0010, 0.0039) 0.702 1.05 (0.89, 1.23) 0.564 0.97 (0.93, 1.02) 0.208 - -  
rs6503534 G -0.0013 (-0.0042, 0.0016) 0.773 0.97 (0.84, 1.13) 0.722 0.99 (0.95, 1.04) 0.801 - -  
Gene; MRPL37 
rs13571 G 0.0006 (-0.0023, 0.0035) 0.112 0.93 (0.80, 1.07) 0.289 0.98 (0.94, 1.02) 0.379 - -  
rs4927071 T -0.0009 (-0.0031, 0.0013) 0.110 0.94 (0.81, 1.08) 0.362 0.99 (0.95, 1.03) 0.512 - -  
Gene; MYT1L 
rs10185662 T 0.0006 (-0.0016, 0.0028) 0.416 1.01 (0.87, 1.17) 0.902 1.01 (0.97, 1.05) 0.627 - -  
rs10865533 T -0.0015 (-0.0040, 0.0010) 0.234 1.04 (0.90, 1.19) 0.613 1.02 (0.98, 1.06) 0.419 - -  
rs11127306 A 4.22×10-5 (-0.0030, 0.0031) 0.773 0.96 (0.80, 1.16) 0.699 0.97 (0.93, 1.02) 0.282 - -  
rs11678039 A 0.0012 (-0.0011, 0.0034) 0.474 1.00 (0.87, 1.15) 0.955 1.01 (0.97, 1.05) 0.620 - -  
rs11684279 A 0.0005 (-0.0028, 0.0038) 0.200 0.98 (0.87, 1.10) 0.691 1.02 (0.99, 1.06) 0.210 - -  
rs11685526 G 0.0010 (-0.0014, 0.0033) 0.614 0.92 (0.76, 1.11) 0.399 0.99 (0.94, 1.05) 0.740 - -  
rs11887279 C -0.0006 (-0.0035, 0.0023) 0.014 0.93 (0.80, 1.08) 0.319 0.99 (0.95, 1.03) 0.520 - -  
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rs11888121 A -0.0014 (-0.0037, 0.0009) 0.272 0.99 (0.81, 1.21) 0.943 1.00 (0.94, 1.06) 0.923 - -  
rs12470297 C -0.0011 (-0.0034, 0.0012) 0.252 0.90 (0.80, 1.02) 0.094 0.99 (0.96, 1.03) 0.678 - -  
rs13006826 T 0.0007 (-0.0016, 0.0031) 0.097 0.94 (0.83, 1.07) 0.333 1.03 (1.00, 1.07) 0.083 - -  
rs13382326 C 0.0009 (-0.0016, 0.0034) 0.732 1.01 (0.75, 1.37) 0.943 0.93 (0.85, 1.01) 0.097 - -  
rs13404264 T -0.0014 (-0.0036, 0.0008) 0.896 0.95 (0.78, 1.15) 0.580 1.04 (0.98, 1.09) 0.204 - -  
rs1368233 G -0.0009 (-0.0045, 0.0026) 0.839 1.05 (0.92, 1.19) 0.500 0.98 (0.94, 1.01) 0.234 - -  
rs1614012 C 0.0032 (0.0010, 0.0055) 0.260 0.93 (0.82, 1.05) 0.254 0.97 (0.93, 1.00) 0.061 - -  
rs17039361 G 0.0034 (0.0007, 0.0061) 0.052 0.95 (0.84, 1.08) 0.436 0.97 (0.93, 1.00) 0.055 - -  
rs17039365 C 0.0020 (-0.0016, 0.0056) 0.796 1.01 (0.85, 1.20) 0.884 0.98 (0.94, 1.03) 0.469 - -  
rs17039395 A -0.0007 (-0.0032, 0.0019) 0.688 0.98 (0.86, 1.12) 0.768 0.99 (0.96, 1.03) 0.675 - -  
rs17338616 T 0.0012 (-0.0014, 0.0038) 0.228 1.10 (0.97, 1.24) 0.135 0.98 (0.95, 1.01) 0.173 - -  
rs1864881 A -0.0013 (-0.0035, 0.0009) 0.251 1.03 (0.91, 1.16) 0.686 0.98 (0.95, 1.02) 0.335 - -  
rs2042142 A 0.0008 (-0.0016, 0.0032) 0.417 0.94 (0.83, 1.07) 0.381 0.98 (0.94, 1.01) 0.198 - -  
rs2241685 T -0.0005 (-0.0034, 0.0023) 0.991 1.04 (0.84, 1.29) 0.744 0.93 (0.88, 0.99) 0.019 - 0.035  
rs2241685 T 0.0012 (-0.0011, 0.0035) 0.991 1.04 (0.84, 1.29) 0.744 0.93 (0.88, 0.99) 0.019 - 0.035  
rs4305302 G 0.0024 (0.0001, 0.0047) 0.784 1.00 (0.86, 1.16) 0.975 0.98 (0.94, 1.02) 0.425 - -  
rs4473412 C 0.0001 (-0.0021, 0.0023) 0.585 1.09 (0.97, 1.24) 0.155 1.00 (0.97, 1.04) 0.990 - -  
rs4571084 T 0.0005 (-0.0024, 0.0034) 0.021 1.10 (0.91, 1.32) 0.322 1.02 (0.97, 1.08) 0.377 - -  
rs4853812 T -0.0003 (-0.0026, 0.0019) 0.952 1.01 (0.88, 1.16) 0.915 0.98 (0.94, 1.02) 0.258 - -  
rs4853946 C -0.0009 (-0.0063, 0.0044) 0.281 1.10 (0.98, 1.25) 0.113 1.03 (1.00, 1.07) 0.080 - -  
rs6710116 C -0.0021 (-0.0048, 0.0005) 0.973 0.89 (0.78, 1.02) 0.090 0.99 (0.95, 1.02) 0.471 - -  
rs6721182 C 0.0002 (-0.0021, 0.0026) 0.348 1.05 (0.90, 1.24) 0.533 0.96 (0.92, 1.00) 0.057 - -  
rs6728613 C 0.0016 (-0.0023, 0.0054) 0.534 1.10 (0.97, 1.24) 0.143 1.03 (1.00, 1.07) 0.066 - -  
rs6755567 G -0.0008 (-0.0030, 0.0015) 0.420 0.96 (0.83, 1.10) 0.538 0.97 (0.93, 1.00) 0.080 - -  
rs7421372 A 0.0009 (-0.0019, 0.0038) 0.610 1.13 (1.00, 1.27) 0.057 1.04 (1.00, 1.07) 0.031 - 0.035  
rs7561518 G 0.0005 (-0.0020, 0.0030) 0.750 1.03 (0.90, 1.17) 0.664 0.97 (0.94, 1.01) 0.090 - -  
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rs7582260 C -0.0028 (-0.0058, 0.0002) 0.591 0.95 (0.84, 1.07) 0.400 0.98 (0.95, 1.01) 0.192 - -  
rs7588942 T -0.0012 (-0.0036, 0.0012) 0.020 0.94 (0.83, 1.06) 0.328 1.03 (1.00, 1.07) 0.074 - -  
rs7592630 G 0.0010 (-0.0014, 0.0033) 0.303 1.04 (0.92, 1.18) 0.519 0.98 (0.95, 1.02) 0.316 - -  
rs891878 T -0.0030 (-0.0057, -0.0003) 0.635 0.99 (0.88, 1.11) 0.844 1.02 (0.99, 1.06) 0.154 - -  
Gene;  NRF1 
rs10239118 T -0.0003 (-0.0052, 0.0045) 0.255 0.98 (0.85, 1.12) 0.768 1.02 (0.98, 1.06) 0.259 - -  
rs10245818 G 0.0001 (-0.0023, 0.0025) 0.390 1.05 (0.89, 1.23) 0.580 1.02 (0.98, 1.07) 0.283 - -  
rs12706898 G 0.0014 (-0.0009, 0.0038) 0.296 0.97 (0.86, 1.10) 0.644 1.02 (0.99, 1.05) 0.274 - -  
rs1882094 G 0.0023 (-19.6000, 0.0046) 0.564 1.05 (0.91, 1.20) 0.525 1.02 (0.98, 1.06) 0.323 - -  
rs1984823 C -0.0004 (-0.0035, 0.0027) 0.288 1.02 (0.90, 1.15) 0.788 0.98 (0.94, 1.01) 0.155 - -  
rs2402968 T 0.0005 (-0.0019, 0.0029) 0.302 0.90 (0.71, 1.13) 0.354 0.98 (0.92, 1.05) 0.575 - -  
rs2402976 G 0.0016 (-0.0006, 0.0037) 0.953 0.96 (0.85, 1.08) 0.492 1.03 (0.99, 1.06) 0.118 - -  
rs3736626 C 0.0014 (-0.0008, 0.0036) 0.158 1.04 (0.92, 1.18) 0.522 0.97 (0.94, 1.01) 0.091 - -  
rs4469397 T -0.0005 (-0.0027, 0.0018) 0.790 0.98 (0.84, 1.15) 0.821 0.97 (0.93, 1.01) 0.163 - -  
rs6467259 T -0.0020 (-0.0052, 0.0012) 0.796 0.92 (0.80, 1.05) 0.196 1.02 (0.98, 1.06) 0.292 - -  
rs6949152 G -0.0024 (-0.0115, 0.0068) 0.040 1.05 (0.88, 1.24) 0.622 1.00 (0.95, 1.04) 0.873 - -  
rs6969441 G -0.0007 (-0.0033, 0.0018) 0.354 1.08 (0.94, 1.23) 0.266 1.02 (0.98, 1.05) 0.369 - -  
rs7796553 C 0.0007 (-0.0016, 0.0030) 0.343 1.06 (0.90, 1.25) 0.470 1.02 (0.98, 1.07) 0.313 - -  
rs9656383 A 0.0008 (-0.0014, 0.0031) 0.333 1.04 (0.91, 1.19) 0.583 1.01 (0.98, 1.05) 0.441 - -  
Gene;  POLG 
rs2307441 C 0.0006 (-0.0018, 0.0029) 0.259 0.74 (0.55, 1.00) 0.051 0.93 (0.84, 1.02) 0.105 - -  
rs2307449 G 0.0007 (-0.0017, 0.0032) 0.602 0.99 (0.87, 1.12) 0.880 0.99 (0.96, 1.03) 0.724 - -  
rs3087374 A -0.0012 (-0.0034, 0.0010) 0.990 0.94 (0.75, 1.17) 0.553 1.03 (0.97, 1.09) 0.404 - -  
rs41549716 C 0.0011 (-0.0012, 0.0034) 0.893 1.44 (0.79, 2.60) 0.231 0.94 (0.79, 1.12) 0.473 - -  
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Gene;  POLG2 
rs1427463 T 0.0010 (-0.0014, 0.0033) 0.419 1.08 (0.87, 1.34) 0.462 1.04 (0.98, 1.10) 0.194 - -  
rs17850455 G 0.0008 (-0.0014, 0.0031) 0.614 1.32 (0.79, 2.19) 0.284 0.98 (0.82, 1.18) 0.851 - -  
rs6504231 





rs10512513 T -0.0012 (-0.0035, 0.0011) 0.434 1.01 (0.89, 1.14) 0.865 0.96 (0.93, 1.00) 0.033 - 0.035  
rs11079662 G -0.0006 (-0.0028, 0.0016) 0.978 0.93 (0.79, 1.10) 0.376 0.99 (0.95, 1.04) 0.765 - -  
rs11079667 A 0.0032 (-0.0023, 0.0087) 0.300 1.06 (0.93, 1.19) 0.398 0.97 (0.94, 1.00) 0.060 - -  
rs11654719 C 0.0004 (-0.0020, 0.0028) 0.349 1.06 (0.93, 1.20) 0.405 0.97 (0.93, 1.00) 0.059 - -  
rs11654719 C 0.0012 (-0.0011, 0.0036) 0.349 1.06 (0.93, 1.20) 0.405 0.97 (0.93, 1.00) 0.059 - -  
rs11869821 T 0.0023 (-0.0020, 0.0066) 0.052 0.84 (0.71, 1.01) 0.059 1.00 (0.95, 1.05) 0.911 - -  
rs12450534 A 0.0001 (-0.0021, 0.0023) 0.373 1.00 (0.87, 1.16) 0.957 0.95 (0.92, 0.99) 0.018 - 0.035  
rs12451026 T 0.0022 (-0.0003, 0.0047) 0.210 0.97 (0.85, 1.11) 0.645 1.06 (1.02, 1.10) 0.003 - 0.016  
rs12938937 T -31.4000 (-0.0041, 0.0040) 0.065 1.12 (0.97, 1.29) 0.118 0.99 (0.95, 1.03) 0.632 - -  
rs16960228 A 0.0002 (-0.0020, 0.0024) 0.890 1.16 (0.88, 1.52) 0.293 1.06 (0.98, 1.14) 0.153 - -  
rs17771145 A 0.0009 (-0.0015, 0.0032) 0.221 0.83 (0.69, 0.98) 0.032 0.99 (0.95, 1.04) 0.787 - 0.035  
rs1806448 G -0.0016 (-0.0039, 0.0006) 0.565 0.90 (0.78, 1.03) 0.118 1.01 (0.98, 1.05) 0.491 - -  
rs2024321 G 0.0006 (-0.0038, 0.0050) 0.340 0.98 (0.86, 1.12) 0.771 0.99 (0.96, 1.03) 0.679 - -  
rs227913 C 0.0006 (-0.0034, 0.0045) 0.326 1.11 (0.97, 1.26) 0.128 1.02 (0.99, 1.06) 0.181 - -  
rs228882 G -0.0008 (-0.0057, 0.0040) 0.597 0.93 (0.82, 1.05) 0.258 1.00 (0.97, 1.03) 0.922 - -  
rs3848423 A 9.95×10-6 (-0.0023, 0.0023) 0.739 1.17 (0.89, 1.55) 0.266 0.92 (0.85, 0.99) 0.033 - 0.035  
rs3889237 T -0.0002 (-0.0025, 0.0020) 0.797 0.96 (0.85, 1.09) 0.556 1.00 (0.96, 1.03) 0.877 - -  
rs4082896 G 0.0001 (-0.0024, 0.0026) 0.843 0.98 (0.86, 1.11) 0.737 0.97 (0.94, 1.01) 0.145 - -  
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rs4144640 G -0.0007 (-0.0112, 0.0098) 0.944 0.97 (0.84, 1.11) 0.631 1.00 (0.96, 1.03) 0.795 - -  
rs4417581 T 0.0004 (-0.0023, 0.0031) 0.919 0.95 (0.79, 1.15) 0.596 0.99 (0.94, 1.04) 0.742 - -  
rs4465636 G -0.0012 (-0.0034, 0.0010) 0.877 1.08 (0.93, 1.26) 0.325 1.01 (0.96, 1.05) 0.822 - -  
rs4528612 A 0.0015 (-0.0009, 0.0039) 0.404 1.04 (0.90, 1.21) 0.571 0.99 (0.95, 1.03) 0.670 - -  
rs4536508 G 0.0002 (-0.0032, 0.0036) 0.656 1.02 (0.86, 1.21) 0.803 0.99 (0.95, 1.04) 0.712 - -  
rs4791072 T -0.0002 (-0.0029, 0.0025) 0.695 0.99 (0.87, 1.13) 0.906 1.00 (0.97, 1.04) 0.959 - -  
rs6504452 A 0.0004 (-0.0025, 0.0033) 0.151 1.06 (0.93, 1.21) 0.350 0.98 (0.95, 1.02) 0.287 - -  
rs6504459 G 0.0006 (-0.0016, 0.0029) 0.023 1.94 (1.31, 2.87) 0.001 1.04 (0.94, 1.14) 0.424 0.016 -  
rs7207499 A -0.0011 (-0.0038, 0.0015) 0.334 0.96 (0.83, 1.11) 0.561 0.99 (0.95, 1.03) 0.558 - -  
rs7210818 C 0.0007 (-0.0024, 0.0038) 0.895 1.02 (0.90, 1.15) 0.760 0.98 (0.95, 1.01) 0.242 - -  
rs721429 A 0.0031 (-0.0012, 0.0073) 0.289 0.88 (0.78, 1.00) 0.042 1.00 (0.97, 1.03) 0.979 - -  
rs7216852 A 0.0039 (0.0006, 0.0071) 0.546 0.91 (0.78, 1.06) 0.210 0.98 (0.94, 1.03) 0.431 - -  
rs7220007 A 0.0012 (-0.0010, 0.0034) 0.910 1.06 (0.93, 1.19) 0.381 1.01 (0.97, 1.04) 0.734 - -  
rs7221968 C -0.0005 (-0.0028, 0.0019) 0.124 0.92 (0.76, 1.11) 0.380 0.99 (0.94, 1.04) 0.674 - -  
rs7224533 C -0.0004 (-0.0028, 0.0021) 0.100 0.98 (0.85, 1.12) 0.720 0.99 (0.95, 1.02) 0.457 - -  
rs7225452 C 0.0012 (-0.0010, 0.0034) 0.461 0.95 (0.84, 1.08) 0.445 0.98 (0.95, 1.02) 0.321 - -  
rs8069696 A -0.0008 (-0.0031, 0.0016) 0.006 0.84 (0.72, 0.97) 0.021 1.00 (0.96, 1.05) 0.940 0.035 -  
rs8070293 T -0.0022 (-0.0049, 0.0005) 0.832 0.89 (0.76, 1.03) 0.109 0.99 (0.95, 1.03) 0.602 - -  
rs8070561 A 0.0003 (-0.0021, 0.0028) 0.345 0.97 (0.86, 1.10) 0.650 1.01 (0.97, 1.04) 0.621 - -  
rs8071862 T 0.0004 (-0.0023, 0.0031) 0.790 0.96 (0.85, 1.09) 0.547 0.99 (0.96, 1.03) 0.726 - -  
rs8072920 G 0.0023 (-0.0041, 0.0087) 0.062 1.22 (1.07, 1.38) 0.002 1.02 (0.98, 1.05) 0.375 0.016 -  
rs8074995 A 0.0017 (-0.0006, 0.0041) 0.743 0.98 (0.83, 1.17) 0.846 0.98 (0.94, 1.03) 0.412 - -  
rs8078231 T 0.0076 (0.0011, 0.0142) 0.316 1.05 (0.91, 1.22) 0.484 0.96 (0.92, 1.00) 0.031 - 0.035  
rs8081512 A -0.0005 (-0.0035, 0.0025) 0.387 1.12 (0.99, 1.27) 0.072 1.01 (0.98, 1.04) 0.617 - -  
rs877447 T -47.6000 (-0.0025, 0.0024) 0.659 1.15 (1.01, 1.29) 0.031 1.01 (0.97, 1.04) 0.691 - -  
rs956952 A -0.0014 (-0.0043, 0.0015) 0.295 0.98 (0.83, 1.17) 0.841 0.97 (0.93, 1.02) 0.273 - -  
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rs9635753 T 0.0007 (-0.0015, 0.0030) 0.875 1.02 (0.90, 1.15) 0.756 0.97 (0.94, 1.00) 0.051 - -  
rs973752 C 0.0011 (-0.0015, 0.0036) 0.487 0.96 (0.77, 1.18) 0.676 0.99 (0.93, 1.05) 0.703 - -  
rs9890506 T -0.0004 (-0.0029, 0.0021) 0.762 0.98 (0.79, 1.21) 0.835 1.02 (0.96, 1.08) 0.511 - -  
rs9890911 T -0.0014 (-0.0037, 0.0009) 0.270 1.05 (0.93, 1.19) 0.403 1.01 (0.98, 1.05) 0.493 - -  
rs9893560 C 0.0033 (0.0002, 0.0064) 0.785 0.98 (0.80, 1.19) 0.805 0.99 (0.93, 1.04) 0.638 - -  
rs9896191 G 0.0011 (-0.0013, 0.0035) 0.523 0.87 (0.73, 1.03) 0.096 0.99 (0.95, 1.04) 0.669 - -  
rs9896282 A -0.0013 (-0.0040, 0.0014) 0.053 1.15 (1.01, 1.30) 0.033 1.00 (0.97, 1.04) 0.947 0.035 -  
rs9897537 T -0.0001 (-0.0024, 0.0021) 0.018 1.11 (0.97, 1.26) 0.134 1.00 (0.96, 1.03) 0.852 - -  
rs9902960 T 0.0009 (-0.0019, 0.0037) 0.044 0.94 (0.83, 1.06) 0.293 1.01 (0.98, 1.05) 0.475 - -  
rs9911259 C 0.0001 (-0.0021, 0.0023) 0.041 1.12 (0.99, 1.27) 0.063 1.00 (0.96, 1.03) 0.859 - -  
rs9912154 T 0.0027 (-0.0008, 0.0062) 0.390 0.99 (0.80, 1.22) 0.910 0.96 (0.91, 1.02) 0.221 - -  
Gene; TFAM 
rs1049432 T 0.0009 (-0.0015, 0.0032) 0.669 0.89 (0.75, 1.04) 0.141 0.99 (0.95, 1.03) 0.560 - -  
rs10826179 G -0.0006 (-0.0028, 0.0016) 0.614 0.90 (0.80, 1.02) 0.092 0.99 (0.95, 1.02) 0.426 
- -  
Gene;  TFB1M 
rs1014664 C -0.0002 (-0.0028, 0.0024) 0.213 0.93 (0.71, 1.22) 0.588 0.95 (0.88, 1.03) 0.242 - -  
rs1555774 T 0.0004 (-0.0020, 0.0028) 0.690 1.00 (0.87, 1.15) 0.989 1.03 (0.99, 1.07) 0.184 - -  
rs162965 A -0.0006 (-0.0028, 0.0016) 0.313 1.01 (0.88, 1.15) 0.929 0.96 (0.93, 1.00) 0.034 - 0.035  
rs324356 C -0.0006 (-0.0038, 0.0025) 0.846 0.96 (0.85, 1.09) 0.558 1.01 (0.98, 1.04) 0.641 - -  
rs34434986 A -0.0026 (-0.0048, -0.0004) 0.368 1.11 (0.68, 1.81) 0.690 0.98 (0.85, 1.13) 0.771 - -  
rs927718 T 0.0012 (-0.0011, 0.0035) 0.077 1.02 (0.90, 1.15) 0.781 0.98 (0.95, 1.02) 0.320 - -  
rs927718 T -0.0004 (-0.0035, 0.0027) 0.077 1.02 (0.90, 1.15) 0.781 0.98 (0.95, 1.02) 0.321 - -  
rs9383750 T 0.0005 (-0.0023, 0.0033) 0.466 1.02 (0.90, 1.15) 0.788 1.04 (1.00, 1.08) 0.028 - 0.035  
rs9384310 A -0.0010 (-0.0032, 0.0012) 0.128 0.97 (0.83, 1.13) 0.656 1.04 (1.00, 1.08) 0.086 - -  
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rs950994 A 0.0010 (-0.0012, 0.0032) 0.450 0.99 (0.87, 1.13) 0.877 1.04 (1.00, 1.08) 0.035 - 0.035  
rs12076987 T 0.0024 (-0.0004, 0.0051) 0.597 1.02 (0.89, 1.18) 0.778 1.02 (0.98, 1.06) 0.256 - -  
rs3129567 G 0.0008 (-0.0017, 0.0033) 0.645 0.98 (0.86, 1.13) 0.822 1.00 (0.96, 1.04) 0.890 - -  
rs4654291 T -0.0001 (-0.0024, 0.0022) 0.285 1.00 (0.88, 1.13) 0.967 0.96 (0.93, 1.00) 0.025 - -  
rs7536768 A 0.0004 (-0.0023, 0.0032) 0.875 1.04 (0.90, 1.20) 0.610 1.03 (0.99, 1.07) 0.147 - -  
Gene; THRB 
rs11129141 G -0.0014 (-0.0044, 0.0015) 0.419 1.11 (0.98, 1.26) 0.103 1.00 (0.97, 1.04) 0.937 - -  
rs11714673 A -0.0040 (-0.0068, -0.0011) 0.004 1.01 (0.89, 1.14) 0.872 1.00 (0.97, 1.03) 0.966 - -  
rs12491199 G -0.0003 (-0.0030, 0.0024) 0.715 1.01 (0.86, 1.18) 0.955 0.98 (0.94, 1.03) 0.462 - -  
rs13077437 A -0.0011 (-0.0033, 0.0012) 0.045 1.04 (0.91, 1.18) 0.573 1.01 (0.97, 1.05) 0.615 - -  
rs13097208 T -0.0003 (-0.0025, 0.0019) 0.911 0.91 (0.81, 1.03) 0.135 1.00 (0.96, 1.03) 0.812 - -  
rs13318276 T 0.0021 (-0.0001, 0.0044) 0.722 0.95 (0.81, 1.12) 0.541 1.03 (0.98, 1.07) 0.226 - -  
rs13320945 T -0.0005 (-0.0036, 0.0026) 0.758 0.96 (0.85, 1.09) 0.563 0.99 (0.96, 1.03) 0.745 - -  
rs1466119 T -0.0013 (-0.0039, 0.0013) 0.503 0.91 (0.81, 1.03) 0.150 1.00 (0.97, 1.03) 0.931 - -  
rs1505296 A -0.0004 (-0.0026, 0.0018) 0.526 0.91 (0.78, 1.07) 0.253 0.97 (0.93, 1.01) 0.132 - -  
rs1562737 G 0.0010 (-0.0012, 0.0032) 0.069 0.96 (0.81, 1.13) 0.632 0.99 (0.95, 1.04) 0.788 - -  
rs1667745 T 0.0011 (-0.0012, 0.0035) 0.744 1.05 (0.91, 1.20) 0.526 1.01 (0.98, 1.05) 0.467 - -  
rs1667765 C -0.0002 (-0.0024, 0.0021) 0.031 0.90 (0.78, 1.05) 0.186 1.01 (0.97, 1.06) 0.581 - -  
rs17014257 C 0.0011 (-0.0018, 0.0040) 0.241 1.02 (0.89, 1.16) 0.793 1.00 (0.96, 1.03) 0.904 - -  
rs1705734 A 0.0012 (-0.0014, 0.0038) 0.164 1.09 (0.96, 1.23) 0.181 1.01 (0.97, 1.04) 0.684 - -  
rs1857793 G -0.0003 (-0.0025, 0.0020) 0.558 0.93 (0.82, 1.05) 0.231 1.00 (0.97, 1.04) 0.992 - -  
rs1868573 T 0.0005 (-0.0017, 0.0027) 0.642 0.98 (0.86, 1.11) 0.736 1.00 (0.97, 1.04) 0.899 - -  
rs2167115 G -0.0005 (-0.0027, 0.0016) 0.468 0.98 (0.86, 1.11) 0.723 0.98 (0.95, 1.02) 0.361 - -  
rs2360957 A 0.0005 (-0.0034, 0.0045) 0.758 1.05 (0.92, 1.19) 0.475 1.02 (0.98, 1.05) 0.359 - -  
rs2362185 G -0.0021 (-0.0043, 0.0002) 0.310 0.90 (0.79, 1.02) 0.108 1.00 (0.97, 1.04) 0.888 - -  
rs2683529 G -0.0021 (-0.0043, 0.0002) 0.082 1.00 (0.87, 1.15) 0.996 1.01 (0.97, 1.04) 0.811 - -  
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rs4563353 A -0.0009 (-0.0031, 0.0014) 0.157 1.07 (0.84, 1.35) 0.597 0.98 (0.92, 1.04) 0.514 - -  
rs4858604 G 0.0022 (-0.0006, 0.0050) 0.519 1.02 (0.89, 1.16) 0.822 1.01 (0.97, 1.04) 0.719 - -  
rs6550858 G -0.0009 (-0.0032, 0.0014) 0.233 0.99 (0.86, 1.14) 0.912 0.98 (0.94, 1.02) 0.250 - -  
rs6781111 C 0.0016 (-0.0014, 0.0047) 0.754 1.01 (0.88, 1.16) 0.863 0.97 (0.94, 1.01) 0.165 - -  
rs6797693 G -0.0002 (-0.0024, 0.0020) 0.227 0.90 (0.79, 1.02) 0.086 0.98 (0.95, 1.02) 0.371 - -  
rs7610039 T 0.0014 (-0.0025, 0.0052) 0.387 1.00 (0.89, 1.13) 0.960 1.01 (0.98, 1.05) 0.481 - -  
rs7619754 G 0.0010 (-0.0018, 0.0038) 0.375 1.12 (0.99, 1.26) 0.073 1.00 (0.97, 1.03) 0.991 - -  
rs7626512 C 0.0028 (-0.0006, 0.0062) 0.088 1.07 (0.92, 1.24) 0.386 1.02 (0.97, 1.06) 0.494 - -  
rs7649511 T 0.0017 (-0.0009, 0.0042) 0.548 0.96 (0.84, 1.10) 0.559 0.98 (0.95, 1.02) 0.389 - -  
rs7652337 C 0.0008 (-0.0014, 0.0031) 0.948 1.08 (0.95, 1.23) 0.217 1.01 (0.97, 1.04) 0.689 - -  
rs7652347 T -0.0009 (-0.0031, 0.0014) 0.766 0.92 (0.79, 1.07) 0.256 1.01 (0.97, 1.05) 0.740 - -  
rs826216 A 0.0018 (-0.0086, 0.0122) 0.345 0.98 (0.86, 1.12) 0.754 1.01 (0.97, 1.05) 0.601 - -  
rs826217 C -0.0005 (-0.0028, 0.0018) 0.875 1.07 (0.94, 1.21) 0.295 1.00 (0.97, 1.04) 0.826 - -  
rs826223 G -0.0009 (-0.0031, 0.0013) 0.908 1.05 (0.86, 1.27) 0.651 0.99 (0.94, 1.04) 0.693 - -  
rs826253 C -0.0002 (-0.0025, 0.0021) 0.450 1.04 (0.88, 1.21) 0.659 0.98 (0.94, 1.03) 0.470 - -  
rs844103 T 0.0006 (-0.0034, 0.0046) 0.360 0.97 (0.84, 1.12) 0.678 1.00 (0.96, 1.04) 0.966 - -  
rs851719 G -0.0013 (-0.0035, 0.0010) 0.818 1.09 (0.96, 1.23) 0.197 1.01 (0.98, 1.05) 0.456 - -  
rs9310736 A 0.0005 (-0.0031, 0.0041) 0.748 1.03 (0.90, 1.17) 0.708 1.01 (0.98, 1.05) 0.469 - -  
rs9310736 A -0.0010 (-0.0041, 0.0021) 0.759 1.03 (0.90, 1.17) 0.706 1.01 (0.98, 1.05) 0.469 - -  
rs9809320 C 0.0022 (-29.2000, 0.0045) 0.474 0.96 (0.82, 1.12) 0.607 1.02 (0.97, 1.06) 0.467 - -  
rs9812189 G 0.0028 (0.0005, 0.0052) 0.109 1.10 (0.91, 1.33) 0.326 1.02 (0.97, 1.07) 0.527 - -  
rs9830674 T -0.0010 (-0.0049, 0.0028) 0.199 1.04 (0.90, 1.20) 0.586 0.99 (0.95, 1.03) 0.646 - -  
rs9831450 G -0.0023 (-0.0046, -0.0001) 0.468 0.91 (0.80, 1.03) 0.139 1.01 (0.98, 1.05) 0.571 - -  
rs9840296 G 0.0023 (0.0001, 0.0045) 0.434 0.96 (0.85, 1.08) 0.497 1.01 (0.97, 1.04) 0.782 - -  
rs9843159 A -0.0016 (-0.0054, 0.0021) 0.733 1.35 (0.74, 2.47) 0.334 1.11 (0.95, 1.30) 0.171 - -  
rs9850879 A -0.0012 (-0.0035, 0.0010) 0.668 1.01 (0.89, 1.15) 0.873 1.01 (0.97, 1.04) 0.743 - -  
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rs9852824 T -0.0009 (-0.0031, 0.0013) 0.439 1.11 (0.98, 1.25) 0.107 0.99 (0.96, 1.02) 0.485 - -  
rs9854304 A -0.0002 (-0.0025, 0.0021) 0.876 0.85 (0.75, 0.97) 0.013 1.02 (0.98, 1.05) 0.399 0.035 -  
 
Pc: corrected p-value for multiple testing through the FDR method, SNP: single nucleotide polymorphism; BP: base position; CI (95%): confidence interval at 95% L95: lower 
confidence interval; U95: upper confidence interval. Notably, all of the information has been extracted from mtDNA copy numberGWAS and gout association analysis in 
European (sourced from CoreExome chipped data) and UK Biobank gout GWAS; Bold text is showing genetic variants in PRKCA gene significantly associated with increased 
mtDNA copy numberalso associated with gout in Europeans. ABHD8: Abhydrolase Domain Containing 8; MRPL37: Mitochondrial Ribosomal Protein 37; MED24: Mediator 
Complex Subunit 24; FOXA3: Forhead Box A3; MYT1L: Myelin Transcription Factor 1 Like; NRF1: Nuclear Respiratory Factor 1; POLG: DNA Polymerase Gamma Catalytic 
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4.5. Discussion 
It is established that mitochondria execute vital functions in eukaryotic cells, such as 
generation of ATP via oxidative phosphorylation, apoptosis, regulation of calcium uptake and 
metabolism of essential nutrients based on interaction between mitochondrial and nuclear 
genomes. While mitochondria harbour 37 genes in their own genome, they are dependent on 
>1,000 genes encoded by the nuclear genome for their function. In addition, the whole 
mitochondrial genome exists at a variable copy number in the cell and this relative copy number 
of mtDNA may reflect differing numbers of mitochondria in different cell populations, which 
may have differing energy requirements (Dickinson et al. 2013, Moyes et al. 1998, Xing et al. 
2008). Thus, variations within the mitochondrial genome (including copy number variations) 
as well as the nuclear genome may influence mitochondrial functionality and lead to 
inflammatory conditions such as gout. Previously, mitochondrial variations have been 
implicated in metabolic and inflammatory disorders (Fuku et al. 2007, Poulton et al. 2002, 
Sobenin et al. 2013), thus it may possibly be involved in developing gout inflammation. In the 
context of gout, a recent study indicated an increased mtDNA copy number conferring 
protection from gout risk in NZ Polynesian individuals, however, the study was unable to 
determine a cause-effect relationship between mitochondrial variations and gout risk (Gosling 
et al. 2018). Therefore, this study aimed to investigate a cause-effect relationship between 
mitochondrial variation and gout by performing a mtDNA copy number GWAS (taking SNPs 
as an explanatory variable and mtDNA copy number as a response) in Polynesian and European 
populations (data were extracted from Illumina CoreExome chip databases) and MWAS in 
Polynesians only with a subsequent gout association analysis in the same cohorts. 
 
4.5.1. Mitochondrial DNA (mtDNA) Copy Number GWAS in Gout; 
Indicating the Potential Interaction of the Nuclear Genome with the 
Mitochondrial Genome Via Controlling mtDNA Copy Number 
Since it is known that communication and interaction between the nuclear and 
mitochondrial genomes is indispensable for normal cell functioning it is reasonable to look for 
a relationship between SNPs in the nucleus and mitochondrial copy number that may associate 
with clinical conditions. Therefore, a mtDNA copy number GWAS was performed to identify 
whether nuclear genetic variants associated with CN also associated with gout. Earlier studies 
evidenced several nuclear genes influencing the regulation of mtDNA copy number including 
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POLG, POLG2, TFB1M, TFB2M, NRF-1, NRF-2, mtDNA replication regulator TFAM, PGC-
1α, MED24 and ABHD8 (Alvarez et al. 2008, Belin et al. 2007, Bornstein et al. 2008, N Cai et 
al. 2015, Carling et al. 2011, Chiaratti et al. 2011, YS Choi et al. 2006, Curran et al. 2007, 
Guyatt et al. 2019, Harvey et al. 2011, Oskoui et al. 2006, Spinazzola et al. 2009, Tyynismaa 
et al. 2009). 
In the current study, all of these loci were also tested for their association with mtDNA 
copy number in Europeans (because all of the previous mtDNA copy number GWAS were 
performed in European populations) with a subsequent gout association analysis in the same 
cohort by a look up in the UK Biobank gout GWAS database (details can be found in the method 
section in Chapter 2). None of them produced convincing results with only a few variants in 
MYT1L, NRF1, PRKCA and THRB exhibited a nominally significant association with the 
mtDNA copy number (Table 4.11). 
Like these previous studies, my study identified a nuclear variant (a missense variant 
rs149132393 in a nuclear gene FCRL6) as a top hit in the EP mtDNA copy number GWAS (ß 
= 0.04, P = 2.09x10-7 close to experiment-wide significant level). This variant also trended in 
the same direction in the WP group (ß = 0.41, P = 0.007), and protected from gout at a nominally 
significant level but only in a WP sample set using HU controls (OR = 0.20, P =0.004). It is 
likely to be a genuine signal because all possible statistical ways were adopted to test whether 
this is a true signal or not. For example, the analysis was adjusted for PCs to adjust for 
population structure and the other set of PCs (1-10) to account for batch effects (PCs1-10). In 
addition, this finding is consistent with the recent finding where reduced mtDNA copy number 
appeared to contribute to gout risk among Polynesians (Gosling et al. 2018) and further 
indicates that alteration in mtDNA copy number could act as a biomarker to determine gout. 
It is important to note that the allele frequency of the rs149132393 variant in FCRL6 is 
low (EP cases ~2%, EP controls 1%, WP cases 1%, WP controls ~2%). Given the inconsistent 
effect with relation to gout risk between Polynesian populations, replication in a larger cohort 
of Polynesians would provide more surety as to whether this is a true association. 
Mitochondrial variants were associated with mtDNA copy number in the European cohort 
(Table 4.4). The mitochondrial encoded variant rs2854128 A-allele contributed to an increased 
risk of gout, but only in the EP group (OR = 2.16, P = 0.043), though its allele frequency was 
low (MAF ~0.03). This is because the A-allele of this variant is not present among the 
mitochondrial lineages endemic to the Pacific – the variant defines the European mitochondrial 
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macrohaplogroup H, which was not present in the Pacific prior to European contact, thus this 
variant’s presence in people of Māori and Pacific ancestry has been via recent admixture with 
Europeans who colonised the region. The variable effect of the mitochondrial variant in 
different ancestral groups may bring attention towards to the effects of European colonialism, 
and might suggest that there is some degree of mitochondrial-nuclear incompatibility which is 
contributing to risk of disease (Zaidi and Makova 2019). 
If this is a genuine signal, it is interesting to note that the variant (rs2854128) lies within 
a mitochondrial ribosomal RNA encoded by the MT-RNR2 gene, and also a small recently 
identified mitochondrial polypeptide named humanin. Therefore, the variant may be having a 
direct functional effect – humanin has been found to have neuroprotective and cytoprotective 
effects against stroke, Alzheimer’s and Huntington disease models (Hashimoto et al. 2001, 
Kariya et al. 2005, XS Xu et al. 2006). Beyond a possible neuroprotective effect humanin has 
also been shown to improve pancreatic beta cell function by increasing insulin sensitivity in the 
body which may help protect from type 2 diabetes (Muzumdar et al. 2009). In a recent study 
the rs2854128 variant was identified associated with a decrease in humanin levels in older 
adults (Yen et al., 2018). It was suggested that this SNP was associated with accelerating 
cognitive aging. Given that gout is an age-related disorder the contribution of the humanin 
variant in accelerating cognitive aging supports its potential effect in gout pathogenesis. Given 
the involvement of humanin in maintaining metabolic and other conditions, it is reasonable to 
suggest that any variation in the humanin-encoded gene might alter its function and induce 
anomalies. If so, then by disruption of insulin production it may contribute to development of 
T2D, which is a comorbidity of gout, so in this way such variation in MT-RNR2 may also lead 
to susceptibility to gout. The other possible way by which alteration in humanin function could 
develop gout (via affecting mitochondrial CN) is the induction of oxidative stress. Oxidative 
stress is one of the major factors that cause mitochondrial dysfunction by affecting 
mitochondrial biogenesis (transcription and replication). Since humanin protects against 
oxidative stress (Bachar et al. 2010) then altered humanin may contribute to oxidative stress 
and cells under oxidative stress may have a high replication of mitochondria, which may reflect 
an increased mitochondrial copy number. 
It is also notable that mitochondrial variants, which were associated with the mtDNA 
copy number in Europeans, did not evidence association with gout in the European population. 
This is consistent with the finding of association analysis conducted between the mtDNA copy 
number and gout in Polynesian and European cohorts (detailed in Result Section 4.4.1), where 
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no evidence of association was found between the mtDNA copy number and gout in the 
European population. This also supports the hypothesis that mitochondrial copy number may 
not affect gout directly but rather be related to confounding factors that may contribute to the 
development of gout particularly in European people. The finding is also supported by a 
previous finding reported by Gosling et al., (2018), in which mtDNA copy number was 
negatively associated with gout in the Polynesian sample set (Gosling et al. 2018). 
 
4.5.2. Gout Association Analysis for Selected mtDNA Copy Number 
GWAS Hits 
After running the mtDNA copy number GWAS a subsequent analysis was conducted in 
the study cohorts (EP, WP and European) to test whether nuclear genetic variants (top hits) that 
associated with mtDNA copy number also associated with gout. For this purpose, a logistic 
regression model was used by adjusting with confounders (detailed in the methodology section) 
to test for association with gout. A similar candidate association study followed by a 
mitochondrial GWAS was also described in previous reports. For example, (Workalemahu et 
al. 2017) and (López et al. 2014) published GWAS studies in pregnant women and idiopathic 
thrombophilia patients, respectively, to search for common nuclear variants influencing 
mtDNA levels that were also associated with study phenotypes. In my study I used the same 
approach with gout. Among selected genetic variants from previous mitochondrial copy 
number GWAS only two PRKCA variants (rs8069696 and rs6504459) exhibited a nominally 
significant association with mtDNA copy number and then with gout in European people 
(included from the CoreExome database) even after adjusting p-values by applying the FDR 
method to correct false positives (Pc = 0.035) (Table 4.11). This might suggest a possible role 
of the PRKCA gene in gout pathogenesis through controlling mitochondrial CN in European 
individuals, however this needs to be replicated in separate datasets of European ancestry. 
PRKCA is a protein kinase C alpha type known for its immune-regulatory role in regulation of 
T-lymphocyte associated activation and proliferation (Wilkinson and Nixon 1998). Previously 
it has also been reported as associated with various phenotypes including multiple sclerosis 
(Barton et al. 2004) and interestingly as a shared locus between gout and type 2 diabetes (Lai 
et al. 2012). 
The top hit in the mtDNA GWAS of EP, FCRL6; rs149132393 was not successfully 
replicated in either Polynesian group, but was among top hits (mitochondrial variants) in the 
European GWAS. The rs2854128 A-allele was detected with an increased risk of gout at 
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nominal significant level in the EP sample set (OR = 2.16, P = 0.043) (Table 4.8). While these 
significant associations between mitochondrial variants and gout support causality, functional 
studies (i.e. DNA transfection or gene knock out assays) in this regard will be important. 
Moreover, similar analysis extended in other European gout databases will be a valuable 
addition to support the hypothesis of this chapter. 
To evaluate an inflammatory role of nuclear and mitochondrial variants identified in the 
mtDNA copy number GWAS, an analysis was conducted in each cohort by splitting controls 
into HU against gout cases. Interestingly, an EP hit (FCRL6; rs149132393) was found to protect 
from gout in the WP sample set (T-allele, OR = 0.20, P = 0.004). Moreover, this locus was only 
detected in Polynesian groups thus indicating a population-specific effect. This is also 
considerable because the sample size of HU controls vs gout cases in the EP group can produce 
bias in detecting this significant association between rs149132393 and gout therefore an 
association analysis in a relatively large sample set should be done to confirm whether this is a 
genuine association with gout or not. 
While the current study is a novel attempt to explore a cause-effect relationship between 
mitochondrial CN and gout by doing a mtDNA copy number GWAS with subsequent gout 
association analysis, the outcome is suggestive of extended analysis in large sample sets 
(particularly gout association analysis using HU controls). Moreover, functional analyses using 
gene expression assays in human cell lines and animal models can be useful to determine 
functional consequences of identified missense variants associated with gout. For example, 
isolate PBMCs from the control group and gout patients carrying varaints of interest and then 
stimulate them with MSU crystals to measure the difference in expression of genes/variants.  In 
a murine model, use of viral vectors to express wild type gene versus mutant gene having 
missense variants in a postnatal mouse can readily assess the consequence of variants on the 
protein function 
 
4.5.3. Mitochondrial Wide Association Analysis (MWAS) In 
Polynesian Mitogenomes 
Mitochondrial wide analysis was conducted in a dataset comprised of mitochondrial 
genome sequences of 616 Polynesian (Māori and Pacific) individuals (detail is presented in the 
method section). The MWAS did not evidence convincing results for the association of 
mitochondrial variants with mtDNA copy number. This may be due to the limitation of the 
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study (as discussed in the last section of this chapter) or perhaps because of an indirect 
relationship between mitochondrial variations and alteration in mitochondrial copy number in 
gout pathogenesis. Interestingly, identification of mitochondrial B-haplogroups variations (709, 
5460, 195 and 16189) associated with gout (Table 4.10) suggest a potential involvement of the 
mitochondrial genome in the development of gout. Additionally, an association of 16189C with 
gout (OR = 2.22, P = 0.045) in the present study is supported by a recent Gosling et al. (2018) 
finding where 16189C was associated with heteroplasmy in Polynesian gout individuals. In this 
study heteroplasmic variants were found associated with the risk of gout including 16189C, 
highly correlated (Pearson’s correlation 0.81, P<2.2×10-16) with the heteroplasmic variant 
16183C that was strongly associated with gout risk. The 16189C variant contributes to the poly-
cytosine tract that was also observed between other heteroplasmic variants 16184 and 16193 in 
the Gosling et al. study, which suggests that such extension of the poly-cytosine tract with 
heteroplasmy could be a risk factor for the development of gout. It is also notable that Gosling 
et al, (2018) also analysed the association of mitochondrial copy number with gout and found 
a reduced mitochondrial copy number in people with gout, suggesting the role of 16189 variant 
in gout via controlling the mitochondrial copy number (reduction). However, the current study 
did not find a significant association between 16189 and mtDNA copy number (but with gout), 
which again may indicate an indirect connection of mitochondrial variants with the copy 
number in triggering gout or may result from other artefacts (discussed in the study limitations). 
Another important thing to consider is that ~96% of the 601 individuals for whom whole 
mitochondrial genomes belonged to the B macrohaplogroup. Because these lineages are so 
closely related, it was not possible to test whether common Pacific mitochondrial variants could 
in themselves be contributing to differences in mtDNA copy number– for instance, variants 
such as 16189C, which have been found in other studies of populations with more variable 
mitochondrial DNA to contribute to copy number variation, and to other phenotypes such as 
risk of diabetes (Liou et al. 2007, KS Park et al. 2008). This domination of the B 
macrohaplogroup has in part come through study design, participants sequenced were 
selectively chosen as individuals with higher Polynesian-derived ancestry and avoiding 
individuals who have a higher degree of European admixture. This admixture could be useful 
from the perspective of this study, as it allows interrogation of some of the potential effects of 
common Pacific variants and also to look further into the possibility of mito-nuclear 
incompatibility. Are those who possess Polynesian-derived nuclear DNA and Polynesian-
derived mitochondrial genomes less likely to have reduced mitochondrial DNA and/or higher 
risk of gout? Could common Polynesian mitochondrial variants such as 16189C be contributing 
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to copy number variation and disease risk among Polynesian people? These are questions that 
could potentially be answered with both a larger number of complete mitochondrial sequences, 
and with the inclusion of more admixed individuals. 
It is also important to note the skew in the present data – because both sets of 
mitochondrial sequencing which were merged together for this analysis were not specifically 
designed to interrogate questions surrounding gout susceptibility, the cohort has relatively few 
healthy controls compared to gout cases. This represents a limitation of the current analysis and 
constrained the ability to robustly test for associations with gout. For the exploration of genuine 
mitochondrial SNP associations further sequencing with the addition of more Polynesian 
individuals is required. However, despite these limitations, this is a novel hypothesis in itself. 
By considering if these mtDNA associations are real then these belong to sub-lineages of 
the B macrohaplogroup (in unadjusted association analyses), which is prevalent in Polynesian 
people. This piece of information supports the evidence of association of particular mtDNA 
haplogroups with a disease prevalent in certain populations. Overall, it might suggest a high 
incidence of gout in Polynesian people in addition to metabolic conditions (also comorbidities 
of gout) may be contributed to by mtDNA variations restricted to only the B macrohaplogroup. 
Earlier lines of evidence also support the prevalence of diseases in a particular population 
restricted to certain haplogroups, for example a mtDNA 16189C variant significantly associated 
with T2D (OR = 1.25, P = 0.003) in Asians only, belongs to a B haplogroup (KS Park et al. 
2008). Likewise, a study published by Huerta et al., (2005) found significant association 
between a polymorphism defining the H5 haplogroup mt.4336 T>C:tRNAGln and increased risk 
of Parkinson’s disease in Spanish females (Huerta et al. 2005). In addition, a meta-analysis of 
more than 2500 MS patients and the same number of controls identified a variant m.13708G 
> A in MT-ND5, defining the haplogroup J, significantly increasing the risk of MS (OR = 1.71, 
P = 0.0002) in Europeans (XH Yu et al. 2008). 
Findings of the present study deliver different pieces of information that may be 
significant in understanding the pathological processes in gout. Following are scenarios that 
can be proposed on the basis of current mtDNA copy number GWAS results in EP, WP and 
European populations. 
The study outcome provides evidence of significant interaction of nuclear genes with the 
mitochondrial genome through controlling mtDNA copy number, as a variant localized in a 
nuclear gene FCRL6 associated with an increasing mtDNA copy number (in EP mtDNA 
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GWAS) was found to protect from gout risk in the WP group. The FCR-like6 (FCRL6) protein 
belongs to the classical Fc receptor for IgG family, is localized on human chromosome 1 and 
plays a fundamental role in positive as well as negative immune regulation (Daeron 1997, 
Nimmerjahn and Ravetch 2008). FCRL6 is distinctly expressed on cytotoxic T and natural 
killer (NK) cells and has been identified as a ligand to the major histocompatibility complex 
(MHC-II). The upregulated expression of FCRL6 has been identified in HIV and B cell chronic 
lymphocytic leukaemia patients (Davis 2007, Davis et al. 2001, Schreeder et al. 2010, 
Schreeder et al. 2008, TJ Wilson et al. 2007).  
The other interesting finding of this study is identification of mtDNA variants’ 
association with increased mitochondrial copy number in Europeans exclusively, though a 
variant (rs2854128) was found to increase the risk of gout in EP individuals. This variant is 
encoded by mitochondrial ribosomal gene MT-RNR2 that also encodes humanin polypeptide 
(as described in detail earlier in this section). 
Alteration in mitochondrial copy number may come from incompatibility between 
mtDNA-nDNA (nuclear DNA) or mtDNA damage itself. While the mitochondrial genome 
encodes 13 proteins of oxidative phosphorylation, the rest of the proteins are encoded by the 
nuclear genome (Staubach et al. 2012). These protein units encoded by different genomes must 
be compatible to maintain structure and biochemical functions of mitochondria. Moreover, 
mtDNA replication and transcription and translation are exclusively governed by nDNA-
encoded factors (Woodson and Chory 2008). Therefore, incompatibly between two genomes 
may affect mitochondrial copy number. The nominal association between the 2706C variant 
and gout among the Eastern Polynesian cohort may provide some hints of potential mito-
nuclear incompatibility– this variant is not endemic to the Pacific and was introduced to Pacific 
populations via admixture with colonists from Europe. 
Reduced mitochondrial copy number has been detected in T2D, metabolic syndrome and 
coronary heart diseases, particularly those diseases associated with aging (Carreira et al. 2011, 
CH Huang et al. 2011, HK Lee et al. 1998). An increased mtDNA copy number was associated 
with better health and longevity in elderly people (Mengel-From et al. 2014). T2D and gout are 
often present as comorbidities and may also share some cellular mechanisms. Therefore, there 
is a possibility that nuclear-encoded variant FCRL6; rs149132393 reduces the risk of gout (in 
WP individuals) following the same pathway via controlling mtDNA copy number that has 
been discovered in T2D studies. In the case of mtDNA, which differs from nDNA, it is more 
vulnerable to oxidative stress resulting from ineffective DNA repair mechanism (Croteau et al. 
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1999, Yakes and VanHouten 1997). Increased oxidative stress associated with mtDNA damage 
may contribute to altering mitochondrial copy number, mtDNA-encoded gene expression and 
mitochondrial burden resulting in mitochondrial dysfunction that leads to disease development. 
Furthermore, ROS generation from damaged mtDNA has also been implicated in inducing 
activation of the NLRP3 inflammasome, that is a key regulator in the development of gout 
(detailed in the previous part of this chapter). Interestingly, a missense variant in PPARGC1B 
is associated with gout (W-C Chang et al. 2017) in the Han Chinese population was replicated 
in the current study in the NZ Polynesian group. PPARGC1B encodes protein PGC1β that is a 
co-activator of PPARγ involved in mitochondrial biogenesis, suggesting that mtDNA variants 
associated with increased mtDNA copy numbermay cause gout. 
Mitochondrial dysfunction and gout may be related by the following proposed 
mechanisms based on the basis of the results of current mtDNA copy numberGWAS and 
existing relevant evidence from the literature. 
Increased or reduced mitochondrial biogenesis and mitophagy may influence the mtDNA 
copy number, directly contributing to pathogenesis of disease by causing an increased immune 
response (Malik and Czajka 2013). Impaired mitophagy has been found to have a pro-
inflammatory effect (Nakahira et al. 2011). Moreover, increased ROS production triggered by 
external stimuli in a condition of oxidative stress could lead to enhanced mitochondrial 
biogenesis that results in increased mtDNA copy number. These altered mtDNA levels may 
increase inflammation and could play a pathogenic role in mitochondrial dysfunction associated 
with disease (Malik and Czajka 2013). One study reported that increased release of ROS in 
fibroblast-like synoviocytes was induced by MSU crystals (Zamudio-Cuevas et al. 2016);this 
supports the possibility that enhanced ROS generation, triggered by MSU crystals, may alter 
(increase) mtDNA copy number which may lead to gout.  
There is also other evidence found in the literature that connects mitochondrial 
dysfunction resulting from mitochondrial dysgenesis with gout, where a missense variant in 
PPARGC1B is associated with gout and increased expression of IL1β as a result of MSU-crystal 
stimulated NLRP3 activation. There is a possibility that changes in PPARCGC1B might disrupt 
the mitochondrial biogenesis maintained by PPARγ and AMPK and may lead to gout. 
Altogether it suggests that alteration in mitochondrial CN may contribute to susceptibility to 
gout, perhaps through disrupting mitochondrial biosynthesis (replication) or mitophagy. 
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Immune cells, particularly white blood cell populations immediately respond to pro-
inflammatory cytokine release in the systemic circulation in an inflammatory condition induced 
by external stimuli (such as MSU crystals). White blood cells may increase in size or number, 
corresponding to differences in underlying biochemical processes. Mitochondria, thereby 
mtDNA, vary in amounts in different tissues according to respective energy requirements e.g. 
spermatocytes and oocytes (5 and more than 50,000 mitochondria, respectively) (Reynier et al. 
2001). Similarly, leukocytes contain a different mt/N (mitochondria/Nuclear genome) ratio. 
Some cells such as neutrophils and eosinophils eject their mitochondria into the extracellular 
environment in response to inflammation but remain viable (Brinkmann and Zychlinsky 2007). 
There are also studies that report the difference of mtDNA in peripheral blood cells in an 
inflammatory response; this evidence along with varying numbers of leukocytes may suggest 
potential involvement of immune cells in inflammatory phenotypes. It will also be worthwhile 
to measure the mt/N ratio in leukocytes to find which cells are predominantly involved in the 
inflammation via altering the mitochondrial copy number. A higher ratio of neutrophils to 
lymphocytes has been recorded in gout patients (Kadiyoran et al. 2019): that is unsurprising 
because pro-inflammatory cytokines elicit ingress of neutrophils at the site of a gout attack. 
Although neutrophils possess less mitochondria compared to other leukocyte types (Maianski 
et al. 2004), the increased number of neutrophils may result in less DNA recovered reflecting 
increased mitochondrial CN relative to genomic DNA in gout patients that may support one of 
the current findings where a mtDNA variant (rs2854128) associated with an increased mtDNA 
copy number was associated with increased risk of the gout in the EP group. 
Gout individuals may have altered mitochondrial function influencing mitochondrial CN 
as a result of changed mitochondrial structure. There are compelling papers on the subject of 
alteration in mitochondrial conformation associated with disease pathology. A mononuclear 
cell study in T2D showed decreased mitochondrial mass in association with hyperpolarization 
of mitochondria (Widlansky et al. 2010). Furthermore, structural abnormalities of 
mitochondrial cristae (inner membrane) were observed in patients with carotid atherosclerosis 
(Sobenin et al. 2013). Another functional study documented an increase in mitochondrial mass 
and mtDNA copy numberwhen human lung fibroblast was treated with hydrogen peroxide to 
induce oxidative stress (HC Lee et al. 2002). The previous literature supports the hypothesis 
that altered mtDNA copy number observed in the present gout study may be a consequence of 
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4.6. Conclusion and Future Directions 
While gout is a complex disorder, various integrated mechanisms could contribute to its 
pathogenesis. With the emerging importance of mitochondrial dysfunction in disease 
pathology, currently a mtDNA copy number genome-wide study was designed to identify the 
role of mitochondrial- or nuclear-encoded mitochondrial genetic variations in gout via affecting 
mtDNA copy number. Collectively the study findings along with a previous report (Gosling et 
al. 2018) suggest the potential contribution of mitochondrial dysfunction either controlled by 
nuclear or mitochondrial variants. To disentangle whether alteration in mtDNA copy number 
is a result of disease processes or if it is providing risk itself, further investigation is required 
(i.e. functional analysis or large-scale genetic analysis in separate cohorts (validation cohorts)). 
Regarding functional analyses ex-vivo techniques using human cell lines, tissue culture and 
mammalian models are quite useful to test the functional consequence of non-synonymous 
variants. Such ex-vivo experiments can be performed by isolating peripheral blood 
mononuclear cells from gout patients (carrying a variant of interest) and using a gene expression 
assay to measure the mRNA expression levels of the targeted gene affected by the variant of 
the interest.  The functionality of the sequence variant can also be tested through ex-vivo 
isogenic human models (patients in test-tubes). In this approach cells are genetically engineered 
to accurately model the genetics of the patient population (‘mutant cells’) that comes with 
genetically matched ‘normal cells’ to research disease (gout) biology. The mutant cells can be 
produced via engineered nucleases (zinc finger or transcription-activator-like effector 
nucleases) to generate pluripotent stem cells, by introducing specific mutations. Moreover, 
differences in allele frequencies and effects of identified variants in different ancestral groups 
may provide evidence of population origin and history settlement.  
 
4.7. Study Limitations 
Though this study provides substantial information to illuminate the role of mitochondrial 
genetic variations in gout pathogenesis study limitations should not be ignored.  
 
1) The Human CoreExome Illumina microarray data were exploited to run a GWAS for 
mtDNA copy number and subsequent gout association analysis that was comprised 
of unequal sample size for each study population (i.e. EP = 1,340, WP = 816 and 
Europeans = 4,579). The significant disparity between the size of these datasets may 
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have limited the replication success of variants found as top signals in mtDNA copy 
number GWAS. 
 
2) Multiple testing in GWAS as well as in MWAS based on testing multiple hypotheses in 
a statistical analysis is another limitation. Every statistical analysis produces false 
positive results (significant results occur by chance) also known as type 1 error, rate- 
that is equal to the threshold set for statistical significance (P > 0.05 in the current study). 
However, this error rate is just for 1 statistical test: for running multiple tests the overall 
type 1 error rate is much bigger than 5% (Farcomeni 2008, Walters 2016). Therefore, 
in the current study to address this problem a FDR method was was applied.  
 
3) The MWAS was conducted in a smaller sample size (comprised of 601 Polynesian 
only) as compared to mtDNA copy numberGWAS sample sets. This is a possible 
limitation in identifying only a few mitochondrial genetic variants (73 in number) as 
compared to mtDNA copy numberGWAS using the CoreExome database (~ 343 
mitochondrial variations). In addition, due to the small size dataset, it may have 
overrepresented some false positive associations because of the large number of gout 
cases compared to controls in the analysis. Another important thing to consider is 
that ~96% of the 601 individuals for whom mitochondrial genomes were sequenced 
belonged to the B macrohaplogroup. These lineages are closely related, therefore it 
was not possible to evaluate whether common Polynesian mitochondrial variants 
could in themselves be contributing to differences in mtDNA copy number. 
 
4) It is also important to note the skew in the data used for the MWAS. The original 
mitochondrial sequencing was not designed particularly to interrogate questions 
around gout susceptibility and had relatively few controls . This limitation of the 
study restricts the ability to test associations with gout by comparing frequency in 
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Summary 
The genetic basis of progression from hyperuricaemia to gout is relatively poorly 
understood. While candidate gene studies have detected association of genes encoding 
inflammatory components (particularly influencing NLRP3 inflammasome activation) with 
gout, a substantial portion of inflammation-related genetics still needs to be addressed. 
Moreover, the markedly high prevalence of gout in New Zealand requires more attention in this 
area of research to find better therapeutic solutions. Therefore, the current study is an attempt 
to add information to fill the gap in genetics of progression from hyperuricaemia to gout (Note: 
in each result section a sub-group categorised as hyperuricaemic controls versus gout cases was 
used to detect associations with the gout risk). Through the implementation of research 
methods, it has been made possible to explore associations of genes potentially involved in 
inflammatory pathways leading to gout. 
The first result chapter (Chapter no. 2) of this thesis aimed to explore possible causal 
associations between gout/urate and non-urate loci including CUX2 (rs4766566), CNIH2 
(rs4073582)), NIPAL1 (rs11733284), HIST1H4E (rs11758351), FAM35A (rs7903456), IRGM 
(rs13361189), PPARGC1B (rs45520937), IL23R (rs11465804, rs11209026, rs7517847) and 
SERPINA1 (rs12884390 and rs1243160) with an emphasis on inflammatory loci. These 
variants have previously been associated with a range of inflammatory and auto-inflammatory 
disorders (e.g. rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and 
ulcerative colitis), chronic obstructive pulmonary disorder and emphysema) including gout. 
Until now, no genetic studies have been conducted to find their relationship with gout in New 
Zealand populations. TaqMan genotyping was performed in NZ Polynesian and European gout 
cohorts. Another larger European dataset (UK Biobank) was also exploited to find genetic 
associations of regions of interest (increasing the power of the study) with gout. The current 
study successfully replicated the association of some urate and non-urate loci in an ancestral-
specific manner with gout such as NIPAL1 (ORUKBio = 1.05, PUKBio = 0.014), FAM35A (ORUKBio 
= 0.94, PUKBio = 0.006), CUX2 (ORUKBio = 0.94, PUKBio = 0.006, ORNPH = 1.75, PNPH = 0.006)  
and CNIH2 (ORUKBio = 0.96, PUKBio = 0.024) in NZ Polynesian and Europeans datasets. Among 
these genes CUX2, CNIH2, NIPAL1 and FAM35A were identified as novel loci associated with 
gout risk in recent gout GWAS studies conducted by Matsuo et al. (2016) and Nakayama et al. 
(2017) in the Japanese population (Matsuo et al. 2016, Nakayama et al. 2017). Regarding 
inflammatory loci PPARGC1B in Polynesian (ORmeta= 1.18, Pmeta = 0.021), IL23R (rs7517847; 
ORUKBio = 0.96 , PUKBio = 0.023, ORWP = 1.75 , PWP = 0.034) and SERPINA1 (rs12884390; 
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ORNZEur= 1.14 , P = 0.044 and rs1243160 ORNZEur = 1.31 , P = 0.029) were replicated in 
different ancestral groups. The ancestral-specific effects may represent the difference in genetic 
backgrounds or different LD structure in such populations. It is also notable that individual 
Polynesian datasets had limited power due to small size to detect the effect of variants however 
the UKBiobank was highly powered to detect significant effect of variants.  Therefore to make 
robust conclusions on an ancestral-specific role of genetic variants in gout pathogenesis large 
gout sample sets are required or a population specific GWAS will be beneficial. 
The 3rd Chapter of this thesis was primarily designed to identify inflammatory gout 
causing loci using the in-silico resequencing approach. The main purpose of this section was to 
explore the genetic associations of non-urate, primarily inflammatory loci with gout, 
progression from hyperuricaemia to gout. Whole genome sequencing gout data from European, 
Polynesians and Asian population were exploited to find such variants and the discovery-phase 
revealed several novel population-specific association signals across the study populations 
(allele frequency filter; AF > 0.05 and (AF < 0.01 in Polynesian and AF < 0.0005 in European). 
These association signals were validated and assessed for their association with gout 
susceptibility in NZ Polynesian and European datasets. The T-allele of CACNA1S;rs13374149 
was significantly associated with gout risk in the Polynesian group (ORmeta = 2.52, Pmeta = 
0.002). The Polynesian-specific allele of TAP2 rs2071471 also associated with increased gout 
risk (ORmeta = 0.72, Pmeta = 0.008). However, it is notable that the significant association for 
these two variants were only detected in the EP group, that is an admixed group of European 
ancestry. Therefore, these associations are likely derived by population stratification effect 
(even though the effect was controlled for by adjusting the analysis with 1-10 PCs). To 
determine the real effect for these variants they should be replicated in other Pacific cohorts. 
Two more Polynesian-specific genetic variants IL37 rs1752113534 and ALDH16A1 
rs78635115 were tested for their association with gout susceptibility in NZ Polynesian and 
European cohorts. The rs1752113534 (G-allele) conferred susceptibility to gout in the 
Polynesian sample set using HU controls-gout cases (ORmeta = 1.81, Pmeta = 0.031). It is also 
notable that the dataset comprised of HU controls vs gout cases under each population of the 
current study was low powered, therefore use of a larger dataset with hyperuricaemic 
individuals (a statistically higher-powerd study) will be useful to clarify association at this locus 
with gout. There is also an interesting finding in the context of identification of novel genetic 
variants (2:113676219, 2:113676298 and 2:113676374) in IL37 exon 5 in the Polynesian (EP 
and WP) gout cohort. These variants also had a high frequency in Polynesian individuals 
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(including the above validated rs175211353 variant). There is a possibility that these variants 
may behave in a population-specific manner but for the validation of new variants for their 
contribution in gout pathogenesis particularly in Polynesian, a genetic association analysis will 
be useful in a large Polynesian gout case and control cohort. 
The current study did not evidence association of ALDH16A rs7863511 with gout in 
either NZ Polynesian or European populations. ALDH16A1 is a unique member of the 
aldehyde dehydrogenase (ALDH) superfamily that is present in an enzymatically-inactive form 
and highly expressed in the kidney (Charkoftaki et al. 2017, Vasiliou et al. 2013). Thereby, it 
interacts with other proteins to produce its functional effect e.g. it interacts with GLUT4 
(SLC2A4)— a member of the glucose transporter family to which SLC2A9 also belongs 
(Kerrien et al. 2012, Niu et al. 2010). An interaction analysis was performed between 
ALDH16A1 rs78635115 and SLC2A9 rs6449144 variant (genotypes data were extracted from 
Human CoreExome Illumina database), the analysis showed a significant association with 
increased risk of gout (OR = 1.84, P = 0.004) only in the EP group. The present study provides 
valuable information on a genetic role of population-specific variants that potentially contribute 
in gout pathogenesis and may be causal to the disease. 
Mitochondria execute roles in diverse cellular pathways. As a danger signal damaged 
mitochondrion can induce inflammation in response to stress through NLRP3 inflammasome 
activation, which is central to gout. Previously damaged mitochondria have been implicated in 
inducing NLRP3 inflammasome activation, in particular involvement in colocalization of 
NLRP3 inflammasome components during its assembly (Akira et al. 2013, Misawa et al. 2013, 
R Zhou et al. 2011). In the light of these immunological findings and the reports of association 
of alterations in mitochondrial DNA copy number with diseases (Crispim et al. 2006, HC Lee 
et al. 2005, Poulton et al. 2002, Y. Wang et al. 2006, J Wong et al. 2009), it was hypothesised 
that mitochondrial genetic variations that control copy number can contribute to the 
development of gout. A recent study reported association of reduced mtDNA copy number with 
prevalent gout in New Zealand Māori and Pacific (Polynesian) people (Gosling et al. 
2018).This study did not find association of mtDNA allelic variation with gout thus pointing 
out the importance of finding a cause-effect relationship between mtDNA copy number and 
gout in terms of providing new insight in gout pathogenesis. Thereby, the current study was an 
attempt to explore this cause-effect relationship (between mtDNA copy number and gout) with 
hypotheses a) to test nuclear genetic variants that associate with mtDNA copy number for 
association with gout and b) test mitochondrial genetic variants for their association with 
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mtDNA copy number and with gout. For this purpose, a mtDNA copy number GWAS (genome 
wide association study) and MWAS (mitochondrial wide association study) were conducted in 
NZ Polynesians (EP and WP), European and Polynesian only, respectively with a subsequent 
association analysis with gout (Chapter 4).  
Interestingly, a loss of function variant rs149132393 (T-allele) in a nuclear gene FCRL6 
reaching close to experiment-wide significance level (1.9x10-7) in the EP group was 
significantly associated with increased mtDNA copy number (ß = 0.04, P = 2.09x10-7) and 
reducing the risk of gout in the WP group using HU controls (OR = 0.20, P =0.004). This is 
consistent with the Gosling et al. (2018) report, in which increased copies of mtDNA were 
found to protect against gout risk when using HU controls in Polynesians (EP and WP). 
Notably, a mitochondrial variant 16189 detected as a result of the MWAS was associated with 
gout in Polynesians, has previously been reported associated with copy number and gout in 
Polynesians (Gosling et al. 2018). Finding the same genetic variant (16189) associated with 
gout in a larger Polynesian sample size is very convincing. However, in the present study, there 
was no evidence found for association between mtDNA copy number and 16189. The lack of 
association of 16189 with mtDNA copy number could be a consequence of using a different 
approach (microarray data) to calculate mtDNA copy number compared to the method used in 
the Gosling study. The other possible explanation could be that mitochondrial genetic variation 
may play a part in the development of gout via indirectly influencing mtDNA copy number. To 
disentangle this query analysis of further mitochondrial genomes of Polynesian ancestry will 
be required. 
Another important finding of this study was that no association of mtDNA copy number 
was detected with gout in the European population (ß=-0.16, P=0.66). Moreover, mitochondrial 
top hits in the mtDNA copy numberGWAS in the European population were also not associated 
with gout in the European sample set. This finding supports one of the hypotheses of this 
chapter that mitochondrial copy number may not affect gout directly, rather related to 
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 Appendix 
A.1 Detailed Description of Study Datasets 
A.1.1 New Zealand Gout Case and Control Datasets 
The genetic analyses in this study mainly centre around the NZ gout case-control cohort, 
although non-NZ gout cohort also imparts a considerable weightage to the study (or analysis). 
The New Zealand gout case-control dataset constitutes demographic and clinical information 
that have been obtained from NZ resident European and Polynesian gout patients and healthy 
individuals to investigate both environmental and genetic risk factors for gout and 
hyperuricemia. At present, this dataset is comprised of 2793 European and 2470 Polynesian 
individuals. 
The recruitment of gout cases for NZ cohort was initiated in 2001, initially with two 
regions of NZ; Auckland and Rotorua and latterly extended to other major parts of the country 
including Wellington, Canterbury and Otago. While, the recruitment of control (non-gout) 
subjects was initiated in May 2009 from the above regions. Since then a significant number of 
participants have been sampled, also by including various community groups, workplaces, 
national institutes, and organizations. In 2010, an additional gout sample set was added through 
 
 
lxxiii | Page 
a collaboration with Ngāti Porou Hauora Charitable trust and recruited approximately 466 
samples mainly of Māori ancestry. Ngāti Porou Hauora operates in the tribal territory of rohe, 
located in the East Coast region (Te Tai Rawhiti). These data were used separately or in 
conjunction to the main NZ-gout case-control cohort. 
Participants involved in this study are categorised into four groups according to their self-
reported grandparental ancestry: The New Zealand European cohort- Pākeha, comprised of 
individuals with British/Irish, Dutch, Australian and German ancestry (cases = 1831, controls 
= 962); Eastern Polynesian- consisting of New Zealand Māori, Tahitian and Cook Island Māori 
individuals (cases = 475, controls = 662), Western Polynesian- includes invidividuals with 
Tongan, Samoan, Niuean and Tokelauan ancestry (cases = 416, controls = 337), and a relatively 
small mixed Eastern Western Polynesian group (cases = 33, controls = 75). The Eastern 
Polynesian group was further split into two groups according to Polynesian grandparental 
ancestry levels; Eastern Polynesian with high grandparent ancestry (EPN) and with low 
grandparental ancestry (EPZ). This subdivision was based on existing information on genetic 
heterogeneity among participants and may help to limit  population stratification that could 
influence analysis results. 
Participants gave written consent before any part of the health examination was conducted 
either globally (for all health examinations) or separately for a specific investigation (volunteer 
signed an informed consent document). participants filled out a questionnaire based on their 
socioeconomic status, ancestry, grandparental ancestry, family history, age, sex, medical 
history, certain dietary habits and amount of exercise. The American College of Rheumatology 
(ACR) gout classification criteria (Wallace et al., 1977) was used to ascertain gout cases and 
the individuals who self reported for gout were further assessed by a research nurse and or 
Rheumatologist to fulfil the ACR criteria. The participants with gout were also provided 
detailed information on the severity of diseases in particular gout characteristics such as the 
frequency of gout attacks (acute and chornic), absence or presence of tophi, dietary components 
triggering gout attacks and being on gout medication (e.g. urate lowering drugs diuretics). 
Participants, who completely responded to above questionnaires, were then sampled for blood 
and urine to be sent to the Merriman Laboratory, University of Otago, Dunedin for further 
processing. After receiving samples at the Merriman laboratory, a small proportion of urine and 
serum was sent to the Southern Community Laboratories (SLC;www.sclabs.co.nz) for 
biochemical analysis and the remainder was stored at -80’c for future study. Serum urate levels 
in mmol/L were measured through Roche Cobas 8000 Modular analyser following the  uricase 
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oxidation method ref, while DNA was extracted using chloroform/ethanol extraction protocol 
ref. 
Ethical approval of the study was primarily granted by the Auckland Ethics Committee 
(97/258) and then by the New Zealand Multi-region Ethics Committee (MEC/05/10/130). The 
recruitment of NPH participants was ethically approved by the Northern Y Region Commiittee 
(NTY/07/07/074) and University of Otago Human Ethics Committee (13/117). The continued 
recruitment of the New Zealand gout cohort were also funded by several funding bodies 
including University of Otago, New Zealand Health research Council, Lottery health Research 
New Zealand and Arthritis New Zealand. 
 
A.1.2 Non-New Zealand Gout Dataset 
Additional gout datasets have also been part of the current study analysis. These datasets 
are relatively small cohorts, recruited from different parts of Europe and Australia on the basis 
of Merriman Lab collaborations. The recruitment of Eurogout samples was initiated in 
collaboration with the European Crystal Network (ECN) Eurogout consortium in 2013 and 
included 762 participants who were sampled at different collection centres in several institutes; 
1) Radboud University Medical Centre, The Netherlands, 2) VieCuri Medical Centre, Venlo, 
The Netherlands 3), University of Dresden, Germany, 4) University of Edinburgh, United 
Kingdom, 5) University of Lausanne, Switzerland, 6) Universidad Miguel Hernandez, Alicante, 
Spain, 7) University College Dublin, Dublin, Ireland, 8) Hospital de Cruces, Vizcaya, Spain, 
9) Nottingham University, United Kingdom, 10) University Hospital La Paz, Paseo de la 
Castellana, Maid, Spain, 11) Leiden University Medical Centre, Leiden, The Netherlands. 
Respective ethical committees of these institutes granted the ethical approval for the 
recruitment of study participants and subsequent analysis; those include Ethikkommission, 
Technische Universität Dresden (EK 8012012), Université de Lausanne, Commission 
Cantonale (VD) D'éthique de la Recherche sur l'être Humain, South East Scotland Research 
Ethics Committee (04/S1102/41), Commissie Mensgebonden Onderzoek regio Arnhem— 
Nijmegen and Partners Health Care System Institutional Review Board. Australian samples 
were recruited in collaboration with the Arthritis Genomics Recruitment Initiative in Australia 
(AGRIA) and included 215 individuals. Particpants in this cohort were sampled at respective 
collection centers in Australia; 1) The University of Queensland and Diamantina Institute at the 
University of Queensland, 2) The University of Adelaide, and 3) The University of New South 
Wales, St. Vincent's Hospital. For this study ethical approval was obtained from Research and 
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Ethics Committee, Repatriation General Hospital, South Australia (32/08); Research Ethics 
Committee, University of New South Wales. All subjects in these study cohorts were gout 
cases, clinically ascertained by ACR criteria (Wallace et al., 1977) used against NZ cohort 
controls in the association analysis. 
 
A.1.2.1 The United Kingdom (UK) Biobank Cohort 
The UK Biobank is a large population-based repository, established in the UK in 2007 
(www.ukbiobank.ac.uk/), to investigate the genetic and environmental determinants that 
contribute to the development of wide range of complex disorders such as cancer, dementia, 
diabetes, osteoporosis, arthritis, eye disorders, depression conditions and heart disease. For the 
study approximately 500,000 people participated voluntarily aged between 40-69 years. All of 
these subjects gave written consent for 25 years follow-up examinations, which include data on 
medical history, baseline demographic variables, dietary habits and socio-economic status. The 
ethical approval for the study was granted by the North West Multicare Ethics Research 
committee.  
For the initial recruitment, participants were required to complete questionnaire 
encompassing information on sociodemographic factors; social class, ethnicity, employment, 
marital status, education and income, early life exposures; family history of major diseases, 
maternal smoking, childhood body measurements, psychosocial factors; depression, neurosis, 
environmental factors; housing, domestic heating conditions, means of travel, sun exposure etc. 
The other baseline measurements of participants included height, weight, blood pressure, and 
biochemical analyses were assessed in designated research centers located throughout the UK. 
For the current study the gout case-control genotype and phenotype data were obtained from 
the UK Biobank Resource under the approval number 12611 (Ollier et al., 2005). In the UK 
Biobank a total of 105,128 individuals of European ancestry were genotyped using the 
Affymetrix Axiom array for 820, 967 SNPs.  For the quality control assessment, data of 
participants where self-reported sex mismatched with genetic sex, genotyping quality control 
failures, and hospital diagnosed renal problems (ICD10 I12, I13, N00-N05, N07, N11, N14, 
N17-N19, Q61, N25.0, Z49, Z94.0, Z99.2) were excluded from the UK Biobank study. Further 
to this, genotyping data of about 73.3M markers were imputed using IMPUTE2 and SHAPEIT3 
platforms along UK10K and 1000 Genomes as the collated reference panel.  
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Gout cases for the UK Biobank study did not follow ACR criteria instead were classified 
on the basis of combination of definitions from earlier epidemiological studies (Cadzow et al., 
2017). It is mainly divided into four distinct groups including self-reported– indicated by 
participants having gout at the time of recruitment, hospital diagnosed– categorized patients 
either with primary and secondary gout based on hospital discharge coding for gout (ICD10 
M10 including subcodes), use of urate-lowering Therapy (ULT)– participants reported either 
taking any of the ULT drugs such as febuxostat, sulphinnpyrazone or allopurinol and not 
suffering from leukaemia or lymphoma, the Winnard-defined gout cases– this includes either 
hospital diagnosed gout ptaients or those who were on gout-specific medication (ULT or 
colchicine), described by Winnard et al. (2012). 
 
A.1.3 Core Exome Dataset 
The Core Exome dataset is comprised of NZ Polynesian and European (Eurogout) gout 
cases and control samples, genotyped using the Illumina CoreExome v24 bead chip array. 
Illumina CoreExome v24 bead chip offers high density cost-effective platform for large genetic 
studies, especially large-scale genotyping studies. This chip has been designed to enable 
informative genome-wide genotyping of tag single nucleotide polymorphisms (SNPs) and 
exome focused markers, generates high-quality data and can also be used for various 
downstream applications such as common variants, sex confirmation, loss of variant, 
insertion/deletion detection, mitochondrial DNA (mtDNA) ancestry studies. For the current 
study 547,644 markers (Nonsense, missense and synonymous markers, indels, exonic markers, 
intronic markers, mitochondrial markers) were genotyped across (n= 6735) samples. These data 
are comprised of Eastern Polynesian (EP; n = 1340; cases = 647, controls = 693), West 
Polynesian (WP; n = 816; cases = 445, controls = 371) and European (n = 4579; cases = 3557, 
controls = 1022). For European cohort it includes data from NZ European, European Crystal 
Network Cohort (EUROGOUT), the Arthritis Genomics Recruitment Initiative in Australia 
Cohort (AGRIA) and Ardea Biosciences. 
 
A.2 Expression Quantitative Trait loci (eQTL) Datasets 
A.2.1 The Genotype-Tissue Expression (GTEx) Dataset 
Correlation between genotypes and tissue-specific expression levels strongly facilitates 
the identification of genomic regions underlying altered gene expression. The GTEx project is 
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a large-scale public resource that provides a platform to study human gene expression across 
tissues and its association with genetic variation {GTEx Consortium, 2017 #1585}. The study 
was initiated with a 2.5 years pilot phase to establish and elucidate high-quality DNA and gene 
expression measurements that has been scaled 900 post-mortem donors in 2015. Donors were 
identified through autopsy, tissue transplantation and low post-mortem-interval procedures. 
The genotyping of participants was conducted through Illumina HumanOmni5M-Quad 
Beadchip to assemble whole-genome SNP and copy number variation (CNV) data across 
multiple reference tissues such as adipose, adrenal gland, brain, artery, skin, whole blood. The 
RNA parallel sequencing was used to quantify gene expression, however some tissues were 
analysed by both sequencing and gene expression array. An updated GTex databse version 
(phase V7) is comprised of a) genotype data of 53 tissues, 635 donors and 10361 samples and 
b) gene expression data of 48 tissues, 620 donors and 10294 samples 
(https://gtexportal.org/home/). 
 
A.2.2 Blood eQTL Dataset 
A large-scale trans and cis eQTL meta-analysis was performed across 5,311 individuals 
with replication in 2,775 individuals (Westra et al., 2013). For this study, non-transformed 
peripheral blood samples were collected from a total of 9 data sets from 7 study populations 
including EGCUT (n = 891), InCHIANTI (n = 611), Rotterdam Study (n = 762), Fehrmann (n 
= 1,240 on the Illumina HT12v3 platform and n = 229 on the Illumina H8v2 platform), HVH 
(n = 43 on the Illumina HT12v3 platform and n = 63 on the Illumina HT12v4 platform), 
SHIPTREND (n = 963), and DILGOM21 (n = 509 on the Illumina HT12v4 platform) (Westra 
et al., 2013). Gene expression data were obtained from RNA isolation either using PAXGene 
or Tempus tubes and then followed by hybridizing RNA to IIlumina whole genome Expression 
BeadChips. This expression data across multiple platforms was harmonized through matching 
probe sequences, mapped against Build 36 of the human genome. The genotype data acquired 
using various platforms was harmonized by imputation, using HapMap 2 reference panel. 
 
A.3 Sanger Sequencing Traces:  
The following sequences are from different EP and WP individuals. 
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A.3.2 Base position: chr2:113676219 
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A.4 Possible reasons for inconsistent association results between sample sets 
a) A difference in ancestral genetic background 
Over millenia mutations occur and are maintained or lost by natural selection and other 
factors among different derived populations. There are 85% of SNPs common to all human 
populations, however 15% of SNPs are population-specific (Barbujani et al., 1997). Different 
SNP prevalences can drive differences among populations such as difference in phenotypes and 
disease susceptibility. They are also important evolutionary markers that indicate difference in 
migratory or evolutionary patterns among various ancestral groups.  
There are also other factors that are responsible for genetic differences among populations 
such as genetic drift, bottle neck effect (small founder populations), migratory patterns, 
geographical distribution, adaptation to different environments etc. Due to these genetic 
phenomena populations undergo haplotype recombinations and have different haplotypic 
structure. The inconsistent direction of association of SNPs between Polynesian subgroups EP 
and WP may be because of specific ancestral recombinations that distinguish the haplotypic 
background around these SNPs between EP and WP subpopulations.  There are studies where 
inconsistent direction of association has been detected between different populations 
(Polynesian and European) for selected markers e.g TLR4; rs2149356 and LRP2;rs2544390 
(Rasheed et al., 2013 and Rasheed et al., 2016). Also if there is undetected gene-gene interaction 
whereby other interacting genetic variants in the genome differ in frequency then this will also 
influence the effect size of the variant being tested.   
 
b) Different LD structure amongst study populations 
This point is closely related to point a) above. LD patterns vary substantially across 
populations even those are present in a same geographical region. Different patterns of LD are 
a result of ancestral recombinations that produce variability in haplotype structure among 
populations e.g. Polynesians and Europeans or even within Polynesian subgroups EP and WP. 
For a particular marker that is not causal but may be in LD with the causal variant in one 
ancestral group e.g EP, the allele of the same variant may be in LD with the protective allele 
(on a different haplotype) in the other ancestral group e.g. WP (Figure). The inconsistencies in 
direction of effect for a SNP in two populations thus could be due to population specific 
recombinations that results in different haplotype structure at that locus in two ancestral groups. 
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For example, the rs2149356 G-allele at TLR4 was detected on the Polynesian risk haplotype 











Figure: Difference in haplotypic structure in individuals of two different sub-
populations. SNP1 and SNP6 are in complete LD (they inherit together). SNP1 is a marker 
while SNP6 is the causal variant. In an EP individual the A allele of SNP1 is in LD with the 
risk T-allele of SNP6 however, the same SNP in an WP individual is in LD with the protective 
allele. These differences in haplotype structure are produced by distinct genetic recombinations 
in these ancestral groups. 
 
c) Population stratification 
This is another factor that affects results of association studies. It is also a major cause of 
false positive results. It can be thought of as a specific type of confounder by ancestry. If cases 
and controls are drawn from different ancestral backgrounds or a population having admixed 
ancestry (if there is more than one ancestry), SNP frequencies will vary due to genotype 
frequency in the population rather than because of an association with disease. In the current 
study admixed populations (with different ancestral genetic backgrounds) have been included 
to test association of SNPs with disease. Though methods were applied (adjusted with PCs and 
proportion of GP ancestry) to control population stratification effects they may be insufficient 
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to correct the effect of stratification in some groups (e.g the EPZ group) and can potentially 
cause the heterogeneity of association in different groups such as SLC22A12 variant. 
 
d) Interaction of non-genetic exposures 
Non-genetic environmental exposures (temperature/weather, food (sea food, meat, 
alcohol and sweetened beverages), smoking etc) if not adjusted or accounted for also affect 
association results. For example there are SNPs (e.g. IRGM;rs13361189, ORNZ European = 1.12 
and ORUK Biobank = 0.98)  for which a difference in effect size was seen in the UK Biobank cohort 
and NZ Europeans even though both are European ancestral populations. 
 
c) Chance findings 
Certainly, chance finding with a modest significance level only detected in one group is 
a reason for inconsistent findings.  
 
 
 
